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ABSTRACT
Background: With a low proportion of children receiving the first line treatment for 
suspected malaria, it has been proposed that artemisinin based combination therapy be 
subsidised in the private sector in order to improve affordability and access. This thesis 
presents an evaluation of a pilot subsidy mechanism in Western Kenya.
Methods: The primary objective was to evaluate the impact of providing subsidized 
artemether-lumefantrine (AL) through trained retailers, on the coverage of prompt 
effective anti-malarial treatment for febrile children aged three to 59 months. I used a 
cluster-randomised, controlled design with nine control and nine intervention sublocations, 
equally distributed across three districts. Provider, mystery shopper and household cross- 
sectional surveys were conducted at baseline and one year later. Data were analysed based 
on cluster-level summaries, comparing control and intervention arms, while adjusting for 
covariates. On average details of 2,706 children and 564 retail outlets were captured per 
year.
Results: Provider survey and mystery shopper data showed that at follow-up a 
significantly greater percentage of retailers stocked and dispensed AL, and knew that AL 
was the first line treatment for uncomplicated malaria in the intervention arm compared to 
the control. Significantly fewer retailers stocked antimalarial monotherapies. Household 
survey data showed that an average of 29% of children had experienced fever within the 
previous two weeks. Within this sample, the percentage receiving AL on the same day or 
following day of fever developing at follow-up was 25.0% points higher in the intervention 
arm than in the control arm, a statistically significant difference. However, adherence to 
dosing for AL purchased in the retail sector and advice given to caretakers by retailers 
remained unchanged post-intervention.
xii
Conclusion: Overall, subsidizing ACTs in the retail sector can significantly increase ACT 
coverage in rural areas. Further research is needed on ways to improve counselling and 
adherence as well as on the impact and cost-effectiveness of such an intervention at a 
national scale.
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CHAPTER 1
INTRODUCTION
Artemisinin-based combination therapies (ACT) are generally accepted as the best 
treatment for uncomplicated malaria and have been widely adopted as national policy 
throughout Africa. However, usage of ACTs remains very low, leading to calls for radical 
solutions to improve access to effective malaria treatment, including expansion of home 
management of malaria (HMM). Prominent among these strategies is a proposal to 
subsidize ACTs in the private sector, proposed by the Institute of Medicine (IOM) 
committee in their report “Saving Lives, Buying Time” in 2004 (Arrow et al., 2004). This 
has led to numerous discussions at the international level on whether and how this should 
be implemented in practice. Limited experience to date indicates that ACT subsidies can 
lead to increased ACT uptake and decreased use of inappropriate monotherapies, but many 
important questions remain unanswered. This thesis aims to address these information gaps 
by presenting the results of a cluster randomised controlled trial evaluating the impact of a 
package including ACT subsidies, retailer training and community awareness on ACT 
coverage, price and adherence in a high malaria transmission area of Western'Kenya. This 
introductory chapter presents the background to and rationale for the research, the 
objectives, and outlines the organisation of the thesis. Chapter 2 reviews the evidence on 
the effectiveness of HMM and chapter 3 explores different evaluation methods involved in 
assessing public health interventions.
1.1: RATIONALE 
1.1.1: Malaria Background
Malaria remains an important health problem with an estimated 2.37 billion individuals 
living at risk of transmission of Plasmodium falciparum, the most virulent of the malaria 
causing plasmodium species (Guerra et ah, 2008). It has been estimated that in 2007 there
were between 349 to 552 million clinical cases of P.falciparum malaria (Hay et al, 2010). 
P. falciparum contributes to 90% of the malaria burden in Africa, and 1 million childhood 
deaths per year are a direct consequence of the parasitic infection (Snow et al., 2005; Snow 
et al., 1999).
The creation of the Roll Back Malaria (RBM) global partnership in 1998 brought 
international hope after a long period where malaria control strategies had received a 
relatively low priority on the global stage. The RBM created a mandate to increase 
international awareness of malaria and to rally support in the control of the disease (RBM, 
2005). It aims to do this by working closely with countries affected by the disease, 
supplementing and strengthening health services therefore, increasing access to prevention 
and treatment measures (Malaria Consortium, 2002). One of its core targets was that ‘80% 
of those suffering from malaria should receive appropriate treatment within 24 hours’ 
(World Health Report, 2008). Reaching this target is still a great challenge for Africa, 
partly because of the development of drug resistance of the malaria parasite to first line 
therapies, such as sulphadoxine-pyrimathamine (SP) and amodiaquine (Nchinda, 1998). By 
contrast, artemisinin derivatives are currently considered very effective in the treatment of 
P. falciparum malaria, the most virulent of the malaria plasmodium species. It is thought 
that the rate of development of resistance to artemisinin derivatives will be much slower 
than that for other antimalarial monotherapies because of their short half-life, and their use 
in combination with other treatments (de Vries & Dien 1996; White et al., 1999). When 
used in combination with other effective anti-malarial monotherapies, ACTs have been 
shown to be well tolerated, to lower transmission rates within communities by reducing 
gametocyte loads, and have demonstrated cure rates of over 90% (IASG, 2004). The 
migration of countries from less effective antimalarial monotherapies such as chloroquine 
(CQ) and SP to ACTs was not straight forward, and this transitional delay is thought to 
have contributed to tens of thousands of childhood deaths per year (Attaran et al., 2004). 
Although evidence was available to show the therapeutic advantage of ACTs over failing
monotherapies, there was resistance from the Global Fund (GF) who were not keen on 
funding country policies that were based on ACTs since these were shown to be ten times 
more expensive than monotherapies (Attaran et al, 2004). This was compounded by a lack 
of direction on international malaria treatment guidelines by the WHO (Attaran et al.,
2004) and poor country sensitivity data on suggested alternative first line treatments (Amin 
et al., 2007).
Since the creation of the RBM global partnership, significant strides have been 
achieved in controlling malaria. There has been a large increase in funding to support 
malaria control initiatives. By the end of 2009, the GF had approved $5-3 billion for 191 
malaria grants in 82 countries. Such funding has contributed to a 17% rise in the use of 
ITNs in just five years and widespread use of ACTs, with every malaria-endemic country 
adopting it as a first-line treatment (Noor et al, 2009; Snow & Marsh, 2010). ACTs are 
now generally accepted as the best treatment for uncomplicated P. falciparum malaria 
(WHO, 2006). However, usage remains very low, with only 16% of febrile children under 
the age of 5 years receiving ACTs in 2008 (World Malaria Report, 2009).
A correlation has also been observed between increase funding and a significant 
decrease in the incidence of severe malaria, such as in the coast of Kenya where severe 
malaria cases dropped by over 90% in just five years (Okiro et al, 2009; Omera et al.,
2008). These observations can be partly attributed to the enhanced control and prevention 
activities, however it is thought that more complex factors are responsible (Snow & Marsh,
2010). Substantial gains have been made in reducing the burden of malaria across parts of 
Africa, however gaps still remain. Although malaria has been observed to be decreasing in 
certain regions, this is not the case across the continent where some areas have either 
shown no change or even an increase in the number of cases or the percentage of 
population at risk (Snow & Marsh, 2010; Okiro et al, 2009). More funding is required to 
expand effective control initiatives to reach the recommended target expenditure of $4.46
3
per person living in Africa per year, estimated to be needed to achieve full effective 
coverage of efficacious intervention strategies (Teklehaimanot et al, 2007).
1.1.2: The Kenyan Health Care System
Kenya’s health care system can be described as pluralistic, where healthcare facilities are 
owned and funded by a wide variety of institutions such as the government, private 
commercial and not-for-profit institutions (Table 1.1). The government funds and is in 
direct control of all public sector health care which consists of government health care 
facilities and community owned resource persons (CORPs) or community health workers 
(CHWs). In 1997, it was estimated that the public sector operated around half of all health 
facilities in the country (Kimalu et al, 2004). Government funded public health facilities 
are organised in a pyramid structure with four levels. On the lowest level are dispensaries 
and medical clinics which provide the most basic services, this is followed by health 
centres and sub district hospitals on the level above. The third level consists of district 
hospitals and provincial general hospitals which provide more comprehensive services. 
Moi Referral and Teaching hospital in Eldoret and Kenyatta National Hospital in Nairobi 
are the two national hospitals which provide health care that supersedes all other facilities 
in the country and act as the last point of referral within the country (NCAPD & Macro,
2005).
Table 1.1: Health care providers in Kenya -  a typology
Sector Definition Constitutes
Public Providers funded by and in direct 
control of the government
• Government health care facilities
• Community Owned Resource Persons
Private Providers who fall outside the direct 
control of and are not funded by the 
government
• Not-for-profit (Mission and Non-governmental 
organisation) health care facilities and community 
owned resource persons
• Private/ commercial health care facilities
• Retailers: registered pharmacies, general 
provision shops and mobile hawkers
• Traditional healers and herbalists
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The private health sector consists of not-for-profit health care facilities and CHWs, and 
commercial facilities, retailers and traditional healers (Kimalu et al, 2004) (Table 1.1).
The treatment seeking behaviour patterns in Kenya are such that a significant 
proportion of healthcare is first sought through the private sector (Chuma et al., 2009; 
Amin et al., 2003; Guyatt & Snow, 2004; Abuya et al., 2007; Gitonga et al., 2007). The 
private commercial sector in Kenya consists of health care facilities such as clinics and 
hospitals, and retail outlets. Private retail outlets that sell medication include both 
pharmacies registered with the pharmaceutical board of Kenya and others which are not 
registered and operate illegally. In 2004, the country was reported to have over 600 legally 
functioning pharmacies (HAI, 2004). Pharmacies can legally sell medicines classified by 
the PPB as Over the Counter (OTC), Pharmacy (P) and Prescription Only Medications 
(POM). It is also common to find medicines being sold in general provision shops and by 
mobile hawkers. Legally these outlets can only sell OTC medications however they are 
also known to stock and sell P and POM medications. CHWs are licensed to sell a limited 
range of treatments (HENNET, 2007).
1.1.3: Treatment of Malaria in Kenya
Kenya is divided into eight provinces, Central, Coast, Eastern, Nairobi, North Eastern, 
Nyanza, Rift Valley and Western. A study carried out in 2009 (Noor et al., 2009) showed 
that a majority of the country falls into low transmission areas with P. falciparum parasite 
rate observed in children 2 to less than 10 years (PfPR2-io) estimated at < 5%. Nairobi, 
Central, Eastern and Rift Valley provinces were estimated to have the lowest transmission 
rates, with PfPR2-io of <0.1%. Nyanza province was estimated to have the highest 
transmission rates with an estimated PfPR2-io of >=40%. Also in 2009, Kenya reported 10 
million suspected cases of malaria, and over 200,000 malaria admissions. The latest data 
collected on malaria deaths was in 2006, when 40,000 deaths were documented to be 
malaria related (World Malaria Report, 2008). Although the country has seen a recent
decline in observed malaria cases (O’Meara et al., 2008), the numbers still remain 
unacceptably high.
In Kenya, CQ was the most commonly used drug to treat uncomplicated malaria 
cases for 50 years. CQ resistance started emerging in 1978 which later led to it being 
replaced with SP. Unfortunately within 2 years resistance to SP developed, forcing the 
country to reconsider alternative treatment options (Shretta et al., 2000, Amin et al, 2007). 
In 2004 Kenya changed its anti-malarial treatment policy to the ACT artemether- 
lumefantrine (AL) (Amin et al, 2007). Free distribution of AL in the public sector began 
in mid 2006. The policy change process was to occur in phases over a five year period with 
the first two years seeing AL distributed through public health facilities. This would allow 
time for the country to develop experience before the policy could be rolled out to a wider 
range of providers such as private-for profit clinics and the retail sector in order to increase 
access (Amin et al, 2007). However, progress in rolling out AL in the retail sector has 
remained very slow, as explained below. The then Kenya malaria treatment policy 
recommended presumptive treatment with AL for all febrile children under the age of 5, 
except those living in low risk areas such as Nairobi and Central Province. All febrile cases 
5 years and above were to be parasitological diagnosed for malaria before treating with 
antimalarial drugs (MOH, 2001). After more than a year of distributing AL free of charge 
within the public sector, studies carried out in Kenya’s public health facilities revealed that 
only 26% of children presenting with fever (a clinical symptom of malaria) in public health 
facilities who would benefit from this treatment were prescribed it. This was despite 
interventions such as in-service training and awareness campaigns implemented to promote 
uptake (Zurovac & Rowe, 2006). A separate study in the form of a household survey, 
published in 2007 evaluated treatment of malaria within the community (Gitonga et al, 
2007). The study was carried out in four endemic districts in Kenya and revealed that 90% 
of caregivers took some action to treat a child’s fever within 48 hours of symptom onset. 
Of these, 47% first sought treatment in the private retail sector and only 35% went to
public or not-for-profit health facilities. A small proportion, 23% of all these fevers were 
treated with an anti-malarial within 48 hours, of which 61% were obtained from the public 
sector, 28% from the retail sector and 10% by self administration of medicines available in 
the household. The proportion of febrile children who received the first line recommended 
AL within 48 hours was only 10%. As expected, the majority of AL (95%) was dispensed 
from public health facilities. A national survey had similar findings, showing 8% of 
children under five with fever taking AL, and 4.2% taking it on the same day or following 
day of fever developing (KNBS & ICF Macro, 2009), with around 70% of all ACTs being 
sourced from a government health facility/ worker (DOMC, 2007). More recent data from 
the Kenya Malaria Indicator Survey (DOMC, 2011) showed some improvements in some 
of the malaria case management indictors for children under five years across the country. 
Fever prevalence was 51%. Of those fevers 35% received an antimalarial, 18% received an 
ACT and 11% received this ACT on the same or next day of fever developing. Of those 
who had treatment sought for their fever, 23% received it from a private sector health 
facility or pharmacy, and 9% from a shop. Only 12% of fevers had blood samples taken for 
malaria testing. What this partly demonstrates is that health care for malaria is heavily 
sourced from the private retail sector; however, the services received remain poor. Care 
provided from this sector for the treatment of malaria is mainly based on ineffective 
medications (Amin et al., 2003; Abuya et al., 2007; Gitonga et al., 2007). Since a high 
proportion of individuals seek treatment within the retail sector (Chuma et al., 2009; 
McCombie, 1996; Williams & Jones, 2004), encouraging AL distribution within this sector 
at an affordable price, along with improving the quality of health care services offered has 
the potential to significantly expand the coverage of effective malaria treatment within the 
community.
More recently, in line the update World Health Organisation (WHO) malaria 
treatment policy (WHO, 2010), the new National Malaria Strategy which commenced in 
2009 now recommends that where possible, all febrile cases should undergo diagnostic
testing either with Rapid Diagnostic Tests (RDTs) or microscopy prior to treating for 
malaria (DOMC, 2009). To achieve this, the Division of Malaria Control (DOMC) intends 
to introduce RDTs in facilities without microscopy equipment, and rehabilitate the 
microscopy equipment present in facilities that have them available (DOMC, 2009). Data 
based on the more recent Kenya National Malaria Strategy released in 2009 (i.e. that all 
febrile patients should be tested for malaria diagnostically, if the test is positive the patient 
should be treated with AL, and if negative the patient should not be treated for malaria) 
showed that only 12% of febrile children under five, presenting at a government health 
facility were treated appropriately (DOMC, 2010). Weaknesses within the public sector 
have been acknowledged by the government who are working in collaboration with both 
local and international organisations to improve performance (DOMC, 2010; DOMC,
2009).
1.1.4: Improving Delivery of Antimalarials through Retailers in Kenya
HMM is a strategy that has been supported by RBM with the aim of increasing prompt and 
effective treatment of malaria within the community. This strategy exploits the strengths of 
providers outside the public facilities and improves their services. It can be delivered 
through retailers, CHWs or other community members, and is generally implemented 
alongside public health sector delivery (RBM, 2005).
Kenya can be considered a pioneer in HMM interventions targeting retailers. 
Training of general shopkeepers in the mid-1990s began on a pilot basis in coastal Kenya, 
combined with community information campaigns (Marsh et al, 1994; Marsh et al, 2004). 
This was followed by a scale up of the intervention to other parts of Kenya, which was 
more recently documented in Abuya et al, (2009). Other interventions were piloted in the 
Western part of Kenya (Muturi, 2001; Tavrow et al, 2003), one involving the training of 
retailers (Muturi, 2001) and the other involving the use of mobile and stationary wholesale 
vendors in educating private sector retailers, such as pharmacies and general shops, on
appropriate selling of antimalarial treatment (Tavrow et al., 2003), results of these pilots 
are reviewed in Chapter 2.
All these interventions were carried out when anti-malarial monotherapies such as SP 
and amodiaquine were still effective and were the first line of treatment for uncomplicated 
malaria. These monotherapies were affordable and readily available in retail outlets. The 
introduction of AL as first line treatment posed major challenges to the shopkeeper training 
strategy. AL was too expensive for the majority of consumers to afford (Arrow et al, 
2004). In addition the Kenyan Pharmacy and Poisons Board classified AL as POM, 
making it officially available only in healthcare facilities and pharmacies and to those 
prescribed it by healthcare professionals. Existing policies to train shopkeepers on the first 
line medicine were therefore no longer appropriate or likely to have a significant impact on 
coverage of appropriate treatment.
1.1.5: ACT Subsidies in the Private Sector
These challenges led to the consideration of subsidising ACT in the Kenyan private sector, 
and the decision to carry out the pilot described in this thesis. Two other ACT HMM pilots 
were implemented at the same time: the Sustainable Healthcare Enterprise Foundation 
(SHEF) introduced subsidised AL and RDTs in their network of Child and Family 
Wellness Clinics (CFW) run by trained healthcare professionals (SHEF, 2008); and the 
Kenya Red Cross piloted provision of AL and RDTs through CHWs (Kenya Red Cross; 
Beyond prevention: HMM in Kenya 2010). However, no other studies in Kenya have 
implemented ACT subsidies through normal drug retailers.
On an international level, similar retail subsidies were being introduced elsewhere, 
including Uganda, Nigeria, Tanzania, Cambodia, Madagascar and Rwanda (Schaferhoff & 
Yamey, 2011). Moreover, the issue has gained increasing prominence with the roll out of 
the Affordable Medicines Facility-malaria (AMF-m), which from 2010 has been 
introduced in 8 countries, including Kenya, under AMF-m Phase 1 (Schaferhoff & Yamey,
2011). The primary function of the AMF-m is to provide a “co-payment” directly to pre­
selected manufacturers of ACTs in order to reduce the price to national level wholesalers 
to approximately $0.05. As a result of this co-payment, it is expected that the price of 
ACTs will be comparable to that of other less effective anti-malarial monotherapies, such 
as CQ and SP in the private sector, and free or low cost in the public sector, crowding out 
the monotherapies. The AMF-m mechanism also provides funding to countries for 
supporting interventions to facilitate the widespread uptake and responsible usage of ACTs 
by patients, targeted at wholesalers (e.g. incentives to distribute to remote areas), retailers 
(e.g. shopkeeper training, suggested retail prices (SRP)), and consumers (e.g. social 
marketing) (AMF-m, 2007).
Limited experience with private-sector ACT subsidies elsewhere indicates that they 
can lead to increased ACT uptake and decreased monotherapy use (Sabot et al., 2009; 
Sabot et al., 2008). However, no data are available on the impact on the key outcome of 
coverage of prompt effective treatment of fever at the community level. With only a subset 
of the community using retail outlets, it is not clear if an intervention targeting the private 
sector will demonstrate a significant effect on overall treatment coverage. In addition, there 
are concerns that shopkeepers may not stock the subsidized medicines due to capital 
constraints; that brief training may be insufficient to change treatment practices; and that 
retailers may not pass on the subsidy to the consumer, preferring instead to maximize their 
profits. Concern has already been raised in the Kenyan media that the subsidy is not being 
passed on to consumers (Nation editorial 7/2/11). Also, it is not known whether caretakers 
of young children will be willing to change their treatment practices and to trust 
shopkeepers to provide good quality ACTs, while there are also fears that the strategy will 
divert careseekers from trained providers. There are concerns that the subsidies will be 
taken advantage of by the relatively well off, with the poorest in the community unable to 
afford even the subsidised ACT (D’Alessandro et al., 2005; Oxfam, 2009). Moreover, the 
increased availability of ACTs may encourage the misuse and over use of the treatment,
increasing drug selection pressure, encouraging parasite resistance to the treatment 
(D’Alessandro et al., 2005; Staedke et al., 2009). Finally trying to improve ACT 
availability may drain resources from other useful malaria interventions in the public sector 
(Oxfam, 2009).
This thesis aims to address some of these research gaps in the context of the Kenyan 
pilot of retail sector subsidized ACT.
1.2: OBJECTIVES 
1.2.1: General Objective:
To evaluate to what extent the provision of pre-packaged, subsidized, AL delivered 
through private sector retailers will improve the coverage of prompt effective anti-malarial 
treatment.
1.2.2: Specific Objectives:
1) To determine the impact on the proportion of children under five with fever being 
treated promptly with appropriate anti-malarial treatment, and adhering to the 
correct dose (accessibility and utilisation)
2) To determine if private sector retailers can deliver AL to appropriate standards of 
quality for the treatment of fever in children under five years (provision)
3) To determine distribution of benefits of retail sector delivery of AL by socio­
economic status (equitable coverage)
4) To explore reasons for the impact observed and identify any challenges in the 
implementation process (explanation o f  experience)
1.3: ORGANISATION OF THESIS
Chapter 2: Review of literature- Home Management of Malaria
This chapter reviews the evidence on different aspects of HMM, including its definition, 
treatment seeking behaviour and evaluations of HMM interventions.
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Chapter 3: Review of literature- Evaluating Public Health Interventions: A Review of 
Approaches
This chapter reviews the available evidence on the advantages and disadvantages of 
different study designs used to evaluate public health interventions.
Chapter 4: Study site and methodology
This chapter describes the setting in which the study took place and the intervention 
design. Three data collection activities took place in this study, a provider survey, a 
mystery shopper survey and a household survey. This chapter describes how the sample 
sizes were derived for each data collection activity, gives details on how the data collection 
activities took place and describes the data analyses used to derive outcome measures.
Chapter 5: Provider survey
Data collection for the provider survey took place by interviewing providers in retail 
outlets that met the selection criteria. The interviews focused on provider behaviour and 
practices in treating malaria. This chapter goes through baseline and follow-up results of 
the provider survey and discusses the findings.
Chapter 6: Mystery shopper survey
Data from this survey were collected by data collectors disguised as caregivers of a child 
with fever seeking help from selected providers to see what treatment and advice the latter 
would offer. This chapter goes through baseline and follow-up results of the mystery 
shopper survey findings and discusses the findings.
Chapter 7: Household survey
Data collection for the household survey activity took place by interviewing caregivers 
who had children suffering from fever within two weeks prior to the interview date to see 
what kind of actions they took in treating the child’s fever. This chapter goes through the 
baseline and follow-up results of the household survey and discusses the findings.
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Chapter 8: Discussion and Conclusion
This final chapter brings together the results from all the data collection activities to 
synthesise the findings and identify the implications for policy and future research. It 
discusses the context in which the study was conducted, the study’s strengths and 
limitations, triangulates outcomes from the three data collection activities, and compares 
the study outcomes to previously available evidence. It ends with the conclusions of the 
PhD.
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CHAPTER 2
HOME MANAGEMENT OF MALARIA
As noted in Chapter 1, a large gap exists between the RBM target that ‘80% of those 
suffering from malaria should receive appropriate treatment within 24 hours’ and current 
coverage. This chapter explores the factors that contribute to this gap, and reviews the 
evidence on the effectiveness of home management for malaria (HMM), a strategy aimed 
at increasing coverage of appropriate malaria treatment.
The chapter begins with an overview of the literature on treatment seeking behaviour 
for malaria-related illness in malaria endemic areas in general (section 2.1) and in Kenya in 
particular (section 2.2). Section 2.3 reviews the literature on HMM in general, while 
section 2.4 focuses specifically on HMM interventions in the retail sector. Since recent 
reviews already exist in most of these areas, the first 3 sections draw mainly from these 
reviews, supplemented by additional papers where necessary. However, for section 2.4 a 
systematic literature search was conducted as up to date reviews were not available.
2.1: OVERVIEW OF TREATMENT SEEKING BEAVIOUR FOR MALARIA; SUB 
SAHARAN AFRICA 
2.1.1: Defining Malaria
The concept of malaria is understood differently across community members and cultures. 
Some community members are aware of the symptoms and transmission of malaria 
through mosquitoes, and acknowledge it as a distinct disease. Others may accept malaria as 
a distinct disease in the absence of understanding its etiology and transmission. Despite the 
differing ways in which malaria is defined, the most common symptom known to 
correspond to uncomplicated malaria is fever (McCombie, 1996; Williams & Jones, 2004; 
Mccombie, 2002). For example, in Ghana the word ‘asra’, translated as fever was closely 
related to malaria, in Zimbabwe ‘nyongo’ described symptoms of fever and headache
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which a large part of the population thought to be caused by mosquito bites; and in Kenya 
the word ‘homa’, used to describe fever is linked to malaria through a specific form known 
as ‘homa ya malaria’ (Agyepong, 1990; Agyepong, 1992; Vundule & Mharakurwa, 1992). 
The initial signs and symptoms of malaria share similar characteristics to pneumonia 
(O’Dempsey et al, 1993), and both diseases are leading causes of morbidity and mortality 
in children under five in sub Saharan Africa (Black et al, 2003, 2010; Kinney et al, 2010). 
This means that there is potential for mis-diagnosis between the two diseases, resulting in 
the overtreatment of malaria, especially in regions where malaria cases are on the decline 
(Okiro et al, 2009; Omera et al, 2008). In addition, malaria as a disease is generally quite 
difficult to diagnose.
Laboratory diagnosis is rarely available in many settings, due to a lack of 
equipment, supplies and trained staff. Clinical diagnosis is challenging as the signs and 
symptoms of uncomplicated malaria include fever, headaches and chills, which overlap 
with the symptoms of many other diseases. As a result, over diagnosis of malaria is 
common (McCombie 2002). For example, in Uganda, 92% of children presenting at 
clinical facilities with fever were clinical diagnosed with malaria, but lab tests came out 
positive in only 62% of cases. In areas of low malaria prevalence, an even higher 
percentage of fevers are likely to be over-diagnosed (Lubanga et al, 1997). It is estimated 
that of all clinically diagnosed malaria patients, an average of 61% (ranging between 28% 
and 96%) will give a negative laboratory diagnosis (Amexo et al, 2004).
2.1.2: Sources of Treatment for Malaria
A review by McCombie (1996) evaluating malaria treatment practices showed that around 
40 to 95% of reported malaria cases will seek some kind of treatment, with the majority of 
studies showing the proportion to be over 90%. Seeking treatment was more likely to occur 
if the patient was suffering from fever and if the illness was taking longer than usual to 
disappear (McCombie, 1996). Most first actions were shown to take place from a few
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hours of symptom onset to within two days (Williams & Jones, 2004). The number of 
cases that took two or more forms of actions varied from 11 to 90%, with most studies 
showing more than 40% of cases likely to take more than one action, but few taking more 
than two. The number of actions taken was shown to be linked to severity of symptoms, 
with more severe cases taking more actions (McCombie, 1996). The three main actions 
identified are self-treatment, use of the formal health care sector and seeking care from 
traditional healers (McCombie, 1996; McCombie, 2002; Williams & Jones, 2004).
Self-treatment can be defined as any treatment that does not involve consulting a 
healthcare provider or a traditional healer. This ranges from use of a cool bath to reduce 
fever, to administering a course of antimalarials purchased from the informal health sector 
such as retail outlets, itinerant vendors, and even other households. The purchasing of 
medications from a pharmacy is also often placed in this category even though this can be 
seen as accessing treatment from someone who is considered part of the formal health 
sector. Although there is variation between studies, it appears that the proportion of 
patients suffering from symptoms of malaria that self treat is high, and that a majority of 
these patients have purchased medication from an informal outlet such as a drug shop or 
general shop selling medicines (McCombie, 1996; McCombie 2002; Williams & Jones,
2004). In Zimbabwe, for example, a drug survey revealed that 43% of antimalarials used 
were obtained from shops (Raynal, 1985).
The formal health sector includes hospitals, clinics, and dispensaries in both the 
public and private sector. In some studies village health workers are included in this 
category. A review looking at treatment seeking behavior in malaria (McCombie, 1996) 
estimated that slightly over half of ‘malaria’ patients will visit this sector (when it includes 
village health workers), though this sector was usually not utilised as the first choice of 
treatment. For example, a study in Uganda showed that only 17% of patients had not tried 
any other form of treatment before visiting a clinic (Kengeya-Kayondo 1993).
20
Traditional healers are described in many terms including ‘demon healers’, ‘wound 
healers’, ‘bone setters’ or ‘old women’, who advise the community through their own 
knowledge and experience (Williams & Jones, 2004). They are believed to cure a range of 
disease that are thought to be either clinical, emotional or spiritually related. Visits made 
to the traditional healer by patients suffering from symptoms of ‘malaria’ are relatively 
rare, with most studies suggesting 10% or less of patients will visit one or use traditional 
medicines, if suffering from malaria symptoms (McCombie, 1996).
2.1.3: Factors Influencing Treatment Seeking Behaviour
Decisions on where treatment is sought are not passive but based on many factors such as 
treatment experience, local beliefs about how the illnesses should be treated, influence of 
social networks, and a realistic appraisal of available options (McCombie, 1996; 
McCombie, 2002; Williams & Jones, 2004). A common method of treatment seeking 
behavior is known as ‘trial and error’, ‘nomadic’, or ‘try and see’, whereas symptoms alter 
or treatment remains ineffective, so do the beliefs and explanations of cause and therefore 
treatment (Williams & Jones, 2004). Generally, for the treatment of febrile illness, the first 
response is self-treatment (Ryan, 1998; McCombie, 2002). As described in the ‘trial and 
error’ approach, if the initial self-treatment attempts result in no improvements, care will 
then generally be sought from what is perceived to be a more qualified healthcare provider. 
These usually include medical health care providers (from the formal private, public or 
Non-Govemmental Organisation (NGO) sector) but sometimes traditional healers 
(McCombie, 2002).
It is thought that conventional medicines from drug outlets are commonly used as a 
first response because such outlets tend to be closer than public health facilities and, unlike 
public health facilities, usually have a reliable supply of drugs. Providers from these outlets 
are thought to be friendly and willing to offer treatment on credit if funds are not currently 
available. Another factor determining where treatment is sought is the severity of
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symptoms (McCombie 2002; Williams & Jones, 2004). Certain symptoms or combination 
of symptoms, for example a high or persistent fever or a combination of fever with 
vomiting, cough or diarrhoea, are perceived to be more serious than others, requiring 
advice, most often directly sourced from the formal health sector. Prevalence of certain 
diseases may also influence behavior. For example, in malaria endemic areas, where 
people are more familiar with its symptoms, self-treatment of the disease may be more 
common than other forms of care (McCombie, 2002). Studies have shown that traditional 
healers may also refer their patients to more conventional healthcare providers if the 
symptoms are perceived to be more amenable to conventional therapy, if physical 
symptoms worsen or if it seems to them that the traditional remedy has failed. It is 
suggested that when it comes to malaria, some healers claim not to cure malaria symptoms. 
Other symptoms such as convulsions have been perceived to be the specialty of a 
traditional healer (McCombie, 2002).
Cost is an important determining factor in treatment seeking behaviour. Incurred 
costs may include what is spent at the point of care, on transport to the source of care, and 
also in the form of time lost from productive activity. For example in Somalia, people 
stated that there was no reason to waste time and money on treatment for malaria if it could 
be cured at home with traditional remedies (Abyan & Osman, 1993). A related determinant 
is socio-economic status. In general poverty has been identified as a major constraint for 
access and use of healthcare facilities (McCombie, 1996). A study in Congo showed that 
those who spoke French, and were therefore viewed to be of a higher financial status were 
slightly less likely to treat their children’s illness at home or buy the drugs in a market, 
suggesting a potentially higher use of health facilities (Carme et al., 1992). A review 
carried out by Barat et ah, (2004) showed that richer individuals are more likely to seek 
treatment for malaria from both the private and public health facilities, while poorer 
individuals are more likely to access treatment from traditional healers. Those with a lower 
level of education have also been shown to access the formal health sector less, probably
due to education being linked to higher SES, and those less educated being less likely to 
understand the seriousness of certain diseases (McCombie, 1996; Williams & Jones, 2004).
Seasonality may also affect treatment seeking behavior. In rainy seasons it may be 
difficult to use roads to access formal healthcare services, making one opt for self­
treatment. During times of harvesting, farming demands may make it time consuming to 
visit facilities that are far away. Also, in times of poor crop yield, money may be saved to 
purchase food instead of purchasing medical treatments. In such cases, treatments may be 
limited to what is already available at home rather than spending money at health care 
facilities (Williams & Jones, 2004).
Some studies have shown age to be an important determining factor to where 
treatment is sought. In some cases, caregivers have been more likely to take a younger 
child directly to a healthcare facility rather than take chances and treat the child at home 
first, an action they are more willing to take with their older children (McCombie, 2002). 
When it comes to gender, women have been shown to experience difficulties in accessing 
the formal healthcare system mainly because of the locus of decision making with the 
household (Williams & Jones, 2004). Women may be prevented by the more ‘senior’ 
males within the household from seeking appropriate treatment. They may also not be 
financially empowered to access treatment if funds are controlled by their spouses. Their 
heavy workloads may not permit them to take time out and seek treatment, and due to 
social pressures they may feel constrained in expressing feelings of being ill and needing to 
access care (Williams & Jones, 2004).
Finally, area of residence has been shown to influence treatment seeking practices. In 
Nigeria, for example, home treatment was more common in rural areas, while health centre 
use was more common in urban areas (Odebiyi, 1992). The location of residence may be 
an indicator of more fundamental factors such as beliefs in different types of treatment, 
ease in accessing different healthcare sectors or be a reflection of socio-economic status 
(McCombie, 1996).
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2.1.4: Quality of Care
Reviews looking at patients’ quality of care have revealed poor healthcare practices within 
both the formal (public and private) and informal healthcare sector. Poor practices 
observed from both sectors include lack of counselling, poor diagnosis, rude treatment of 
patients and caregivers, as well as over prescription of drugs, incorrect dosing, and delays 
in initiation of treatment and diagnosis. Studies carried out in the formal healthcare sector 
have shown that despite providers being knowledgeable about malaria and its treatment, 
this knowledge is not always implemented (Brugha & Zwi, 1998; Ofori-Adjei & Arhinful, 
1996; Williams & Jones, 2004). One of the reasons given for this is that prescribers are 
often influenced by demands from the community (Ofori-Adjei & Arhinful, 1996; 
Williams & Jones, 2004). In the informal health sector, the situation is often worse since 
many practicing have insufficient pharmaceutical or healthcare training. This has led to 
studies observing drugs being sold that are not recommended by national guidelines, 
inappropriate dosages being recommended, poor if any advice given to patients, and poor 
storage and labeling of medications (Williams & Jones, 2004). Apart from the lack of 
knowledge and clinical skills, and client demand, poor quality of care in the informal 
sector has been thought to be attributed to the influence of pressure from pharmaceutical 
companies trying to increase market share in order to maximize profits, and ineffective 
local regulation (Williams & Jones, 2004; Goodman et al., 2007).
The quality of care is also determined by poor patient adherence. Inappropriate drug
dosages and incorrect timing between doses are frequently observed (Williams & Jones,
2004; McCombie, 1996). Despite being given the correct administration advice, patients
may not follow this advice at home. In Kenya for example, 55% of those seen at a health
centre did not follow dosing instructions (Mwenesi et al., 1995). A 2005 review looking at
adherence in the community to CQ, which also has a 3 day regimen, showed only a median
of one third using it correctly (Yeung & White, 2005). Other studies on ACT adherence
have shown varying results, ranging from 39% to 90% (Depoortere et al., 2004; Beer et al.,
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2009; Fogg et al, 2004; Kachur et al., 2004; Piola et al., 2005). Predictors of adherence 
have been shown to include the level of education, receiving the correct number of tablets 
(Beer et al., 2009) and counselling practices (Kachur et al, 2004).
The most common practices seen in poor adherence is failure to complete full 
courses of treatment. This has been observed in both the formal and informal sector 
(McCombie, 1996). It has been observed that patients tend to stop taking medication when 
they feel better and save the tablets for later (McCombie, 1996). A review carried out by 
Yeung & White (2005) concludes that adherence to antimalarial treatment is affected by 
patients not having access to affordable treatment or not receiving the correct advice on 
how the treatment should be administered. The review highlights that patients seem to be 
adherent to treatments known to be effective than those that are less efficacious (Yeung & 
White, 2005).
2.2: OVERVIEW OF TREATMENT SEEKING BEHAVIOUR FOR MALARIA; 
KENYA
A review looking at treatment seeking behaviour in Kenya reports similar outcomes to 
reviews carried out across SSA (Chuma et al, 2009; Chuma et al, 2010). The review 
showed a majority of patients with fever would take some kind of action to treat their fever 
with up to 25% of fevers left to resolve without any action taken (Chuma et al, 2009). 
Most of the time only one type of action would be taken (Chuma et al, 2009; Chuma et al, 
2010). This was demonstrated in Gucha and Kisumu districts where 87% and 75% of all 
fevers respectively were treated with only one action (Guyatt & Snow, 2004; Ruebush et 
al, 1995). As seen in other SSA counties, self-treatment with OTC medication was the 
first most common form of care sought, with care sought from the formal health sector 
being much less common (Chuma et al, 2009). In one study, close to half of all fevers 
experienced in children under five were treated with drugs brought from either a shop or a 
chemist. Only one third reported accessing treatment from a public health facility (Chuma
et al., 2010). Treatment was not usually sought immediately on the onset of symptoms; 
rather a median of 2 days delay was observed (Chuma et al, 2009; Chuma et al., 2010). 
Patients were more likely to wait longer than 2 days to seek treatment from the formal 
health sector (Chuma et al., 2009).
The review showed that variability exists across the country in the proportion of 
fevers being treated with an anti-malarial, with results ranging from 23% to 91% (Chuma 
et al, 2009). Fevers were more likely to be treated with the government recommended 
antimalarial from the formal health sector compared to the informal sector, and were more 
likely to be treated with an antipyretic from the informal sector (Chuma et al., 2009). This 
has been demonstrated in a cross-sectional study carried out by Gitonga et al., (2007) soon 
after the policy change to AL as the first line treatment for uncomplicated malaria. The 
study showed that of the 31% of resolved fevers, 10% received AL of which 95% was 
sourced from the formal health sector (Gitonga et al., 2007).
The factors determining patterns of treatment seeking behaviour in Kenya remain 
similar to those identified in other SSA countries described above. A key factor identified 
is community members’ perceptions of the quality of care received from government 
health facilities and effectiveness of treatments offered (Chuma et al., 2009; Chuma et al., 
2010). In a focus group discussion (FGD), members claimed the government sector was 
staffed with young health care workers with inadequate training and disrespectful 
behaviour, deterring them from this sector (Chuma et al., 2010).
Issues regarding quality of care received from both the informal and formal sector
also remain similar to those observed in other SSA countries. The uptake of the policy
change to AL in Kenya has been slow in all sectors, with ineffective anti-malarial
monotherapies still being prescribed, as shown in the study carried out by Gitonga et al.,
(2007) and described above. Studies have identified several factors that may have
contributed to this poor uptake. These include poor supply chains which result in frequent
stockouts, and prescribers being cautious in prescribing AL, fearing stock outs if the drug
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is prescribed to all deserving cases; ineffective monotherapies still being supplied to 
government health facilities; health care staff shortages, combined with high workloads 
and poor follow-up supervision and training; unclear treatment guidelines and 
contradictory training messages that confused health workers (Wasunna et al, 2008; 
Kangwana et al, 2009). It is argued that better regulatory enforcement of the policy 
change, education of the public on malaria treatment with awareness of ineffective 
treatments, and buy-in from pharmaceutical companies on the policy changes may have 
helped improve the quality of care received for the treatment of malaria in all health care 
sectors (Chuma et al., 2009).
Patient adherence is also seen as a problem in Kenya (Chuma et al., 2009; Chuma et 
al, 2010). Poor adherence has been blamed on complex drug regimens that are difficult to 
follow, and inconvenient drug timings that are difficult to follow especially for mothers 
who leave their children at home to go work on the farms or look for casual work (Chuma 
et al, 2010).
The above reviews demonstrate some of the key challenges faced in malaria 
treatment in both Kenya and the rest of SSA. These challenges affect care givers, providers 
and the government. In summary, challenges affecting caregivers include being equipped 
with the knowledge in identifying malaria and knowing where to seek effective treatment. 
Caregivers also need to be able to overcome the physical barriers in seeking effective 
treatment such as cost of treatment and distance to treatment outlets. Challenges affecting 
providers include making accurate diagnoses, knowing how to treat malaria patients 
effectively and creating the appropriate environment to be able to put that knowledge into 
practice. Governments face challenges in creating an enabling environment to allow 
successful implementation of their malaria policies. This includes providing training to 
providers, rolling out community awareness campaigns to inform consumers on effective 
malaria treatment, ensuring sufficient supplies of antimalarial medications at government
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facilities and monitoring all sectors providing health care to ensure adherence to policy 
guidelines. I now turn to a strategy aimed at addressing some of these challenges.
2.3: HOME MANAGEMENT OF MALARIA
HMM was designed to overcome barriers to accessing effective malaria treatment and 
improve quality of care received, by working with both the formal and informal services 
offered within communities, outside of clinical settings. HMM is designed to enable 
caregivers to recognise malaria illnesses early and respond appropriately; to ensure that 
targeted health care providers have adequate knowledge and capacity to respond to malaria 
illness; and to create an environment that enables successful implementation of the 
strategy. In order to achieve these objectives it is argued that an HMM strategy should 
have an effective communication strategy, should train community based service providers 
on the skills and knowledge necessary to delivery adequate healthcare, and should 
guarantee sufficient supplies of effective high quality, pre-packaged anti-malarial 
medication at the community level. Monitoring and evaluation of all these activities and 
their impact is also necessary to ensure effective implementation of the strategy (RBM 
2005).
The RBM has integrated HMM as part of its strategy to improve malaria treatment 
especially for non-immune individuals at risk of malaria, primarily children under five 
residing in high malaria transmission areas. Others who may benefit from HMM are people 
residing in low to moderate malaria transmission areas who may be exposed to malaria 
epidemics. This strategy is designed to provide care in areas that are inadequately served 
by the public healthcare system, augmenting rather than replacing public healthcare (RBM,
2005).
2.3.1: Current Evidence on HMM
A review on HMM was carried out by Hopkins et al., (2007), specifically to evaluate the
health impact of community- and home-based treatment for malaria in Africa. Studies were
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included in the review if they used antimalarial treatments to presumptively treat for fever 
and if the treatment was administered by local community members with no formal 
healthcare education. The outcomes monitored were specific health care indicators such as 
malaria morbidity or mortality, malariometric indices including parasite rates, 
haemoglobin or packed cell volume (PVC). A total of six studies were identified and 
evaluated, one in Kenya, The Gambia, The Democratic Republic of Congo, Ethiopia and 
two in Burkina Faso.
Five of the studies implemented HMM interventions through community healthcare 
workers (CHW) and one directly targeted caregivers. Only one study carried out in 
Ethiopia was able to show significant changes in mortality. This was a randomised 
controlled trial carried out in a rural seasonal malaria transmission area, where 24 clusters 
of villages with the highest malaria morbidity were paired by their under 5 mortality rates. 
Within each pair one was assigned into the intervention arm and the other the control arm. 
The intervention involved educating mothers to recognise symptoms of malaria in their 
sick children and treat with CQ promptly. Free CQ was distributed to all households 
through mother coordinators and it was up to the mothers to replenish supplies when need 
be. The results showed a significant reduction (p < 0.003) in under five mortality rate of 
40.6% (95% Cl 29.2 -  50.6) in the intervention arm compared to the control arm (Kidane 
& Morrow, 2000).
Four studies were able to demonstrate some improvements in malaria morbidity or
malariometric indices, but not mortality. In Burkina Faso for example, a study compared
outcomes of morbidity in children who received the intervention compared to those who
did not receive it. The study was carried out in an area with hyper-endemic seasonal
malaria. The intervention involved training of CHWs and a group of mostly older mothers
on aspects of malaria. Health centre staff were trained to package age specific CQ
treatment doses with aspirin and sell them to the CHWs, who in turn would sell them to
local mothers requiring treatment for their child, at a price that would create some profit,
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and therefore creating an incentive to continue selling. The outcomes of the study showed 
a significant reduction in the progression to severe malaria between children who received 
prompt treatment (within 24 hours) with pre-packaged CQ compared to those who did not 
receive the treatment (risk ratio 0.47, 95% Cl 0.37 -  0.60; p < 0.0001) (Sirima et al., 
2003).
One study in Kenya observed no significant change in any of the outcome indicators 
measured. The study was conducted in the hyper to holo-endemic malaria area near Lake 
Victoria, comparing two community intervention areas to one control area. Households 
within the communities were interviewed at six to nine month intervals on births, deaths 
and migration. In addition two biannual surveys were conducted in randomly selected 
villages to assess parasitaemia and antimalarial antibodies. The intervention involved 
training CHWs to give CQ free of charge for the presumptive treatment of fever, and to 
refer any serious cases. The study showed high usage of CHWs, however the presumptive 
treatment with CQ was found to have no impact on malaria specific or overall mortality, 
nor was a change seen in the parasite prevalence or serological markers. The low impact 
of the intervention was thought to be as a result of the high use of CQ prior to the study 
(Spencer et al., 1987a; Spencer^ al., 1987b).
The authors of the review concluded that a more robust meta-analysis could not be 
conducted due to the heterogeneity of the study designs and outcome measures. The 
evidence available on the effect of HMM on health outcomes was considered to be limited 
since only a total of six studies were identified, of which only one was able to show any 
benefits on mortality as an endpoint. The authors were therefore left with a list of 
unanswered questions, such as what is the optimal HMM intervention, would programme 
outcomes be similar in different settings such as rural versus urban, what are the safety 
risks in delivering treatment in this manner, and are HMM interventions sustainable and 
cost effective? They suggested that these questions could only be addressed through further 
studies (Hopkins et al., 2007).
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Another review evaluated the effects of differing types of interventions on provider 
practice and user behaviour, in order to improve prompt treatment practices for children 
under five suffering from fever. In this review providers were defined as those responsible 
for dispensing antimalarials and were further categorized as public and private; formal, and 
informal or community-based (Smith (b) et al., 2009). This review also looked at 
interventions targeting users, such as caregivers. Most interventions targeting this group 
focused on health education messages or the use of pre-packaged drugs with pictorial or 
verbal instruction. The trial designs were either randomised controlled trials, time series 
measurement, pre-post with or without a control group or post design with a control. The 
studies had to have reported on at least one RBM- Monitoring and Evaluation Reference 
Group indicator (RBM-MERG), with numerators and denominators presented (Smith (b) et 
al., 2009). The main findings are summarised below. The examples used here are limited 
to the non-clinical setting as this is the target area for HMM interventions. The examples in 
this section exclude studies on interventions targeting private informal providers (drug 
vendors, chemical sellers and regulated or unregulated general shopkeepers that stock and 
sell medicines) as these are discussed in more detail in section 2.4.
Only one study in Uganda (Nsungwa-Sabiiti et al., 2007) looked at the key RBM 
outcome of ‘prompt and effective treatment’. The intervention was developed into a 
national strategy and involved recruiting and training community drug distributors, who 
had the role of treating presumptive fevers in children with pre-packed CQ-SP (known as 
Homapak®). Mothers were also educated on appropriate treatment practices. The 
intervention resulted in a significant (P=0.01) 14% point increase in effective treatment in 
the intervention group, when compared to the control.
The majority of studies not monitoring promptness but looking more generally at
effective treatment (defined as the combination of receiving the correct antimalarial at the
correct dose and for the correct duration) showed improvements in this outcome measure.
For example, an intervention in Mali involved the training of informal providers in the
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community, also known as village drug kit managers. They were trained on appropriate 
presumptive treatment of fevers, while the rest of the community was exposed to 
sensitization and education activities in order to increase their demand for services offered 
by the managers. The intervention improved provider treatment behaviour by 11% points 
(P=0.042) when compared to a control where providers only received basic training. 
Adherence to treatment in the intervention group was also greater by 41% points when 
compared to the control group (p<0.001) (Winch et al, 2003). One study in Ghana showed 
that training teachers to treat fever presumptively and supplying them with pre-packed 
malaria treatment resulted in 8% point increase in children in the intervention group 
receiving correct treatment compared to the control arm (P<0.001), however, no significant 
difference was observed in adherence (P=0.94) (Afenyadu et al., 2005).
Studies that looked at individual components of effective treatment on their own 
(either receiving the correct treatment, dose or number of doses) showed varied outcomes. 
Three studies carried out in The Gambia, Cameroon and Zambia, evaluating interventions 
designed to educate carers on malaria treatment showed significant increases (P<0.001) in 
their knowledge of the correct anti-malarial treatment and doses required (Kaona & Tuba, 
2003, Nkuo et al, 2005; Menon et al, 1988). Another study in Burkina Faso (Pagnoni et 
al, 1997) used community based mother educators to educate women to actively seek the 
correct treatment for their children, while making pre-packaged treatment available 
through CHWs. The results showed significant improvements (P<0.0001) in the use of the 
correct antimalarial, the correct dose and for the correct duration. However, in Kenya, 
when behaviour was assessed in an intervention involving education of mothers, no 
significant difference between the groups was observed when it came to using the correct 
dose (Tavrow & Rennie, 2004).
The authors of the review conclude that an HMM model based on training CHWs on 
presumptive treatment and providing them with pre-packaged antimalarials to distribute, as
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well as having community awareness activities is the most common HMM model, which 
tends to lead to statistically significant but modest improvements in treatment behaviour. 
The authors suggest that the addition of supervision and provision of incentives to this 
model may further improve behavioural practices. The authors felt that pre-packaging of 
anti-malarial treatment was one of the most effective ways of increasing adherence. 
Similar to the previous review (Hopkins et al., 2007), the authors’ main concerns regarding 
the studies include the scarcity of high quality evaluations that allow for concrete 
conclusions to be made on the effectiveness of interventions; the short periods between 
implementation of the intervention and their evaluation do not allow one to judge the 
sustainability of the observed outcomes; and finally most studies were implemented on a 
local level, meaning that the impact of interventions at a national level remains unknown 
(Smith (b) et al, 2009).
2.4: HMM INTERVENTIONS IN THE PRIVATE RETAIL SECTOR 
2.4.1: Evaluation of HMM Interventions Targeting the Private Retail Sector
This thesis evaluates the impact of a specific HMM intervention on the proportion of 
children under five, with fever, receiving appropriate anti-malarial treatment. The HMM 
intervention targets providers within the private retail sector, and includes training and 
providing subsidised effective antimalarial treatment through these outlets, combined with 
community awareness activities educating caregivers on appropriate malaria treatment 
practices. This section reviews current evidence of the effects of HMM interventions in the 
private retail sector. A PubMed search was carried out using the ‘PICO’ search strategy 
(population, intervention, comparison and outcomes) (Higgins & Green, 2011) and the 
terms such as the following, for each category:
• Population: specialised drug stores, pharmacies, shop, mobile hawkers, kiosk, retail 
outlet, sub Saharan Africa (MeSH) (this group reflects the targeted population in 
the thesis);
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• Intervention: home management of malaria, training, information education 
communication, community awareness, subsidy, social marketing;
• Control: not applicable;
• Outcome: coverage, access, counseling, dispensing, adherence, knowledge, 
behaviour, cost (these indicators were selected to correspond to those evaluated in 
chapters 5-7 of the thesis to allow for comparison).
A separate search was carried out for each category, each term in these searches was 
separated by ‘OR’. Then all categories were combined using ‘AND’. The search was 
limited to sub Saharan Africa due to the distinctive nature of the retail pharmaceutical 
sector in these areas; all literature was restricted to the English language. An initial search 
was carried out in December 2010 and updated in July 2011. A further search was carried 
out in the grey literature under Google scholar, and also through discussion with experts in 
the field. In addition, previous reviews carried out on similar topics were sourced and used 
to identify additional studies (Goodman et al, 2007; Abuya et al., 2009; Smith (a) 2009; 
Smith (b) et al., 2009; Wafula & Goodman, 2010; Patuoillard et al., 2007, Hopkins et al, 
2007). Relevant studies from these reviews were then accessed through websites, through 
contacting authors and through work colleagues. No limit was placed on the date of the 
study.
Search outcome: A total of 21 reports were identified as evaluating HMM strategies in the 
private retail sector. 10 were published in peer reviewed journals, the rest were reports in 
the grey literature. The reports constituted 22 HMM evaluation studies. Six studies were 
from Kenya, five from Nigeria, three from Uganda, three from Tanzania, and one each 
from Cambodia, Zambia, Ghana, Madagascar and Senegal. Although the study was limited 
to sub Saharan Africa, a study in Cambodia was included as it formed one of only four 
studies (three of which were based in sub Saharan Africa) that evaluated the impact of 
ACT subsidies on HMM and provided some very useful findings. The components of
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HMM intervention strategies evaluated varied and included provider training, franchising 
of trained outlets, supervision of trained outlets, provision of pre-packaged drugs, 
provision of cheaper anti-antimalarial treatment either through pooled procurement or 
through the use of subsidises, and community awareness activities (Table 2.1). Each 
intervention consisted of one or more of these components (Table 2.1). Methodologies in 
study design varied. Only one study was planned as a probability design having a cluster 
randomised controlled approach; most studies were plausibility or adequacy designs, with 
only one being initially designed as a randomised controlled trial however ended up as a 
plausibility design. The years in which the reports came out ranged from 1992 to 2010. 
Data collection activities included quantitative (such as retail audits, provider survey 
interviews and mystery shopper surveys) and qualitative methods, with studies using one 
or more of these techniques. This review will focus on the quantitative outputs from the 
results.
The effect of subsidies on the cost of antimalarial treatment: Four studies looked at 
how interventions involving subsidised ACTs were able to control costs of these 
antimalarials at the retail level. Two studies were successful in showing their intervention 
having the desired effect on the cost of the drugs. One was a study carried out in the rural 
parts of Tanzania where AL was highly subsidised and distributed through the normal 
supply chains to drug stores known as £duka la dawa baridV. This led to the mean price 
being paid for ACTs for children under five years of age ($0.35) being significantly lower 
than less efficacious antimalarials SP ($0.51) and amodiaquine ($0.30). This study also 
showed that having a suggested retail price (SRP) artificially inflated AL prices, above 
those that would have been determined by the market, implying that SRPs should be used 
with caution until their impact on pricing is better understood (Sabot et al., 2009). In 
Senegal the government launched the distribution of subsidized artesunate+amodiaquine 
through private pharmacies where artesunate+amodiaquine was assigned a SRP to match
that of the public sector. The intervention looked to be successful as a pricing survey 
showed private outlet prices of the antimalarial to be similar to those in the public sector 
(Sabot et al., 2008). In Kenya, an intervention carried out by the Sustainable Healthcare 
Enterprising Foundation (SHEF) that was supposed to supply free AL through trained and 
franchised CFW retail outlets found that more than half of patients interviewed paid for 
their antimalarial (Sabot et al., 2008). In Cambodia, the NGO Population Services 
International (PSI) supplied pre-packaged ACT to wholesalers, who were recommended to 
sell their antimalarials to retail outlets at a subsidised price of $0.55. However, retail 
outlets ended up paying an average price of $0.75 per adult dose and $0.69 per child dose. 
This was 36% and 25% points higher, respectively than the recommended price (Sabot et 
al., 2008).
Caregivers’ knowledge: Two studies looked at the effect of education of caregivers on 
their knowledge of malaria. In Zambia a study carried out in Nakonde district in the 
Northern Province by Kaona & Tuba (2003) evaluated an intervention informing mothers 
of issues relating to malaria through trained village health motivators and vendors. The 
intervention increased caregivers’ ability to identify symptoms of simple and complicated 
malaria in their child by 1.32 and 1.51 times respectively. The same caregivers were also 
more likely to know the correct dose of the recommended antimalarial (CQ) to give their 
child. The study in Cambodia, where subsidised pre-packaged ACT was distributed 
through wholesalers to the private retail sector, also showed a 22% point increase in 
caregivers’ awareness of the recommended malaria treatment after a parallel mass media 
campaign was run promoting the subsidised treatment (artesunate+mefloquine) (Sabot et 
al., 2008). All results on caregivers’ knowledge were descriptive, it is therefore not known 
if the changes observed were statistically significant.
Provider knowledge: Seven studies carried out across three countries, Kenya, Nigeria and
Tanzania, evaluated the effect of training retail providers on their knowledge of malaria.
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The studies covered different aspects of malaria. Two studies evaluated more general 
knowledge of malaria, including diagnosis, treatment and prevention. One of these studies, 
based in the Igbo-Ora town of Western Nigeria (Oshiname & Brieger, 1992) showed that a 
5 day training session significantly improved general knowledge of malaria by 29% points. 
Another study based in Bungoma district, Kenya (Tavrow et al., 2003), which involved 5 
days training of trainers of wholesale suppliers improved by 16% points the general 
knowledge of retail outlet providers, who had been trained by the wholesalers. Three 
studies evaluated the effect of their interventions training on knowledge of signs and 
symptoms of malaria. The greatest improvement of knowledge was observed in an HMM 
study in Nigeria carried out by the Society for Family Health (SFH)/ PSI (Gilpin et al,
2006) in Abia State, which showed a 36% point increase after 1 day of training. The 
smallest improvement was observed in a separate study carried out also in Abia state, 
Nigeria, prior to the SFH/ PSI study, where a 17% point increase was documented also 
after 1 day of training (Greer et al, 2004). A study that was carried out by the NGO Merlin 
in the Kisii and Gucha districts of Kenya showed an increase of knowledge of 27% points 
after 2 days of training (Muturi, 2001). Four studies evaluated the effect of training on 
providers’ knowledge on the correct treatment and dose for malaria in differing age groups. 
Three of these studies were in Kenya, one was the study in Bungoma district showing a 
significant 33% point increase after 5 days of training (the recommended treatment in this 
intervention was SP) (Tavrow et al, 2003), another was the Merlin study that showed a 
significant 9% point increase after 2 days of training (with SP being the recommended 
treatment) (Muturi, 2001). A further Kenyan study carried out in three districts Kwale, 
Makueni and Busia, with differing malaria transmission rates showed that providers in the 
intervention group were significantly (P<0.001) more knowledgeable about the correct 
treatment and dose of the recommended antimalarial treatment (amodiaquine) after 2 days 
of training compared to those with no training (Abuya et al, 2009). A study in Kibaha 
district, Tanzania, showed a significant 45% point improvement in knowledge of the
correct dose of SP for a 2 year old child after only one hour of one on one training, though 
the sample size was very small (N = 18 respondents) (Nsimba, 2006).
Provider behaviour: Four studies reported on the advice that staff gave on how to 
administer antimalarials purchased from their outlets. All these studies had some 
component of provider training or negotiation sessions in their HMM strategy. Two 
studies, both carried out at the coast of Kenya were able to show outlets targeted with the 
intervention giving statistically significantly more advice than those left to function as 
normal. These studies were related, with the first being designed as a small scale pilot 
study, which was followed by the second larger scale implementation study. The small 
scale pilot study, involving 3 days of training, direct observation, supply of work aids and 
refresher training of providers showed a difference of up to 96% points giving advice on 
anti-malarial treatment, however it was not specified whether this advice was appropriate 
or not (N = 99 & 119 respondents at baseline and follow-up respectively) (Marsh et al., 
1999). The larger scale intervention demonstrated an increase of 86% points, with more 
intervention outlets giving appropriate advice on recommended antimalarials (CQ or SP) 
dispensed after 4 days of training with a refresher course, accompanied with biannual 
monitoring (N = 299 & 224 respondents at baseline and follow-up respectively) (Marsh et 
al, 2004). The Kenyan study that evaluated an intervention in Kwale, Makueni and Busia 
districts, involving 2 days of training resulted in a 26% point increase in providers 
recommending the correct antimalarial (SP or amodiaquine) with the correct advice 
(Abuya et al, 2009). Other studies looked at similar interventions in Nigeria and Uganda 
(Greer et al., 2004). The Ugandan study in Luwero district, involving 3 days of education, 
negotiation and persuasion training, combined with mentoring and supervision showed a 
significant 58% point increase in providers explaining to customers how to administer 
medication (CQ combined with SP) in cases of simple malaria (N = 57 & 66 respondents at 
baseline and follow-up respectively). However a 9% point (p>0.05) decrease was observed
in providers giving similar advice in complicated cases of malaria. The study in Abia state, 
Nigeria, which combined a one day training with supply of pre-packaged treatment (SP 
packaged separately to CQ), led to an 18% point significant increase in advice given on 
recommended malaria treatment.
When it came to discussing malaria danger signs with customers purchasing 
antimalarials, only the one study in Bungoma district in Kenya, involving the training of 
wholesalers to inform their retail counterparts, as well as provision of job aids and 
monitoring, showed a statistically significant difference of 20% points in intervention 
outlets (Tavrow et al., 2003). Three studies showed increases ranging from 30-42% points. 
These were the small scale coast study in Kenya, the Ugandan study in Luwero district and 
the Tanzania study in Kibaha district. All these studies had training as a large component 
of their HMM intervention (Marsh et al., 2004; Twafik et al., 2006; Nsimba, 2007). The 
study in Abia state, Nigeria with training and pre-packaged treatment showed an 
insignificant 5% point decrease in providers informing customers on danger signs, but in 
Uganda negotiation sessions, monitoring and supervision support led to a 34% point 
significant increase in the same (Greer et al., 2004).
Three studies looked at the influence of the intervention on the availability of
recommended antimalarials found in targeted outlets compared to those not exposed to the
intervention. These studies were the Kenyan study where subsidised AL was made
available in CFW outlets, the Nigeria study in Abia state (Greer et al., 2004) and the study
based in rural parts of Tanzania where subsidised treatments were made available to the
private sector outlets ‘duka a dawa baridV (Sabot et al., 2009). Both the Kenyan and
Tanzanian study reported significant increases in outlets stocking the recommended
antimalarial (Sabot et al., 2009). In Tanzania, the provision of heavily subsidised AL using
the normal distribution chain led to a significant 72% point increase in stocks of the
antimalarial in the target outlets (N =133& 151a t  baseline and follow-up respectively). In
the Kenyan study, the distribution of free AL to the franchised CFW outlets led to a 39%
39
point increase in availability of the antimalarial in the outlets (Sabot et al, 2008). The 
study in Nigeria involving the introduction of age specific, pre-packaged antimalarial (CQ 
packaged separately to SP) together with provider training led to a large increase of 88% 
points in availability of the treatment in retail outlets, which is likely to be a significant 
improvement although no hypothesis testing was carried out (N = 147 & 204 at baseline 
and follow-up respectively) (Greer et al., 2004).
Adequacy of treatment received for malaria symptoms and patient adherence: Eight 
studies evaluated the effect of the intervention on adequacy of antimalarial treatment 
received and patient adherence. Four studies were in Kenya, two in Tanzania and one in in 
Uganda and in Nigeria. Of the three Kenya studies, one was the small scale study based at 
the coast which showed that training of shopkeepers and distribution of job aids led to a 
significant 50% point increase of caregivers purchasing any antimalarial treatment to treat 
their child’s fever, and a significant 58% point increase in caregivers purchasing an 
adequate dose of the recommended antimalarial (CQ) at follow-up compared to baseline 
(N = 289 & 150 at baseline and follow-up respectively) (Marsh et al, 1999). The same 
study was able to show a significant 71% point increase from baseline to follow-up in 
caregivers administering adequate doses of the antimalarial to their child (N = 109 & 108 
at baseline and follow-up respectively) (Marsh et al, 1999). The larger scale study at the 
coast showed that training of providers increased the percentage of childhood fevers being 
treated with any anti-malarial by 37% points, at one of the follow-up time points. An 
increase was also observed in the percentage of shop treated fevers receiving adequate 
doses of the recommended treatment (SP) by 29% points (Marsh et al, 2004). The Kenyan 
study in Bungoma district which involved training of mobile and stationary wholesalers, 
who were to train retailers and distribute job aids and consumer awareness posters resulted 
in a significant 15% point increase in shoppers purchasing an adequate drug (SP) and dose 
for their malaria symptoms (Tavrow et al, 2003). In one of the Nigerian studies based in
Abia state, the intervention involving training of providers, pre-packaged antimalarial (CQ 
and SP in separate packages), and community awareness activities led to significant 39 and 
33% point increases in patients receiving the correct dose for simple and complicated 
malaria, respectively and a 44% point increase in the percentage of private medicine 
vendors recommending or giving the correct dose of antimalarial. The same report 
evaluated a similar study in Luwero district, Uganda that showed training through an 
education, negotiation and persuasion method (this involved critically evaluating current 
practices and using this as a point for negotiating changes to improve practice), with 
monitoring and support resulted in large significant 71% and 88% point increase of 
providers recommending the correct medication (CQ and SP combined) for simple and 
complicated malaria respectively, and 68% point increase in recommending the correct 
dose of that treatment (Greer et al, 2004; Twafik et al, 2006). Another study in Zambia, 
Nakonde district showed 60% more children were likely to receive the correct dose of the 
antimalarial (CQ) after drug vendors and village health motivators were trained on malaria 
and its treatment (Kaona & Tuba, 2003).
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Only two studies looked at the impact of distributing subsidised ACT on adequacy of 
treatment received and patient adherence. The Kenyan study that involved community 
awareness activities and training of health care workers in the franchised CFW drug outlets, 
together with the provision to patients of subsidised AL after confirmation by an RDT 
(patients had to pay $0.65 for a consultation and RDT). The intervention resulted in no 
significant difference between the percentage of children adhering to the recommended 
malaria treatment (AL), when compared to government health facilities. The intervention also 
had no significant effect on the proportion of patients who took, effective anti-malarial 
treatment on the same or next day after development of malaria symptoms (Sabot et al, 2008; 
SHEF 2008). The study however did show that between the two provider types, 19% point 
increase in children from the trained outlets received the recommended treatment according to 
their weight (which is the recommended method of dosing for that drug) (Sabot et al., 2008). 
In rural Tanzania, the HMM strategy that involved the provision of heavily subsidised 
treatment (AL) sold to a wholesaler and supplied to small drug shops ‘duka la daw a baridV 
through the normal supply chains. The AL was pre-packaged with simple dosing instructions 
in the local dialect (Kiswahili). The intervention was evaluated across three study areas 
(districts). One area remained as a control, another area had subsidised AL supplied to the 
‘duka la daw a baridi ’ outlets using existing supply chains, and the third area also was supplied 
with subsidised AL but it had a SRP marked onto the packaging. The intervention areas 
supplied with AL also had supporting interventions such as a one day training of attendants in 
the ‘duka la dawa baridi ’ outlets, regulatory strengthening to promote effective distribution of 
the treatment, and Information, Education and Communication (IEC) campaigns such as radio 
adverts and cultural shows. Data were collected at five different time points, one at baseline 
and the other four during the first year of implementation. The study showed that subsiding
AL led to a significant 53% point increase in shoppers being offered it at the drug outlet 
(Sabot et al, 2009).
Discussion: The HMM retail interventions evaluated have covered a wide range of strategies 
and antimalarials. Nearly all showed improvements in their outcome indicators. Most 
interventions included training of either providers or users as part of their HMM intervention, 
however there was no obvious correlation between the length of training and success of the 
intervention. It was difficult to assess the quality of training and its impact on outcomes as 
very few studies used training as the sole component of the HMM intervention. Most 
combined training with other supporting activities such as the provision of job aids, follow-up 
monitoring and provision of pre-packaged anti-malarial treatment with pictorials 
demonstrating administration. Other studies have observed that training of providers alone 
does not have much effect on practice of malaria treatment (Zurovac et al., 2008; Wasunna et 
al., 2010; Osterholt et al., 2006; Rowe et al., 2000; Rowe et al, 2003). Some reasons for these 
observations include a narrow approach to training that uses a didactic approach without 
considering wider determinants of practice such as patient demand and traditions and values of 
the society from which the providers originate from (Chandler et al., 2008; Rowe (b) 2005). 
Possible ways of improving the impact of training on practice include ensuring that the 
training is of a high standard; making the training sessions more interactive; increasing health 
worker morale to encourage them to implement and maintain the taught methods of practice 
(Gouws et al., 2004), provision of supporting material at the provider’s place of work such as 
job aids (Zurovac et al, 2004; Ross-Degnan et al, 1997) and following on from training 
having onsite refresher training and a good level of supervision post training to ensure training 
practices are maintained (Ofori-Adjei & Arhinful, 1996; Rowe (b) et al, 2005).
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It is also difficult to make any further general conclusions on HMM interventions in the 
retail sector from this review. Studies differed in the study design, data analysis techniques 
used and the type of outcome measures used. The interventions implemented were also varied, 
with few if any studies having exactly the same strategy. Many of the interventions 
incorporated more than one component, for example training of providers may be included 
with community awareness programmes or the provision of subsidised pre-packaged 
antimalarial treatment. Few studies carried out hypothesis testing on their outcome results so it 
is difficult to interpret the importance of any observed differences. All these factors make 
comparability across studies difficult. Furthermore, there are limitations in interpreting data 
from the individual studies due to certain weaknesses in the study designs. Some studies had 
very small sample sizes. Only one study planned its study design as a cluster randomised 
approach, however in the end, due to the way in which the intervention was implemented, 
randomisation of it into control and intervention areas was not possible. Most studies did not 
even include a control group, relying instead on pre and post data only. This may have 
exposed studies to possible confounders. Very few studies have been published in peer 
reviewed journals, thus the quality of the data available may also be questionable.
A review carried out by Goodman et al, (2007) evaluated interventions designed to 
improve malaria practice of medicine sellers (commercial retailers supplying fever/malaria 
drugs, except formal pharmacies that are required to be staffed by a qualified pharmacist) in 
sub- Saharan Africa. Most of the studies mentioned in the Goodman review have been 
included in the above review. The review concluded that medicine sellers were willing to take 
part in studies and similar to the above, most studies did report improvement in the outcome 
measures monitored, in particular providers’ knowledge and performance. Since medicine 
sellers were already active within communities, there was minimal requirement to invest in 
any further infrastructure to allow for the implementation of the interventions. This improved
the cost-effectiveness of the interventions, however significant costs were still incurred in 
other aspects of the interventions such as training. Although the studies provided insufficient 
evidence to determine which interventions were most successful, certain recommendations 
were made: that prior to planning an intervention, carrying out a comprehensive situation 
analysis is important in understanding the environment and tailoring a suitable strategy; 
interventions are more likely to be successful if there is broad buy-in from all key 
stakeholders, and that to enhance sustainability of the intervention and its outcomes the 
intervention needs to be implemented as a continuous processes combined with supervision 
(Goodman et al., 2007). Limitations to making further conclusions and recommendations 
remained similar to those mentioned in the above.
Another review (Schaferhoff & Yamey, 2011) evaluated how private sector subsidies on 
ACTs affect their price, market share, availability and use. The review looked at four sub­
national pilots and six national programs. All, apart from one sub-national study in Angola 
have been included in the above review. The HMM intervention evaluated in this thesis was 
also included. The review also looked at six national programs, one in Senegal and one in 
Cambodia, which have also been discussed in the above review under ‘The effect of subsidies 
on the cost of antimalarial treatment’. Other national programmes included were in Cameroon, 
the Democratic Republic of Congo, Madagascar and Rwanda. The review concluded that 
private sector subsidies have shown to reduce consumer prices, increase ACT market share by 
crowding out monotherapies, however are unlikely to benefit the poorer in society. The 
reviewers acknowledged weakness across the study designs such as most studies not being 
randomised, others not having a control group or baseline data. These factors mean that bias 
and confounding may have not been controlled for, therefore limiting the reliability of the 
data.
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In all these reviews, it is notable that only four studies reported on interventions 
involving ACT, one in Kenya, Tanzania, Cambodia and Senegal (Sabot et al, 2008). There is 
also one study in Uganda that showed ACT subsidies led to their increased availability in drug 
shops, however data on this study are yet to be published in full (Talisuna et al., 2009). In 
2007, Rwanda also introduced subsided ACTs into pharmacies, but similarly there are no 
published findings. A report indicates that 18 months later 80-90% of pharmacies stocked 
ACTs from a baseline level of 10%, and there had been large falls in the availability of other 
antimalarials such as SP, CQ and artemisinin monotherapies, thought to be due to significant 
government engagement in ensuring the successful implementation of their antimalarial 
treatment policy (Schaferhoff & Yamey, 2011). Data on Rwanda is also yet to be published. 
As AMF-m roll out only began in late 2010, no evaluations are yet available on this strategy. 
Similar to all the other HMM studies, of the existing studies focusing on ACTs, variation 
exists between them on the design of the HMM intervention, including the use of different 
distribution systems, the way the subsidy was implemented, and the supportive interventions 
used to promote uptake of the programme’s antimalarial. There is also variation in the study 
designs and outcomes evaluated. These variations make it difficult to collate the data and 
make any broad conclusions. Limitations also exist within studies, for example, in Cambodia, 
no formal evaluations took place and no baseline survey was undertaken, instead the results of 
the intervention were drawn from a number of different studies with different study 
methodologies, so it is hard to know the true effects of the intervention. In both Kenya and 
Senegal, the studies were of a small scale making it difficult to generalise the study findings to 
other settings or to a larger scale. In Kenya, only a small number of specially trained and 
supported outlets were used to distribute the programme’s antimalarial. These outlets are only 
available in a small area of the country, limiting the impact of the intervention if it was scaled
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up. Also, none of these studies address the key RBM indicator of access to prompt effective 
treatment. Further research is required to address these issues (Sabot et al., 2008).
Three other reviews have looked at the effects of interventions in the retail sector on a 
wider range of diseases such as acute respiratory infections, diarrhoeal diseases, and sexually 
transmitted infections (Smith, 2009; Wafula & Goodman, 2010; Patouillard et al., 2007). 
Their main conclusions were that although there are a wide number of innovative schemes to 
improve care in this sector, training of providers remained the most popular. Also, like the 
above reviews, most interventions tended to show some form of improvement in the outcome 
measures. All reviews raised similar concerns as those mentioned above. These include the 
limited number of studies falling into the selection criteria, the lack of rigour in study design 
including the few studies reporting data on how well the interventions were able to target 
different socio economic groups, and the relatively short follow-up periods making it difficult 
to gauge long term effectiveness of the interventions (Smith, 2009; Wafula & Goodman, 2010; 
Patouillard et al., 2007).
2.5: CONCLUSION
Much is known about treatment seeking patterns and the reasons for these, and evidence has 
shown that quality of care for malaria is poor in both public and private sectors. HMM was 
proposed to address this, but the evidence base remains patchy. Many studies show that such 
interventions can impact provider knowledge, and some show changes in provider behavior 
and patient adherence. However, only one retail sector study has looked at the impact on 
coverage of prompt effective treatment. Only one study carried out in Ethiopia, involving 
CHWs has shown an impact on mortality. None of these studies involve the use of ACT. They 
therefore stem from a very different era when recommended antimalarials were relatively 
cheap, meaning that interventions mainly focused on training and communication. In the
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current ACT era, widespread uptake requires antimalarial subsidies as well, yet the evidence
in this area is particularly limited. This evidence gap urgently needs to be addressed to inform 
the roll out of AMF-m and other HMM strategies.
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CHAPTER 3 
EVALUATING PUBLIC HEALTH INTERVENTIONS: A REVIEW OF 
APPROACHES
This review looks at the evaluation process in assessing public health interventions. It starts 
off in section 3.1 with a description of evaluation and public health interventions. This is 
followed in section 3.2 by a description of the methodology used for this review. Section 3.3 
and 3.4 consider first steps in selecting a study design and indicators respectively. In section 
3.5 the review then discusses the available evidence on 3 key classes of study designs: 
randomised controlled trials, plausibility, and adequacy studies. Within each class the 
strengths and weaknesses of the designs are discussed as well as ways to try to overcome some 
of the design weaknesses. The chapter ends with a brief review of more recent methods that 
can be used in evaluation of public health interventions.
3.1: INTRODUCTION
Evaluation can be described as the process of carrying out a systematic investigation through
the collection of data (CDC, 1999). Public health interventions are programmes that are
implemented with the intention of protecting and preventing ill health. They may range from
direct service interventions, training and educational services, to community mobilization
efforts and communication campaigns. Unlike clinical interventions which predominantly
focus on targeting individuals, public health interventions tend to be oriented more towards
whole communities or populations (Rychetnik et al, 2002).
Evaluation is said to have four main purposes. It can be used to gain insight into
innovative approaches of practice. It can also be used to review what an intervention has
achieved and help decision makers describe, improve and fine tune the intervention in order to
enhance its quality, effectiveness and efficiency. The results of an evaluation can be used as a
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catalyst to influence stakeholders to supplement the intervention or to empower participants, 
by increasing their sense of control of the direction of an intervention. Evaluation can also 
examine the relationship between the programme’s activities and observed consequences 
(CDC, 1999; Quigley & Taylor 2004; Moore et al., 2011).
Evaluation of public health interventions can be seen as a process made up of many 
components organized into a cyclical progression. The different stages of the cycle include 
engaging of stakeholders; describing to stakeholders the intervention including its mission and 
objectives; deciding on the appropriate study design; programme implementers implementing 
the intervention and evaluators implementing the study design to collect credible evidence; 
evaluators then come up with conclusions justified by the evidence and share any lessons to be 
learned (CDC, 1999). Although it is easy to portray this cycle as a neat progression from one 
action to the next, applying this in the real world may be very difficult.
The purpose of this review is to discuss how to best evaluate public health interventions,
focusing on the stage of deciding the appropriate study design. There has been a lot of debate
on choice of design, with views divided into two broad camps (though many analysts see
merits in the arguments on both sides). On one side of the argument are those who support the
use of randomised controlled trials (RCTs), which are considered by some as the gold standard
in scientific research, providing high internal validity, significantly reducing chance, bias or
confounding, and therefore viewed as providing high quality evidence for decision makers. On
the other side are those that argue that despite their advantages, RCTs are often inappropriate,
impossible or unnecessarily resource-intensive for evaluating public health interventions, and
they also exhibit poor external validity or generalisability. They argue that the context of
where a public health intervention is implemented significantly affects its outcomes, therefore
designs used in evaluating them need to take this into consideration. Some claim that RCTs’
lack of external validity means that one cannot determine the influences of external factors on
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the outcome of an intervention, something that plausibility and adequacy studies are better at 
doing. This review explores the strengths and weaknesses of these three main designs used in 
evaluating public health interventions: RCTs, plausibility evaluations and adequacy studies.
3.2: METHODOLOGY
A PubMed search was carried out using the ‘PICO’ search strategy (population, intervention, 
comparison and outcomes) (Higgins & Green, 2011) and the following terms, for:
• Population: sub Saharan Africa (MeSH);
• Intervention: public health interventions or programs;
• Comparison: randomised controlled, probability, pragmatic, quasi-experimental, 
plausible, adequacy or observation;
• Outcomes: positive, negative, limitations, feasibility, cost, effectiveness or efficacy. 
From the papers retrieved, references were scanned for any further relevant papers. In 
addition, publications including grey literature were sourced from colleagues. All literature 
was in the English language, no limits were placed on date of publication. An initial search 
was carried out in December 2008, and updated in January and June 2011. A total of 33 papers 
and reports considered to have a direct relevance to this review.
3.3: FIRST STEPS TO SELECTING A STUDY DESIGN
Engaging stakeholders is recommended as the first step in the evaluation cycle and in many 
cases is considered important in deciding the appropriate study design. Stakeholders should 
represent groups of people and/ or organizations that have some investment or interest in what 
will be learned from the process and what will be done with the knowledge. They can be 
engaged in a variety of ways including participation in meetings and communication through 
reports. Stakeholders may play a role in promoting the evaluation’s credibility, enhancing
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cultural competence, protecting human subjects and avoiding real and perceived conflicts of 
interest (CDC, 1999).
Three groups that may be considered as stakeholders are those involved in the 
intervention’s operation, those served or affected by the programme and primary users of the 
intervention. A group of stakeholders that includes staff, binding bodies and external partners, 
may bring a range of perspectives or agendas for the intervention. It is important to include 
those involved in the intervention’s operation as lessons learned from the evaluation may 
cause changes in the intervention and it is therefore important that they participate in this 
process from the beginning. Including participants who play a role in the intervention’s 
operation will also make them feel part of the evaluation process and less like they are being 
evaluated or judged which may create some ill feelings (CDC, 1999). Those served or affected 
by the programme and primary users of the intervention should be made aware of the 
intervention, its goals and objectives. Their thoughts and opinions on what changes are needed 
and how they can be achieved may add to the evaluation’s recommendations. It is also 
suggested that the needs and perspectives of the primary users of the evaluation be taken into 
consideration (CDC, 1999). Both antagonistic and sceptical group representatives should be 
involved as they can play a role in strengthening the evaluation’s credibility. Stakeholder 
meetings should bring up questions regarding the intervention, one main purpose of an 
evaluation being to provide answers to these questions (CDC, 1999; Habicht et al., 1999).
An example of groups to involve can be taken from the multi country evaluation of the 
Integrated Management of Childhood Illnesses (IMCI) (Bryce et al., 2004). IMCI is a strategy 
developed to improve child health and development, and has been implemented in over 80 
countries. The evaluation of IMCI took place in three countries and focused on its 
effectiveness, cost and impact. Stakeholders involved in the discussions of the evaluation
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included the evaluators, ministries of health and staff of the WHO, UNICEF, and bilateral 
agencies supporting IMCI implementation in the chosen study sites at country, regional and 
headquarters level. The stakeholders were responsible for making decisions in planning the 
evaluation, selecting study sites and investigators, commenting on the study design and 
instruments, reviewing preliminary data and formation of recommendations. Involving all 
these bodies was thought to increase the likelihood of the results being relevant to the needs of 
the programme decision makers and, that the results and recommendations would be 
understood, accepted, and acted on (Bryce et al, 2004).
3.4: INDICATORS
Indicators translate questions or issues regarding the intervention into specific variables that 
can be measured; they therefore address criteria that will be used to judge the intervention. 
Usually multiple indicators will be needed to evaluate different aspects of an intervention 
(CDC, 1999). A range of frameworks have been suggested for grouping indicators into 
categories, each category representing a separate level of the intervention. To give an idea of 
the different frameworks, two are discussed below: ‘process, impact and outcome’ (Quigley et 
al., 2003) and ‘provision, utilization, coverage and impact’ (Habicht et al., 1999).
Evaluation indicators can be split into process, impact and outcome. The process of an 
intervention looks at how the intervention was undertaken and is important as it can be 
responsible for the intervention’s successes or failures. Quigely et al., (2003) give examples of 
questions that can be transformed into process indicators, these include ‘how were key 
stakeholders identified and involved in the key stages throughout the process?’, ‘what time 
and resources were spent by individuals on specific stages of the process?’ and ‘how and when 
were recommendations delivered to the relevant decision makers?’. Impact indicators address 
questions on the intermediate and short-term outcomes achieved by the intervention, they
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include such questions as ‘were the aims and objectives of the intervention achieved?’ or ‘how 
and when were recommendations for the intervention considered, accepted and implemented 
by the decision makers?’. Outcome indicators look at the more long term effects of the 
intervention for example changes on the overall health of the population (Quigely et al, 
2003).
A slightly more elaborate framework has been presented by Habicht et al., (1999). 
According to them, indicators used to evaluate an intervention can be divided into four main 
categories, namely provision, utilization, coverage and impact. Provision looks at the services 
that have been provided, made available and accessible to the target population. Questions on 
provision may include ‘are the services of the programme available?’ or ‘is the quality of care 
offered adequate?’. The indicators for the following can translate to ‘what number of health 
facilities are offering the intervention’s services per 100,000 population?’ and ‘what 
proportion of health staff have received recent training on the services that should be 
delivered?’.
Utilization looks at how the population accepts the services and makes use of them. A 
common question on utilization is ‘are the services being used?’, the indicator for this could be 
‘what number of patients presenting at the health facility receive the intervention?’.
Coverage is determined by utilization and looks at the coverage of the intervention in a 
given population. Coverage is described as the interface between service delivery (the 
managerial process) and the population (the epidemiological picture). A question in this 
category can be ‘is the targeted population being reached?’, and the indicator for this question 
may measure the proportion of the targeted population that received the intervention.
Finally, the intervention’s influences on behaviour or health can be measured through
impact. Alternatively, results from the other categories may indicate what the impact of the
project is likely to be. Questions on impact ask whether the aims of the intervention were
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achieved. In the case of a diarrheal disease control programme, an impact indicator could look 
at ‘time trends in diarrheal deaths and hospital admission’ (Habicht et al., 1999).
3.5: STUDY DESIGNS
Once indicators have been categorized, it is easier to decide which study design to use in 
measuring each of the categories. This section will discuss the most common study designs 
used in evaluating interventions, their advantages and disadvantages.
3.5.1: Randomised Controlled Trial
A randomised controlled trial (RCT), also known as a probability design, evaluates the effects 
of an intervention by randomly assigning the intervention into groups or individuals and 
comparing outcomes to controls that have not received the intervention. The randomisation 
process acts to ensure that all characteristics within the control and intervention arms are 
similar and so any differences seen between groups can be directly attributed to the 
intervention. RCTs are therefore often described as the gold standard design in academic 
research because they minimise influences of chance, confounding or bias seen compared to 
other study designs (Habicht et al., 1999; Vandenbroucke, 2008; Victora et al., 2004; Atkins, 
2007).
It is argued that there are instances in the evaluation of public health interventions where 
RCTs may be considered unnecessary, inappropriate or even impossible to implement (Black, 
1999). The key concerns centre around poor external validity, blinding, ethics, resources 
required including allowing sufficient time for planning, political influence, beliefs and 
preferences, spillover effects and difficulties in measuring rare outcomes.
As previously mentioned, a good quality RCT is considered to have high levels of
internal validity, where differences identified between randomised groups can be attributed,
with a high level of confidence, directly to the intervention being tested (Eldridge et al., 2008).
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To allow for this, RCTs require the study population and environment to be controlled in such 
a way as to eliminate any other influences that may affect the outcome, apart from the 
intervention (Habicht et al., 1999). What RCTs may gain in internal validity they therefore 
lose in external validity, or generalisability, where the stringencies of such a design provide 
information on the intervention disregarding the context in which it is placed. In reality, there 
are likely to be external factors that may affect the intervention-outcome association. These 
external factors are commonly referred to as effect modifiers. Two types of effect modifiers 
are possible: 1) behavioural effect modification affects the actual dose of the intervention 
delivered to the target population. The dose of the intervention that reaches the population is 
dependent on the behaviours of the institution it is delivered through, the provider and 
recipient. Table 3.1 shows the different ways in which an intervention is implemented and 
how this will affect the dose of the intervention delivered and received by the target 
population. The study types are all RCTs, but range from clinical efficacy trials to programme 
effectiveness studies. In clinical efficacy trials maximum effort is used to ensure the exact 
dose reaches and is taken up by the recipients. This is done through a variety of strategies 
including intensive training and supervision of those delivering the dose, and facilitating 
recipients in receiving the dose through for example re-imbursement of travel costs to the 
point of delivery. Having to apply such unrealistically tight controls to a trial makes the design 
more suitable in evaluating efficacy outcomes, which aim to show whether an intervention can 
produce the desired outcomes under ideal conditions (Habicht et al., 1999, Vandenbroucke, 
2008; Victora et al., 2004). A step below clinical trial studies is the public health programme, 
efficacy studies where no extensive efforts are made to ensure recipients receive the 
intervention or comply with how it should be administered. However the presence of an 
evaluation team and participation into the trial is argued to encourage ‘best practice’ where 
health workers may try to perform better than usual and managers may try to improve the
routine running of the healthcare system. The other extreme to clinical efficacy studies is 
public health programme effectiveness studies, where no intervention whatsoever is used to 
promote delivery of the intervention or compliance to the intervention’s requirements. Instead 
these factors are left to be influenced by the ‘routine’ external influences such as poor health 
worker performance and drug shortages. It is argued that this last type of study is extremely 
rare, since the knowledge of being involved in a study will have some influence on behaviour 
(Table 3.1), (Victora et al., 2004).
Table 3.1: Different types of studies aimed at evaluating the impact of an intervention, with 
emphasis on the dose of the intervention that reaches programme recipients
Type of Study Units of 
Treatment
Delivery
Mechanism
of
Intervention
Compliance
with
intervention
by
recipients
Example
A: Clinical efficacy 
trial
Individuals Ideal Ideal Classical clinical trial of drugs, 
vaccines, etc.
B: Public health 
regimen efficacy
Clusters of 
individuals
Ideal Ideal Same as above, but delivered to 
clusters rather than individuals
C: Public health 
delivery efficacy
Clusters of 
individuals
Ideal Best
practice
Ideal delivery is ensured, and 
compliance is actively promoted 
according to best practice
D: Public health
programme
efficacy
Clusters of 
individuals
Best
practice
Best
practice
Randomised allocation of 
geographical areas to best practice 
implementation
E: Public health
programme
effectiveness
Clusters of 
individuals
Routine Routine Randomised allocation of 
geographic areas to routine 
implementation
Source: Victora et al., (2004)
2) Biological effect modification affects the dose- response association between the 
intervention and the outcome (Victora et al., 2004). RCTs tend to exclude subjects at high risk 
of harms such as the elderly or children, those on multiple medications or with multiple 
conditions. This selection process may be very restrictive, only representing a small sub­
sample of a typical real life population, therefore even after a RCT, the effects of placing the 
intervention on a random population may still remain unknown (Black, 1996; Atkins, 2007). If 
the selection criterion is very limiting then the population and therefore the outcomes seen in
the trial may not be reflective of what would be seen if the intervention was implemented in a
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wider community. Table 3.2 gives examples of different categories of biological effect 
modification.
Table 3.2: Types of biological effect modification affecting the generalisability of findings from 
randomised controlled trials
Category of Effect Modification Example
A: Presence of other factors reduced the dose-response 
slope (antagonism)
Iron and zinc supplementation will be less effective in 
places where the local diet contains substances that 
reduce their absorption (e.g. phytates and polyphenols)
B: Presence of other factor increases the dose-response 
slope (synergism)
Iron supplementation will be more effective if the local 
diet is rich in meat and ascorbic acid which will 
enhance absorption.
C: Curvilinear dose-response association Iron supplementation will have different effects on 
haemoglobin according to baseline iron stores. Also, 
iron absorption is inversely related to iron status.
D: Limited scope for improvement in the impact 
(outcome) indicator because other interventions 
already provide protection
Use of insecticide-treated bed nets will have a limited 
effect on malaria mortality if case-management is 
already appropriate
E: Intervention is inappropriate because a critical 
cofactor is missing
Improving water quality will have an impact on 
diarrheal diseases only if water quantity is adequate
F: Intervention is addressing a determinant that is not 
important
Energy supplementation in pregnancy will have limited 
impact on low birth weight if the latter is mostly due to 
maternal smoking and to preterm deliveries caused by 
infections.
Source: Victora et al., (2004)
Usually in RCTs, the dose delivered, compliance to the designed intervention, and recipient 
population in a study will be different to that seen in real life situations. It is therefore 
important to provide detailed information on all these factors to allow results to be interpreted 
accurately (Victora et al., 2004; Atkins, 2007).
Blinding of recipients and providers is an important way to reduce bias in RCTs, and 
lack of blinding is considered to be a serious source of potential bias (Eldridge et al., 2008). 
However, blinding in public health interventions is not always feasible (Black, 1996; Atkins, 
2007). To give an example, a clinical trial testing the efficacy of a medication may blind 
recipients and providers by providing placebos that look similar to the real medication. 
Blinding in such cases is often easy to do and is commonly done. However, a public health 
intervention may involve community awareness messages distributed through mass media, 
aimed at changing health seeking behaviour practices. In such a case both participants and
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providers know which communities have received the intervention and which ones have not 
(Stephenson et al., 1998).
The ethics of carrying out an evaluation may make it inappropriate to use an RCT. If it is 
known that an intervention does work and is needed in a certain community it may be 
unethical to withhold it from those who need it, purely for the purposes of evaluation. For 
example, non-randomised studies have provided strong evidence for the efficacy of condoms 
in preventing HIV. Given the seriousness of HIV, it could be argued to be unethical to carry 
out an RCT that restricts condom use to the control population just to see if the outcomes 
would be similar to those in the non-randomised studies (Stephenson et al., 1998). A possible 
way around this problem is that an RCT may be able to take place if resources are not enough 
to cover the population in need. In such situations, randomisation may be justified until 
enough resources can be provided for the whole community (Victora et al., 2004; Black, 
1996).
RCTs may also not be possible to implement because of lack of prior planning. 
Decisions on whether to evaluate an intervention and how to do so should be made before the 
intervention is implemented, preferably while implementation plans are being made since the 
type of study design may influence how the intervention should be implemented. This is 
particularly important for RCT designs since deciding how to randomise the study population 
into groups, then randomly allocating participants into the intervention and control requires 
sufficient time and planning (Habicht et al., 1999; Sanson-Fisher et al., 2007). RCTs should 
therefore at least be designed during the planning of the intervention’s implementation. For 
many interventions, the evaluation is often thought of towards the end of the cycle, even after 
its implementation, making an RCT design hard to implement (Habicht et al., 1999).
Difficulties may also be experienced in the randomisation process. Interventions
associated with the delivery of resources and positive health outcomes may be desirable
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campaigning tools. Politicians may want to influence and direct the delivery of the 
intervention to their voters making it hard for it to be implemented in a randomised manner. It 
may not be advisable to override the opinions of politicians since without their support or 
approval the intervention may not be able to take place. As a way around this, evaluation can 
take place in a ‘stepped wedge design’ where the intervention is introduced in a random 
fashion but coverage increases over time to eventually include all eligible communities or 
populations (Moore et al., 2011; Bonell et al., 2011). If this option is not possible then other 
methods of analysis will need to be considered. Other similar problems arise in situations 
where changes in legislation are required or a national policy must be developed to support the 
intervention, and these processes may be either slow or even halt the evaluation (Habicht et 
al., 1999; Mills et al., 2008; Black, 1996). Acceptance of the intervention, not just by 
authoritative bodies, but also by the providers and receivers is important in allowing for better 
evaluation. Understanding the beliefs and preferences of participants and therefore improving 
the community’s support of the intervention and evaluation before implementing the study is a 
way of ensuring that participants consent to the arm they have been randomised to. This can 
be achieved by involving key representatives in the stakeholders meetings if possible from the 
beginning (mentioned above) (Atkins, 2007).
Another factor which may be out of the control of the evaluators is that of contamination 
or spillover of the intervention outside of the intervention arm (Black, 1996; Sanson-Fisher et 
al., 2007). It may sometimes be difficult to contain the resources supplied by the intervention 
within its allocated communities and stop significant pilferage into the control communities. 
For example, if the intervention involved the provision of mosquito nets to certain 
communities, it may be hard to stop the nets leaking into the control communities, especially 
if nets are perceived to have a beneficial effect on health. Where large scale pilferage is
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unavoidable it may be worth considering another design as the true effects of the intervention 
may not be reflected accurately through an RCT (Black, 1996).
It is difficult to evaluate rare outcomes in RCTs as they would require large sample sizes 
that may not be attainable. This is typical in post marketing surveillance of pharmaceuticals 
where an evaluation of rare adverse events usually takes the form of observational studies. An 
example of why to avoid RCTs in such situations can be taken from the drug benoxaprofen 
(Oparen®). Despite clinical trials in over 3000 patients, the drug had to be withdrawn after 2 
years of being released due to serious adverse events and 61 deaths. These serious adverse 
events had not been picked up in the clinical trials as the events were rare and were not shown 
in the smaller groups studied (Black, 1996). Finally, when it comes to resources, RCTs are 
known to be costly and resource intensive, requiring evaluators with the necessary skills 
(Stoltzfus et ah, 2002; Sanson-Fisher et al., 2007). A rigorous RCT cannot take place if the 
required finances, expertise and other resource are not made available to support the process 
(Stoltzfus et al., 2002).
Given the factors mentioned above, it would probably be inappropriate to use an RCT
design if there is insufficient time and resources to plan and implement the design properly, if
the ethics of restricting the intervention to a particular group are questionable, if blinding is
necessary to evaluate outcomes but not practical to implement, and if the outcomes are very
rare and therefore huge numbers may need to be recruited. RCTs will probably be impossible
to implement if consent or approval for the study cannot be gained from politicians, especially
where legislation requires amendment to legally roll out the intervention and, if it is not
possible to contain the intervention in the designated areas, making spillover a likely bias.
Despite the limitations mentioned, there are times when RCTs are essential in the evaluation
of public health interventions. RCTs are thought to be best placed for determining with the
greatest confidence possible whether the intervention can produce the desired outcomes
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without the influence of external factors, therefore in evaluating the efficacy of an intervention 
(Habicht et al., 1999; Sommer et al., 1986).
3.5.1.1: RCTS: Dealing with Limitations
Due to the complex nature of many public health interventions, it may not be possible to 
randomly allocate individuals to receiving the intervention or acting as a control. An 
alternative method of randomisation is the cluster randomised trials, where randomisation 
occurs in blocks consisting of groups of individuals, with some groups falling into the 
intervention arm and receiving the intervention and others into the control (Bowater et al., 
2009; Craig et al, 2008).
Other methods of randomisation include the randomised stepped wedge design (also 
mentioned above). Here randomisation takes place according to who or which group should 
receive the intervention and at what time. This process of evaluation is useful in situations 
where there are restrictions on who can receive the intervention at certain time points. 
Preference trials can be used in situations where patients have very strong preferences as to 
whether they would like to receive the intervention or not. For example, those with strong 
preferences are put in their preferred arm, those without strong preferences are randomised. 
Any imbalances in potential confounders between the arms can then be controlled for in the 
analysis. The N-of-1 design, is where individuals receive interventions with the order or 
scheduling decided at random. This allows one to observe the impact an intervention has on 
individuals and between individuals over time, and allows theoretical interpretations to factors 
that cause these changes (Craig et al., 2008).
Miguel and Kremer (2004) address how to deal with contamination or spillover effects
of the intervention to those outside the intervention arm. They suggest that this should be
addressed in the study design, and use the example of a public health intervention involving
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deworming school children. Previous reviews on deworming have concluded that there is little 
evidence to show deworming has a positive effect on school attendance. However, Miguel and 
Kremer found that deworming significantly decreased school absenteeism and is therefore a 
cost-effective way to improve school participation. Their explanation for this difference in 
outcome is that other studies had randomised the intervention at an individual level, so failing 
to account for potential benefits a child who had not been dewormed was gaining from his or 
her dewormed fellow students. If any benefits of the deworming programme extended to the 
children in the control arm then the effects of the intervention were not seen. In this case, 
children who were not in the programme benefited from dewormed students in the same 
school as their chances of acquiring worms decreased. They suggest that this pilferage/ 
spillover of benefits to those in the control arm can be corrected for by randomizing at a 
higher unit level, so for example randomizing at the school level instead to the individual 
level, therefore clustering at the school level. This would mean that all children in the same 
school would be in the same arm, therefore any externalities amongst pupils will be captured 
in each school. Changing the level at which one randomises may reduce spillover effects, 
however when clustering at a higher level, one should bear in mind that the level of spillovers 
that can be corrected for is limited and so cannot be used to control for spillovers that occur at 
a more global level (Miguel & Kremer, 2004).
Other obstacles mentioned above in carrying out an RCT can be addressed in similar
practical ways. For example, to be able to improve their sensitivity in evaluating rare
outcomes, sample sizes can be increased where possible; to address lack of generalisability,
over restrictive patient eligibility criteria can be relaxed by undertaking more pragmatic trials;
to encourage uptake, participants and providers can be encouraged to participate in studies by
using more acceptable participation and enrolment terms; and political and legal obstacles can
be addressed through persuasion. Suggestions on how to tackle a variety of RCT obstacle have
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been addressed in various literatures (Stephenson et al., 1998; Black 1996; Bonell et al., 
2010).
3.5.2: Plausibility Design
Like RCTs, plausibility designs also use comparison groups to draw causal inferences, 
however in plausibility studies randomisation is not used to identify the treatment and control 
groups. Instead a treatment group may already have been identified and a control group will 
then be selected to match the treatment group either at the beginning or during the 
implementation period or afterwards at the analysis stage. The inclusion of a control group 
allows for inferences on incremental impacts of the programme to be analysed (CDC, 1999; 
Victoria et al., 2004; Black, 1996).
One of the main shortcomings of plausibility studies is that their levels of internal 
validity may not match those of RCTs for various reasons. By not randomly assigning 
intervention and comparison groups, plausibility studies are less able to account for the 
influences of chance, confounding or bias to their outcomes (Eccles et al., 2003; Habicht et 
al., 1999). To be able to account for this, the intervention and comparison groups should be 
similar in all characteristics apart from exposure to the intervention, however due to lack of 
randomisation of individuals or groups into each arm it is difficult to ensure this (Rosen et al, 
2006). In plausibility studies, where an intervention group is matched to a comparison group, 
selection into the comparison or intervention arm may be driven by the participant or provider 
of the intervention. This is fine if reasons as to why individuals or groups are put in each arm 
are given, as this can be controlled for in the analysis. However, when selection leads to 
unobservable differences in characteristics between the control and intervention arm, 
differences cannot be controlled for, and the study outcomes may therefore not reflect the true 
outcomes of the intervention, as they may only be due to the differences between the two arms
(Rosen et al, 2006; Ravallion, 2006). The same is true for plausibility studies that use the 
same people initially as a comparison and then as an intervention group. Changes may occur 
to the group over time, making their characteristics different between baseline and post­
intervention.
Spillover effects are a possible limitation seen not only in RCTs but also in plausibility 
studies. Depending on the type of intervention, its effects may spread to those in the 
comparison group, dampening the true outcomes of the intervention. An example of this can 
be seen in Maharashtra, India where in 2005 the government rolled out an ‘Employment 
Guarantee Scheme’ (EGS). The scheme was designed to provide employment and a salary to 
anyone as long as they were willing to work. The wage rate for the scheme was considered 
low and therefore it was believed to be self-selecting to the income poor. However, the EGS 
ended up creating a lower bound wage distribution where on a national scale workers would 
not take up work offering salaries lower than that provided by the scheme. Without 
consideration of this spillover effect, an evaluation of this scheme would reveal that the EGS 
had no impact since the difference in wages had not changed between participants and non­
participants. However, this interpretation underestimates the effects. The true outcome was 
that the scheme did increase the wages of the poorest in society, but it also lifted the lower 
wage rate for those in the control arm who were more income rich. When relatively comparing 
wages, the gap between the income poor to the rich did not change but when comparing 
baseline wages in the poor to post-intervention wages, an increase in wages was observed 
(Ravallion, 2006).
Another problem may arise if the placement of the intervention is determined by a proxy
means test. A proxy test may be used to determine who qualifies as a possible study
participant to receive the intervention, and is a function of observed characteristics. It can be
assumed that all those who have a similar proxy test have similar characteristics. If uptake for
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all those who have the required proxy test is 100% then there will be no individuals left to be 
placed in the control group who have similar characteristics to those in the intervention, 
leaving comparisons to take place between individuals who do not share the same proxy test 
score (Ravallion, 2006).
It is argued that, to answer the question of whether an intervention has an effect under 
ideal circumstances (i.e. to look at the efficacy of the intervention), the best study to use would 
be an RCT where the intervention will be implemented in carefully selected and restricted 
areas and under close supervision. Plausibility studies are thought to be better at measuring the 
effectiveness of a study, in other words, whether the intervention will have an effect under real 
life situations (Bryce et al, 2004). The overall result of such a plausibility study will look at 
how the context in which the intervention is implemented affects its outcome (Barreto et al, 
2005; Black, 1996).
The advantages and limitations mentioned above refer to plausibility studies in general. 
There are various sub-sets of plausibility study designs, each with its additional advantages 
and disadvantages. The three most common designs used are: uncontrolled before and after 
studies, controlled before and after studies and time series designs (Eccles et al, 2002; 
Habicht et al, 1999).
Uncontrolled before and after studies: With this design a survey is carried out before and 
after the introduction of an intervention in the same study site(s). Any differences observed 
between the two surveys are equated to the effect of the intervention (Eccles et al, 2003). 
Although this study is named ‘uncontrolled’, this may be a bit mis-leading as the same study 
site acts as the historical control arm (before implementation of the intervention), and the 
intervention arm (after implementation of the intervention). This type of study is considered 
relatively simple to conduct and superior to observational studies, which will be explained
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further on. Their main limitation is that secular trends or changes within the study group may 
not be detected making it hard to attribute observed change to the intervention (Eccles et al, 
2003; Rosen et al, 2006, Victoria 2010).
Time series design: This design can be used when a comparison group cannot be identified, 
for example after the dissemination of national guidelines or mass media campaigns. 
Intervention groups are selected and followed up with data collected at several time points 
before and after the intervention. The data collected after implementation of the intervention 
will allow for the effects of the intervention to be assessed, by controlling for any underlying 
cyclical trends that have been identified through the pre-intervention data collection activities 
(Eccles et al, 2003; Cousens et al, 2011). The accuracy of this design improves with 
increasing number of data entry points, therefore it is useful where routine data sources are 
available. There are situations where data collected close in time are more similar to those 
collected far apart. This is known as auto-correlation and can create biases in interpretation of 
the data. To reduce this bias, data collected between time points prior to the intervention 
should be collected over a sufficient amount of time. In addition autocorrelation effects can be 
allowed for in time series regression models and auto regressive integrated moving average 
(ARIMA) modelling. What time series designs cannot do is control for changes occurring after 
implementation of the intervention (Eccles et al, 2003).
Controlled before and after studies: As with RCTs, a control population is identified 
containing similar characteristics to the intervention population, however the selection is not 
done randomly. Data are collected from both populations before and after implementation of 
the intervention, and observed differences seen in the data are assumed to be due to the 
intervention. This design is also known as the double difference or difference in difference 
estimator, where the difference between the mean differences from each arm is seen as a result
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of the intervention (Ravallion, 2006). Limitations to this design include that because the 
decision of where to implement the intervention may not be in the hands of the evaluators, it 
may not be evident who will form the intervention and the comparison group in the survey. 
One solution is to have an informed guess when designing the sampling for the baseline 
(Eccles et al., 2003). Another solution is to carry out a ‘within group’ analysis where baseline 
and post-intervention data are compared within and not across each group. Results from such 
an analysis should be interpreted with caution because if the comparison and control groups 
are not similar then they may not experience the same secular changes, therefore any 
conclusions made about the intervention’s effect may in fact be false (Eccles et al., 2003). The 
double difference estimator method can also be used to identify biases in randomised 
controlled studies. It can be used to confirm that there are no selection or compliance 
differences or biases between the control and intervention arms (Ravallion, 2006).
Case control studies: This study uses retrospective data and would be best used in situations 
where an intervention has already been implemented. In such studies, a group experiencing the 
intervention’s outcome (cases) are compared to a control group without the same experiences 
(control). Retrospective data are then used to assess those exposed to the intervention in the 
case and control group and this is then used to calculate the likelihood of experiencing the 
outcome if exposed to the intervention (Bonell et al, 2011).
3.5.2.1: Plausibility Studies: Improving Programme Designs
Certain analyses techniques have been developed which can be used to improve the usefulness 
of plausibility studies. This section will mention a few of these techniques.
The Propensity score matching method (PSM) is a way of ensuring that the comparison 
group chosen to match the intervention group are of similar characteristics, increasing the 
probability that any differences seen between the two are purely as a result of the
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intervention’s effects. To briefly describe this method, participants’ characteristics are chosen 
based on economic, social, political and other factors that may influence the assignment of the 
programme. These may be run through a logit or probit regression to determine each 
participant’s propensity score (PS). Participants in the intervention group are then matched to 
a comparator with a similar PS. Outside of plausibility studies, PSM can be used in RCTs to 
provide insight into how random the selection process for the intervention has been, by 
comparing the PS of those in the intervention and control arms (Ravallion, 2006; Bonell et al., 
2011; Cousens et al, 2011).
Discontinuity designs can be used in controlled before and after studies. They are useful 
with interventions that need to be assigned to participants with certain characteristics, for 
example extra tuition for school children who get test scores below a certain level or anti­
poverty programs targeted at those who earn below a certain income level. In discontinuity 
designs, pre and post evaluation data are collected for the intervention group which has been 
defined by certain characteristics, and a comparison group that forms those who fall outside of 
the required characteristics, but are close to the relevant thresholds. Changes seen between pre 
and post evaluation data are compared between the comparison and intervention groups. The 
effect of the intervention is measured by how much the difference in the outcome in the 
intervention group varies from the difference observed in the comparison group (Ravallion, 
2006).
Pipeline comparisons is a method that can be used when the implementers are unable to
supply the intervention to all those who would like it and qualify to receive it, for example due
to resource constraints. It can also be used where the intervention is being introduced in a
staggered way, where all those who successfully applied for the programme may not receive it
at the same time. The selection process in this design means that all those who qualify have
very similar characteristics. Those that have already received the intervention can then be
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compared to those who are yet to receive it. An assumption made with this design is that the 
timing of treatment allocation is random. To ensure that the comparison and intervention 
groups are similar one can carry out the propensity score analysis. Pipeline comparisons may 
also be combined with discontinuity designs where the intervention’s cut off points for 
selection change in a progressive manner as development takes place, therefore as the cut off 
points modify, the current intervention group is compared to the current comparison group 
(Ravallion, 2006).
The Instrumental Variable (IV) technique is used to better estimate causal effects in 
observational studies when analyses carried out directly between treatment and outcome may 
be biased by reverse causality, unobserved variables or measurement error. An IV is a variable 
that is logically related to, and statistically correlated with the treatment variable, but does not 
necessarily have to be directly linked to the outcome. The ideal IV will be void of biases 
present in the treatment variable. An example of use of an IV would be in the study carried out 
by Leigh et al where the effect of smoking status on health in a population was estimated 
indirectly through the use of cigarette price as an IV (Ravallion, 2006; Leigh et al., 2004; 
Cousens et al., 2011).
3.5.3: Adequacy Design
Adequacy studies are also known as observational studies. In this design, there is no 
assignment of participants into intervention or comparison groups. Instead the intervention is 
implemented on a population and what is key to these designs is that the outcomes evaluated 
from the study population are compared to previously established adequacy criteria to see if 
they have been met. An example of criteria include absolute outcomes such as: the
intervention should distribute 10 million packs of oral rehydration therapy to children with 
diarrhoea; or may refer to change, for example the intervention should result in a 20% point
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decline in reported diarrhoea deaths. Adequacy studies can either be cross sectional, where 
data are collected at a single time point, or longitudinal where more than one measurement is 
taken over a given period of time to detect any trends (Habicht et al., 1999). The design is 
useful in situations where more complex designs are not required, when the evaluators have a 
very limited budget, not much time to carry out a more detailed investigation or where human 
resources and skills available will not be able to support a more complex analysis design. The 
outcomes from adequacy studies allow for decisions to be made on whether more analyses 
need to be done using more complex methods to further identify reasons for the intervention’s 
effects, or reasons for failure to meet expected criteria (Habicht et al, 1999).
The advantages of these types of studies are that no resources need to be used in finding 
a good comparison group; the nature of the design is such that an evaluation can take place 
just with secondary data, meaning in some instances that no data collection activities need take 
place; and due to a low requirement for resources these studies tend to be cheaper and less 
time consuming. However, these advantages come at a cost. Because this design does not 
control at all for bias, chance or confounding, it does not allow for an interpretation of 
association to be made between the intervention and outcomes seen. The interpretation of the 
outcome results in this type of study is limited to giving information on whether the expected 
changes have taken place or not. Further explanations as to how or why certain outcomes were 
seen have to be sought through more complex designs. Since adequacy studies do not have a 
comparison group, it may be difficult to conclude that the outcomes seen are purely as a result 
of the intervention or due to other contributing factors experienced during the implementation 
of the intervention, such as general socio-economic improvements or secular trends in the 
study population such as mortality or malnutrition. Not having a comparison group means that 
the study may not always reveal positive outcomes of the intervention. For example, if an 
intervention is implemented under deteriorating socio-economic conditions, the outcome of
the evaluation may reveal that the intervention has not had an effect when in fact the lack in 
change may be due to the programme being effective in providing a safety net for the affected 
population (Habicht et al., 1999).
Victora et al., (2011) suggest methods of data collection in programme evaluation, 
designed for the developing world that is suitable for plausibility and adequacy studies and can 
be used in settings where control areas are not possible because all areas are scaling up the 
same programmes and many programmes may be scaling up at the same time. Their proposed 
methods use the district as the unit of design since the district is usually considered as the 
main administrative unit of health programmes in many countries. The process involves 
continuous monitoring of the programme with evaluations taking place at an interim and 
summative period. Data will be collected from the district level through the use of existing 
national databases that may need to be developed further. National level data will be obtained 
from government headquarters such as the ministry of health, while more local data can be 
obtained at the provincial level. These data can be compared for accuracy. Cost data can be 
obtained directly from the programme implementers. Additional data collection methods such 
as household surveys and health facility assessments may be necessary to allow specific 
indicators to be measured and assess data quality from the existing data. The broad range of 
data collection activities will allow for data to be analysed in a variety of ways including 
health outcome estimates, dose-response relationships and modelling. Contextual factors can 
also be incorporated. Victora et al, (2010) feel that the incorporation of government into the 
various processes of the evaluation will support country ownership of the programme and 
encourage human and structural development. The evaluation also builds on existing data 
collection activities which makes the process cost effective; the continuity of data collection 
and evaluation allows the programme to be moulded to fit the changing environment, making
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it sustainably effective; and the method of data collection creates independence for the 
evaluators, easing control from programme funders (Victora et al, 2011).
3.5.4: Other Study designs
In understanding process, all study designs should incorporate a process evaluation which 
should be carried out to high methodological standards with outcome reported 
comprehensively. A process evaluation may play a significant role in unravelling study 
findings. Such an evaluation may help identify factors that could have contributed to 
unexpected study findings or help in understanding important external factors that make an 
intervention a success or failure, and the mechanisms of these factors in influencing the study 
outcomes (Craig et al., 2008). An example of type of process evaluation is explained by 
Pawson and Tilley (1997). They suggest a method of evaluation known as ‘realistic 
evaluation’, which is designed to better predict patterns of outcomes of a programme given the 
context it is implemented in and the mechanisms used to implement it. The evaluation claims 
to do this by trying to answer deeper questions at each step of the evaluation cycle. Currently, 
a typical traditional evaluation cycle will start by framing a theory, from which a hypothesis is 
postulated. This hypothesis is then tested through observations of various kinds, and the 
observations are then used to make empirical generalizations. The generalizations may or may 
not conform to the expected form of theory; if not then the theory will have to be re-framed. 
The realistic evaluation cycle has similar steps, however each step includes more content. For 
example, the theory step looks further into the underlying mechanism of how the programme 
may function, the context in which the programme should be implemented to be effective, and 
how these factors may affect outcome; the hypothesis stage looks at ‘what might work, for 
whom, and in what circumstances’; the observations carried out will consist of many methods 
and types of analyses to obtain data on the programme outcomes, in relation to the observed
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mechanism of the programme and context. The observations will then be able to determine 
what works for whom, and under what circumstances, in relation to that specific programme 
(Pawson & Tilley, 1997).
Figure 3.1: The realistic evaluation cycle (courtesy of Pawson & Tilley (1997)
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Another form of evaluation suggested by Deaton, 2009 is that experiments be used to 
estimate parameters, and these parameter should be incorporated into theoretical models to 
determine the outcomes of the programmes under certain conditions (Deaton, 2009). An 
example of the use of this technique is by Duflo, Hanna and Ryan (2008) who used their 
experimental findings on improving teacher attendance in India to construct a model to aid in 
understanding teacher behaviour. This model has been used by others to interpret their 
experimental findings (Todd et al, 2006).
3.6: CONCLUSION
There is no internationally agreed formula on deciding which study design to implement when
evaluating public health interventions. Evaluation of public health interventions is not always
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straight forward as they tend to come with a range of relevant research questions which cannot 
be answered by just one study design. An added complexity is that understanding the context 
in which the outcomes were created is also of great importance (Black, 1996; Mills et al, 
2008; Victora et al, 2004).
What can be deduced from the above is that the decision on which design to use is based 
on a variety of factors. These include the questions that need to be answered (some designs 
answer certain questions better than others), and the level of confidence required in answering 
the questions: RCTs tend to give a higher level of confidence in interpretation of the outcome 
compared to the other less controlled studies. The feasibility of carrying out a study is also an 
important consideration. Feasibility ranges from the resources made available for the 
evaluation, how the implementers have decided to roll out the intervention, the ethics of the 
design and the willingness of the politicians and community to provide the necessary support 
(Black, 1996; Victora et al, 2004; Moore et al, 2011; Sanson -Fisher et al, 2007).
It has been suggested that if possible, public health researchers should draw on the 
strengths of all studies and use a mosaic of the different designs to come up with conclusions 
of the intervention. Plausibility studies can be used then to show an association between the 
intervention and outcomes observed in the adequacy study. More expensive RCTs can be used 
at the end to test for a causal hypothesis (Habicht et al, 1999; Rychetnik et al, 2002; 
Vandenbroucke, 2008).
Regardless of the method/ design used to evaluate an intervention, the quality of the
study is of great importance (Rychetnik et al, 2002). The same weight placed on deciding
which design is best to evaluate an intervention should also be given to how rigorously the
study design is implemented. An example of where the choice of design was considered
appropriate but the outcome of the evaluation was misleading because of poor quality of
evaluation is in health financing. A few plausibility studies were highly regarded as providing
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evidence that user fees in health had potential benefits, and these studies were used in 
promoting policy reforms that supported user fees. However, more careful analyses of the data 
revealed the presence of confounding and inappropriate economic specifications. It became 
clear that the data provided poor evidence to support the use of user fees in other contexts, not 
because of the choice of design but because the poor quality of study implementation (Mills et 
al., 2008). The importance of having high quality studies, regardless of the design used has 
been addressed by guidelines such as the CONSORT, TREND and STROBE which provide 
information on how to improve the rigor of pragmatic RCT, quasi experimental and 
observational studies (Zwarenstein et al., 2008; Rosen et al., 2006; Mills et al., 20Q8).
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CHAPTER 4
STUDY SITE AND METHODOLOGY OVERVIEW
This chapter includes a description of the study design, the intervention that was implemented 
and timelines for each aspect of the study. Also included are explanations of the techniques 
used to select the study areas, collect and analyse the data.
4.1: STUDY SITE
The study was conducted in three districts in Western province in Kenya: Busia, Butere- 
Mumias and Teso1 (Figure 4.1). These areas were selected because of their high malaria 
endemicity; the presence of relatively active retail markets; the absence of other malaria 
treatment interventions; and the familiarity of the implementation team with the local areas. 
Within Western province, Bungoma district was excluded because of the extent of previous 
malaria-related interventions which may make it atypical. Mount Elgon district was excluded 
because of the then political insecurity in that area.
Table 4.1: Study district demographics
BUSIA TESO BUTERE/
MUMIAS
NO. OF SUB-LOCATIONS 99 83 79
% OF SUB-LOCATIONS RURAL 76 66 75
% HOUSEHOLD HEADS COMPLETED 
PRIMARY SCHOOL
57 54 58
NO. OF HEALTH CARE FACILITES* 39 21 51
% POOR (RANGE ACROSS SUB-LOCATIONS) 67 (53-74) 50 (44-68) 62 (53-73)
ESTIMATED POPULATION 2007 (AVERAGE 
PER SUB-LOCATION)
370,608
(4,964)
227,058
(2,769)
573,275 (7,350)
POPULATION DENSITY/ KM2 433 406 611
* These include Ministry of Health and other ministries, mission and non-governmental health facilities (CBS, 1999; Noor et 
al., unpublished data)
The percentage of the population living below the poverty line in the study districts averaged 
67% in Busia, 62% in Butere-Mumias and 50% in Teso, with population densities per km2 of
1 each of these districts has been officially divided into two or more districts since the intervention began
433, 611 and 406 respectively (Table 4.1). The western region of Kenya suffers from the 
highest malaria prevalence in Kenya, with Plasmodium falciparum parasitaemia prevalence in 
children aged 2 to 10 years greater than or equal to 40% (Figure 4.1). At the time of the 
survey, Butere-Mumias had 51 government health facilities, Busia 39 and Teso 21, consisting 
of dispensaries, health centres and one district hospital per district (Noor et al, unpublished 
data). In 2009, across the 3 districts, school attendance averaged 45% (country’s average 
40%), the percentage with access to piped water averaged 6% (country’s average 30%), the 
percentage who owned a mobile phone was 51% (country’s average 63%), the percentage 
owning a radio was 71% (country’s average 74%) and an average of 54% claimed to have 
some sort of employment (country’s average 52%). Not much difference was observed 
between the districts.
As with other areas of Kenya, all government health facilities in the study sites were 
supposed to supply AL for free to patients, although stock-outs and unofficial fees were 
common (Kangwana et al., 2009, Chuma et al, 2009). Malaria diagnosis was predominantly 
clinical in both public and private health sectors (Zurovac et al, 2008; Wasunna et al, 2008).
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Figure 4.1: Map of Kenya showing the district boundaries for Western Kenya and parasitaemia 
levels across the country
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Courtesy o f Noor et al, (2009) predicted parasite rate (PR) among 2-10 year olds based on a geo-statistical risk 
model.
4.2: STUDY DESIGN
The intervention was implemented at the sub-location level. The study employed a pre-post 
cluster randomised controlled design, with randomisation occurring at the sub-location level, 
which is the fifth and lowest administrative level in Kenya, governed by a sub-chief. A 
randomised controlled trial was used because the randomisation process ensures that all 
characteristics within the control and intervention arms are similar, minimising influences o f 
chance confounding and bias seen in other studies. This significantly increases the reliability 
o f the results. The strengths and weaknesses o f using a cluster randomised controlled design in 
evaluating this intervention are discussed in more detail in Chapter 8. Randomisation occurred
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in clusters because the nature of the intervention is such that it could not be targeted at 
individuals. Therefore randomisation occurred in blocks consisting of groups of individuals, 
with some groups falling into the intervention arm and others into the control arm (see Chapter 
3). Carrying out the study at this level allowed for a reasonable scale for implementation, 
contained the total medicine cost for the intervention and limited contamination between 
control and intervention areas, which would more likely occur if larger areas such as locations 
or divisions were used. The sub-locations included in the study had to be rural, since 
contamination would be better controlled in such areas, as opposed to supplying the drug in 
urban and peri-urban areas which represented between a quarter and a third of all sub­
locations, and serve a wider population, including those who travel from surrounding 
sublocations to purchase medications. The populations within the sub-locations had to be 
between 2,500 to 10,000 (Table 4.2); smaller sub-locations were excluded to ensure there was 
a reasonable scale for implementation and adequate sample sizes for the evaluation; larger 
sub-locations were excluded to contain costs.
A modified randomisation process was used to select the study sublocations. A random 
list of all eligible sublocations was formulated per district in Microsoft Excel. The first 
intervention sub-location was selected from the top of the list. In order to reduce the potential 
for contamination a ‘buffer zone’ was created where all sublocations located within two sub­
location boundaries of the selected sub-location were removed from the list. The list was 
reshuffled randomly and the first sub-location on the new list allocated to the control arm. The 
same procedure of creating a buffer zone around this sub-location was continued, alternating 
between the selection of intervention and control sublocations, until three intervention and 
three control sublocations had been selected within the district (Figure 4.2). The estimated 
population in the control and intervention arms were 38,620 and 44,538 respectively (average 
population per selected sub-location of 4,620, range 2,703 to 9,294) (appendix 1).
Table 4.2: Demographics for the selected sub-locations
SUBLOCATION DISTRICT %POOR UNIQU
E I D 1
EST
POP
2007
POP DENSITY/ 
KM2
ARM
Magombe central Busia 64 89 3575 200 Control
Kanjala Busia 68 36 2703 389 Control
Nanderema Busia 66 74 3490 298 Control
Muyafwa Busia 65 34 4053 473 Intervention
Lupida Busia 68 2 4418 328 Intervention
Sikinga Busia 69 10 5945 392 Intervention
Akachachata Teso 48 23 2626 293 Control
Apokor(angurai) Teso 51 2 3185 374 Control
Kamunuoit Teso 49 61 3273 297 Control
Aludeka Teso 48 48 3275 285 Intervention
Okatekok Teso 52 75 3955 375 Intervention
Kakalet Teso 49 18 3370 372 Intervention
Shianda(bm) Bm 58 61 3030 748 Control
Buchifi Bm 61 27 8659 574 Control
Musamba Bm 62 3 8079 476 Control
Eshibinga Bm 69 71 4134 643 Intervention
Lunza Bm 61 31 9294 482 Intervention
Malaha(bm) Bm 63 18 6094 612 Intervention
Represents the numbers assigned to the sub-locations on the district maps below; BM=Butere Mumias
Figure 4.2: Maps of (a) Busia district, (b) Teso District, and (c) Butere-Mumias District, showing 
control (orange) and intervention (green) sub-locations. (N.B: ‘Other’ (see Legend) refers to all 
sub-locations that do not fit the sub-location criteria (e.g. urban or peri-urban and with populations 
<2,500 or >10,000))
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The characteristics o f the study sub-locations that were selected are displayed in Table 4.2.
The populations within the selected Teso sub-locations tended to be less poor than the other
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two districts, with the percentage living below the poverty line ranging from 48-52%. In
Busia the percentage living under the poverty line ranged from 64-69% while in Butere-
Mumias it was from 58 to 69%. In Kenya, the poverty line (the cost of a basic basket of food
and non-food items) in 2003 was about 1,239 KSH (15.25USD) per person per month for rural
inhabitants (CBS, 2003). Butere-Mumias was the most densely populated with sub-location
population densities ranging from 476 to 748 per KM2. Busia and Teso’s population densities
were quite similar with Teso ranging from 293-374 per KM and Busia from 200 to 473 per
KM2. Across the three districts, the average percentage poor and population densities between
the control and intervention sub-locations were similar (Table 4.3).
Table 4.3: Comparison of percentage poor and population density between intervention and 
control sub-locations, across all three districts (CBS, 1999)
ARM AVERAGE%POOR
AVERAGE POP 
DENSITY/ KM2
Control sub-locations 58 4291
Intervention sub-locations 60 4949
The intervention targeted retail outlets serving intervention sub-locations, which were 
identified through an outlet census carried out in May 2008. Outlets were included in the 
census if they were located in the intervention sub-locations or were just outside these sub­
locations but were identified by key informants as serving their populations. Initial lists of 
retail outlets were sourced from the local public health officers, and updated with input from 
local chiefs and sub-chiefs. The lists were further amended after walking around the study 
areas with the village elders to confirm the presence of outlets and add missed outlets. The 
snowball technique was then used where each shop visited was asked about the presence of 
other outlets in their area. Finally, members of the community passing by were 
opportunistically asked about the location of outlets known to them. Enumerated outlets were 
invited for training if they had been functioning for a minimum period of six months, and
reported selling antimalarials and/or antipyretics within the 12 months prior to the census. In
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the study areas these were found to consist of registered and unregistered pharmacies (referred 
to here as specialised drug stores), and general stores which sold medicines alongside general 
household goods. Similar outlets identified in the non-intervention sub-locations remained as 
controls. A second census was conducted in May 2009, to update the list of functioning outlets 
for the follow-up provider survey.
4.3: THE INTERVENTION
The intervention package was designed and implemented by the DOMC in collaboration with 
PSI, Ministry of Health (MOH) staff at the province and district level and other key 
stakeholders. The role of KEMRI Wellcome Trust Research Programme (KWTRP) was 
limited to evaluation. The three main components of the intervention were provision of 
subsidized packs of paediatric AL to retail outlets, training of retail outlet staff, and 
community awareness activities. No interventions were implemented in the control arm. In 
both intervention and control arms the policy of provision of free AL at government facilities 
continued unchanged.
4.3.1: The Product -  Pre-packaged AL for children 3-59 months
PSI and the DOMC developed a branded pre-packaged AL product for the treatment of 
malaria in children. In line with dosing recommendations, two doses were developed: a yellow 
six tablet pack for 3 months to less than 3 year olds (5-15kg) and a blue 12 tablet pack for 3 to 
4 year olds (15-25kg) (Figure 4.3a & b). The lower age limit of three months was set because 
at the time of the study, AL was not recommended in children under 5kg. Although the blue 
pack would be appropriate for children up to 7 years of age, the target group for this 
intervention was children under five years of age, being the most vulnerable age category to 
suffer from malaria. Additional consumer friendly information was added to the product’s 
outer packaging using pictorials and instructions on safe use of the medication, in a form that
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was suitable for those with low literacy levels. The information was designed to promote 
appropriate dose recognition by caregivers and shopkeepers and promote adherence to the full 
regimen. The process o f product development was based on extensive formative research and 
pre-testing, and modified in consultation with the case management team o f the DOMC. The 
product’s instructions also included details on the IMCI danger signs and the need to refer to 
the public health service severe conditions and children under three months. The AL was 
branded as Tibamal®, a pretested name derived from the Kiswahili words ‘ Tibaya Malaria’, 
meaning malaria cure. Kiswahili is one o f the official languages o f Kenya which is commonly 
understood by all tribal groups in the country, including those participating in the study.
Figure 4.3: Additional consumer friendly information added to standard AL packaging for (a)
blue 12 tablet pack (3-<5years of age); and (b) yellow 6 tablet pack (3months to <3 years)
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4.3.2: Drug Regulation
At the time of the survey, AL was classified as a POM and could only be sold from registered 
pharmacies on furnishing of a prescription. However, despite this regulation it was not 
uncommon to be able to obtain the treatment without a prescription. For the purposes of this 
study, special dispensation was requested and granted from the Expert Committee of Clinical 
Trials within the PPB to allow for the treatment to be deregulated to an OTC treatment so that 
providers would be legally able to dispense the treatment without the requirement of a 
prescription.
4.3.3: Price
PSI sales staff delivered the treatment directly to selected outlets on a monthly basis at a 
subsidised wholesale cost of 8 Kenya Shillings (KSH) (0.10 US USD)2 per treatment pack, 
both packs being the same price. The outlets were instructed to sell the packs at a retail price 
of 20 KSH (0.25 USD), and this price was printed on the drug packaging (Figure 4.3a & b). 
The retail price was set to provide outlets with a mark-up of 12 KSH (0.15 USD) per pack, 
equating to a 150% retailer mark-up, and was designed to be competitive with pther available, 
but less effective monotherapies such as SP and amodiaquine, which were sold at around 30 
KSH (0.37 USD) per full dose. The average retail price of AL without the subsidy was around 
500 KSH (6.16 USD).
4.3.4: Distribution and Training
As described above, outlets were identified from the baseline retail census and selected for 
inclusion into the intervention if they had been functioning for a minimum period of six 
months and sold either an anti-malarial or antipyretic within the past year. A total of 225 
outlets were selected in the intervention area, of which 61 were specialised drug stores
2 Source of exchange rate: http://www.exchangerate.com/past_rates_entry.html.accessed 13/4/2010. On 1st 
Novermber 2008, when the subsidised drugs were first distributed, 1 US dollar was equivalent to 81.23KSH.
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(registered or unregistered pharmacies) and 164 general stores (which sold medicine alongside 
general household goods). Outlet staff attended a one day malaria-related training offered 
between August to October 2008 covering clinical diagnosis, treatment, adverse drug reactions 
(ADRs) and patient referral. Training materials were developed by the implementation team, 
building on those used previously for shopkeeper training in Kenya (Marsh et al., 2004). In 
addition, shopkeepers were supplied with two job aids, one an algorithm explaining steps to 
take if a child presented at the outlet with a history of fever, the other showing dosing 
schedules for both the Tibamal® packs. These job aids were designed to improve the quality 
and quantity of information given by providers to consumers. Retail owners were given the 
option to supply Tibamal®. From November 2008, subsidised AL was provided to trained 
retail outlets in packs of six tablets (for children aged 3-35 months) and 12 tablets (for children 
aged 36 to 59 months). Supportive supervision of the retailers by PSI took place in February 
2009. This involved PSI trainers going to trained outlets and testing staff on information learnt 
during the training sessions. The purpose of this exercise was to assess retention of knowledge 
and to remind shopkeepers of key messages.
4.3.5: Supporting interventions
A series of promotional activities in the intervention areas and related dominant market 
centres was carried out by PSI. Messages targeted caregivers of children under five and 
promoted appropriate treatment seeking behaviour including the benefits of AL and its 
availability both in public sector facilities and identified private sector outlets. Messages were 
delivered through small group sessions and community leader workshops. The main 
community awareness activities began in March 2009, and then intermittently in August and 
September 2009. Activities were continued to the end of the pilot in May 2010. They 
consisted of nine community leader workshops that targeted 47 people; nine community
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events that targeted 11,500 people, ten small group discussions that targeted 200 people and
outreaches carried out by community based organisations that targeted 21,000. These activities
were designed to make the community aware o f malaria, the availability o f Tibamal®, and the
importance o f adherence to the medication. Tibamal® was also advertised through posters and
paintings on shops that sold the treatment. Tibamal* branded headscarves, t-shirts and pens
were also freely distributed to the intervention community (Figure 4.4) (appendix 2). Above
the line communication strategies, which use media that are broadcast and published to mass
audiences such as newspapers, television and radio were not used in this pilot to avoid
possible contamination between intervention and control arms. In 2006/7 the government had
carried out AL awareness campaigns across the country, so both arms had previously received
some general information on the current malaria treatment policy (personal communication,
Andrew Nyandigisi, DOMC, M inistry o f Public Health and Sanitation Kenya).
Figure 4.4: Ladies from one of the intervention sub-iocations wearing Tibamal® promotional 
items, standing in front of a Tibamal “ wall painting
Coartem® 20/120
artemether 20 mg 
lumefantrine 120 mg
4.3.6: Pharmacovigilance
The PPB had developed guidelines and tools for the collection o f pharmacovigilance data on
AL since its release in the public sector. The intervention package was implemented in
collaboration with the PPB to ensure that pharmacovigilance requirements were met.
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Shopkeepers were supplied with a Daily Activity Register to document AL dispensed. 
Shopkeepers were also educated on possible adverse effects and were instructed to advise 
caregivers to seek care from the nearest health facility for any suspected ADRs. They were 
provided with CHW referral forms which were to be filled in and given to patients being 
referred to health facilities for suspected ADR symptoms, or failed AL treatment. A copy of 
the form was to remain at the outlet to be collected by the PSI sales staff and handed over to 
the PPB. All ADRs seen within health facilities were to be reported back to the PPB. The PPB 
along with district investigation teams were to be involved in following up any serious ADRs.
4.4: DATA COLLECTION 
4.4.1: Field workers
Field workers were identified through job adverts circulated within the study districts, as well 
as using the snowballing technique, where potential field workers were asked whether they 
knew others who were willing and able to do the job. They were shortlisted for an interview 
based on their secondary school grades (Kenyan Certificate of Secondary Education (KCSE) 
B+ and above), their level of field work experience, and their ability to speak the required 
local dialect. Those either with a university degree or currently in university, meeting all the 
other requirements were more likely to be shortlisted. In total 20 field workers were selected 
per district. Selected field workers were trained on the purpose of the study, basic data 
collection techniques, and how to administer the informed consent forms and data collection 
tools. Training was supported by training manuals, role plays and mock interviews. Field 
workers worked in two teams of ten, with one person per group being assigned the role of a 
field supervisor. Field workers selected at baseline were retained to carry out follow-up 
surveys if their work at baseline was satisfactory. A second interview process was carried out 
at follow-up to replace field workers who had left after the baseline survey.
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4.4.2: Survey indicators
Prior to this study, a list of key indicators for all operational research looking to improve 
access to anti-malarial treatment was developed in collaboration with the DOMC, and was 
approved by them (appendix 3). The indicators were divided into compulsory and optional 
indicators. The indicators were identified through consideration of relevant DOMC targets; GF 
indicators; RBM monitoring and evaluation reference group indicators; and Global ACT 
subsidy monitoring and evaluation frameworks. The compulsory indicators (see appendix 3) 
were to be monitored by all studies evaluating interventions to increase anti-malarial access 
outside the public sector within Kenya. The purpose was to standardise outcome measures 
between studies to allow for data to be compared, and to also ensure that the DOMC are 
provided with the relevant information required to inform policy. This study was designed to 
address all the compulsory indicators (see appendix 3) and some optional indicators that were 
considered to be relevant in monitoring the effect of the intervention. In this study, data 
collection activities used to provide outcomes for indicators consisted of household, mystery 
shopper and provider surveys. A context analysis was also carried out to comprehend the 
environment in which the intervention was being implemented and identify potential effect 
modifiers. FGDs took place at follow-up with caregivers and retailers to explore reasons for 
the impact observed and identify any challenges in the implementation process. This activity 
was not included as part of the thesis, however important findings from the discussions were 
used as part of the documentation of context, to better understand the effect of the 
intervention. The different surveys allowed for the intervention to be evaluated from the angle 
of the consumer, and through reported and observed behaviour of the provider. Data from the 
three surveys were then triangulated for a more comprehensive understanding of the 
intervention effect.
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All surveys were conducted in July-August 2008 and July- August 2009 (Figure 4.5). In 
each district, the mystery shopper was conducted first, followed by the household survey and 
then the provider survey. Data collection for all the activities took place on questionnaires 
derived from similar studies, and amended to capture the desired information. Questionnaires 
for the household and provider surveys were translated into local dialects o f the study 
communities (Sarnia for Busia district, W anga for Butere-M umias and Kiteso for Teso) and 
back translated to confirm the accuracy o f the translations. The mystery shopper survey took 
place in the form o f a roll play and the questionnaire completed afterwards by the fieldworker. 
The mystery shopper questionnaire was only in English. All tools were piloted in two sub­
locations in Busia that had not been selected for the study, but resembled the study sub­
locations, and changes made where necessary. The tools were piloted in April 2008 and April 
2009. More details on the pilot are described in section 4.4.3.
Figure 4.5: Intervention and study timelines
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Household survey: The household survey primarily addressed specific objectives 1 (To 
determine the impact on the proportion of children under five with fever being treated 
promptly with appropriate anti-malarial treatment, and adhering to the correct dose), and 3 (To 
determine distribution of benefits of retail sector delivery of AL by socio-economic status).
The primary indicator for this activity was defined as: ‘the proportion of children aged 3 
to 59 months reporting fever in the past two weeks who started treatment with AL on the same 
day or following day of fever onset’. Household surveys are increasingly using the “same day 
or following day” terminology to increase the feasibility of data collection as it is very 
difficult to collect data on the specific number of hours since symptom onset, as required by 
the original 24 hour formulation of the RBM indicator.
The household survey consisted of a structured questionnaire divided into seven 
sections. Section one captured characteristics of all members residing in the household. 
Residential members were defined as those who plan to live or who have lived in the 
household for a period of six months or more. Characteristics collected included identification 
of the household head, members’ age and sex; mosquito net usage in the night prior to the 
interview; identification of the parents or guardians of members under 16 years; and 
identification of members that had suffered from fever within the last two weeks of the 
interview. The purpose of this section was to identify those who needed to be interviewed in 
the other sections of the questionnaire.
Section two collected further details on mosquito net use in the household. This 
included details on the net’s source, net cost, and which nets had been treated with insecticide.
Section three captured information on household geography and demographics, and 
section four on assets owned by the household, to determine household wealth. Wealth assets 
included housing quality, sources of income, education status and ownership of livestock and 
amenities in the household.
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Section five captured information on treatment actions caregivers took to treat their 
under five year old child’s fever. Fevers were captured only if they occurred within the two 
week period prior to the interview, and had started within this period. The survey was 
restricted to fevers occurring in this period since the recall period beyond this time point is 
questionable (McCombie, 2002). Both resolved and unresolved fevers were captured. Details 
on the type of treatment sourced to treat identified fevers were documented. Types of 
treatments included: any action taken to try to relieve the child’s symptoms, such as 
conventional treatment received from a doctor, nurse or any other healthcare professional; 
self-medication at home; treatments with home remedies; prayers or seeing a traditional 
healer. Other information collected in this section included any costs incurred for accessing 
treatment, whether advice was given from providers regarding any medication dispensed, and 
adherence practices of caregivers to any antimalarial received. Adherence was defined as 
giving the child the quantity of medicine as specified in the MOH treatment guidelines 
(DOMC, 2007). Both under and over dosing were considered as non-adherence. The timing of 
administration between doses was not considered as recall of specific times may have proved 
difficult, therefore increasing the potential for recall bias.
Section six assessed caregiver’s knowledge on malaria treatment and diagnosis for 
children under five. It also identified where knowledge on malaria was gained from. Section 
seven captured information on the proportion of non-target household members receiving 
intervention AL.
The questionnaire was administered to different members of the household. Sections one
to four were administered to the household head. The household head was identified as the
person in the household who is acknowledged as such by members of the household and who
is usually responsible for the upkeep and maintenance of the household. Sections five and six
were administered to all caregivers within the household who had a child under five that had
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suffered a fever within two weeks prior to the interview. Section seven was administered to all 
members of the household who had suffered a fever within two weeks prior to the interview. 
In this section, where a child with a fever was below 16 years, information was collected from 
their parent or guardian. Written consent was obtained from all household heads or their 
representative, and verbal consent from all others who were interviewed. The village elders 
were informed about the survey in advance and aided the field team in identifying households 
to be interviewed.
Visual aids, consisting of pictures of common anti-malarial and anti-pyretic medication, 
nets, malaria related posters, calendars and leaflets were used to help field workers and the 
respondents to correctly identify malaria treatments and information education and 
communication material mentioned in the interviews. Birth charts were used to quickly 
calculate ages and calendars to determine dates of when fevers began and treatment sought.
Provider survey: The provider survey mainly addressed specific objective 2 of the thesis (To 
determine if private sector retailers can deliver AL to appropriate standards of quality for the 
treatment of fever in children under five.)
The purpose of this survey was to assess the knowledge and practices of the provider 
when it came to the treatment of malaria. The provider survey consisted of a structured 
questionnaire divided into six sections. Section one captured details on the geographical 
location of the outlets. Directions to the outlet obtained from the retail census were included in 
this section to aid field workers in locating the outlet. Details captured in this section were 
compared to those in the retail census to ensure the right shop was interviewed. Section two 
captured information on the type of malaria related IEC materials available in and around the 
outlet. This included whether the outlet possessed any of the intervention’s promotional 
materials such as posters, job aids and wall paintings. This section gave an indication of what
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information providers and caregivers using that outlet may be exposed to. Section three 
captured information of staff characteristics such as their age, level of education and health 
qualifications. The information gave an idea of the level of expertise available in the outlet as 
this may affect the quality of care received. Section four asked questions on the stocking of 
antimalarials in the outlet. The questions were designed to determine the median price charged 
for AL treatment, the proportion of outlets with expired AL in stock and the proportion of 
outlets reporting stock outs within the past 2 weeks. To assess the proportion of outlets with 
expired AL, all expiry dates of available AL, entered by batch number, were recorded. Stock 
outs were only recorded within the past two weeks to reduce recall bias. Stock outs were 
assessed by asking providers how many days over the past two weeks have they not had AL 
available. Only outlets that currently had AL stocks were asked this question. This section was 
also designed to assess if AL was being stored appropriately (appropriate storage refers to 
keeping medicines off the floor, in a dry area, away from direct sunlight, and with the 
packaging intact). Section five captured information on factors that determined which 
medicines outlets stock and sell to customers and how customers with insufficient funds were 
dealt with. The last section captured information on provider knowledge of malaria. This 
included knowledge of malaria diagnosis and treatment in children under five and adverse 
effects of AL. The questionnaire was administered to the shopkeeper present at the outlet at 
the time of the visit. If two or more providers were available in the outlet, the interview was 
administered to the one responsible for selling medication to customer. Written consent was 
obtained from the interviewee prior to interviewing.
Mystery shopper survey: The mystery shopper survey also addressed thesis objective 2 (To 
determine if private sector retailers can deliver AL to appropriate standards of quality for the 
treatment of fever in children under five years.)
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The purpose of this study was to analyse the patient provider interaction to give better 
information on actual rather than self-reported provider behaviour. In this survey field 
workers, disguised as local residents visited selected outlets seeking treatment for a four year 
old child with fever. The fieldworkers presented the following scenario: a 4 year old child 
(weighing 15kg), under their care who has been suffering from a recurring fever for 3 days, 
especially at night. The child had no other symptoms, and no medication had been given to the 
child so far. The field worker was then to wait for the provider to ask further questions and/ or 
prescribe a medication. If no medicine was recommended, field workers were to prompt the 
provider to recommend a medicine. If after prompting no medicine was recommended then the 
field worker was instructed to find out reasons as to why. If a medicine was recommended 
then the field worker was to find out why the provider suggested that particular medicine. 
Details of the interview were discretely filled in on structured questionnaires away from the 
outlet, once the interview was completed. Questions asked on the questionnaire included 
whether the provider asked about any signs and symptoms of the disease to determine need for 
referral; what advice if any was given on how to treat the child’s fever; details of each 
medicine sold including cost, quantity and the reason for it being dispensed; if AL was 
dispensed, whether information was given on how to administer it. The information allowed 
for an assessment to be made on the proportion of providers offering appropriate medication in 
response to malaria symptoms and providing appropriate OTC advice for this treatment.
This mystery shopper method was chosen instead of direct observation or exit interviews 
because it minimises any potential bias that may occur through knowing one is being 
observed. In addition, achieving a reasonable sample size for exit interviews could be very 
time consuming in outlets which receive very few fever customers per day. The mystery 
shopper technique did raise some ethical concerns as informed consent could not be obtained
from the medicine seller at the time of the interview (Marsh et al., 2004; Madden et al., 1997;
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Chalker et al, 2000). Written consent was therefore sought from all shopkeepers during the 
retail census for their willingness in principle to participate in the mystery shopper survey. 
Outlets were informed on what the survey involved, however neither whether their shop was 
to be selected for the survey nor the date of the visit was revealed as this could have affected 
the study outcomes.
Documentation of context: Documentation of activities at national and district level which 
may have influenced the study outcomes in both the intervention and control areas was carried 
out in the form of a context analysis. Throughout the study, a series of desk-work analyses of 
newspaper articles, minutes to meetings, draft proposals, budget allocations and memos, as 
well as in-depth discussions with the DHMTs at the local level took place. From this, a 
chronology of events was documented, as well as a summary of the events, the locations and 
the duration. These data were taken into consideration during evaluation of the study 
outcomes.
4.4.3: Feasibility Study and Pilot
A three day feasibility study was carried out in December 2007 to counter check some of the 
assumptions made in the research proposal. The feasibility study was carried out to bring some 
clarity on the average number of retail outlets serving a rural sub-location, the percentage of 
these outlets selling antimalarials and antipyretics, the type of antimalarials available and the 
distance people will walk to seek antimalarial treatment. The information collected from this 
study was used to amend the proposal, where applicable.
A more comprehensive two week pilot study was carried out four months later, in April 
2008, to test the tools’ acceptability, and see if they were collecting the desired data; to get a 
clearer idea of the time lines, budget and workforce that would be required for the baseline 
survey; and to test the data entry screens. The pilot was carried out in Busia, one of the three
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selected districts for the intervention. Two sub-locations not included in the main study were 
chosen for the pilot. These study areas were separated by a distance of two sub-locations and 
displayed contrasting types of rural activity. The two were Alungoli, a sub-location with the 
5th lowest rural estimated population (estimated for 2007) of 2,889 and Bukhalalire, with the 
2nd largest rural population of 9,272. The percentage living in poverty in Alungoli was 
estimated at 67.3% while in Bukhalalire 64.8%. The distance between the two sub-locations 
was chosen to enable us to determine whether a buffer zone of 2 sub-locations was enough to 
limit contamination. In each of the two sub-locations, the following data collection activities 
were administered: the retail census, the household census (mapping), the household survey, 
the provider survey and the mystery shopper survey. The tools that were tested comprised all 
informed consent forms, all data collection questionnaires, the training manual and visual aid. 
A retail census was carried out to identify outlets selling medication and serving the study sub­
location population. From the census, 20 shops were randomly selected where provider and 
mystery shopper surveys were carried out. One enumeration area (EA) was randomly selected 
in each sub-location. GPS mapping was done on every household in each of these EAs and the 
name of each household head was listed. From this list, random selections of 71 households 
were chosen per EA. Household survey questionnaires were administered to these selected 
households.
For each survey that was piloted, issues that were brought up during the pilot were 
addressed. The tools were also sent to PSI to confirm if they collected the type of data that 
would best answer the questions they were interested in. A similar pilot was carried out a year 
later, prior to the follow-up survey to test new questions added into the questionnaire.
4.5: DATA MANAGEMENT
Baseline data were captured on paper questionnaires and double entered into Microsoft Access
(2007). Follow-up data only for the household survey was captured using personal digital
1 1 3
assistants and Pendragon Forms version 5.1 (Pendragon Software Corporation, Libertyville, 
Illinois [http://www.pendragon-software.com] and downloaded onto Microsoft Access 
[2007]).
The questionnaire on the PDAs was designed to limit error through incorporating 
restrictions into what could be entered for certain questions, and notifications for missed 
questions. Both baseline and follow-up questionnaires were checked at the end of each day to 
maintain a high quality of work. Errors in the questionnaires that were identified as straight 
forward were corrected by the responsible field worker; more complicated errors resulted in 
the household or provider being re-interviewed. At the end of each survey, three to four days 
were allocated as ‘call back’ days. This time allowed for re-interviews where errors needed to 
be corrected, and it also allowed for households to be interviewed if members were previously 
absent.
4.6: SAMPLE SELECTION 
4.6.1: Sample selection: Household survey
The primary outcome was defined as the proportion of children aged 3-59 months reporting 
fever in the past 2 weeks who started treatment with AL on the same day or following day of 
fever onset. Secondary outcomes included the adequacy of AL doses obtained and consumed, 
and the price paid per pack. These were assessed using pre- and post-household surveys 
conducted in July-August 2008 and July-August 2009. The study was based on an intention- 
to-treat analysis where clusters were not adjusted or further selected depending on the 
proportion of retail outlets which actually received the intervention. The sample size was 
based on detecting a 20% point difference in the primary outcome, with 5% significance, 80% 
power, and an estimated design effect of 2 to account for the cluster survey design (percentage 
point refers to the absolute difference observed between two percentages, in this case between
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the outcome percentages observed between the intervention and control arm). I estimated that 
the primary outcome would be 20% at baseline (based on data collected by Gitonga et al., 
(2007), and allowing for some increase since that survey took place). A design effect of 2 was 
considered conservative based on an intra-class correlation coefficient of 0.16 from a similar 
previous survey in Kenya (Gikonyo, KEMRI Wellcome Trust Research Programme, 
unpublished data), and an estimated 43 homesteads per cluster. This led to a required sample 
size of 158 childhood fevers in each arm, which I estimated would require data collection from 
1,138 homesteads in each arm, equivalent to around 210 households per sub-location. A 
homestead is a group of households within the same compound belonging to a single extended 
family. A household consists of a person or a group of related or unrelated persons who live 
together in the same dwelling unit, who acknowledge one male or female as the head of the 
household, who share the same housekeeping arrangements, and who are considered to 
constitute one unit. A homestead can contain one or more households.
Three EAs were randomly selected within each intervention and control sub-location on
the basis of probability proportional to population size. A homestead census was carried out in
the selected EAs in May 2008 and each homestead was mapped using GPS hand-held
receivers (Garmin etrex and Trimble 12 band GPS units). From the homesteads enumerated,
43 were randomly selected using simple randomisation with Excel 2007, within each EA. To
achieve the sample size, homesteads selected for sampling but not available during data
collection were replaced by the next available from a randomly ordered list of homesteads,
formulated during the census. A pretested questionnaire was administered to all household
heads within the selected homesteads to ascertain household socioeconomic status, and to all
caregivers of children under 5 years of age reporting fever episodes in the 2 weeks prior to the
interview to assess treatment-seeking behaviour and medicine use. All homesteads agreeing to
participate at baseline were revisited at follow-up. All households within each homestead were
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interviewed at each time point, including new households that were established at follow-up 
(Figure 4.6).
Figure 4.6: Flow diagram showing households and retail outlets sampled and interviewed
InterventionControl
Baseline
Follow up
18 sub-locations randomised
O f 1,609 households interviewed at 
baseline:
Lost to follow up1: 114 
Declined: 1
New households (within 
homesteads selected at baseline): 93
O f 1,679 households interviewed at 
baseline:
Lost to follow up1: 152 
Declined: 4
New households (within 
homesteads selected at baseline): 72
Retail outlets censused (cross section):
A llocated to intervention: 351 outlets 
functioning for at least 6 months and sold 
antimalarials or antipyretics within the 
past year. O f these, 136 outlets reported 
having received the intervention 
(Tibamal® training).
Households interviewed at follow up 
(cross section o f all households within 
homesteads selected at baseline): 1,587
Retail outlets censused (cross section):
Allocated to control: 369 outlets
functioning for at least 6 months and sold 
antimalarials or antipyretics within the 
past year.
Households interviewed at follow up 
(cross section o f all households within 
homesteads selected at baseline): 1,595
9 sub-locations:
Retail outlets censused (cross section):
Allocated to control: 295 outlets
functioning for at least 6 months and sold 
antimalarials or antipyretics within the 
past year.
Households interviewed at baseline (cross 
section): 1,679 (within 1,161 homesteads)
9 sub-locations:
Retail outlets censused (cross section):
Allocated to intervention: 225 outlets 
functioning for at least 6 months and sold 
antimalarials or antipyretics within the 
past year. All invited to participate in 
intervention (Tibamal® training).
Households interviewed at baseline (cross 
section): 1,609 (within 1,158 homesteads)
households lost to follow up included those that had migrated out o f the study area or were temporarily absent for the duration of the study.
4.6.2: Sample selection: Provider and Mystery shopper survey
The sampling frame for the provider and mystery shopper surveys was based on the retail 
censuses carried out in May 2008 and 2009 described above, when details of any anti-malarial 
medicines stocked, date of establishment and physical location of each outlet were recorded. 
Outlets were included in the sampling frame if they had been functioning for a minimum 
period of six months and sold either an anti-malarial or antipyretic within the past year, and all 
outlets in the sampling frame were included in the surveys. From the feasibility study, it was 
estimated that around 150 outlets would be surveyed in each group (i.e. control and 
intervention groups) (Figure 4.6).
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4.7: DATA ANALYSIS
The data were analysed in STATA version 11 (College Station, Texas) by a two-stage process, 
with baseline and post-intervention data analysed separately. In the first stage a summary 
cluster measure was obtained for each cluster. The second stage involved comparing the sets 
of cluster-specific measures in control and intervention arms at follow-up using the unpaired t- 
test (Hayes & Moulton, 2009). A crude analysis was carried out on the cluster summaries 
using the simple two tailed t-test to obtain the means, 95% confidence intervals (CIs) and 
standard deviations (SDs) for the outcome of interest. In addition, an adjusted analysis was 
carried out at follow-up on all indicators using an individual level logistic regression run on 
the pooled data set (control and intervention arms). To control for potential confounders for 
each survey type, the following covariates were considered:
1) Provider survey: distance, outlet type (specialized drug store or general store) distance of 
shop to nearest road)
2) Mystery shopper survey: outlet type (specialized drug store or general store) distance of 
shop to nearest road), clinically related training and district
3) Household survey: patient age and sex, caretaker's and household head's education level, 
wealth score, bed net use last night, district, and, when adjusting for the adequacy of AL doses 
obtained and consumed, the source of treatment.
All covariates significant at a /?-value of >0.2 were retained in the regression model.
Baseline values for the outcome in question were also included as covariates if a difference of
5% points or more was observed between the arms at baseline. Adjusting for baseline values
by including them as covariates in the regression analysis was selected as a more reliable
approach than adjusting the values by analysing the change in the endpoint of interest
(difference in difference approach). According to Hayes & Moulton (2009), analysis of change
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can be subject to the phenomenon of ‘regression to the mean’ where low values at baseline are 
expected to increase at follow up and high values decrease. These changes are due to random 
variation in measured endpoints and not the intervention. To explore the implications of this 
decision, where large differences were observed at baseline, the analysis was re-run using a 
difference in difference approach. In the difference in difference approach, adjustments are not 
made for covariates, so this analysis was carried out unadjusted. The intervention status of the 
cluster was not included in the logistic regression model. Rather, the regression model 
provided the predicted outcome in the absence of the intervention effect. Mean predicted and 
observed outcomes were obtained per cluster and residuals were obtained by subtracting the 
predicted outcomes from those observed in each cluster. The /-test was used on these residuals 
to assess the intervention effect, adjusted for the covariates included in the logistic regression 
model. The /-test was used for both crude and adjusted analyses, as it has been shown to be 
highly robust even for small numbers of clusters. A separate analysis allowing for clustering 
within homesteads was also conducted but did not affect the statistical significance of the 
results. Both crude (unadjusted) and adjusted analyses were carried out on all primary and 
secondary indicators, which were then used to calculate p values. All sub-analyses were kept 
descriptive due to their low sample sizes, and also to limit the running of multiple hypothesis 
tests on underpowered outcomes and therefore control for false significant outcomes.
As part of the household survey, the presence of certain household assets, selected on 
the basis of those included in the 2003 Kenyan Demographic and Health survey (DHS) (CBS, 
2004) was recorded to assess the wealth of the household. The assets included source of water, 
type of toilet, amenities (electricity, radio, fridge, TV, bicycle, motorbike, car or truck, phone 
and solar power); household and land ownership, floor type, roofing material, type of cooking 
fuel and waste management. The PCA analysis run included all items as those included in the
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DHS survey, except for whether a household had domestic help or not, which was omitted in 
error (appendix 4).
A wealth index was constructed by assigning weights to each asset using principal 
components analysis (PCA), with weights based on the first principal component only (Filmer 
& Pritchett, 2001). Each household was then assigned to a specific wealth quintile, those 
falling into the first quintile being most poor and those in the fifth quintile being least poor. 
All interviewed households were included in the PCA, regardless of whether they contained 
children under five, but the PCA was conducted separately for baseline and follow-up surveys 
to allow for the wealth of new households present at follow-up to be calculated. There are a 
variety of alternative methods for measuring socio-economic status, such as evaluating 
consumer expenditure or income, participatory wealth ranking and self-assignment. The 
advantages and disadvantage of these techniques have been described in Howe et al., (2012). 
The PCA methodology was selected because this technique provided a more stable long term 
view of wealth of a household, which will not be influenced as much by short term economic 
fluctuations that may affect other measurements such as income or expenditure. In addition, 
this technique provides a simple and reliable way of measuring wealth with minimal influence 
of bias as data are collected on observation rather than solely relying on response from the 
interviewee. Finally, this technique has been widely used in similar surveys, which allows for 
comparability of findings from this study to others.
In the analysis I tested for heterogeneity in the effect of the intervention across wealth 
quintiles using ANOVA on cluster percentages for the primary outcome.
Calculating distances
Distances of homesteads to the nearest retail outlet (specialised drug store or general store) 
stocking AL was calculated using data from the retail census which was carried out in May
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2008 and May 2009, and the household census carried out in June 2008. Homesteads and 
retail outlets were mapped using handheld global positioning system (GPS) (Garmin etrex, 
Garmin Ltd., Kansas, USA). Three readings within an accuracy of below 10.0 meters were 
taken, and an average derived as the final reading. Current estimates indicate that the accuracy 
of GPS readings is within 15 meters of the true position (Noor et al., 2005).
Ancillary spatial data on roads, rivers, digital elevation model (DEM) and land cover 
(e.g. forest, large water bodies, cultivated fields, cultivated trees and aquatic areas) were used 
in calculation of travel time from homestead to the nearest AL retail outlet. Road data within 
the study area were classified according to three surface conditions: tarmac (very good or good 
condition), gravel (fair condition), and natural or earth surface roads (poor or very poor 
condition). A DEM obtained from Shuttle Radar Topography Mission (SRTM) 
(http://srtm.csi.cgiar.org/) (Huggel et al., 2008) at a 90 meter spatial resolution was used to 
derive elevation while different land use and land cover classes such as forests, grass land 
areas, shrubs and crop cover were derived from FAO Africover land cover map (available at 
http://www.africover.org/LCCS.htm (Fao, 2000)). These different GIS layers were first 
combined into a single land use or land cover layer and various travel speeds assigned to 
various classes representing different modes of transport such as walking or motorised 
transport.
Travel time grids were then calculated using Access Mod version 3 (Ray and Ebener,
2008). The model applied a correction for walking on earth surface roads, crop and grass land
areas while a correction for motorised transport was applied to tarmac roads, an anisotropic
model corrected for elevation for up slope and downslope movement (Tobler, 1993). The
resulting travel time grid was used to calculate cumulative extract travel time (minutes) from
homesteads to retail outlets using ArcGIS (ESRI, Redland, CA, USA) spatial analysis tools.
Finally, travel times were converted into ground distances (kilometres) at a rate of 5 km/hr'1. 5
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km/hr rate has been used in previous studies (Noor et al., 2003) and was recommended in 
national policy guidelines for monitoring access (Ministry of Health, 1997). These distances 
were then used in subsequent analyses.
Euclidean (straight line distances): Distances from retail outlets to nearest roads were 
calculated using the Euclidean tool in ArcGIS (ESRI, Redlands, CA, USA) spatial analysis 
tool. The resulting Euclidean grid was used in spatial analysis extraction tools to calculate 
distance of retail outlets to the nearest road.
4.8: ETHICAJL APPROVAL
Ethical approval was obtained from the Kenya Medical Research Institute Ethical Review 
Committee (# 1361), the Kenya Pharmacy and Poisons Board Ethical Committee for Clinical 
Trials (# PPB/ECCT/08/07), and the London School of Hygiene and Tropical Medicine 
Ethical Review Committee (# 5288). The study is registered with the International Standards 
Randomised Controlled Trial Number (# ISRCTN59275137). Informed consent was obtained 
from all by respondents for each activity has been as described discussed in the above, under 
in section 4.4: data collection.
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CHAPTER 5
PROVIDER SURVEY
5.1: INTRODUCTION
This chapter reports the results of the provider survey of drug outlets. The purpose of these 
surveys was to assess the knowledge and practices of the provider when it came to the 
treatment of malaria, contributing to addressing the second specific objective of the thesis: To 
determine if private sector retailers can deliver AL to appropriate standards of quality for the 
treatment of fever in children under five years. Full details of the methods for the provider 
survey are presented in Chapter 4. To briefly recap, a provider survey questionnaire was 
administered to retail outlets identified from the retail census, two months after the retail 
census, at baseline and follow-up. The questionnaire was administered to the member of staff 
present at the outlet. If more than one member of staff was available then the main employee 
responsible for selling medications to clients was selected. Outlets were included into the 
provider survey sample if they had been functioning for a minimum period of six months prior 
to the start of the retail census and had been selling either antimalarials or antipyretics within 
the past year. Written consent was obtained from the interviewee at the start of the interview 
and village elders were informed about the survey in advance.
The results are presented in section 5.2. Section 5.2.1 describes the characteristics of the
outlets interviewed. Sections 5.2.2 and 5.2.3 look at the effect of the intervention on the
awareness of interviewees about AL and Tibamal®, as well as the availability of AL and
antimalarial monotherapies. Section 5.2.4 looks at the interventions effects on AL drug
management issues, such as storage and retail price. Section 5.2.5 to 5.2.8 look at how the
intervention has affected provider knowledge of malaria including diagnosis, treatment and
referral practices, knowledge of treatment of malaria with AL and how it should be dispensed,
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its possible ADRs, and the documentation of malaria cases. Section 5.2.9 looks at factors that 
determine what antimalarials providers stock and sell to customers, and what action they 
would take if a customer had insufficient funds to purchase appropriate antimalarial treatment. 
The results are discussed in Section 5.3.
5.2: RESULTS 
5.2.1: Shop Characteristics
Table 5.1 shows the total number of outlets selling an antimalarial or antipyretic by sub- 
location, identified from the retail census at each study time point. Overall there were 196 
more outlets identified at follow-up than baseline. At both time points Teso had the least 
number of outlets per sub-location, averaging a mean of 30 at baseline and 39 at follow-up. 
Butere-Mumias and Busia had a similar number of outlets. In Busia the mean number of 
outlets was 39 at baseline and 48 at follow-up while in Butere-Mumias it was 32 at baseline 
and 45 at follow-up.
At both time points and in both arms general stores constituted the most common type of 
retail outlet, forming 77% of all outlets at baseline and 80% at follow-up (Table 5.2). As 
previously described, only outlets that had reported having functioned for a minimum period 
of six months were included into the sample frame for the survey. At baseline this constituted 
a total of 295 and 225 in the control and intervention arms respectively, and at follow-up 369 
and 351 in the control and intervention arms respectively (Table 5.3).
Of the outlets included in the sampling frame, a total of 468 were successfully 
interviewed during the provider survey at baseline, 263 in the control arm and 205 in the 
intervention arm.
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Table 5.1: Total number of retail outlets identified in the selected sub-locations (from the retail 
censuses)
District Sub-Location Arm Number of outlets 
selling antimalarials 
or antipyretics in the 
past year -Baseline
Number of outlets 
selling antimalarials or 
antipyretics in the past 
year-Follow-up
BUSIA Kanjala Control 52 58
Nanderema Control 49 58
Magombe central Control 33 43
Muyafwa Intervention 26 44
Sikinga Intervention 38 44
Lupida Intervention 34 63
BUTERE
MUMIAS
Buchifi Control 26 40
Shianda Control 53 52
Musamba Control 30 44
Malaha Intervention 25 38
Lunza Intervention 32 55
Eshibinga Intervention 24 43
TESO Akachachat Control 31 38
Kamunuoit Control 26 49
Apokor Control 33 39
Aludeka Intervention 27 35
Okatekok Intervention 36 38
Kekalet Intervention 25 37
Total 600 818
Table 5.2: Total number of retail outlets selling antimalarials or antipyretics in the selected sub­
locations, by type
Baseline Follow-up
Number of outlets by Control Intervention Control Intervention
type: n n n n
Specialised drug store 6 6 71 77 89
General store 267 195 343 308
Other1 0 1 1 0
Total 333 267 421 397
Other= a bicycle repair shop and an agrovet.
At follow-up 639 retail outlets were interviewed, 319 in the control arm and 320 in the 
intervention arm. General stores constituted more than 70% of all shops evaluated at baseline 
and follow-up, and specialised drug shops made up almost all the remainder (Table 5.4). 
These numbers form the denominators for the following figures and tables in this chapter.
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The average mean distance of retail outlets interviewed to the nearest road (any road excluding 
footpaths) was 188 and 327 meters in the control and intervention arms respectively at 
baseline, and 203 and 231 respectively at follow-up (Table 5.5).
Table 5.3: Outlets successfully interviewed, by outlets selected for the study at baseline and 
follow-up (functioning for 6 months or more)
Number of outlets by 
type:
Specialised drug store 
General store 
Other1 
Total
Baseline
Control 
n(%) 
49/53 (92.5) 
214/242 (88.4) 
0
263/295 (89.2)
Intervention 
n(%) 
53/59 (89.8) 
152/165 (92.1) 
0/1 (0) 
205/225 (91.1)
Control
n (%) 
56/69 (81.2) 
262/299 (87.6) 
1/1 ( 100) 
319/369 (86.4)
Follow-up
Intervention
n (%) 
74/79 (93.7) 
246/272 (90.4) 
0
320/351 (91.2)
'Othei^ a bicycle repair shop and an agrovet
Table 5.4: Distribution of outlets successfully interviewed, by type (mean of cluster summaries 
from the 9 intervention and 9 control clusters)
Baseline Follow-up
Percentage of outlets 
by type:
Specialised drug store 
General store 
Other1
Control (N=9) 
% (SD) 
19.6(8.4) 
80.4 (8.4) 
0(0)
Intervention (N=9) 
% (SD) 
26.2(16.3)
73.8 (16.3) 
0(0)
Control (N=9) 
% (SD)
17.8 (7.3) 
81.9(7.6) 
0.3 (1.0)
Intervention (N=9) 
% (SD)
22.9 (8.7)
77.1 (8.7) 
0 (0)
'Othei^ a bicycle repair shop
Table 5.5: Distance of interviewed outlets from nearest road (mean of cluster summaries from the 9 
intervention and 9 control clusters)
Baseline
Control (N=9) Intervention (N=9) 
mean (SD) mean (SD)
Distance from outlet to the 
nearest road (meters) 187.7 (123.8) 326.6 (286.9)
Follow-up 
Control (N=9) Intervention (N=9) 
mean(SD) mean(SD)
201.6(121.5) 231.4(98.8)
The mean number of staff serving customers was just under 2 (Control: 1.9 (SD:0.2), 1.8 
(SD:0.2): Intervention: 1.9 (SD:0.1), 1.9 (SD:1.9); baseline and follow-up respectively). 
Respondents were asked whether members of staff who often or occasionally serve customers 
had any kind of clinical related training (Table 5.6). Clinical related training was classified as 
those who had some kind of nurse, pharmacy or medical training. Nurse training included a
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range of qualifications from certificate courses to full degrees; pharmacy training included 
pharmacists and pharmacy technicians; and medical doctor training included clinical officers 
as well as fully qualified physicians. There were no significant differences between the arms 
in the percentage of outlets that had at least one member of staff with a particular type of 
training, and percentages did not alter greatly from baseline to follow-up. Having some kind of 
nurse related training was the most common type of training received, with a mean of 11% of 
outlets having staff with this type of training at baseline and 13% at follow-up. Most of the 
qualified staff were working in specialised drug shops (<appendix 5). A mean of one quarter of 
outlets at baseline and follow-up, averaging across the arms, had at least one member of staff 
who was either uneducated or had not completed primary school, and less than 4% of outlets 
had a child below 16 years usually or occasionally serving customers (Table 5.6). Appendix 5 
contains analysis of the important outcome indicators carried out below, by outlet type.
5.2.2: Tibamal® training and awareness
As part of the intervention, one or more staff from retail outlets selected to participate in the 
intervention attended a one day training course. In order to identify outlets that had been 
trained on Tibamal®, respondents were asked whether they or any of their colleagues had 
received any type of health related training, including training on Tibamal®. As expected 
therefore, at follow-up, there was a significantly greater percentage of outlets reporting to have 
a trained member in the intervention arm (43%; n=136) compared to 1% (n=3) in the control 
arm (Table 5.7). It should be noted that unless otherwise stated, results are presented below for 
all retail outlets surveyed in the intervention arm, as opposed to just those with staff who 
attended the Tibamal® training.
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Table 5.6: Educational background and age of staff who usually or occasionally serve customers
(mean of cluster summaries from the 9 intervention and 9 control clusters)
Percentage of outlets with at least one employee Control (N=9) Intervention (N=9)
occasionally/ usually serving customers with: % (SD) % (SD)
Any clinical related training1:
Baseline 21.3 (8.1) 23.5(18.8)
Follow-up 15.7 (6.7) 18.9(8.4)
Pharmacy/ pharmacy related training2:
Baseline 10.3 (7.0) 10.9 (8 .8 )
Follow-up 7.2 (4.2) 5.5 (5.0)
Nurse/ Nurse related training3:
Baseline 10.9 (7.5) 11.9(11.4)
Follow-up 10.7 (7.3) 14.8 (7.0)
Medical doctor training4:
Baseline 1.3 (2.3) 2.7 (2.1)
Follow-up 0.7 (2.1) 1.0 (1.5)
Primary school incomplete or no education:
Baseline 26.3 (11.6) 28.8 (17.0)
Follow-up 23.5 (11.3) 28.5 (12.6)
Below 16 years of age:
Baseline 3.5 (5.8) 3.3 (3,5)
Follow-up 3.4 (3.5) 2.1 (2.7)
1 Any clinical related training consists of: pharmacy, nurse and medical doctor related training; 2 Pharmacy related training 
includes pharmacy studied to a certificate or diploma level; 3Nurse related training includes studying nursing to a certificate 
level (nurse aid) and diploma level; 4 Medical doctor training includes clinical officer who studied medicine to a diploma level
Table 5.7: Percentage of outlets that had at least one Tibamal® trained staff (mean of cluster 
summaries from the 9 intervention and 9 control clusters)
Tibamal® training: Control (N=9) Intervention (N=9) Difference in means
% (SD) % (SD) (95%CI)
Baseline
Follow-up 1.0 (2.0) 43.1 (10.8) 42.1 (34.4,49.9)
Respondents were asked whether they had heard of ‘AL’ or ‘Tibamal®’. Across the arms 
at baseline, an average of 71% had heard of AL, which increased to 77% at follow-up, with no 
significant difference observed between the arms (unadjusted p=0.8222; adjusted p=0.7122) 
(difference in means: 1.1%; 95%CI: -8.8, 10.9) (Table 5.8). After adjusting for outlet type, the 
p value remained insignificant. At follow-up, 14% of respondents had heard of Tibamal® in 
the control arm and 92% in the intervention arm, resulting in a significant difference in
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Tibamal® awareness between the arms (p=0.0001) (difference in means: 77.6%; 95%CI: 67.7,
87.6 ).
Table 5.8: Percentage of respondents that had heard of AL and Tibamal (mean of cluster 
summaries from the 9 intervention and 9 control clusters)
Knowledge of AL 
and Tibamal®:
Heard of AL:
Baseline
Follow-up
Control (N=9) Intervention (N=9) Difference in means P-value 
% (SD) % (SD) (95%CI) Unadjusted
 n__________________ n______________________________ Adjusted
74.1 (10.2) 
119 
76.4 (9.0) 
243
68.5 (9.3) 
140
77.5 (10.7) 
244
1.1 (-8 .8 ,10.9) 0.8222
0.7122
Heard of Tibamal : 
Baseline 
Follow-up 13.9(11.2)
44
91.6 (8 .6 ) 
289
77.6 (67.7, 87.6) 0.0001
0.0001
Of those who had heard of AL in the intervention arm, 80% of all outlets and 87% of 
just Tibamal® trained outlets thought it was more effective than other antimalarials (Figure 
5.1). Of those who had heard of both AL and Tibamal® in the intervention arm at follow-up, 
34% thought Tibamal® was more effective than other AL brands, with 40% stating that 
Tibamal® was equally effective compared to other AL brands (Figure 5.2). When Tibamal® 
was compared to other antimalarials, 81% of all outlets and 95% of Tibamal® trained outlets 
thought Tibamal® was more effective than other antimalarials (Figure 5.3).
Tibamal® promotional items such as posters and job aids had been distributed to outlets 
and the Tibamal® logo and colours painted on or near some Tibamal® trained outlets. By the 
end of the intervention, PSI reported to have distributed 6,500 posters and calendars, 500 job 
aids, 51,000 square feet of Tibamal® wall branding/ paintings, and other items which included 
5,418 headscarves, 3,938 T-shirts and 2,000 pens. At follow-up in the intervention arm, 37% 
of retail outlets were observed to be in possession of a Tibamal® poster or calendar, 22% 
possessed a Tibamal® job aid, and 8% possessed other items including Tibamal® t-shirts, head 
scarves or pens. A Tibamal® wall painting could be observed from the entrance of 45% of the
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shops. The majority of these promotional items were found at Tibamal® trained outlets (Figure
5.4), and no promotional items were found in the control arm.
Figure 5.1: Respondents’ perception of the effectiveness of any brand of AL compared to other 
antimalarials in the intervention arm at follow-up (of those who had heard of AL*) (mean of 
cluster summaries from the 9 intervention clusters)
100% -| 
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80% - 
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60% - 
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30% - 
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More effective As effective Less effective Don't know
n=control=243; intervention=244
Figure 5.2: Respondents’ perception of the effectiveness of Tibamal® compared to other AL 
brands in the intervention arm at follow-up (of those who had heard of AL and Tibamal®) (mean 
of cluster summaries from the 9 intervention clusters)
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Figure 5.3: R espondents’ perception of the effectiveness of T ib am ar com pared to other 
antim alarials in the intervention arm  at follow-up (of those who had heard  of Tibamal®) (mean of 
cluster summaries from the 9 intervention clusters)
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Figure 5.4: Tibamal® prom otional items present in retail outlets in the intervention arm  at 
follow-up (mean of cluster summaries from the 9 intervention clusters)
All ou t le t s
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Other items include pens, head-scarves and t-shirts available in the outlet.
5.2.3: Antimalarial availability in retail outlets
I assessed whether there was a difference in the percentage o f retail outlets with any type o f
antimalarials in stock at the time of the interview, between the arms. At baseline, the
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percentage of outlets with antimalarials in stock was relatively similar between the arms with 
53% (SD:12.0) and 65% (SD:10.3) in the control and intervention arms, respectively. 
However, at follow-up there were significantly fewer outlets in the control arm with 
antimalarials in stock compared to the intervention arm p=0.0008 (difference in means: 
16.3%; 95%CI: 24.6, 2.9) (Table 5.9).
Table 5.9: The percentage of outlets found with one or more antimalarials in stock (mean of 
cluster summaries from the 9 intervention and 9 control clusters)
Percentage of retail outlets Control (N=9) Intervention (N=9) Difference in P value
with antimalarial in stock: % (SD) % (SD) means (95%CI) Unadjusted
Adjusted
Baseline 52.8 (12.0) 64.6 (10.3)
Follow-up 39.8(10.23) 56.1 (6.0) 16.3 (7.9,24.6) 0.0008
0.0364
!P value refers to the level of significance of the unadjusted difference between control and intervention arms at follow-up
I then assessed which antimalarials were more likely to be found in stock. Of the 
monotherapies, amodiaquine was the most available at baseline, found in 50% (SD:10.6) and 
58% (12.4) of outlets in the control and intervention arm, respectively. However, by follow- 
up, the availability of amodiaquine had dropped by more than half across both arms, making 
sulphadoxine-pyrimethamine the most commonly stocked monotherapy at 23% (SD:10.8) and 
30% (SD:3.9) in the control and intervention arms respectively. Apart from amodiaquine, the 
availability of all other monotherapies remained relatively similar from baseline to follow-up 
and across the arms. Quinine was present in around 10% of outlets, CQ and the artemisinin 
monotherapies remained rare at less than 5%. As for the combination therapies, AL was 
stocked in less than 3% at baseline across the arms; by follow-up stocks had increased to 38% 
(SD: 12.4) in the intervention arm, but were significantly lower in the control arm at 6% (SD: 
3.7) (p value: 0.0001). The increase in AL stocks observed in the intervention arm was 
predominantly due to Tibamal® stocks. The availability of other artemisinin combination 
therapies was less than 3% from baseline to follow-up and across both arms (Table 5.10).
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Table 5.10: Availability of antimalarial monotherapies and combination therapies (mean of 
cluster summaries from the 9 intervention and 9 control clusters)
Percentage of retail outlets 
with specified antimalarials 
in stock:
Control %(SD) Intervention % (SD) Difference in means 
(95% Cl)
Amodiaquine:
Baseline 49.6 (10.6) 57.6 (12.4)
Follow-up 18.7 (8 .8 ) 14.2 (5.5) -4.4 (-11.8, 2.9)
Sulphadoxine-pyrimethamine:
Baseline 29.2 (8.7) 37.9 (10.5)
Follow-up 23.2(10.8) 29.5 (3.9) 6.3 (-1.8,14.4)
Quinine:
Baseline 10.8 (5.7) 11.2(5.6)
Follow-up 10.7 (4.9) 10.8 (5.5) 0.0 (-5.2, 0.5)
Chloroquine:
Baseline 1 . 0  (2 .1) 2.6 (7.7)
Follow-up 0 (0 ) 0 (0 ) 0 (0 , 0 )
Artemisinin monotherapy:
Baseline 4.7 (4.6) 2 . 8  (2 .2 )
Follow-up 2.5 (15.7) 1.6 (12.4) -0.9 (-3.1, 1.3)
AL (including Tibamal®):
Baseline 0.5 (1.2) 2.4 (4.6)
Follow-up 5.5 (3.7) 37.6 (12.4) 32.1 (23.0,41.3)
Tibamal®:
Baseline - -
Follow-up 0 (0 ) 35.5 (11.9) 35.5 (27.1,43.9)
Other ACT:
Baseline 0 . 8  (1 .6 ) 0 (0 )
Follow-up 2 . 1  (2 .8 ) 0.4 (1.1) -1.7 (-3.9, 0.4)
Other1:
Baseline 0.5 (1.4) 0 (0 )
Follow-up 0 (0 ) 0.2 (0.7) 0.2 (-0.3, 0.7)
’Othei^ Proguanil
Unexpired AL (including Tibamal®) stocks at baseline were found in only 0.5% of 
outlets in the control arm and 1.5% in the intervention arm. By follow-up, AL stocks had 
increased to 37% in the intervention arm but to only 5% in the control arm. No stocks of 
Tibamal® were found in the control arm, but in the intervention arm, Tibamal® was present in 
36% of outlets. The difference in availability of unexpired AL between the arms was 
significant at a p value of 0.0001 (difference in means: 32.1%; 95% Cl: 23.0, 41.3). When 
adjusted for outlet type, the p values of availability of AL and unexpired AL remained 
unchanged at 0.0001. Less than 1% of outlets had expired stocks of AL in both arms and at
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both time points (Table 5.11). A test for interaction indicated that outlet type was not a 
potential effect modifier for the percentage of outlets with unexpired AL (p>0.05 at baseline 
and follow-up).
In the sub-sample of Tibamal® trained outlets, 72% were found to be stocking AL, 69% 
of which was Tibamal® branded AL (Table 5.11). 9% of all outlets in the intervention arm at 
follow-up were out of stock of Tibamal® at the time of the interview but reported usually 
stocking the drug (calculated as the difference between the percentage of retail outlets with 
unexpired stock (35.5%) and the percentage of outlets claiming to usually stock Tibamal 
(44.1%)) (Table 5.11). This was also true for one shop in the control arm. 21 outlets in the 
intervention arm and 1 in the control arm at follow-up did not report having any staff attending 
the Tibamal® training however, they mentioned that they usually sold Tibamal®, and of these, 
15 in the intervention arm were found with stocks of unexpired Tibamal®. Stocks of Tibamal® 
were not available in 16% of the sub-sample of trained Tibamal® outlets who claimed to 
usually stock this medication (Table 5.11).
5.2.4: AL drug management
Outlets stocking AL were assessed to see if the treatment was being stored appropriately. The 
definition of appropriately was all AL packs kept off the floor, out of direct sunlight, in a dry 
area and with packaging intact. At follow-up, 79 and 82% of outlets were observed to be 
storing all AL stocks appropriately in the control and intervention arms respectively (Table 
5.12). Expired AL stocks did not seem to be a problem, with less than 1% of outlets in both 
arms and timepoints having expired stocks of AL (Table 5.11). Storage conditions of AL in 
Tibamal® trained outlets were similar to those observed in all outlets in the intervention arm. 
Stock outs of AL within 2 weeks prior to the interview date were experienced in 33% of the 
119 outlets stocking AL at follow-up in the intervention arm, with a median of 5 days of
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continuous stock out (Table 5.13). Only one (6%) of the 19 outlets stocking AL in the control 
arm at follow-up reported experiencing a stock out of AL which lasted for three days (Table 
5.12).
The median cost of a tablet of AL at baseline was 14.58 KSH (0.18 USD) in the control 
arm; by follow-up this had fallen slightly by 3.54 KSH (0.04 USD) to 11.04 KSH (0.14 USD). 
In the intervention arm the cost of an AL tablet fell from 12.57 KSH (0.15 USD) at baseline to 
3.33 KSH (0.04 USD) at follow-up, a difference of 9.24 KSH (0.11 USD) (Table 5.13).
Table 5.11: Availability of AL in retail outlets (mean of cluster summaries from the 9 intervention 
and 9 control clusters)
AL availability: Control (N=9) 
% (SD) 
n
Intervention (N=9) 
% (SD) 
n
Difference in means 
(95%CI) 
n
P value 
Unadjusted 
Adjusted
Percentage of retail outlets with 
AL (including Tibamal®) in stock: 
Baseline
Follow-up 
Tibamal® trained outlets
0.5 (1.1) 
2
5.5 (3.7) 
19
2.4 (4.6)
5
37.6(12.4) 
119 
72.1 (11.4) 
99
32.1 (23.0,41.3) 0 . 0 0 0 1
0.0001
Percentage of retail outlets with 
unexpired AL (including 
Tibamal®) in stock:
Baseline
Follow-up 
Tibamal® trained outlets
0.5 (1.1) 
2
5.2 (4.0) 
18
1.5 (3.2)
3
36.8(13.1) 
117 
69.9 (12.4) 
97
31.7(22.0,41.3) 0 . 0 0 0 10.0001
Percentage of retail outlets with 
unexpired Tibamal® in stock : 
Follow-up
Tibamal® trained outlets
0 (0 )
0
35.5 (11.9) 
1 1 1  
69.3 (11.9) 
96
35.5 (27.1,43.9) 0 . 0 0 0 10.0001
Percentage of outlets claiming to 
usually stock Tibamal® at follow- 
up1:
Follow-up 
Tibamal® trained outlet
0.3 (0.9) 
1
44.1 (12.6) 
139 
85.3 (12.6) 
118
43.8 (34.9, 52.7) 0.00010.0001
1 This variable includes outlets that usually sell Tibamal® but may have been out of stock at the time of the interview.
136
Table 5.12: AL storage and stock outs at follow-up (mean of cluster summaries from the 9 
intervention and 9 control clusters)
AL storage and stock outs: Control (N=9) Intervention (N=9) Difference in means P value
% (SD) % (SD) (95%CI) Unadjusted
___________________________________________________________________  Adjusted
Percentageofretail outlets storing ?g g , 8L9(17.0) 3.1 (-18.6,24.9)
all packs of AL appropriately: 0.7357
Tibamal® trained outlets - 83.2(16.6)
Percentage of retail outlets with AL
available, reporting stock outs of  63(17 .7 ). 32.5(18.1) 24.0(3.6,44.4)
any of the AL packs withm the past v 0.0023
2 weeks:
Tibamal® trained outlets - 32.5(18.3)
Cluster summaries from 8 cluster; Denominators: control=19; intervention^ 19; Tibamal ® trained outlets=99
Table 5.13: Median stock out days and tablet price of AL at follow-up (cluster summaries from the 
9 intervention and 9 control clusters)
Control (N=9) Intervention (N=9)
Median Median
________________________________________ (25%, 75% IQR)_________(25%, 75% IQR)
Median stock out days over the past two
weeks in outlets where AL was available 3(3, 3) 1 4.9 (4.2, 8.1)
on the day of interview______________________________________________________________
Retail price per AL tablet -KSH 
(including Tibamal®):
Baseline 14.58(4.17,25.0) 12.6(5.0,20.13)
Follow-up 11.04(7.29, 12.5) 1 3.33 (2.5,3.33)
'cluster summaries from 8 cluster; Denominators: control=19; intervention^ 19
5.2.5: Provider Knowledge of Malaria cause, symptoms and prevention
Respondents were asked to list all factors they thought caused malaria and factors that would
prevent malaria (Table 5.14). Correct responses were based on what was taught during the
Tibamal® training sessions. At baseline 6% in the control arm and 11% in the intervention arm
were able to correctly mention malaria being caused only by a parasite in mosquitoes. These
percentages remained relatively similar at follow-up, with no significant difference observed
between the arms. A larger number of respondents (averaging 65% in both arms and time
points) stated that malaria was caused by mosquitoes. More than 90% of respondents in both
arms at baseline mentioned sleeping under a net as one way of preventing malaria, and this
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percentage remained similar at follow-up. The use of insecticide residual spraying and 
mosquito repellent were mentioned by less than 20% of respondents at both time points and 
across both arms. There was no significant difference in knowledge of preventive measures 
across the arms, nor was there a difference in knowledge in the sub-sample of outlets that 
attended the Tibamal® training in the intervention arm compared to the whole sample in the 
same arm (Table 5.14).
Table 5.14: Providers’ knowledge on cause and prevention of malaria (mean of cluster summaries 
from the 9 intervention and 9 control clusters)
Provider’s knowledge of malaria cause Control (N=9) Intervention (N=9) Difference in
and prevention % (SD) % (SD) means (95%CI)
Percentage who said that malaria was only 
caused by a parasite in a mosquito: 
Baseline 
Follow-up 
Tibamal® trained outlets
6.2 (3.0) 
6.9 (6.3)
11.3 (12.4)
10.3 (8.1) 
1 2 . 1  (8 .6 )
3.3 (-3.9,10.6)
Percentage of providers mentioning one 
of the below as a malaria preventative
measure:
Sleeping under a net: 
Baseline 
Follow-up 
Tibamal® trained outlets
93.5 (5.4) 
94.3 (4.7)
91.3 (6 .6 ) 
96.4(1.8) 
97.5 (3.9)
2.1 (-1.5, 5.7)
Indoor residual spraying: 
Baseline 
Follow-up 
Tibamal® trained outlets
13.9(11.3) 
17.0 (6.4)
15.7(10.2)
19.0(12.0)
23.9(13.6)
2.0 (-7.6, 11.6)
Mosquito repellent: 
Baseline 
Follow-up 
Tibamal® trained outlets
1 1 .6 (8 .1) 
7.2 (5.7)
11.4 (8.3) 
1 1 . 0  (6 .0 ) 
13.7 (8.5)
3.7 (-2.1, 9.6)
Respondents were asked to list common symptoms they would expect to observe in a
four year old child suffering from uncomplicated and complicated malaria (Table 5.15). Fever
was the most commonly reported symptom of uncomplicated malaria, mentioned by an
average of 67% of respondents at baseline. The number of respondents mentioning fever rose
more in the intervention arm compared to the control arm, resulting in a significant difference
between the means at follow-up of 9.7% points (95% CT. 2.4, 17.0). There was not much
difference seen in respondents mentioning other symptoms of malaria between the arms from
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baseline to follow-up, except for vomiting where, although a similar percentage of respondents 
mentioned vomiting as a symptom at baseline, the percentage decreased in the control arm and 
increased in the intervention arm creating an 11.1% point (95% Cl: 2.0, 22.4) difference 
between the means. The responses given by the sample of respondents in the intervention arm 
were similar to those given in the sub-sample of outlets trained on Tibamal® (Table 5.15).
Table 5.15: Providers’ knowledge on symptoms of uncomplicated malaria in a four year old child
(mean of cluster summaries from the 9 intervention and 9 control clusters)
Symptoms of uncomplicated 
malaria:
Control (N=9) 
% (SD)
Intervention (N=9) 
% (SD)
Difference in means 
(95%CI)
Fever:
Baseline 
Follow-up 
Tibamal® trained outlets
66.4(10.7) 
74.3 (8.0)
6 8 . 1  (1 1 .6 ) 
84.0 (6.5) 
87.3 (8.9)
9.7 (2.4, 17.0)
Sweating:
Baseline 
Follow-up 
Tibamal® trained outlets
20.4 (21.2) 
13.7(10.5)
19.9 (19.7) 
12.7 (9.2) 
13.6 (14.7)
-1.1 (-10.9,8.8)
Shivering:
Baseline 
Follow-up 
Tibamal® trained outlets
28.4(10.1)
30.2(11.8)
30.5 (6 .8 )
26.5 (11.0) 
21.2 (13.5)
-3.7 (-15.1,7.7)
Headache:
Baseline 
Follow-up 
Tibamal® trained outlets
45.2 (8.7) 
40.5 (8.3)
43.7 (12.7)
35.5 (7.7)
40.6 (9.5)
-5.0 (-13.0, 3.1)
Body pain:
Baseline 
Follow-up 
Tibamal® trained outlets
36.0(12.0) 
39.2 (10.6)
30.6 (9.6) 
35.1 (15.6) 
39.6(16.2)
-4.1 (-17.5, 9.2)
Mild cough or cough: 
Baseline 
Follow-up 
Tibamal® trained outlets
7.0 (6.7) 
6 . 6  (4.3)
5.9 (4.5) 
8.2 (4.8) 
11.3 (8.0)
1.6 (-3.0, 6.2)
Vomiting:
Baseline 
Follow-up 
Tibamal® trained outlets
39.7 (5.8) 
28.4 (9.2)
38.0 (11.1) 
40.6(11.1) 
49.3 (16.0)
11.1 (2.0, 22.4)
Diarrhoea:
Baseline 
Follow-up 
Tibamal® trained outlets
1 1 . 1  (1 0 .0 ) 
8.4 (6 .6 )
11.5 (7.5) 
10.3 (6.0) 
15.1 (7.9)
1.9 (-4.4, 8.1)
Irritability:
Baseline 
Follow-up 
Tibamal® trained outlets
2.1 (2.5)
4.2 (4.5)
2 . 2  (2 .1) 
3.7 (2.6) 
6.4 (7.8)
-0.5 (-4.2, 3.2)
Loss of appetite: 
Baseline 
Follow-up 
Tibamal® trained outlets
19.0 (9.5) 
21.5 (.10.5)
20.8 (6.7)
26.2 (7.2)
30.3 (8.7)
4.6 (-4.4, 13.7)
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The most mentioned symptom of complicated malaria was the child being unable to eat 
or drink, being mentioned by 35% and 36% of respondents at baseline in the control and 
intervention arm respectively; this rose to 40% in both arms at follow-up (Table 5.16). There 
was a 17% point increase in respondents in the intervention arm mentioning severe vomiting 
as a symptom from baseline to follow-up, and no change in percentage in the control arm 
resulting in a large 12% point (95%CI:3.5, 19.9) difference in means between the two arms at 
follow-up. The percentage mentioning convulsions as a symptom of complicated malaria 
increased by 11% points in the intervention and control arms. No significant difference was 
observed between the arms at follow-up for other symptoms of severe disease; responses from 
Tibamal® trained outlets remained relatively similar to all outlets in the intervention arm 
(Table 5.16).
5.2.6: Provider Knowledge of Malaria treatment
At baseline 38% of respondents in the control arm and 34% in the intervention arm were able 
to identify AL as the first line treatment recommended for malaria (Table 5.17). At follow-up 
knowledge of the first line treatment had improved in both arms, but was significantly greater 
in the intervention arm compared to the control arm (difference in means: 24.2% (95%CI: 
14.8, 33.6) p=0.0001 (p value remaining unchanged when controlled for outlet type). 
Knowledge of the first line treatment was 85% in Tibamal® trained outlets, 14% points higher 
than the average of all outlets in the intervention arm. Respondents were asked where they 
would recommend a four year old suspected to be suffering from uncomplicated malaria to 
seek treatment first (Table 5.18). At baseline, across both arms, just over one third said they 
would refer the child directly to a health facility. The percentage recommending this action 
remained similar at follow-up in the control arm, while in the intervention arm, there was a
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significant 13% point decrease in the percentage that would make the same recommendation, 
resulting in a 19.9% point (p value=0.0003; 95% Cl: 10.7, 29.1) difference at follow-up 
observed between the arms. At baseline just over half of respondents said they would advise 
the child’s caregiver to buy medicine from a retail outlet.
Table 5.16: Providers’ knowledge on symptoms of complicated malaria in a four year old child
(mean of cluster summaries from the 9 intervention and 9 control clusters)
Symptoms of complicated malaria: Control (N=9) 
% (SD)
Intervention (N=9) 
% (SD)
Difference in means 
(95%CI)
Convulsions:
Baseline 32.2 (8.7) 33.4(11.3)
Follow-up 41.3 (14.5) 41.3 (10.6) 0.0 (-12.7, 12.7)
Tibamal® trained outlets - 52.8 (12.7)
Severe Weakness:
Baseline 24.4 (12.0) 24.8 (12.8)
Follow-up 33.8(11.6) 35.8 (12.2) 2.0 (-9.9,13.9)
Tibamal® trained outlets - 36.6 (14.7)
Abnormal Breathing:
Baseline 23.9(11.3) 24.0(11.9)
Follow-up 15.8 (7.7) 23.0 (6.0) 0.1 (-11.5, 11.7)
Tibamal® trained outlets - 24.7 (15.6)
Unconsciousness:
Baseline 13.2 (7.0) 10.6 (5.3)
Follow-up 10.3(7.9) 17.0 (6.7) 6.7 (-0.6,14.0)
Tibamal® trained outlets - 20.1 (11.7)
Unable to eat or drink:
Baseline 35.1 (14.2) 36.0(15.6)
Follow-up 39.5 (12.7) 40.3 (13.7) 0.8 (-12.4, 14.0)
Tibamal® trained outlets - 43.2 (16.7)
Severe vomiting:
Baseline 17.4 (7.6) 12.7 (7.6)
Follow-up 17.9 (8.5) 29.6 (7.9) 11.7 (3.5,19.9)
Tibamal® trained outlets - 37.6(16.0)
Severe diarrhoea
Baseline 6.7 (6.2) 5.4 (5.3)
Follow-up 6.1 (3.2) 5.9 (3.2) -0.1 (-3.4, 3.1)
Tibamal® trained outlets - 8 . 8  (5.7)
The percentage of respondents recommending this action remained similar at follow-up 
in the control arm but increased to 71% in the intervention arm (difference in means: 19.3%; 
95% Cl 9.9, 28.8). Changes observed in the intervention arm outlets were reflected in the sub­
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sample of Tibamal® trained outlets but were more exaggerated. No respondent said they would 
refer caregivers to a traditional healer (Table 5.18).
Table 5.17: Providers knowing the recommended 1st line treatment for uncomplicated malaria
(mean of cluster summaries from the 9 intervention and 9 control clusters)
Percentage of outlets knowing Control (N=9) 
the first line antimalarial for % (SD)
uncomplicated malaria:
Baseline 37.8 (9.0)
Follow-up 46.9 (7.6)
Tibamal® trained outlets
Intervention (N=9) 
% (SD)
34.3 (16.6)
71.1 (10.9)
84.8 (7.7)
Difference in 
means (95%CI)
24.2 (14.8, 33.6)
P value 
Adjusted 
Unadjusted
0.0001
0.0001
Table 5.18: Advice on where to first seek treatment for uncomplicated malaria in a four year old 
child (mean of cluster summaries from the 9 intervention and 9 control clusters)
Advice on where to seek treatment: Control (N=9) 
% (SD)
Intervention (N=9) % 
(SD)
Difference in means 
(95%CI)
Health facility:
Baseline 39.0 (17.7) 38.0 (16.8)
Follow-up 44.7 (10.0) 24.8 (8.4) -19.9 (-10.7, -29.1)
Tibamal® trained outlets - 7.4 (4.3)
Buy medication from a retail outlet :
Baseline 52.5(18.2) 56.0 (19.6)
Follow-up 51.6(11.9) 70.9(6.1) 19.3 (9.9, 28.8)
Tibamal® trained outlets - 88.9 (4.3)
Traditional healer:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0 (0 )
Tibamal® trained outlets - 0 (0 )
Would not know what to do:
Baseline 4.9 (1.7) 2 . 6  (2 .6 )
Follow-up 2.3 (2.6) 1 . 2  (1 .8 ) -1.1 (-3.3, 1.2)
Tibamal® trained outlets - 0 (0 )
Other1:
Baseline 0.7 (1.5) 0.4 (1.7)
Follow-up 0 (0 ) 0.4 (1.2) 0.4 (-0.4,1.2)
Tibamal® trained outlets - 0 (0 )
1 Other includes treatment at home with western medications, keeping the child warm when it is cold and maintaining good 
hygiene.
Denominators: refer to table 5.3; Tibamal® trained outlets: control=3, intervention^36
When it came to treating complicated malaria in children of four years, over 70% of 
respondents at baseline, in both arms said they would refer the child directly to a health 
facility (Table 5.19). This increased to 80% or more at follow-up, across the arms, and reached 
91% in the sub-sample of Tibamal® trained outlets. At baseline, 16% in the control arm and
19% in the intervention arm said they would advise the child to be treated with medication 
from a retail outlet; at follow-up this decreased to 11% in both arms, and 8% in Tibamal® 
trained outlets (Table 5.19). The distance of providers from a public health facility had no 
significant impact on place of referral (appendix 11).
Table 5.19: Advice on where to first seek treatment for complicated malaria in a four year old 
child (mean of cluster summaries from the 9 intervention and 9 control clusters)
Advice on where to seek treatment: Control 
(N=9) % (SD)
Intervention 
(N=9) % (SD)
Difference in means 
(95%CI)
Health facility:
Baseline 74.1 (12.0) 75.9 (7.3)
Follow-up 83.7 (6.4) 86.9 (4.0) 3.21 (-2.1, 8 .6 )
Tibamal® trained outlets - 90.6 (2.5)
Buy medication from a retail outlet:
Baseline 16.0(10.3) 18.6(6.9)
Follow-up 11.1 (5.9) 10.5 (5.0) -0.6 (-6.1, 4.9)
Tibamal® trained outlets - 8.0 (7.8)
Traditional healer:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0 (0 )
Tibamal® trained outlets - 0 (0 )
Would not know what to do:
Baseline 4.4 (2.3) 2.1 (3.3)
Follow-up 4.2 (3.3) 1 . 8  (2 .2 ) -2.4 (-5.2, 0.4)
Tibamal® trained outlets - 0 (0 )
Other1:
Baseline 0 . 6  (1 .1 ) 1.5 (3.2)
Follow-up 1.5 (1.5) 1.0 (1.5) -0.5 (-2.0, 1.0)
Tibamal® trained outlets - 0 . 6  (1 .8 )
'Other includes praying and sponging the child
Denominators: refer to table 5.3; Tibamal® trained outlets: control=3, intervention=136
5.2.7: Provider knowledge of AL dispensing practices
Respondents were asked about the advice they would give to a caregiver purchasing any brand 
of AL for their four year old child (Table 5.20). Respondents were asked to advise on AL 
administration, what to do if the child vomits, what to do if the child does not improve, and 
foods to administer with the medication . Less than 1% of respondents at baseline were able
3 Correct advice: AL administration: two tablets twice daily for three days with an eight hour gap between the 
first and second dose; Vomiting: repeat dose vomited if child vomits up to an hour after administration. Those 
purchasing Tibamal® should return to the outlet to get a replacement for the tablets vomited; if the child does not 
improve: go to the health facility. Those trained on Tibamal® were to advise the caregiver to return to the outlet 
for a referral form before proceeding to the health facility; Foods to administer: milk, bananas, honey and fatty 
foods to be given with the tablets.
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to give the correct advice on AL administration, and this remained the case in the control arm 
at follow-up. However in the intervention arm 13% of respondents were able to give the 
correct advice at follow-up (difference in means 11.7%; 95% Cl: 3.7, 19.8)). Similarly, advice 
on what to do if the child vomits was 0% at baseline in both arms, rising to 2% in the control 
arm at follow-up, and 9% in the intervention arm (difference in means: 7.9% (95% Cl: 2.9, 
12.9)). Respondents were most knowledgeable on the type of advice to give if the child does 
not improve, with 46% and 49% giving the correct response at baseline in the control and 
intervention arms respectively. This percentage remained constant in the control arm at 
follow-up, however in the intervention arm the percentage increased to 66% (difference in 
means: 26.2 (95%CI: 15.0, 37.4)). The correct advice on what foods to give the child also 
improved by 19% points from baseline to follow-up in the intervention arm and by 2% points 
in the control arm (difference in means: 21.1% (95%CI: 12.1, 30.0)). Tibamal® trained outlets 
were more knowledgeable in treatment advice, however only 3% in the intervention arm stated 
that they would tell the patient to return to the outlet to replace any Tibamal® doses that the 
child vomited, and only 13% would tell the caregiver to return for a referral form to go to the 
health facility if the child had taken Tibamal® and did not improve (Table 5.20).
5.2.8: Provider knowledge of adverse drug reactions to AL
At both baseline and follow-up, and between control and intervention arms, less than 13% of 
respondents were able to identify each of the possible AL ADR symptoms highlighted during 
the training. Tibamal® trained outlets did not perform much better than all outlets in the 
intervention arm (Table 5.21).
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Table 5.20: Respondents giving the correct dispensing advice for AL use in a four year old child
(mean of cluster summaries from the 9 intervention and 9 control clusters)
Percentage of respondents that Control (N=9) Intervention (N=9) Difference in means 
knew the correct advice to give % (SD) % (SD) (95%CI)
while dispensing AL
concerning:_______________________________________________________________________
AL administration:
Baseline 0.7 (1.4) 0 (0 )
Follow-up 1.2 (1.5) 13.0(11.3) 11.7 (3.7, 19.8)
Tibamal® trained outlets - 22.5 (19.3)
What to do if the child vomits 
after taking the medication:
Baseline 
Follow-up 
Tibamal® trained outlets
0 (0 ) 
1.5 (2.4)
0 (0 )
9.4 (6.7) 
18.6(11.2)
7.9 (2.9,12.9)
What to do if the child does not 
improve:
Baseline 46.4 (10.0) 49.0 (12.6)
Follow-up 39.8 (13.6) 66.0 (8.3) 26.2(15.0,37.4)
Tibamal® trained outlets: - 94.0 (6.3)
Foods to give the child with AL
Baseline 8.3 (5.7) 8 . 6  (9.8)
Follow-up 6.3 (5.9) 27.4(11.2) 21.1 (12.1,30.0)
Tibamal® trained outlets - 46.8 (15.4)
Denominators: refer to table 5.3; Tibamal® trained outlets: control=3, interventional36
Correct advice: AL administration: two tablets twice daily for three days with an eight hour gap between the first 
and second dose; Vomiting: repeat dose vomited if child vomits up to an hour after administration. Those 
purchasing Tibamal® should return to the outlet to get a replacement for the tablets vomited; if the child does not 
improve: go to the health facility. Those trained on Tibamal® were to advise the caregiver to return to the outlet 
for a referral form before proceeding to the health facility; Foods to administer: milk, bananas, honey and fatty 
foods to be given with the tablets.
Around 27% to 29% of respondents at follow-up across both arms said they would refer 
a patient directly to a health facility if they identified symptoms of an AL ADR (Table 5.21). 
This increased slightly to 38% at follow-up in the control arm and 45% in the intervention arm 
(no significant difference between arms, p value= 0.1535 (difference in means 7.7%; 95%CI: - 
3.2, 18.5). An average of 13% of respondents across both arms and time points said that they 
had observed what they thought was an ADR to AL. Of those who said they had observed an 
ADR, 35% and 52% at baseline in the control and intervention arm respectively reported to 
have referred patients directly to a health facility. At follow-up the percentages were similar in 
the two arms at 33% and 35% in the control and intervention arms respectively (p
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value=0.8982) (difference in means: 1.8%; 95% Cl: -27.8, 31.4). AL ADR referral practices of 
Tibamal® trained outlets were similar to all outlets in the intervention arm (Table 5.22).
Table 5.21: Percentage of respondents knowing AL ADR symptoms (mean of cluster summaries 
from the 9 intervention and 9 control clusters)
Percentage of outlets that 
can identify symptoms of 
suspected AL/ Tibamal® 
ADRs
Control (N=9) 
% (SD)
Intervention (N=9) % 
(SD)
Difference in means 
(95%CI)
Nausea:
Baseline 11.2 (7.45) 9.8 (8 .8 )
Follow-up 7.6 (7.5) 6.4 (6.3) -1.1 (-8.0, 5.7)
Tibamal® trained outlets - 8.9 (14.2)
Vomiting:
Baseline 11.3 (8 .6 ) 11.1 (7.9)
Follow-up 6.4 (7.0) 6.1 (5.1) -0.3 (-6.4, 5.8)
Tibamal® trained outlets - 7.6 (7.1)
Diarrhoea:
Baseline 4.8 (7.3) 4.8 (6.4)
Follow-up 2.1 (2.7) 1 . 6  (2 .2 ) -0.4 (-2.9, 2.1)
Tibamal® trained outlets - 2.2 (3.4)
Dizziness:
Baseline 12.6 (9.0) 7.5 (6.2)
Follow-up 12.9 (11.8) 11.8(9.6) -4.9 (-15.7,5.9)
Tibamal® trained outlets - 11.7(13.6)
Skin rash:
Baseline 4.5 (5.0) 2.9 (2.9)
Follow-up 5.3 (3.8) 9.2 (6.0) 3.9 (-1.2, 8.9)
Tibamal® trained outlets - 2.2 (3.4)
Itching/ scratching:
Baseline 7.4 (5.1) 8.3 (5.6)
Follow-up 5.7 (2.8) 10.5 (5.0) 4.8 (0.7, 8.9)
Tibamal® trained outlets - 14.8 (8.3)
Denominators: refer to table 5.3; Tibamal® trained outlets: control=3, intervention^36
Outlets were supplied with CHW referral forms by PSI. These were to be filled out for 
each suspected ADR or failed treatment with AL and taken by the patient to the facility. A 
copy was to remain in the outlet to be collected by one of the PSI sales staff and sent to the 
Pharmacy and Poisons Board. 40% of outlets at follow-up in the intervention arm had CHW 
referral forms and 19% of outlets said they had filled in a form during the past one month 
(Table 5.23). Around 2% of outlets in the control arm reported having referral forms of which 
half said they had filled a form in within the past month. 78% of Tibamal® trained outlets in
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the intervention arm had referral forms of which 18% had been filled in within the past month. 
Although 19% of 125 outlets with CHW forms said they had filled in a referral form within 
the past month only one filled in form was received by PSF PPB over the 8 months that 
Tibamal® drug distribution was on-going. CHW referral forms are also used outside of the 
Tibamal® study by Child and Family Wellness Clinics and also CHWs who may also own or 
work in drug shops. From the data available, it was not possible to distinguish forms from the 
study and those from other sources. Also, since it seems a large proportion of the forms did 
not reach the PPB, it is not possible to identify the proportion of forms filled in that 
represented ADRs and those that represented treatment failures.
Table 5.22: Respondents’ referral practices for suspected AL ADRs (mean of cluster summaries 
from the 9 intervention and 9 control clusters)
Referral practices for suspected AL 
ADRs:
Control (N=9) 
% (SD) 
n
Intervention (N=9) 
% (SD) 
n
Difference in 
means (95%CI)
Percentage of outlets that would 
immediately refer patients to a health 
facility for a suspected ADR*: 
Baseline 
Follow-up 
Tibamal® trained outlets
27.1 (10.6) 
37.5 (9.3)
29.3(10.1)
45.2(12.2)
55.0(11.3
7.7 (-3.2,18.5)
Percentage of outlets that had observed 
a suspected AL ADR1:
Baseline
Follow-up
Tibamal® trained outlets
13.2 (8.7) 
27 
11.6 (9.6) 
36
13.6(11.2)
23
11.4(4.6)
35
20.4 (9.6)
-0.2 (-7.7, 7.3)
Of those observing a suspected AL 
ADR: percentage that referred a 
suspected AL ADR directly to a health 
facility:
Baseline 32.1 (34.0) 2 52.4 (31.1)1
Follow-up 32.9 (29.1)1 34.7(26.0) 1.8 (-27.8,31.4)
Tibamal® trained outlets 32.4 (22.2)
1 cluster summaries from 7 clusters;2 cluster summaries from 8 clusters; Denominators: refer to table 5.3; Tibamal® trained 
outlets: control=3, intervention=136
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Table 5.23: Respondents’ use of CHW referral forms at follow-up (mean of cluster summaries 
from the 9 intervention and 9 control clusters)
CHW referral forms: Control (N=9) Intervention (N=9) Difference in P value
% (SD) % (SD) means (95%CI) Unadjusted
_____________________________________ n_______________ n___________________________ Adjusted
Percentage of outlets with CHW 2.2 (1.7) 39.6(14.2) . .. .  . 0.0001
forms: 7 125 { } 0.0001
Tibamal® trained outlets 78.0 (15.5)
"   110 "
50.0 (54.8) 1 19.8 (12.6)
18.2 (15.9)
1 cluster summary from 6 clusters; Denominators: refer to table 5.3; Tibamal® trained outlets: control=3, intervention^36
5.2.9: Factors influencing antimalarial stocking and selling practices
The five most common factors determining which antimalarials to stock at follow-up are 
shown in Figure 5.5 (interviewees could specify more than one factor). By far the most 
frequently cited factor in both arms was customer demand, mentioned by 90% and 82% in the 
control and intervention arm respectively. The next most common factors mentioned were 
MOH recommendations and affordability. The percentage mentioning the importance of the 
medication being recommended by the MOH was almost twice as high in the intervention 
group than in the control (21% and 11% respectively). The need for the drug to be affordable 
to the provider was mentioned by 31% of respondents in the control arm and 19% in the 
intervention arm, while the influence of PSI staff on what to stock was only mentioned in the 
intervention arm by 12% of respondents. In Tibamal® trained outlets, customer demand was 
also mentioned the most, followed by the influence of the MOH (30%) and PSI sales staff 
(20%) (Figure 5.5).
Figure 5.6 displays the five most mentioned factors influencing which antimalarial a
retailer will sell to a customer, if the outlet usually stocked more than one antimalarial. The
percentage of responses remained similar at baseline and follow-up for each factor. The most
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Of which:
Percentage of outlets that had filled 
in a CHW form in the past month 
Tibamal® trained outlets
common influence was again customer demand, mentioned by 65% and 66% of respondents in 
the control and intervention arm respectively. In Tibamal® trained outlets, customer demand 
was also the most commonly mentioned (65%). If a customer came to buy antimalarials from 
an outlet and did not have enough money, 63% of respondents in the control arm and 71% in 
the intervention arm said they would give the antimalarial to the customer on credit; credit was 
more likely to be given if the respondent knew the customer (Figure 5.7). Around one third of 
respondents in both arms said they would refuse to sell the medication to the customer. Less 
than 20% said they would refer the customer elsewhere (for example to a health facility where 
treatment should be free); offer cheaper alternatives, or sell part of a frill dose. Responses 
given by Tibamal® trained outlets were similar to those of all outlets in the intervention arm 
(Figure 5.7).
Figure 5.5: Factors influencing which antimalarials to stock at follow-up (mean of cluster 
summaries from the 9 intervention and 9 control clusters)
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Figure 5.6: Factors influencing which antimalarials to sell, if more than one antimalarial is 
available, at follow-up (mean of cluster summaries from the 9 intervention and 9 control clusters)
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Figure 5.7: Actions respondents take if customer has insufficient funds, at follow-up (mean of 
cluster summaries from the 9 intervention and 9 control clusters)
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5.3: DISCUSSION
Exposure of the control arm population to the intervention (“contamination”) was minimal, 
with only one control respondent saying that they had attended the Tibamal® training and 
usually sold Tibamal® (though they had none in stock on the day of the survey), and only 14% 
having heard of Tibamal®.
However, several other limitations should be borne in mind when interpreting the study 
findings. It is well known that there is often a difference between provider knowledge and 
provider behaviour. Therefore the percentage correctly answering questions on areas such as 
counselling advice should be considered as the upper bound of those actually providing such 
advice to consumers. There is also generally a gap between reported and actual behaviour, 
reflecting social desirability bias i.e. the respondents aim to present themselves in a favourable 
light to the survey team. This may lead them to for example under-report the frequency with 
which they would sell under-doses to caregivers with insufficient funds, or to report lower 
than actual retail drug prices. It will be possible to investigate these issues further by 
comparing the provider survey data with that obtained from the mystery shopper activity 
(Chapter 6). Stock outs were assessed by asking providers if they had experienced any stock 
outs of AL over the past two weeks prior to the survey. Since very few outlets keep any 
documentation of their stocks, the recall period was limited to the previous two weeks to 
minimise re-call bias. Only outlets that currently had stocks of AL were asked about the 
duration of any past stock outs, as they were therefore able to provide a definite end date of 
any stock-outs. This may have underestimated the real duration of stock outs since outlets 
currently out of stock were excluded from the analysis and they could have been the outlets 
that had suffered from the longest duration of stock-outs.
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Shops that had undergone Tibamal® training were identified by asking the respondent if 
any of the staff had attended the training. There may have been some respondents that wrongly 
informed us that no staff had attended the training either because of recall bias or because they 
were not aware that anyone did attend the training. However the differences observed in 
responses given from Tibamal® trained outlets to all outlets in the intervention arm (trained or 
not) do indicate that most Tibamal® trained outlets were correctly identified. The intervention 
improved access to AL treatment by significantly increasing the availability of AL in retail 
outlets to 37% in the intervention arm compared with 5% in the control, and decreasing its 
median cost by around 9 shillings per tablet (0.11 USD). This is equivalent to a 12 pack dose 
given to children 3 to 7 years costing 40 KSH (0.48 USD) instead of 151 KSH (1.86 USD) and 
an adult’s 24 pack dose costing 79 KSH (0.97 USD) instead of 300 KSH (3.69 USD). 
Providers also became more knowledgeable on how to treat uncomplicated malaria with 71% 
in the intervention arm compared to 47% in the control arm knowing the government 
recommendation for the first line drug. Tibamal® was also seen as effective, with the vast 
majority of intervention respondents at follow-up reporting it to be more effective than other 
antimalarials. The findings from this survey also show the key importance of consumer 
demand in determining what drugs are stocked and sold to customers, and indicate that the 
Tibamal® community awareness activities were also likely to have made an important 
contribution to provider awareness. Slightly worrying is that a percentage of providers, albeit 
small (<5% in Tibamal® trained outlets) were willing to sell customers less than the 
recommended dose of treatment if the customer had insufficient funds. Patients taking less 
than the recommended dose of AL treatment reduces levels of adherence and is a potential 
factor for increasing drug selection pressure and hence parasite resistance to the treatment. 
Ideally no provider should sell insufficient doses to customers. This is something that needs to
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be reinforced in training and follow-up supervision, and providers should be made aware of 
the negative effects of such practices.
The finding that only slightly over one third of outlets in the intervention arm stocked 
AL at follow-up reflects the fact that not all retailers were eligible or willing to stock 
Tibamal®. The subsidised drug should only have been stocked by those who had attended the 
Tibamal® training (i.e. 43% of intervention outlets). The remaining 57% of outlets were not 
trained for a number of reasons. Outlets selected for training were identified during the 
baseline retail census and had to have been functioning for a minimum period of six months 
and have been selling an anti-malarial or anti-pyretic within the past year. Some new outlets 
were added to the sample frame at follow-up that met the criterion of being established for at 
least 6 months, but would not have been eligible for Tibamal® training at baseline. Also as 
businesses sometimes change the type of business they run, outlets previously never selling 
medication may have decided to do so between the two study time points, but would not have 
met the training criteria at baseline. In addition, some outlets identified for inclusion were 
unable to attend the training due to other commitments; and some outlets may have been 
closed when invitations to attend training were being given. Even after receiving training some 
outlets may have changed the type of business they were running and stopped selling 
medication, closed up their business, or relocated to outside the study area. These issues 
highlight the challenges of maintaining a trained cadre of retailers in such a dynamic market.
All trained shops were given the option of stocking AL but not all opted for this, mainly
because they did not have sufficient funds to purchase AL from the PSI sales staff (personal
communication Mbogo Mbunyi, PSI). On the other hand 15 intervention outlets stocked
Tibamal® even though none of the staff were reported to have attended the Tibamal® training.
It was not clear whether this was because the staff member who had attended training was not
present on the day of survey and other staff were not aware that they had attended, whether
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this indicated that some untrained shops were selling the subsidised drug, or whether the 
trained staff were no longer working in the outlet.
There was low availability artemisinin monotherapies in the retail outlets. This was not 
likely to be as a result of the intervention since stocks were low both at baseline and follow-up 
and in both arms. Further enquiry of this observation from FGDs with shopkeepers revealed 
that one of the reasons for this is the high cost of these treatments making it unaffordable for 
both retailers to purchase them from wholesalers and for consumers (Kedenge, 2011).
Storage of AL was generally good in shops. However, at follow-up 33% of intervention 
outlets reported a stockout of at least one AL pack in the past 2 weeks, indicating that 
consistent availability of all pack sizes could be problematic.
Providers’ knowledge of causes and prevention of malaria did not change post­
intervention. However, in intervention areas providers were significantly more aware that 
fever was an important symptom of uncomplicated malaria. Knowledge of the symptoms of 
complicated malaria did not change post-intervention with the exception of severe vomiting.
There were significant improvements observed in the knowledge of counselling advice
when selling AL in the intervention arm compared to the control arm, especially in the
Tibamal® trained outlets. However, with the exception of advice on what to do if the child
does not improve, overall the percentages remained low. Of particular concern was the low
percentage knowing the correct dosing for AL. These results reflect in part the partial
coverage of training described above, but may also indicate poor understanding of these
concepts in training, or the 9 month gap between training and the follow-up survey. During
FGDs one of the providers commenting on this observation stated ‘ those that were trained the
first time could have forgotten some o f the information; because it was a one day training, and
they probably did not get time to go over the notes that they were given, so they only give the
advice that they remember and leave the rest that they have forgotten’. Another factor
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possibly contributing to this is the low percentage of trained outlets that had Tibamal® job 
aids. These jobs aids contained dosing advice and were designed to support the provider in 
correctly dispensing AL/ Tibamal®. No reasons were given as to why so few outlets contained 
job aids.
Knowledge of the symptoms of AL ADRs remained low post-intervention, not reaching 
15% for any individual symptom. Although at follow-up over 80% of providers in both arms 
knew to refer children directly to a health care facility to treat complicated malaria, this was 
not the case for children suffering from potential ADRs, with less than half in both arms 
saying they would refer the child directly to a health facility. The utility of the CHW referral 
forms remains questionable since many patients may not return to the retailer if they have 
ADR symptoms. From these data, it is not clear from the 40% of outlets with CHW forms how 
many had them supplied by the PSI sales staff and how many had them supplied from 
elsewhere, nor is it clear how many of the referrals were due to AL adverse events or 
treatment failure.
Summary: The intervention was successful in significantly improving access to AL treatment 
by increasing the availability of AL in retail outlets, improving the affordability of the 
treatment and increasing the percentage of providers knowing the government 
recommendation for the first line treatment of uncomplicated malaria. However, the 
intervention was not as successful in improving provider’s knowledge of causes and 
prevention of malaria; knowledge of AL counselling advice (except on what to do if the child 
does not improve), and knowledge of symptoms of AL adverse drug reactions. A very low 
percentage of providers reported having used the CHW forms. The provider survey mainly 
focused on how the intervention was able to improve provider knowledge on appropriate 
standards of quality for the treatment of fever in children under five. The following chapter
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(Chapter 6) presents the mystery shopper survey, which was used to assess whether the 
intervention was able to improve provider behavior when selling drugs.
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CHAPTER 6 
MYSTERY SHOPPER SURVEY
6.1: INTRODUCTION
This chapter reports the results of the mystery shopper survey of drug outlets. The purpose of 
this study was to analyse the patient provider interaction to give better information on actual 
rather than self-reported provider behaviour, contributing to the second specific objective of 
the thesis: To determine if private sector retailers can deliver AL to appropriate standards of 
quality for the treatment of fever in children under five years. The mystery shopper survey 
took place a month after the retail census, at baseline and follow-up. Field workers, disguised 
as local residents visited selected outlets seeking treatment for a four year old child with fever. 
The fieldworkers presented the following scenario: a 4 year old child (weighing 15kg) under 
their care who has been suffering from a recurring fever for 3 days, especially at night. The 
child had no other symptoms, and no medication had been given to the child so far. The field 
worker was then to wait for the provider to ask further questions and/ or prescribe a 
medication. If no medicine was recommended, field workers were to prompt the provider to 
recommend a medicine. If after prompting no medicine was recommended then the field 
worker was instructed to find out reasons as to why. If a medicine was recommended then the 
field worker was to find out why the provider suggested that particular medicine. Details of 
the interview were discretely filled in structured questionnaires away from the outlet, once the 
interview was completed. As with the provider survey, outlets were included in the mystery 
shopper survey sample if they had been functioning for a minimum period of six months prior 
to the start of the retail census and had been selling either antimalarials or antipyretics within 
the past year. Mystery shoppers interacted with whichever retailer was present at the time of 
the survey. Written consent for the mystery shopper survey was obtained during the retail
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census carried out two months prior to the mystery shopper visits, from the provider present at 
that time in the outlet. Full details of the methods for the mystery shopper survey are 
presented in Chapter 4.
The results are presented in section 6.2. Section 6.2.1 describes the characteristics of the 
outlets interviewed. Section 6.2 looks at what signs and symptoms providers enquired about 
before making a diagnosis and prescribing treatment. Section 6.3 onwards looks at the 
percentage of providers who dispensed an antimalarial, and in particular AL. For those outlets 
that did dispense AL, these sections further analyse the type of advice given on how to take 
the AL and the amount paid for AL by the mystery shopper.
6.2: RESULTS 
6.2.1: Outlet characteristics
During the retail censuses, a total of 600 outlets were identified at baseline and 818 at follow- 
up, selling an anti-malarial, an anti-pyretic or both. Of these, only outlets that had been 
reported to be functioning for 6 months or more were included in the sampling frame for the 
survey comprising 295 and 225 outlets in the control and intervention arms respectively at 
baseline and 369 and 351 respectively at follow-up (Table 6.1). A total of 499 outlets were 
successfully interviewed at baseline, 284 and 215 in control and intervention arms 
respectively, and 653 outlets at follow-up, 336 in the control and 317 in the intervention arm. 
These numbers form the denominator for other tables and figures in this chapter. Both at 
baseline and follow-up, over 90% of the outlets sampled were successfully interviewed, with 
the majority (over 70%) of outlets interviewed being general stores (Table 6.2). During the 
provider survey described in Chapter 5, retailers were asked for details on outlet staffing and 
training of employees. The characteristics of the outlets and staff surveyed for the mystery 
shopper survey remained similar to those of the provider survey (see Chapter 5).
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Table 6.1: Outlets included in the mystery shopper survey
Outlets sampled 
Outlets interviewed1
Baseline 
Control Intervention
n (%) n (%)
295 225
284/295 (96.3) 215/225 (95.6)
Follow-up 
Control Intervention
n (%) n (%)
369 351
336/369(91.1) 317/351 (90.3)
Reasons for an outlet not being interviewed included: temporary closure, permanent closure, change of type of business, 
moving location, declining to be interviewed for the mystery shopper survey at the time of the retail census or duplication 
during the retail census.
Table 6.2: Distribution of outlets successfully interviewed, by type (mean of cluster summaries 
from the 9 intervention and 9 control clusters)
Baseline Follow-up
Control Intervention Control Intervention
(N=9) (N=9) (N=9) (N=9)
% (SD) % (SD) % (SD) % (SD)
n n n n
Specialized drug stores1 17.9 (10.0) 25.0 (13.7) 17.3 (8 .6 ) 2 2 . 0  (8 .2 )
48 55 58 71
General stores 82.1 (1 0 .0 ) 74.6 (14.0) 82.7 (8 .6 ) 77.9 (8.2)
236 159 278 246
Other outlet type2 0 . 0  (0 ) 0.4 (1.3) 0 . 0  (0 ) 0 . 0  (0 )
0 1 0 0
1 Specialized drug stores included: pharmacies, chemists, drag shops, clinics with over the counter services, Bamako Initiative (BI) outlets 
and Child and Family Wellness Clinics.
2
Other outlet type= an agro vet shop
6.2.2: Asking about signs of severe disease
To determine need for referral of a child to a health facility, retailers were expected to ask 
about various symptoms that the child could be experiencing. As per the retailer training, these 
signs included: inability to eat, drink or breastfeed, convulsions, severe weakness, 
unconsciousness (coma), abnormal breathing, severe vomiting and severe diarrhoea. At 
baseline, staff at 27% of outlets in the control arm and 22% in the intervention arm asked 
whether the child had at least one of these signs of severe disease. At follow-up there was a 
slight increase (12% points) in the intervention arm to 33% for all outlets. There was a 19% 
point increase in the intervention arm for general stores from 11% at baseline to 30% at 
follow-up but a 17% point fall from 55% to 38% in specialized drug stores. There was no
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evidence of a significant difference between the control and intervention arms at follow-up 
(unadjusted p=0.4295; adjusted p=0.3824). On average about 45% of outlets with staff with 
clinically related training asked about at least one severe sign at baseline and about 35% at 
follow-up across both arms (Table 6.3). In the intervention arm at follow-up, 41% of outlets 
with staff with Tibamal® training, compared to 22% of those without Tibamal® training asked 
about signs of severe disease.
Table 6.3: Percentage of outlets where retailers asked whether the child had at least one sign of 
severe disease (mean of cluster summaries from the 9 intervention and 9 control clusters)
All outlets:
Control 
(N=9) 
% (SD)
Intervention
(N=9)
% (SD)
Difference in means 
(95% Cl)
P-value
Unadjusted
Adjusted
Baseline
Follow-up
By outlet type:
26.5 (14.1) 
27.4 (10.7)
21.6(12.4) 
33.3 (14.2) 5.9 (17.7, -7.9) 0.42955
0.2667
Specialized drug stores: 
Baseline 
Follow-up 
General stores:
Baseline
Follow-up
50.2 (29.9) 
37.2(18.1)
21.6 (12.7) 
24.4 (12.8)
55.1 (15.2) 
37.8 (25.0)
11.0 (9.2)
30.1 (17.9)
0.6(22.4, -21.2) 
5.6(21.2, -9.9)
By whether any staff have 
clinically-related training2:
Outlets with clinically-related 
training:
Baseline 
Follow-up 
Outlets without clinically-related 
training:
Baseline
Follow-up
47.5 (28.6)
34.5 (25.4)
22.0 (13.2) 
26.3 (14.7)
44.8 (29.7)
37.4 (31.1)
15.9 (9.9)
29.5 (18.6)
2.9 (31.3,-25.5) 
3.3 (20.0, -13.5)
1 P-value: The p value appearing on top refers to the level of significance of the unadjusted difference between control and 
intervention arms at follow-up. The p value underneath in italics refers to the level of significance of the adjusted difference 
between the control and intervention arm at follow-up.
2 Information based on outlets interviewed both for mystery shopper and provider survey, 
difference in difference analysis, unadjusted p value=0.2283 (appendix 12)
6.2.3: Drugs dispensed, reasons for not dispensing and referral advice 
Tables 6.4-6.6 show the various drugs dispensed by the retailers and reasons given by outlets 
that did not dispense drugs. Tables 6.7 & 6.8 show referral advice given by retailers and 
specifically by outlet type. Tables 6.9 & 6.10 give similar details of drugs dispensed
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comparing specialized drug stores and general stores. 70% and 60% of outlets visited at 
baseline and follow-up respectively dispensed drugs to mystery shoppers. Retailers that 
dispensed drugs dispensed antipyretics, antimalarials and other drugs including antibiotics, 
anti-histamines, antihelminthics and bronchodilators (see footnote to Table 6.9 for details of 
specific drugs). At baseline, 44% in the control and 29% in the intervention arm sold an anti­
pyretic on its own. At follow-up, there was a significant 17% point difference between arms 
for this indicator (unadjusted p=0.0074; adjusted p=0.0175), with 36% of outlets in the control 
and 19% in the intervention arm dispensing an anti-pyretic on its own. At baseline 25% of 
outlets in the control arm and 41% in the intervention arm, dispensed antimalarials, which was 
fairly similar at follow-up with 20% of outlets in the control and 40% in the intervention arm 
dispensing an antimalarial (Table 6.4). The difference between arms at baseline was 16% 
points and 20% points at follow-up.
Table 6.4: Drugs dispensed by retailers (mean of cluster summaries from the 9 intervention and 9 
control clusters)
Type of drugs 
dispensed:
Control 
(N=9) 
% (SD)
Intervention
(N=9)
% (SD)
Difference in means 
(95% Cl)
P-value
Unadjusted
Adjusted
Any drug:
Baseline
Follow-up
69.6 (10.0) 
56.8 (6.1)
69.4 (8.2) 
59.7 (6.9) -2.9 (-3.6, 9.3) 0.3651
0.9116
Type of drugs dispensed 
Anti-pyretic alone: 
Baseline 
Follow-up
43.6(13.3) 
35.7 (7.7)
28.7 (9.1) 
18.6 (5.3) -17.1 (-10.5,-23.7) 0.0074
0.0203
Anti-pyretic with anti- 
malarial:
Baseline
Follow-up
20.2 (7.5) 
15.1 (3.6)
26.9 (8.0) 
23.4 (7.3) 8.3 (14.0, 25.7) 0.5808
0.1317
Any anti-malarial
Baseline 25.2 (8.9) 40.7 (9.3)
Follow-up 20.2(3.7) 40.3(6.5) 20.1 (25.4,14.8) <0.0001
0.0260
1 P-value: The p value appearing on top refers to the level o f significance o f the unadjusted difference between control and intervention arms 
at follow-up. The p value underneath in italics refers to the level o f significance o f the adjusted difference between the control and 
intervention arm at follow-up.
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The reasons for this difference between arms at baseline are not clear. However, the 
difference at follow-up was significant, even controlling for the baseline values (unadjusted 
p=<0.0001; adjusted p=0.0260), possibly due to an increase in antimalarials in the intervention 
arm at follow-up, likely attributable to the presence of Tibamal® in the intervention outlets.
About 90% and 50% of specialised drug stores and general stores, respectively, 
dispensed drugs. The proportion of outlets dispensing any anti-malarial remained fairly similar 
in the specialised drug stores but a 21% point difference was seen in the general stores 
between control and intervention arms at follow-up (Table 6.5).
Table 6.5: Drugs dispensed, by outlet type (mean of cluster summaries from the 9 intervention and 9 
control clusters)
Specialised drug stores General stores
Type of Control Intervention Difference in Control Intervention Difference in
drugs (N=9) (N=9) means (N=9) (N=9) means
dispensed: % (SD) % (SD) (95% Cl) % (SD) % (SD) (95% Cl)
n n n n
Any drug:
Baseline 95.6 8 8 . 6 64.0 58.6
(9.1) (17.3) (1 1 .1) (17.0)
Follow-up 97.1 89.0 8 . 2 48.1 51.6 -3.6
(6 .0 ) (11.9) (-17.6, 1.2) (8 .8 ) (5.7) (3.8, -11.0)
Anti-pyretic
alone:
Baseline 15.0 7.5 50.2 35.3
(16.4) (1 2 .1) (14.4) (1 2 .1)
Follow-up 18.1 13.6 -4.5 38.5 21.3 -17.2
(19.2) (19.7) (14.9, -24.0) (9.9) (8.4) (-8.0, -26.4)
Anti-pyretic
with anti-
malarial:
Baseline 63.6 6 8 . 8 11.4 11.3
(30.0) (13.8) (7.9) (8 .2 )
Follow-up 55.4 58.6 3.2 6.5 11.9 5.4
(1 1 .6 ) (25.0) (22.6, -16.3) (3.6) (5.3) (9.9, 0.9)
Any anti-
malarial:
Baseline 79.5 79.6 13.4 24.0
(23.5) (15.7) (8.7) (17.9)
Follow-up 75.1 72.6 -2.5 9.3 29.9 2 0 . 6
(2 0 .1 ) (24.8) (20.1,-25.1) (4.3) (8.4) (27.3,14.0)
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In outlets where retailers did not dispense any drugs, the main reasons given were referral to a 
specialised drug store or health facility. A significant difference (17% points) was seen at 
follow-up in referral to a health facility (unadjusted p=0.0339; adjusted p=0.0103) with 
intervention outlets being less likely to refer (Table 6.6). Other reasons given for not 
dispensing drugs included: lack of drugs in stock, lack of antimalarials in stock, and lack of 
suitable drugs to treat a child.
Table 6.6: Of those retailers not dispensing any drugs, reasons given for not dispensing (mean of 
cluster summaries from the 9 intervention and 9 control clusters) (multiple responses allowed)
Reasons for not 
dispensing any 
drug:
Control 
(N=9) 
% (SD)
Intervention
(N=9)
% (SD)
Difference in means 
(95% Cl)
P-value1 ,3 
Unadjusted 
Adjusted
No drugs in stock: 
Baseline 
Follow-up
19.8(19.0) 
30.7 (12.6)
36.8 (24.2) 
20.3 (7.9) -10.4 (0.2, -20.9) 0.0531
0.0308
No antimalarials in 
stock:
Baseline
Follow-up
8 . 0  (1 1 .2 ) 
18.1 (14.3)
7.3 (9.0) 
31.1 (16.3) 13.0 (28.3, -2.3) 0.0915
0.1145
No suitable drugs in 
stock2:
Baseline
Follow-up
19.7(15.2)
33.7(13.7)
21.8(15.2)
35.5(16.9) 1.8 (17.2,-13.6) 0.8061
0.6892
Referred to a 
specialized drug 
store:
Baseline
Follow-up
72.4 (23.2) 
75.3 (17.6)
67.6 (20.0) 
72.0 (19.9) -3.3 (15.6, -22.1) 0.7188
0.4017
Referred to a health 
facility:
Baseline 33.4(25.9) 29.2(23.5)
Follow-up 38.2(21.1) 21.6(4.5) -16.7 (-1.4, -31.9) 0.0339
0.0109
1 P-value: The p value appearing on top refers to the level o f significance of the unadjusted difference between control and 
intervention arms at follow-up. The p value underneath in italics refers to the level of significance of the adjusted difference 
between the control and intervention arm at follow-up.
2 Shopkeeper said they had no suitable drugs in stock which generally meant that either they did not feel they had appropriate 
drugs to treat the stated symptoms, or that they did not have appropriate drugs to treat children of the stated age (4 years) 
difference in difference analysis: unadjusted p values for the difference in difference analysis gave similar results to those in 
table 6.6 apart from 'no antimalarials in stock’ and ‘referred to a health facility’, where the difference in difference 
unadjusted p values were 0.0343 and 0.2979, respectively (appendix 12).
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In terms of all outlets, at baseline, 7.8% of control outlets and 6.4% of intervention outlets 
referred patients directly to a health facility without dispensing any drugs or offering any other 
suggestions for treatment. At follow-up, significantly fewer outlets in the intervention arm 
referred mystery shoppers directly to the health facility (unadjusted p=0.0416; adjusted 
p=0.0119) compared to the control (Table 6.7).
Table 6.7: Percentage of retailers referring mystery shoppers to health facilities (mean of cluster 
summaries from the 9 intervention and 9 control clusters)
Control (N=9) Intervention Difference in means P-value1
Percentage of referrals: % (SD) (N=9) (95% Cl) Unadjusted
% (SD) Adjusted
Direct referral to health 
facility (no drugs 
dispensed or other option 
suggested):
Baseline 7.8 (7.9) 6.4 (5.7)
Follow-up 9.4 (6.7) 4.0 (3.2) -5.5 (-0.2,-10.7) 0.0416
__________________________________________________________________________________ 0.0119
Drugs given with referral 
to health facility:
Baseline 27.1 (9.9) 22.3 (12.7)
Follow-up 19.1 (11.5) 14.5(3.4) -4.6 (3.8,-13.1) 0.2632
0.1768
1 P-value: The p value appearing on top refers to the level o f  significance o f the unadjusted difference between control and intervention arms 
at follow-up. The p value underneath in italics refers to the level of significance o f the adjusted difference between the control and 
intervention arm at follow-up.
None of the specialized drug stores at follow-up in either arm referred the mystery shoppers 
directly to a health facility. In the general stores at follow-up, however, there was a 6% point 
difference between arms with 11% and 5% of outlets in the control and intervention arms, 
respectively, referring the mystery shoppers directly to a health facility (Table 6.8).
Sales of AL at baseline were minimal at 0.5% in the control arm and zero in the
intervention arm. At follow-up, in the control arm, sales of AL remained low at about 2% but
rose significantly to 25% in the intervention arm, a difference of 24% points between arms
(unadjusted p=<0.0001; adjusted p=<0.0001) (Table 6.9). Of those outlets dispensing an anti-
malarial in the intervention arm, the share of AL dispensed rose markedly from 0% at baseline
to 61% at follow-up (Figure 6.1). Notably, sales of amodiaquine dropped from 18% of outlets
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at baseline to 7% at follow-up in the control arm, and 27% to 3% in the intervention arm 
(Table 6.10), and there was a 55% point drop in amodiaquine’s share of antimalarials 
dispensed in the intervention arm from baseline to follow-up (Figure 6.1). This is possibly due 
to the cessation of production of one of the main amodiaquine brands (Malaratab®) 
communicated to the survey team after baseline, by the production company.
Table 6.8: Percentage of retailers referring mystery shoppers to health facilities, by outlet type
(mean of cluster summaries from the 9 intervention and 9 control clusters)
Percentage of 
referrals:
Specialised drug stores
Control Intervention Difference in Control
(N=9) (N=9) means (N=9)
% % (95% Cl) %
(SD) (SD) (SD)
General stores
Intervention Difference in 
(N=9) means
% (95% Cl)
(SD)
Referral to a health facility 
(no drugs dispensed or other 
option suggested):
Baseline 0.0 7.3
(0) (17.5)
Follow-up 0.0 0.0
 (0)_________ (0)
0.0
(0)
9.2
(9.1)
11.0
(7.4)
7.6
(6.4)
4.9
(3.8)
- 6.1 
(-2 .1, - 12.0)
Drugs given with 
referral to a health 
facility:
Baseline 18.8 21.6
(15.7) (15.3)
Follow-up 17.2 19.8
(19.4) (10.0)
2.6
(18.0,-12.8)
28.1
(11.1)
19.0
(11.7)
21.2
(16.7)
13.5
(3.8)
-5.5 
(3.2, -14.2)
To further explore the possible reasons for not dispensing AL, I looked at the frequency of AL 
dispensing among only those outlets with any antimalarials and among those specifically with 
AL in stock at the time of the provider survey. As provider surveys were carried out 
approximately two weeks after the mystery shopper survey it is possible that there were some 
changes in stock between the two, but these were not likely to be major. Of those that had an 
anti-malarial in stock during the provider survey at follow-up, 5% dispensed AL in the control 
arm and 41% in the intervention arm. Of those that had AL in stock during the provider 
survey, 21% and 57% of outlets in the control and intervention arms respectively, dispensed
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AL at follow-up to the mystery shoppers. In the intervention arm at follow-up, o f the outlets 
with Tibamal® in stock during the provider survey, 58% dispensed Tibamal^ to mystery 
shoppers.
Table 6.9: Specific antimalarials dispensed by retailers (mean of cluster summaries from the 9 
intervention and 9 control clusters)
Anitmalarials
dispensed:
Control (N=9) 
% (SD)
Intervention (N=9) 
% (SD)
Difference in means 
(95% Cl)
P-value1' 4 
Unadjusted 
A djusted
AL3:
Baseline
Follow-up
0.5 (1.6) 
1.8 (1.3)
0.0 (0) 
25.4 (6.9) 23.6 (28.6, 18.7) <0.0001
<0.0001
TibamaL
Baseline
Follow-up
0.0 (0) 
0.0 (0)
0.0 (0) 
24.4 (7.0) 24.4 (29.3, 19.5) <0.0001
<0.0001
Amodiaquine:
Baseline
Follow-up
18.8(5 .6) 
7.1 (4.9)
27 .5 (13 .6 )  
3.9 (4.1) -3.2 (1 .3 ,-7 .7 ) 0.1502
0.0670
SP:
Baseline
Follow-up
6.1 (4.8)
9.2 (6.3)
13.8(8 .8) 
8.8 (4.7) -0.4 (5 .1 ,-6 .0 ) 0.8713
0.5884
Quinine:
Baseline
Follow-up
rwi— ,
0.2 (0.6) 
2.1 (2.4)
0.4 (1.1) 
2.2 (2.8) 0.1 (2.7, -2.5) 0.9196
0.9300
Baseline 1.6 (2.8) 1.4 (2.8)
Follow-up 2.0 (2.5) 1.6 (2.4) -0.4 (2.1,- 2.9) 0.7309
0.5732
1 P-value: The p value appearing on top refers to the level of significance of the unadjusted difference between control 
and intervention arms at follow-up. The p value underneath in italics refers to the level of significance of the adjusted 
difference between the control and intervention arm at follow-up.
2 Other drugs are non-antimalarials and non-antipyretics and include: Antibiotics (Amoxicillin, Cotrimoxazole and 
Trimethoprim), Antihistamines (Chlorpheniramine), Antihelminthics (Levamisole), and Bronchodilators (Salbutamol).
3 Rank sum test: unadjusted analysis, p=0.0003; adjusted analysis, p=0.0003. This test was carried out on the main 
outcome indicator because of its robustness and its sensitivity to any shifts in distribution between control and 
intervention clusters. (Hayes & Moulton, 2009)
Difference in difference analysis gave similar unadjusted p values to all indicators reported in table 6.9 (appendix 12)
Figure 6.1: Share of specific antimalarials dispensed, by outlets that dispensed an anti-malarial 
in the intervention arm
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Sales of AL at follow-up were 21% points higher in the intervention arm than in the control 
arm for specialized drug stores and 22% higher for general stores (Table 6.10 & Figure 6.2). 
No Tibamal® was dispensed at baseline. At follow-up, none was dispensed in the control arm; 
in the intervention arm, 24% of all outlets dispensed Tibamal® (Table 6.9), 31% of specialized 
drug stores and 22% of general stores (Table 6.10).
Table 6.10: Specific antimalarials dispensed, by outlet type (mean of cluster summaries from the 9 
intervention and 9 control clusters)
Specialised drug stores General stores
Anitmalarials
dispensed:
Control
(N=9)
%
(SD)
Intervention
(N=9)
%
(SD)
Difference in 
means 
(95% Cl)
Control
(N=9)
%
(SD)
Intervention
(N=9)
%
(SD)
Difference in 
means 
(95% Cl)
AL:
Baseline 2.5 0 .0 0 . 0 0 .0
(7.4) (0 ) (0 ) (0 )
Follow-up 11.4 32.6 2 1 . 2 0 . 0 2 2 .1 2 2 .1
(1 0 .1 ) (25.9) (40.9, 1.6) (0 ) (9.5) (28.8,15.3)
Tibamal®:
Baseline 0 .0 0 .0 0 . 0 0 .0
(0 ) (0 ) (0 ) (0 )
Follow-up 0 .0 30.7 30.7 0 . 0 21.7 21.7
(0 ) (25.7) (48.9, 12.6) (0 ) (9.7) (28.5, 14.9)
Amodiaquine:
Baseline 57.6 51.0 9.6 17.5
(17.0) (17.3) (6 .6 ) (16.7)
Follow-up 24.8 8.9 -15.9 4.4 2.9 -1.5
(27.9) (18.3) (7.7, -39.5) (3.2) (2 .6 ) (1.5, -4.4)
SP:
Baseline 19.9 26.0 3.7 7.0
(18.6) (17.7) (3.9) (10.3)
Follow-up 28.5 20.9 -7.6 4.9 4.9 0 . 0
(20.9) (19.8) (1 2 .8 , -28.0) (5.5) (4.6) (5.1,-5.0)
Quinine:
Baseline 2 .2 2.5 0 . 0 0 . 0
(6.7) (7.1) (0 ) (0 )
Follow-up 10.5 1 0 .2 -0 .2 0 .0 0 .0 0 . 0
(10.7) (12.5) (11.4,-11.9) (0 ) (0 ) (0 )
Other drugs:
Baseline 6.7 4.9 0.3 0 .0
(14.1) (9.5) (1 .0 ) (0 )
Follow-up 12.4 6 .8 -5.6(11.4, -22.6) 0.3 (0.9) 0.7 (1.3) 0.4 (1.5, -0.8)
(17.4) (16.6)
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Sales of AL in both the control and intervention arms rose in outlets with clinically related 
training to 14% and 28% respectively. There was no AL dispensed in outlets without clinically 
related training at baseline. Only 1 outlet in the control arm at follow-up reported as not 
having any staff with clinically related training, dispensed AL. In the intervention arm, 
however, 24% of outlets without clinically related training dispensed AL (Figure 6.2).
Figure 6.2: Percentage of outlets dispensing AL (including Tibamal®) to mystery shoppers, by 
outlet characteristic (mean of cluster summaries from the 9 intervention and 9 control clusters)
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Of outlets in the intervention arm at follow-up reported as having at least one staff with 
Tibamal® training, 47% dispensed AL. Of those outlets that dispensed an anti-malarial and 
reported having at least one staff with Tibamal® training as well as Tibamal® in stock during 
the provider survey 82% dispensed Tibamal® to the mystery shoppers. Tibamal® accounted for 
about 96% of all AL dispensed in the intervention arm at follow-up and 92% and 98% in the 
specialized drug stores and general stores respectively (Figure 6.3).
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Figure 6.3: Tibamal® as a share of AL dispensed in the intervention arm  at follow-up (mean of 
cluster summaries from the 9 intervention clusters)
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6.2.4: Dosing of AL dispensed
The mystery shopper scenario involved a four year old child, who would be required to 
receive 12 tablets o f AL in total, two tablets, twice daily over a period o f 3 days. At baseline 
neither o f the outlets dispensing AL (n=2) dispensed it at the correct dose. At follow-up, in the 
intervention arm 97.4% (75/77) o f outlets dispensed the correct dose compared to 16.7% (1/6) 
in the control arm. At follow-up, 81.3% (26/32) o f specialized drug stores dispensed the 
correct dose, all except one, being from the intervention arm. The percentage dispensing the 
correct dose was even higher in the general stores; 98.0% (50/51) dispensed the correct dose, 
all from the intervention arm. All the outlets that dispensed Tibamal® dosed it correctly.
6.2.5: AL counselling advice
W hen dispensing AL (including Tibamal®), retailers were expected to give advice to clients on
how to take the AL dispensed, highlighting four key areas. First, on how to administer the
drugs, they were to advise clients to give two tablets immediately and then repeat the dose
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after 8 hours and then twice a day for the next two days until the dose is complete. Second, on 
what to do if the child vomited, the retailer was expected to explain that they should repeat the 
dose if the child vomited within 30 minutes of taking a dose. In outlets where Tibamal® was 
being sold, they were to further advise the client to return to the shop and buy another dose of 
Tibamal® if there was need to repeat the dose, so as to replace the lost dose. Third, if the child 
did not get better, the client was to be advised to take the child to a health facility for further 
treatment. In outlets selling Tibamal®, they further needed to explain to the client the need to 
return to the outlet and collect a health facility referral form. Fourth, retailers needed to tell the 
client to give foods such as milk, bananas, honey and/or foods rich in fat.
Figure 6.4 below shows that in all the outlets that dispensed AL in the intervention arm 
at follow-up most gave some form of advice, mainly on how to administer drugs (over 80%) 
and what to do in case the child did not feel better (about 40%). However, not all outlets gave 
appropriate advice. The outlets did fairly poorly across all the four main advice areas, with all 
areas falling below 40% to as low as 3% across all outlets (Figure 6.5).
Figure 6.4: Percentage of outlets dispensing AL to mystery shoppers who provided some advice 
in the intervention arm at follow-up (mean of cluster summaries from the 9 intervention clusters)
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Figure 6.5: Percentage of outlets dispensing AL to mystery shoppers who provided appropriate 
counselling advice in the intervention arm at follow-up (mean of cluster summaries from the 9 
intervention clusters)
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Most appropriate advice was given on what to do if the child did not get better (34%). 
Specialized drug stores were more likely than general shops to give appropriate advice on how 
to administer the drugs (46% v. 24%) and general stores were more likely to give appropriate 
advice on what to do if the child did not get better (37% v. 27%). Advice on what to do if the 
child vomited and the appropriate foods to give was particularly poor in both specialized drug 
stores and general stores (Figure 6.5). None of the outlets that dispensed Tibamal® during the 
survey reminded the mystery shoppers to come back and buy a pack of Tibamal® in case a 
dose is repeated, and only 9.5% (7/74) advised them to come back for a referral form to the 
health facility if the child did not get better. At baseline, only 2 doses of AL were dispensed 
and both were from specialized drug stores in the control arm (Figure 6.2); in both cases 
appropriate advice was only given on what to do in case the child does not feel better. At 
follow-up, in the control arm there were 6 doses of AL dispensed (Figure 6.2), all of which 
were from specialized drug stores. As at baseline, appropriate advice was only given on what 
to do if the child did not get better by 3 outlets.
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6.2.6: Median price charged for an AL dose
At baseline, there were only 2 doses of AL sold at a cost of 200 KSH (2.46 USD) and 180 
KSH (2.22 USD). At follow-up, the 12 tab Tibamal® was sold at a median price of 20 KSH 
(0.25 USD, IQR: 20-20) which was the recommended retail price. Of those not paying the 
recommended price, two paid 30 KSH (0.37 USD), another two paid 40 KSH (0.49 USD) 
because of buying two packs of the 6 tab to meet the required dose, and one other paid 60 
KSH (0.74 USD). Other AL sold at a median cost of 60 KSH (0.74 USD) in both arms for 6 
tabs, and 80 KSH (0.98 USD) in the control arm for the 12 tab AL (Table 6.11).
Table 6.11: Median price1 charged for an AL dose at follow-up (cluster summaries from the 9 
intervention clusters)
6  tab Tibamal® 12 tab Tibamal® 6  tab any other AL 12 tab any other AL
(range) (range) (range) (range)
Intervention - 20 (20-60) 60 (20-100) 20 (20-20)
(n=0) (n=74) (n=2) (n=l)
Control - - 60(40-150) 80(80-80)
(n=0) (n=0) (n=3) (n=l)
1 Source o f exchange rate: http://www.exchangerate.com/past_rates_entry.html. Accessed 13/4/2010. On 1st November 2008, when the 
subsidized drugs were first distributed, 1 US dollar was equivalent to 81.23 KSH.
6.3: DISCUSSION
Some limitations of the mystery shopper survey should be noted. Due to the covert nature of
the survey close supervision was not feasible; it could be possible that in a few instances, the
mystery shopper may have visited the wrong outlet as they relied on directions given by
colleagues and deliberately did not visit outlets they had previously been to themselves during
the census. In addition, given the prior consent process, it cannot be ruled out that there may
have been retailers who were suspicious and therefore altered their behaviour and the advice
they gave to the mystery shopper visiting their outlet. However, if this were the case then the
data would display ‘best practice’ of providers, which still shows considerable room for
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improvement, especially in areas such as the provision of appropriate counselling. Finally, in 
our scenario, the mystery shoppers waited for the retailer to recommend treatment and paid 
whatever price they were asked to. However in practice, the consumer often asks for a specific 
treatment instead of the provider recommending it and may also bargain on the retail price, a 
possible limitation. Despite randomising sub locations to control and intervention arms, some 
outcome indicators were not equal across both arms. The reasons for the differences observed 
between the arms at baseline are not clear however it is known that cluster randomised 
controlled trials are susceptible to imbalances especially with small numbers of clusters. 
However, these imbalances have been controlled for in the adjusted analyses (refer to chapter 
4, data analyses). For certain indicators which contained data raising the possibility of a 
differential effect between the arms but do not necessarily appear to be of statistical 
significance, a difference in difference analysis was carried out. The limitations of such an 
analysis have already been described in Chapter 4, however for these indicators it was thought 
that carrying out such an analysis may provide better insight into the data. Generally, the 
difference in difference outcomes gave similar significance outocmes to those originally 
calculated, except for reasons given for retailers not dispensing any drugs, where unlike the 
original analysis, ‘having no anti-malarials in stock’ became a significant factor and ‘referring 
patients to a health facility’ became insignificant.
The intervention improved access to AL treatment by significantly increasing AL
availability as evidenced by the increased dispensing of AL in the intervention arm at follow-
up to 25% of mystery shoppers as compared to 2% in the control arm. This was consistent
with the 32% points difference between the arms at the provider level in the availability of AL
in retail outlets as described in Chapter 5. Majority of outlets dispensing AL dispensed at the
correct dose and price. The price of the only AL dose dispensed at follow-up in the control
arm was 80 KSH (0.98 USD) for 12 tablets compared to a median of 20 KSH (0.25 USD) in
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the intervention arm, a marked difference of 60 KSH (0.74 USD). The percentage of outlets 
dispensing AL increased significantly in both general stores, and specialized drugs stores and 
all outlets of both types that dispensed Tibamal®, dosed it correctly. One of the aims of the on­
going AMF-m is to crowd out anti-malarial monotherapies. These results can be cautiously 
interpreted to show how this could work as AL market share increased in the intervention arm, 
while overall antimalarial provision did not change. However, it should be noted that anti- 
malarial monotherapy provision also declined by 5%in the control area.
Despite this increase in sales, in the intervention arm at follow-up, AL was sold to 
mystery shoppers in only 25% of the outlets. Possible reasons for this have been discussed in 
Chapter 5 and include that even where outlets had trained staff, AL may not have been 
dispensed because it was not in stock; all trained shops were given the option of stocking AL 
but not all did so: 86% of trained outlets had antimalarials in stock during the provider survey 
but only 69% had AL in stock. Many not stocking AL blamed insufficient funds, with other 
reasons given being a change in type of business and the person trained having left the outlet. 
Another potential reason for lack of AL stocks could be temporary stock outs of Tibamal® due 
to supply problems. The provider survey showed that 32.5% of Tibamal® trained outlets 
reported stock outs of AL within the past 2 weeks from the day of the survey, and 9% of 
outlets in the intervention arm that reported usually stocking Tibamal® were out of stock on 
the day of the survey (Chapter 5). During one of the FGDS, one of the retailers commented 
that, they only supply once a month and... You will find that they only give one...one packet
and it ends  Then in the middle o f the month we are without Tibamal®’. During the study,
drugs were being supplied directly to the outlets so as to curb possible contamination between 
control and intervention areas. The comments raised by the retailers highlight the challenge of 
identifying and maintaining a steady supply of sufficient drugs in such a restricted context. 
Supply could likely be improved by use of established supply distribution channels.
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If only those intervention outlets are considered which had a staff member who had 
attended Tibamal® training, and had Tibamal® in stock during the provider survey, 60% 
dispensed Tibamal® to the mystery shoppers. Of the 40% (39 outlets) that did not dispense 
Tibamal®, 16 (mainly general stores) referred the mystery shopper to a specialized drug store, 
13 (mainly drug stores) dispensed another anti-malarial (mainly SP), 6 dispensed an 
antipyretic only, 3 referred to a general shop, and 1 referred to a health facility. The reasons 
for these behaviours remain unclear, but it is possible that trained staff members did not 
recognize the mystery shopper scenario as appropriate for Tibamal® treatment, that the staff 
member who received training was not present at the time of the mystery shopper survey, or 
that, although Tibamal® was in stock during the provider survey, it was not in stock at the time 
of the mystery shopper visit. The review from Rowe et al., (2005) explores factors that may 
prevent providers from translating knowledge from training into practice. Some of these 
factors have been briefly described in Chapter 2. What is encouraging is that in the sub 
population of outlets that reported having at least one staff trained on Tibamal® and had 
Tibamal® in stock, 82% that dispensed an antimalarial dispensed Tibamal®.
Retailers dispensing AL were expected to ask about signs of severe disease that would 
determine need for referral to a facility. However, they did not routinely ask about these signs 
both at baseline and follow-up. Even in outlets with a Tibamal® trained employee, only 41% 
asked about signs of severe disease. Those outlets with an employee with clinical training did 
not do much better. A significant difference (6% points) was seen in direct referrals to a health 
facility at follow-up between intervention and control arms, with intervention outlets being 
less likely to refer.
Retailers were poor at giving advice to clients to whom they dispensed AL. In the
intervention arm at follow-up, outlets did not accomplish the 4 advice tasks expected of them.
Majority of outlets (over 80%) gave some form of advice on how to administer the drugs and
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40% on what to do if the child did not feel better. The advice given though was not usually 
appropriate, as less than 35% of outlets gave appropriate advice on how to administer the 
drugs and on what to do if the child did not feel better. Advice on what to do if the child 
vomited and appropriate foods to give with the drugs was particularly poor, falling as low as 
3%. One possible reason for this could be the poor availability of job aids in retail outlets, 
observed in the provider survey (Chapter 5). Job aids were deigned to help improve dispensing 
practices. However it should be noted that poor provision of advice is also common among 
health workers at health facilities. One report from Kenya showed that health workers from 
public, NGO and FBO facilities gave advice on what to do if the child vomited in only 7.8% 
of the cases of children aged less than 5 years receiving AL (DOMC, 2010). This 
demonstrates a generic need across providers for more innovative strategies to aid in ensuring 
dispensing guidelines are adhered to on a constant basis.
Summary: In summary, the mystery shopper survey showed that the intervention led to a 
significantly larger percentage of providers prescribing AL for the treatment of fever in a four 
year old child. More than 90% of providers dispensing AL dispensed the correct dose. 
Providers were also able to pass on the treatment subsidy to caregivers, selling Tibamal® at 
the recommended retail price of 20KSH. However, the intervention did not improve the 
percentage of providers enquiring about signs and symptoms of severe disease nor was it able 
to significantly increase the percentage of providers giving appropriate advice on 
administration of AL, and what to do if the child vomits or does not improve. The following 
chapter (Chapter 7) presents the household survey. This chapter reveals how findings from the 
provider and mystery shopper survey translated into the impact of the intervention on the 
proportion of children under five being treated promptly with appropriate anti-malarial 
treatment, within the community.
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CHAPTER 7
HOUSEHOLD SURVEY
7.1: INTRODUCTION
This chapter reports the results of the household surveys. These surveys addressed specific 
objective 1 of the thesis (To determine the impact on the proportion of children under five 
with fever being treated promptly with appropriate anti-malarial treatment, and adhering to the 
correct dose) and objective 3 (To determine distribution of benefits of retail sector delivery of 
AL by socio- economic status), and also contributed to objective 2 (To determine if private 
sector retailers can deliver AL to appropriate standards of quality for the treatment of fever in 
children under five years).
At both baseline and follow-up, the household survey questionnaire was administered to 
all household heads or their representatives on household demographics and wealth. 
Caregivers were interviewed on any children under five years who had experienced a fever 
within two weeks prior to the interview. At follow-up, further information was gained from 
the household head on fevers experienced in members five years and above, to assess the 
number of non-targeted members using Tibamal® as a form of treatment.
The results are presented in section 7.2. Section 7.2.1 describes the characteristics of 
children sampled. Section 7.2.2 and 7.2.3 focus on those children who have had a fever within 
the two weeks prior to the interview, to assess the impact of the intervention on how 
caregivers go about treating these children’s fever. This includes where they seek treatment, 
and the type of treatment obtained. Of those children who obtained appropriate treatment, 
further analysis is presented in Section 7.2.4 on the effect of the intervention on whether the 
dose and advice given by the provider was correct and if the caregiver was able to administer 
the medication in the correct manner to the child. This is followed in section 7.2.5 by analysis
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of whether the intervention changed caregivers’ knowledge on malaria and its treatment. In 
Section 7.2.6 and 7.2.7 other aspects of the intervention are evaluated such as its effect on the 
cost of fever treatment in children and physical access to effective malaria medication. The 
results end by looking at how well the intervention did in limiting its exposure to the target 
population (Section 7.2.8). The results are discussed in Section 7.3.
7.2: RESULTS
7.2.1: Characteristics of sampled children three to 59 months
Interviews were completed at 2,319 homesteads at baseline (3,288 households), and 2,204 
homesteads at follow-up (3,182 households). Data were collected on 2,749 children between 
three to 59 months at baseline (1,381 and 1,368 in the control and intervention arms 
respectively), and 2,662 at follow-up (1,305 and 1,357 respectively) (Table 7.1). In the 
following, all results will be addressing this age group, unless otherwise specified.
Children were evenly distributed between the districts in both arms, with around one 
third of sampled children residing in each district. Around half the children were male. Just 
under half had slept under an insecticide treated net (ITN) the night before the interview at 
baseline, and just over half at follow-up. Reported fever within two weeks prior to the 
interview ranged from 26% in the control arm at baseline to 32% in the intervention arm at 
follow-up. Around half the household heads for the sampled children had completed primary 
school or above. Sampled children were relatively equally distributed across the different 
wealth quintiles (Table 7.1). Fewer homesteads needed to be visited to find one childhood 
fever than originally estimated, resulting in more fevers being detected than expected from the 
sample size calculation.
The intervention was designed to improve treatment of malaria specifically in children 3 
to 59 months. This age group formed roughly 95% of the under five population.
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Table 7.1: Characteristics of surveyed children aged 3-59 months (mean of cluster summaries 
from the 9 intervention and 9 control clusters)
Baseline Follow-up
Characteristic Control 
% (SD1)
Intervention 
% (SD)
Control 
% (SD)
Intervention 
% (SD)
Total children present in 
interviewed households 1,381 1,368 1,305 1,357
Percentage of children >=36 
months 40.6 (3.8) 39.6(2.1) 43.1 (4.1) 42.1 (3.3)
Male 50.5 (3.6) 53.1 (3.9) 51.6(3.4) 52.1 (2.9)
Household heads had completed 
primary school or above 54.7 (8.5) 47.8 (6.9) 53.2 (9.4) 47.5 (8.4)
Slept under an ITN1 last night 49.7 (9.2) 46.2 (5.6) 57.1 (7.7) 57.8 (10.3)
Wealth quintile2
Quintile 1 (most poor) 
Quintile 2 (very poor) 
Quintile 3 (poor) 
Quintile 4 (less poor) 
Quintile 5 (least poor)
20.6 (8.9)
22.7 (9.3)
18.0 (3.8) 
19.6 (6 .8 )
19.1 (6.9)
21.9(6.3) 
21.3 (7.6) 
21.0(4.5) 
19.8 (7.2) 
16.0 (4.5)
2 0 .1 (8 .6 ) 
22.3 (8.2) 
19.0 (5.0) 
18.7 (10.6) 
19.9 (8.7)
23.6 (7.2)
23.2 (8 .8 ) 
20.1 (5.7) 
19.5 (9.7)
13.3 (4.6)
Fever prevalence within the past 
two weeks 26.0 (8 .6 ) 30.3 (8.7) 27.0 (7.4) 32.4(10.3)
1 ITN= Insecticide treated net; SD= standard deviation
2 Wealth quintiles are based on all households interviewed. The percentages represent the number o f households with children 
3-59 months that fall within each quintile.
7.2.2: Treatment seeking behaviour of caregivers of children 3-59 months
Over 86% of children who experienced a fever within two weeks of the interview had some 
kind of action taken by the caregiver to treat the fever. There were no significant differences 
seen in the actions taken at follow-up across the two arms (p>0.05) (Table 7.4). Caregivers 
made a total of 779 actions at baseline across both arms, and 728 at follow-up (some 
caregivers took more than one action for a given fever). Of all actions taken, the most common 
were visits to government facilities and specialised drug stores (each accounting for around a 
third) (Table 7.2). These were followed by visits to general stores and missionary/private 
health facilities, with use of traditional healers very rarely reported. When the analysis was 
restricted to first actions only, similar patterns were observed. Analyses were carried out to see 
whether the intervention had affected use of retailers for fever treatment. Although there was 
no significant difference between the arms in the proportion of visits to the general shop or 
specialised drug store visits (Table 7.2), an increase was seen in the number of visits to general
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stores and a decrease in visits to specialised drug outlets from baseline to follow-up, in both
arms.
Table 7.2: Actions taken for treating children aged 3-59 months with fever in the previous two 
weeks (a comparison of 9 intervention and 9 control clusters).
Care sought:
Control Intervention (N=9) 
(N3=9) % (SD)
% (SD3) n
Difference in 
means 
(95% Cl3)
P-value1
Unadjusted
Adjusted
Government facility: 
Baseline
Follow-up
32.6 (12.6) 
119 
36.4(15.1) 
118
27.6 (14.9) 
137 
29.0 (10.6) 
116 -7.4 (5.7, -20.4) 0.2483
0.1018
Specialised drug store: 
Baseline
Follow-up
34.2 (12.9) 
113 
23.8(9.1) 
78
42.0(13.1) 
168 
30.4 (16.6) 
1 2 1
6 . 6  (2 0 .0 , -6 .8 ) 0.3140
0.3642
General store:
Baseline
Follow-up
10.9 (5.2) 
41
20.3 (9.5) 
67
13.5 (5.2) 
55
27.2(14.1)
115 6.8(18.8, -5.1) 0.2442
0.2158
Missionary/Private facility: 
Baseline
Follow-up
7.4 (4.8) 
24 
9.3 (5.0) 
30
8.7 (7.5) 
30 
5.4 (8.5) 
19 -3.9 (3.0, -10.9) 0.2504
0.3208
Traditional healers: 
Baseline
Follow-up
0.5 (1.5) 
1
0.7 (1.3) 
2
0 (0 )
0
0.6 (1.9) 
2
0(1.6,-1.7) 0.9794
0.9994
Others :
Baseline
Follow-up
14.4 (5.8) 
51 
9.5 (6.3) 
31
8.3 (7.3) 
40 
7.2 (3.9) 
29 -2.3 (2.9, -7.6) 0.3625
0.6592
1 P value: The p value appearing on top refers to the level of significance of the unadjusted difference between control and 
intervention arms at follow-up. The p value underneath in italics refers to the level of significance o f the adjusted difference 
between the control and intervention arm at follow-up.
2Others include: prayers, treatment with western medications present at home and treatment with home made 
remedies
3n= Total number of visits, N=number of clusters, SD= standard deviation, CI= confidence interval
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No obvious reasons could be identified for this observation. There appeared to be some 
indication that caregivers sourcing care from a government health facility tended to live 
physically closer to a public health facility than those who sourced care from other outlets, 
although these differences did not seem significant (appendix 11).
Further investigation was carried out at follow-up to see whether there was any 
difference between the intervention and control arms in the percentage of febrile children 
seeking care at specific outlet types by the children’s characteristics (<appendix 6). In general 
there were no significant differences in the pattern of seeking care from these sources between 
the intervention and control arms for the majority of sub-groups. However, in the intervention 
arm there was a larger proportion of febrile children in the younger age group (3 to <36 
months) visiting general stores (difference in means 11.8% points; 95%CI: 2.7, 20.9) than in 
the control arm, and a larger proportion of febrile children in the older age group (36 to 59 
months) visiting specialised drug stores (difference in means 21.5% points; 95%CI: 5.6, 37.3) 
than in the control arm (<appendix 6).
Less than 10% of children who experienced a fever within two weeks of the interview 
were reported to have had a malaria test, with over 80% of the tests said to be positive (Table
Table 7.3: Percentage of children three to 59 months with fever in the past two weeks who had a 
malaria test (mean of cluster summaries of the 9 intervention and 9 control clusters)
7.3).
Control (N=9) 
% (SD)
Intervention (N=9) 
% (SD)
Difference in
means
(95% Cl)
Obtained a blood test for 
malaria:
Baseline 
_______ Follow-up
8.4 (5.8)
8 .8  (5.4)
5.9 (2.8)
8.9 (5.3)
-2.5 (2.1,-7.1) 
0.2 (5.6, -5.2)
Of those with a blood test, 
percentage with a positive 
result:
Baseline
Follow-up
94.1 (12.2) 
82.5 (24.3)
81.7(22.9) -12.4(5.9,-30.8)
92.5(14.9) 10.0(31.6,-11.6)
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7.2.3: Antimalarials obtained
Between the two study points, there was a significant increase in children 3-59 months 
receiving anti-malarial treatments in the intervention arm compared to the control arm, 
resulting in a 13.7% point difference (95%CI 2.5, 24.9; unadjusted p=0.0192; adjusted 
p=0.0074) between the arms at follow-up (Table 7.4).
The percentage of children receiving an anti-malarial monotherapy (mainly 
amodiaquine, SP and quinine) fell by 7.0% points in the control arm and 26.6% points in the 
intervention arm. At follow-up, the percentage of children receiving an anti-malarial 
monotherapy in the intervention arm was lower than that in the control arm, although this was 
only of borderline significance in the adjusted analysis (difference in means: -10.5%: 95%CI: - 
3.9,-16.9; unadjusted p=0.0036; adjusted p=0.0518) (Table 7.4). Of those receiving 
monotherapies, an average of 1% at baseline and 0.2% at follow-up received an artemisinin 
monotherapy. Further breakdown of monotherapies received from the different sources of care 
can be found in the appendix 7.
The percentage receiving any brand of AL (including Tibamal®) rose by 17.5% points in 
the control arm and 46% points in the intervention arm, resulting in a significantly greater 
percentage receiving AL at follow-up in the intervention arm (difference in means: 26.4%: 
95%CI: 12.6, 40.2: unadjusted p=0.0009; adjusted p=0.0001) (Table 7.4; Figure 7.1). The 
significant increase in children receiving any brand of AL in the intervention arm was largely 
due to the uptake of Tibamal®, which made up 63% of all AL received in this group. No 
caregivers reported purchasing Tibamal® in the control arm. Of all those children who 
received any brand of AL, a significant proportion received it either on the same day or 
following day of the fever developing (Table 7.4, see appendix 8 for results by cluster).
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Table 7.4: Anti-malarial treatment obtained for children aged 3-59 months with fever in the 
previous two weeks (a comparison of the 9 intervention and 9 control clusters)
Treatment seeking behaviour 
indicators
Control2 
(N7=9) 
% (SD7)
Intervention3
(N=9)
% (SD)
Difference in 
means 
(95% Cl7)
P-value1 ,9 
Unadjusted 
Adjusted
Children who had care sought for them 
after developing fever:
Baseline
Follow-up
8 6 . 6  (6.4) 
88.9 (4.3)
90.1 (4.7)
89.1 (4.9) 0.2(4.8, -4.4) 0.9304
0.8759
Children who received an antimalarial: 
Baseline 
Follow-up
38.9 (7.8) 
50.3 (11.8)
45.5 (9.4) 
64.0 (10.5) 13. (2.5, 24.9) 0.0192
0.0074
Children who received an antimalarial 
monotherapy:
Baseline
Follow-up
29.8(11.1) 
22.8 (7.8)
39.0 (7.7) 
12.4 (4.8) -10.4(-3.9, -16.9) 0.0036
0.0518s
Children who received any brand of AL: 
Baseline 
Follow-up
9.8 (8.3) 
27.3 (15.2)
7.7 (5.1) 
53.7 (12.3) 26.4 (12.6,40.2) 0.0009
0.0001
Children who received Tibamal®: 
Baseline 
Follow-up
0 (0 )
0 (0 )
0 (0 ) 
33.7 (6 .8 ) 33.7 (28.8,38.5) 0 .0 0 0 1
0.0001
Children who received any brand of AL 
on the same day or following day of 
fever onset:4,6
Baseline
Follow-up
5.3 (3.2) 
19.9 (10.0)
4.7 (3.4) 
44.9 (11.7) 25.0 (14.1,35.9) 0 . 0 0 0 2
0.0001
1 P value: The p value appearing on top refers to the level o f significance of the unadjusted difference between control and 
intervention arms at follow-up. The p value underneath in italics refers to the level of significance of the adjusted difference 
between the control and intervention arm at follow-up.
2 Total number of children with fever in the previous two weeks present in the control arm: Baseline=353; Follow-up=344
3 Total number of children with fever in the previous two weeks present in the intervention arm: Baseline=413; Follow- 
up=417
4Intraclass correlation coefficient control arm: Baseline: 0.009, Follow-up: 0.02; intervention arm: Baseline: 0.01; Follow-up: 
0.01 (Based on formulae provided in Rowe A, Lama M, Onikpo F, Deming M (2002) Design effects and intraclass correlation 
coefficients from a health facility cluster survey in Benin. International Journal Quality Health Care 14: 521-523 [48])
5Test for interaction between wealth quintiles and the intervention at follow-up: For the indicator ‘receiving any brand of AL 
on the same day or following day of fever developing’, p=0.8749; for the indicator ‘receiving Tibamal® on the same day or 
following day of fever developing’, p=0.7445
6Rank sum test: unadjusted analysis, p=0.0013; adjusted analysis, p=0.0003 
?SD= standard deviation, CI=confidence interval, N= number of clusters
8The reduced significance of the p value after adjusting mainly reflects the significant negative relationship between baseline 
and follow-up values for this indicator. This negative relationship is likely to be caused by a tendency for those already using 
some kind of antimalarial at baseline to be more likely to start using Tibamal® at follow-up (substituting one similarly priced 
product for another), as compared to those not using any antimalarial at baseline (for whom using Tibamal® would represent 
an increase in average expenditure compared with their baseline purchases).
difference in difference analysis gave similar unadjusted p values to those reported in the above indicators apart from 
‘children who received an antimalarial’, p value=0.1740 {appendix 12)
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In the analysis, the proportion receiving AL on the same day of fever developing or 
following day in the intervention arm compared to the control remained significant at 
p=0.0002 (difference in means 25.0%: 95%CI: 14.1, 35.9; adjusted p=0.0001) (Table 7.4). 
This represents a substantial increase for this primary outcome, with the percentage of children 
receiving prompt AL treatment in the intervention arm being more than double that in the 
control arm at follow-up. There seemed to be no correlation between increasing wealth and the 
probability of receiving any brand of AL (p=0.8749) or Tibamal® (p=0.7445) on the same day 
or following day of fever developing (Table 7.4, refer to footnotes).
The variance observed between clusters was not large enough to warrant a weighted 
analysis (appendix 8) (Hayes & Moulton, 2009). Only 5.5% of homesteads had more than one 
child with fever in the past 2 weeks; allowing for homestead level clustering in the logistic 
regression did not affect the adjusted estimated.
Figure 7.1: Children 3-59 months who received any brand of AL on the same day or following 
day of fever developing (mean of cluster summaries of the 9 intervention and 9 control clusters)
60 n
50 -
40 -
20  -
10 -
Baseline Control Baseline
(n=353) Intervention
(n=349)
45
20
Follow up Follow up 
Control (n=413) Intervention 
(n=429)
Study arm
n= total number of children with fever
Horizontal line within each box represents mean (percentage mean typed adjacent to each horizontal line), horizontal line at 
the top and bottom of each box represents 25% and 75% inter quartile range, error bars represent upper and lower 95% 
confidence intervals.
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Investigations were carried out to see whether these significant differences between the 
intervention and control groups held for specific sub-groups defined by the child’s 
characteristics. Significant differences were found in the probability of obtaining both any AL 
and Tibamal® specifically for all sub-groups investigated (Tables 7.5 and 7.6).
Table 7.5: Percentage of febrile children aged 3-59 months at follow-up who obtained any brand 
of AL on the same day or following day of fever onset, by child’s characteristics (mean of cluster 
summaries of the 9 intervention and 9 control clusters).
Children obtaining any brand of AL 
on the same day or following day of 
fever onset at follow-up:
Control 
(N=9) 
% (SD)
Intervention
(N=9)
% (SD)
Difference in means 
(95% Cl)
Total number of febrile children 344 417
Age:
<36 months 21.3 (11.9) 43.3 (13.7) 22.0 (9.2, 34.8)
36-59 months 18.2(15.2) 48.1 (12.4) 29.9(16.0,43.7)
Sex:
Male 20.7 (11.5) 47.7 (9.2) 27.1 (16.7, 37.4)
Female 18.8 (10.9) 42.1 (16.8) 23.3 (9.2, 37.5)
Caregiver’s education:
Primary incomplete 15.7(8.3) 42.6 (10.6) 26.8(17.3,36.3)
Primary complete and above 26.3 (14.7) 50.4 (19.1) 24.1 (7.1,41.2)
Household head’s education:
Primary incomplete 19.6 (11.0) 46.3 (8.2) 26.8(17.1,36.4)
Primary complete and above 21.3 (15.2) 44.5 (17.5) 23.2 (6 .8 , 39.6)
ITN use:
ITN use last night 22.1 (15.4) 48.3 (13.4) 26.2 (11.8,40.6)
No ITN use last night 14.9 (7.1) 42.3 (16.6) 27.4 (14.7,40.2)
Wealth quintile5:
Quintile 1 (most poor) 14.8 (20.6) 38.9 (18.3) 24.1 (4.6,43.6)
Quintile 2 (very poor) 16.6(16.9) 40.0(22.1) 23.4 (3.7, 43.0)
Quintile 3 (poor) 16.6(18.6) 50.8 (33.3) 34.2 (7.3, 61.2)
Quintile 4 (less poor) 21.7(18.6) 43.8 (22.4) 22.1 (1.5, 42.7)
Quintile 5 (least poor) 15.4(15.9) 47.8 (24.3) 32.4 (11.9, 52.9)
5Test for interaction between wealth quintiles and the intervention at follow-up: For the indicator ‘receiving any brand of AL 
on the same day or following day of fever developing’, p=0.8749
Significant differences were observed between the arms for both age groups, both genders, 
and both ITN users and non-users. Importantly, significant differences were also found 
regardless of the caregiver or household head education, and for all wealth quintiles, 
demonstrating that all population groups appeared to have benefited from the intervention. It
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was notable that the percentage obtaining Tibamal® in the intervention arm at follow-up was 
similar across all wealth quintiles (ranging from 20.8% (SD: 22.1) in the 5 quintile to 30.4% 
(SD: 21.3) in the 3rd quintile).
Table 7.6: Percentage of febrile children aged 3-59 months at follow-up who obtained Tibamal® 
on the same day or following day of fever onset, by child’s characteristics (mean of cluster 
summaries of the 9 intervention and 9 control clusters)
Children obtaining Tibamal® on the 
same day or following day of fever 
onset at follow-up:
Control2 
(N=9) 
% (SD)
Intervention3
(N=9)
% (SD)
Difference in means 
(95% Cl)
Total number of febrile children 344 417
Age:
3 months to < 36 months 0 (0 ) 27.7 (10.2) 27.7 (20.5, 34.9)
36-59 months 0 (0 ) 33.9 (9.2) 33.9(27.4,40.4)
Sex:
Male 0 (0 ) 31.2 (8.5) 31.2(25.2, 37.2)
Female 0 (0 ) 28.1 (16.4) 28.1 (16.5,39.8)
Caregiver’s education:
Primary incomplete 0 (0 ) 26.9 (7.1) 26.9 (21.9,31.9)
Primary complete and above 0 (0 ) 37.0 (17.9) 37.0 (24.3, 49.6)
Household head’s education:
Primary incomplete 0 (0 ) 31.9 (10.2) 31.9 (24.7,39.1)
Primary complete and above 0 (0 ) 28.0 (1 0 .8 ) 28.0 (20.3, 35.6)
ITN use:
ITN use last night 0 (0 ) 31.2 (15.0) 31.2(20.7,41.8)
No ITN last night 0 (0 ) 26.5 (6.1) 26.5 (22.2, 30.8)
Wealth quintile5:
Quintile 1 (most poor) 0 (0 ) 30.1 (14.3) 30.1 (40.2, 20.0)
Quintile 2 (very poor) 0 (0 ) 25.5 (19.9) 25.5 (39.6, 11.4)
Quintile 3 (poor) 0 (0 ) 30.4(21.3) 30.4 (45.4,15.3)
Quintile 4 (less poor) 0 (0 ) 32.5 (22.3) 32.5 (48.3, 16.8)
Quintile 5 (least poor) 0 (0 ) 2 0 . 8  (2 2 .1) 20.8 (36.4, 5.2)
5Test for interaction between wealth quintiles and the intervention at follow-up: For the indicator ‘receiving Tibamal® on the 
same day or following day of fever developing’, p=0.7445
Investigations were carried out on the percentage of actions by source which resulted in any 
brand of AL being obtained on the same day or following day of fever developing (Figure 
7.2). The significance of difference between the arms at follow-up was not assessed since the 
study was not powered for this type of sub-analysis. At follow-up, AL dispensing increased 
from zero to 65% in the intervention arm in specialised drug stores and from zero to 63% in
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general stores. Substantial increases were also seen at government facilities and private/ 
mission facilities, but similar increases were observed in both arms.
Figure 7.2: Percentage of visits to different source of care at which any brand of AL was 
dispensed on the same day or following day of fever developing (mean of cluster summaries of the 
9 intervention and 9 control clusters)
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Notes: n= total number of visits on the same day or following day o f child’s fever developing; Govn= government; inter= 
intervention; SDS= specialised drug store; GS= general store; Priv/ Miss= Private/ Missionary facility. Other includes 
treatment at home with home-made remedies or western medication, traditional healers or prayers.
Standard deviations for each facility: Baseline control arm: govemment=20; SDS=4; GS=0; priv/miss=0; other=0. Baseline 
intervention arm: govemment=32; SDS=0; GS=0; priv/miss=33; other=10; Follow-up control arm: govemment=18; SDS=20; 
GS=0; priv/miss=49; other=36; Follow-up intervention arm: govemment=18; SDS:21; GS=25; priv/miss=53; other=34.
7.2.4: Adequacy of AL doses obtained and consumed
Caregivers were asked to state the number of AL tablets (including Tibamal®) they were
provided with and the number their child consumed, in order to assess providers’ dispensing 
practices and children’s adherence to the treatment. The accuracy of dose obtained was 
defined as obtaining at least the correct number of tablets for their child’s age. The accuracy of 
dose consumed was defined as reporting consumption of exactly the correct number of tablets
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for the child’s age within three days of receiving the medication. The precise timing of tablet 
consumption was not assessed due to the challenges of obtaining accurate recall for these data.
Of all children receiving any brand of AL, just under 70% in both arms obtained an
accurate dose at baseline (control 69.9% (SD: 33.8); intervention 68.6% (SD: 35.9)), and just
over 70% at follow-up (control 71.6% (SD: 20.9); intervention 76.9% (SD: 7.2). Not
surprisingly, no significant difference was recorded at follow-up between the two arms
(difference in means 5.3%: 95% Cl 20.9, -10.3; unadjusted p=0.4836; adjusted p=0.6545). Of
all children obtaining AL, at baseline a correct dose was consumed by 40.5% (SD: 23.3) in the
control group and 53.1% (SD: 40.2) in the intervention group. At follow-up this rose to 49.4%
(SD: 24.8) in the control arm and 67.0% (SD: 8.5) in the intervention arm, but the difference
was not significant at the 5% level (unadjusted p=0.0606; adjusted p=0.1095) (Table 7.7). In
the intervention arm, 80.6% (SD: 9.6) of caregivers received the correct dose of Tibamal® for
their child at follow-up compared to 70.7% (SD: 17.8) receiving the correct dose of any other
brand of AL. Adherence to Tibamal® was 71.8% (SD: 11.8) compared to adherence to any
other brand of AL at 61.1% (SD: 22.5) also at follow-up in the intervention arm.
Table 7.7: Adequacy of AL doses obtained and consumed (mean of cluster summaries from 9 
intervention and 9 control clusters)
Control2 (N4=9) Intervention3 (N=9) Difference in means P-value1
% (SD4) % (SD) (95% Cl4) Unadjusted
___________________________________________________________________________________ Adjusted
Adequacy of dose obtained 
from the provider:
Baseline 69.9 (33.8) 5
Follow-up 71.6(20.9)
Adequacy of dose 
administered:
Baseline 40.5 (23.3)5 53.1 (40.2)
Follow-up 49.4(24.8) 67.0(8.5) 17.6(36.1,-0.9) 0.0606
0.1095
1 P value: The p value appearing on top refers to the level of significance of the unadjusted difference between control and 
intervention arms at follow-up. The p value underneath in italics refers to the level of significance o f the adjusted difference 
between the control and intervention arm at follow-up.
2 Total number of doses in the control arm: Baseline=26; Follow-up=89
3 Total number of doses in the intervention arm: Baseline=30; Follow-up=221
4 N= number o f clusters, SD= standard deviation, CI= confidence interval
5 cluster summary from 8 clusters
6 8 . 6  (35.9)
76.9 (7.2) 5.3 (20.9, -10.3) 0.4836
0.6545
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Reported advice given to caregivers receiving AL thorough the retail sector was evaluated, the 
denominator being the total number of cases in which any kind of AL was dispensed in 
general stores and specialised drug stores (reported advice at facility visits was not recorded as 
the focus was on advice provided by outlet types targeted for training during the intervention). 
As only eight AL doses were dispensed from the retail sector in the control arm at follow-up, 
and only four doses from both arms at baseline, the analysis focuses on the intervention arm at 
follow-up (Figure 7.3).
The most common correct advice given in the general store was on ‘how to administer 
the medication’, given in 61.1% (SD: 24.2) of cases, compared to 47.1% (SD: 15.8) in 
specialised drug stores. For this indicator, advice was deemed to be correct if the caregiver 
was told to give their child one tablet twice daily for three days if the child was less than three 
years, and two tablets, twice daily for three days if the child was 3-<5years of age. Giving the 
first two doses 8 hours apart was not assessed. Advice on what to do if the child did not 
improve was given in 43% of cases in both types of retail outlet. Advice was very rarely given 
on actions to take if the child vomited (2.4% (SD: 5.1) in general stores; 1.2% (SD: 3.5) in 
specialised drug stores), or on how to give foods with the drugs (4.2% (SD: 9.6) in general 
stores; 2.2% (SD: 4.6) in specialised drug stores).
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Figure 7.3: AL treatment advice given by source, in the intervention arm, at follow-up (mean of
cluster summaries of the 9 intervention clusters)
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7.2.5: Caregivers’ Knowledge
Data on 679 and 672 caregivers were assessed at baseline and follow-up respectively.
Caregivers included in this analysis had to have had a child suffering from fever within two
weeks of the interview. In this group, just over one third of all caregivers interviewed reported
to have been schooled to the end of primary level and above.
Caregivers’ knowledge was based on their awareness of Tibamal® and/ or AL, together
with awareness on the signs and symptoms of uncomplicated and complicated malaria. Just
under half of caregivers had heard of AL at baseline (Figure 7.4). This increased to 60% (SD:
20.6) in the control arm and 55% (SD: 13.3) in the intervention arm at follow-up, with no
significant difference observed between the arms (p=0.5803). At follow-up 82% (SD: 9.5) in
the intervention arm had heard of Tibamal®, which was 74.5% points greater (95%CI: 66.4,
83.2, p=0.0001) than those that had heard of Tibamal® in the control arm. 40% of the 26
caregivers in the control arm reported having heard of Tibamal® from healthcare staff (Figure
7.5). In the intervention arm 16% had heard of Tibamal® from healthcare staff, a similar
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percentage (17%) from other people (friends, family and colleagues), and 12% from the PSI 
wall paintings and ‘barazas ’ (Figure 7.6).
In both arms, some caregivers reported having heard of Tibamal® from the radio 
(media). Tibamal® was not advertised on the radio, but one of the members from the DHMT in 
Butere-Mumias reported having heard an interview on the radio with a youth group where 
Tibamal® was mentioned as a cure for malaria that could be accessed in the communities 
(communication with District Medical Officer for Butere).
Figure 7.4: Knowledge of Tibamal® and AL (mean of cluster summaries of the 9 intervention and 9 
control clusters
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Figure 7.5: Source of Tibamal information at follow-up in the control arm (mean of cluster 
summaries from 7 control clusters)
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Figure 7.6: Source of Tibamal® information at follow-up in the intervention arm (mean of cluster
summaries from 9 intervention clusters)
■  I ntervent ion
Source of informtion
n (number of caregivers who have heard of Tibamal®)=321
Other includes Tibamal® promotional t-shirts and shopkeepers selling the medication.
Caregivers were asked to mention symptoms they would expect to see in a child o f four years
suffering from uncomplicated malaria. O f all reported symptoms, fever was most commonly
mentioned (average o f 69% and 83% between the arms, at baseline and follow-up
respectively), followed by vomiting (average o f 32% and 40% between the arms, at baseline
and follow-up respectively) (Figures 7.7 and 7.8). The knowledge o f uncomplicated m alaria
symptoms remained similar between arms at the two time points. There was a 10% point
increase in the reporting o f fever as a common symptom from baseline to follow-up, however
this increase was seen in both arms. For complicated malaria, caregivers were most
knowledgeable o f children o f four years being unable to eat (average o f 30% and 43%
between the arms, at baseline and follow-up respectively). The knowledge o f complicated
malaria symptoms also remained similar between the arms at follow-up. In general, symptoms
of uncomplicated malaria were better known than complicated malaria (Figure 7.9 and 7.10).
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Figure 7.7: Caregivers’ knowledge of symptoms of uncomplicated malaria in a four year 
old, baseline (mean of cluster summaries of the 9 intervention and 9 control clusters)
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Figure 7.8: Caregivers’ knowledge of symptoms of uncomplicated malaria in a four year old,
follow-up (mean of cluster summaries of the 9 intervention and 9 control clusters)
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Figure 7.9: Caregivers’ knowledge of symptoms of complicated malaria in a four year 
old, baseline (mean of cluster summaries of the 9 intervention and 9 control clusters)
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Figure 7.10: Caregivers’ knowledge of symptoms of complicated malaria in a four year 
old, follow-up (mean of cluster summaries of the 9 intervention and 9 control clusters)
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7.2.6: Household cost of fever treatment
Price paid for subsidised Tibamal1'3: 95.2% (SD: 5.87) o f caregivers in the intervention arm
who purchased Tibamal^3 at follow-up said they bought Tibamal" at the recommended retail
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price of 20 KSH (0.25 USD). Of those not paying this price, three paid less than 20 KSH (0.25 
USD) and five paid between 25 KSH (0.31 USD) and 100KSH (1.23 USD).
Household cost of treatment seeking: The household cost of treatment seeking was defined 
as the total amount spent per child on travelling to and from sources of care, medications, 
consultation fees, laboratory tests and any other costs incurred as a direct result of seeking 
treatment for this illness, for example bed costs if the child was admitted. Household costs 
were evaluated only if the child’s fever had resolved at the time of the interview (including 
unresolved fevers leads to under-estimation of total household costs per episode as further care 
may be sought after the interview). It was observed that median household spending per 
child’s fever was higher in both arms at baseline compared to follow-up. Costs fell from 
30KSH (0.37USD) to 28KSH (0.34USD) and 58KSH (0.71USD) to 28KSH (0.34USD), in 
control and intervention arms respectively (Figure 7.11), with no significant difference 
between the arms at follow-up (unadjusted p= 0.6143; adjusted p=0.1925).
Figure 7.11: Household cost of treatment seeking per completed episode of childhood fever
(median o f cluster summaries o f the 9 intervention and 9 control clusters)
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Baseline Baseline Follow up Follow up
control Intervention control Intervention
(n=191) (n=249) (n=216) (n=273)
Study arm
n= total number of children with resolved fevers
Horizontal line within each box represents median spending, horizontal line at the top and bottom of each box represents 25% 
and 75% inter quartile range, error bars represent upper and lower 95% confidence intervals, numbers adjacent to each box 
represent median KSH.
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The median costs incurred per provider visit showed that caregiver spending was highest for 
visits to private/ mission health facilities (averaging 113 KSH (1.39 USD) across the arms), 
followed by specialised drug shops and government facilities (both averaging at around 
40KSH (0.49USD) across the arms), with the lowest costs incurred for care from general 
stores (averaging 18 KSH (0.22 USD) across the arms) (Figure 7.12). Costs incurred from 
prayers, visiting a traditional healer or treatment with either home made remedies or western 
medications found at home were negligible.
Figure 7.12: Household cost per provider visit at follow-up (median of cluster summaries of the 9 
intervention and 9 control clusters)
Control Intervention
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Graphs by arm
.n (total number of visits to outlet): Control arm- Priv_miss_facility=30; Govemment_facility=l 18; SDS=76; 
General_store=67; Others=33. Intervention arm- Priv_miss_facility=19; Govemment_facility=l 15; SDS=121; 
General_store=115; Others=28
.Horizontal line within each box represents median spending, and numbers above each box quantifies median spending in 
Kenya shillings. Horizontal line at the top and bottom of each box represents 25% and 75% inter quartile range, error bars 
represent upper and lower 95% confidence intervals. .Priv_Miss_facility= private/ missionary health facilities; SDS= 
specialised drug stores. Others include treatment with western medications at home, treatment with home-made remedies and 
visits to a traditional healer.
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7.2.7: Travel time to the nearest AL retail outlet
The average travel time at baseline was 39 minutes (SD: 13.5) in the control arm and 32 
minutes (SD: 15.8) in the intervention arm. At follow-up travel time was significantly lower in 
the intervention arm, at 9.8 minutes (SD: 3.14) compared to 28.3 (13.3) in the control arm, 
with a mean difference of 19 minutes (95% Cl: -8.8, -28.3 p= 0.0010) between the arms 
(Table 7.8). Further analysis of travel times at follow-up showed 91% of households in the 
intervention arm were less than 20 minutes away from the nearest AL outlet, while in the 
control this was slightly more than one third (Figure 7.15).
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Table 7.8: Average travel time of homesteads to nearest retail outlet AL source in minutes
(mean of cluster summaries from the 9 intervention and 9 control clusters)
Travel time to Control (N=9) Intervention(N=9) Difference in means P-
nearest AL retail % (SD) % (SD) (95% Cl) value1
outlet:
Baseline 38.8(13.5) 32.3 (15.8) -6.5 (8.8,-21.8)
Follow-up 28.3 (13.3) 9.8(3.14) -18.5 (-8.8,-28.3) 0.0010
]P value refers to the level of significance of the unadjusted difference between control and intervention arms at 
Follow-up
Figure 7.15: Average travel time of homesteads to nearest AL retail outlet at follow-up (mean 
of cluster summaries from the 9 intervention and 9 control clusters)
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7.2.8: Use of Tibamal® by non-Targeted Age Groups
Tibamal® was supposed to be used by children aged 3 - 5 9  months only. I therefore 
assessed whether the drug was used by any patients outside this age range. Tibamal® was 
reportedly obtained in only 0.1% of fevers in those 5 years and above in the control arm 
and 6.7% in the intervention arm. The median age of those 5 years and above receiving 
Tibamal® was 8 years. There were ten children at follow-up less than three months old who 
suffered a fever within two weeks prior to the survey. None of these children received 
Tibamal®, though two did receive AL from government health facilities (Table 7.9).
Table 7.9: Use of Tibamal® in non-targeted household members reporting fever, at follow-up
(mean of cluster summaries from the 9 intervention and 9 control clusters)
Household members aged: Control (N=9) Intervention (N=9)
% (SD) % (SD)
5 years and above 0.1 (25.9) 6.7 (3.8)
Less than three months 0(0) 0(0)
Total number of people five years and above with fever in the past two weeks, in the control arm=l,003; intervention 
arm= 1,049
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7.3: DISCUSSION
There has been considerable debate about how access to and quality of malaria treatment 
can be improved (Arrow et ah, 2004; Goodman et ah, 2007; Smith et al., 2009; 
D’Alessandro et ah, 2005; Oxfam 2009). This chapter shows that a suite of ACT subsidies, 
retailer training, and community awareness activities can lead to substantial improvement 
in the uptake of prompt effective treatment for febrile children in rural Kenya. Although 
coverage still fell well below the 80% target set by the RBM, the percentage of children 
receiving AL during a fever episode in the intervention arm was more than double that in 
the control arm at follow-up, with more than half of those receiving Tibamal®, usually on 
the same day or the following day after fever onset. This was accompanied by a significant 
fall in the proportion of children being treated with antimalarial monotherapies. This is 
likely to have reflected “crowding out” of these antimalarials by the more effective 
subsidised AL. It may also have reflected government directives to phase out 
monotherapies such as amodiaquine at this time (personal communication with PPB and 
local amodiaquine manufacturer), though this would have affected both the control and 
intervention arms. In the vast majority of cases, subsidised AL was purchased at the 
recommended retail price. The intervention was able to bring AL physically closer to the 
community.
The increase in AL coverage observed does not appear to have resulted from a 
change in choice of providers, with treatment seeking patterns remaining relatively 
constant before and after implementation in both arms. Instead, the intervention appears to 
have led to a change in the type of drugs dispensed in specialised drug and general retail 
outlets, with a major shift towards AL in both of these provider types.
It was notable that a substantial increase was also seen in AL coverage in the control 
arm between baseline and follow-up. This is likely to have reflected a reduction in AL 
stock outs at government facilities between the two surveys in both arms. At baseline
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public sector AL stock outs were common, with only one third of facilities serving the 
study areas stocking both the six and twelve tablet packs of AL (Kangwana et al, 2009), 
whereas at follow-up stocks had almost doubled to 65% {appendix 9). This highlights that 
ensuring health facility AL stocks is also essential for improving AL access.
The intervention was able to significantly impact on caregiver knowledge regarding 
Tibamal® in the intervention area, with a very high percentage having heard of Tibamal® 
(82%) at follow-up, exceeding the percentage that knew the name ‘AL’. However, 
caregivers’ knowledge on symptoms on uncomplicated and complicated malaria in 
children remained constant between the two time points.
There was no significant difference in the overall cost of care incurred by caregivers 
between the intervention and control areas. This was not surprising since the subsidy 
allowed for Tibamal® to be sold at similar prices to other antimalarial monotherapies, so a 
substitution from previously more popular monotherapies to Tibamal® would not be 
expected to change costs.
Investigations were carried out on adherence to AL in terms of both obtaining and
consuming the correct dose. In the intervention arm at follow-up, 77% of children
receiving AL obtained an accurate dose, and 67% consumed the correct dose. No
significant difference was observed in the accuracy of doses obtained or consumed
between Tibamal® (obtained only from retail outlets) and other AL brands (obtained
mainly from government and private/mission facilities), although there was room for
improvement in patient adherence to AL from both sources. Adherence levels fall within
the varying ACT adherence levels quoted in other studies and mentioned in Chapter 2, of
39% to 90%, though the higher figures obtained in some studies may reflect study designs
where caretakers were aware that their compliance would be monitored. There are a
number of limitations to the measurement of adherence used in this and similar studies. It
may be difficult for caregivers to recall such details over a two week period, or they may
deliberately mis-report tablet consumption if they are concerned about revealing
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inappropriate dosing. In formal health structures such as government health facilities the 
child’s weight as opposed to age may be used to determine the dose (Njogu et al, 2008), 
so children who did not fall into the standard weight range for their age may have appeared 
to have obtained the wrong number of tablets. However, given these provisos, there was no 
evidence that retail provision of AL led to an increase in poor AL use. There was no 
difference between adherence to Tibamal® (received entirely from retailers) and other AL 
brands (received mainly from facilities), and no significant difference was observed in the 
accuracy of AL doses overall obtained or consumed between the control and intervention 
arms at follow-up. In fact there was some indication that the probability of a child 
receiving the correct dose was higher at follow-up in the intervention area (67%) than in 
the control area (49%). However, there remains room for improvement in adherence to AL 
obtained from all sources, as even at follow-up in the intervention area around a third of 
children were not consuming the correct dose. Reasons for this may include poor 
knowledge of dosing regimens, lack of advice from providers, and stockouts of one of the 
AL pack sizes meaning that children may have been sold an inappropriate pack for their 
age. During FGDs carried out by Kedenge (2011) caregivers also reported stopping 
medication as soon as the fever subsides, and believing that the child’s recovery would 
hasten if all the tablets were given at more frequent intervals than stipulated in the dosing 
regimen. Interventions to improve adherence could include reducing stock-outs of specific 
pack sizes, encouraging shopkeepers to talk through the package dosing instructions with 
caretakers, and the use of mass media to emphasise the importance of completing the full 
dose (Yeung & White, 2005).
There was also room for improvement in the advice given to caregivers by retail staff
on AL. Just under half of caregivers reported receiving advice from specialised drug store
staff on how to administer the medicine. In contrast up to 70% of caregivers reported
receiving dosing advice from general stores. Hardly any caregivers reported any advice on
what to do if the child vomits, or which foods to give with AL. However, it should also be
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noted that qualified health workers often also perform poorly on the provision of such 
advice, as noted in Chapter 5. In a health facility survey carried out in Kenya, only 38% of 
health workers gave advice on administering AL after a meal and only 8% on what to do if 
the child vomited after taking AL (Zurovac et al, 2008)
Although Tibamal® was targeted at children 3 to 59 months, a significant minority of 
adults and children above this age band reported taking the drug to treat a fever in the 
intervention arm. Moreover, it is likely that Tibamal® use in older age groups may have 
been under-reported if respondents were aware that only younger children were supposed 
to receive this drug (Kedenge, 2011). No children less than 3 months with fever received 
Tibamal®.
Finally, a number of potential limitations to the household survey results should be 
borne in mind. Contamination was very minimal with only 7% of caregivers in the control 
arm having heard of Tibamal® at follow-up, and none reporting having purchased it to treat 
their under five child. However, the study is likely to have faced other limitations common 
to such surveys including problems of recall and potential social desirability bias 
(respondents may report what they believe to be appropriate behaviour rather than what 
they actually did). Further limitations that apply to the evaluation in general are discussed 
in chapter 8.
Summary: In summary, the main finding of the household survey was that the 
intervention was able to significantly increase the percentage of children receiving AL 
treatment on the same day or following day to more than double the coverage observed in 
the control arm at follow-up, and this effect was also demonstrated among the poorest in 
the community. Observations possibly contributing to this finding included that the 
subsidised Tibamal® resulted in increased competitiveness of this treatment compared to 
other monotherapies, and a tendency for those using some kind of antimalarial 
monotherapy at baseline to substitute it for Tibamal®. Over 95% of caregivers in the
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intervention arm who purchase Tibamal® purchased it at the recommended price of 
20KSH. Furthermore, the intervention was able to significantly increase caregivers’ 
awareness of the treatment and bring the treatment physically closer to the community. The 
intervention did not deter caregivers from healthcare facilities, but instead influenced those 
who usually bought treatment for fever from a retail outlet to purchase AL. The 
intervention had no significant impact on the proportion of children receiving or adhering 
to the correct dose of AL treatment nor was there any significant improvement in the 
percentage of caregivers receiving appropriate counselling advice on how to administer the 
treatment and what to do if the child vomits or does not get better.
REFERENCES
Arrow KJ, Panosian C, Gelband H, Institute of Medicine (U.S.). Committee on the
Economics of Antimalarial Drugs (2004) Saving lives, buyingtTime: Economics of 
malaria drugs in an age of resistance. Washington, DC: National Academy Press.
D’Alessandro U, Talisuna M, Boelaert M (2005) Should artemisinin-based combination 
treatment be used in the home-based management of malaria. Trop Med Int Health 
10: 1- 2 .
Goodman C, Brieger W, Unwin A, Mills A, Meek S et al., (2007) Medicine Sellers and 
Treatment in sub-Saharan Africa: What do they do and how can their practice be 
improved? Am J Trop Med Hyg 77 (Suppl6): 203-218.
Hayes RJ & Moulton LH (2009) Cluster Randomised Trials. Boca Raton: CRC Press.
Institute of Medicine (IOM) of the National Academies (2004) Saving Lives, Buying 
Time. Economics of malaria drugs in an age of resistance. Washington DC:
National Academies Press .
Kangwana BB, Njogu J, Wasunna B, Kedenge SV, Memusi DN et al, (2009) Malaria drug 
shortages in Kenya: A major failure to provide access to effective treatment. Am J 
Trop Med Hyg 80: 737-738.
Kedenge S (2011) The Impact of Retail Sector Delivery of Artemether-Lumefantrine in
Malaria Treatment of Children Under Five in Kenya, Focus Group Discussions. 
Unpublished report. KEMRI Wellcome Trust Research Programme
Njogu J, Akhwale W, Hamer DH, Zurovac D (2008) Health facility and health worker 
readiness to deliver new national treatment policy for malaria in Kenya. East Afr 
Med J 85: 213-221.
Oxfam (2009) Blind optimism: Challenging the myths about private healthcare in poor 
countries. Oxfam Briefing Paper. Available: http://www.oxfam.org/
205
sites/www.oxfam.org/files/bpl25-blind-optimism-0902.pdf. Accessed: 3 May 
2010.
Smith LA, Jones C, Meek S, Webster J (2009) Provider practice and user behaviour
interventions to improve prompt and effective treatment of malaria: Do we know 
what works? Am J Trop Med Hyg 80(3): 326-335.
Yeung S & White NJ (2005) How do patients use antimalarial drugs? A review of the 
evidence. Trop Med Inti Health 10: 121-138.
Zurovac D, Ngigi J, Akhwale WS, Hamer DH, Snow RW (2008) Translation of
artemether-lumefathrine paediatric malaria treatment policy into clinical practice: 
the example of Kenya. Trop Med Int Health 13: 99-107
206
CHAPTER 8 
DISCUSSION & CONCLUSION
8.1: INTRODUCTION
ACTs are generally accepted as the best treatment for uncomplicated malaria, however 
access to this treatment remains low. One way of improving access is through HMM. 
According to the RBM partnership, HMM strategies should aim to overcome barriers to 
accessing effective malaria treatment and improve quality of care received by working 
with both the formal and informal services offered within communities, outside of clinical 
settings.
One possible strategy is to roll out HMM using existing medicine retailers. Due to 
the high free market prices of ACT, this strategy requires drug subsidies to ensure wide 
coverage. Kenya is in the process of rolling out such an approach in the private sector, 
supported by the AMF-m framework which provides a co-payment directly to preselected 
manufacturers of ACTs, in order to reduce the price of this treatment to first-line buyers. 
However, there is limited evidence to guide this process or similar subsidy strategies, with 
certain questions regarding this roll out strategy remaining unanswered. These include, 
with only a sub set of the community using retailers, will an HMM intervention targeting 
this sector have significant impact on coverage; will a brief training of providers be able to 
change their behaviour; will providers be willing to pass on a subsidy to consumers or will 
they be more inclined on retaining the original treatment price in order to maximize profits; 
and what barriers may providers experience that may prevent them from stocking the 
subsidised treatment. It is also not known whether community awareness activities will be 
sufficient to improve consumer treatment seeking behaviour and whether such an 
intervention will reach the poorest, who would most benefit from better access.
The purpose of this thesis is to provide some insight into these questions by
evaluating the provision of pre-packaged subsidised AL treatment, provided to trained
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retail outlets with community awareness activities to stimulate consumer demand. The 
intervention was evaluated using a cluster randomised controlled design, with data 
collected at baseline and 8 months post-intervention.
In this chapter, I will first evaluate the general study strengths and limitations. In 
section 8.2 I will bring key findings together from the previous chapters to see how they 
have informed the objectives of the study, and assess how external factors may have 
affected the study outcomes. In section 8.3 I will go on to describe the policy implications 
of the study and in section 8.4 conclude by reviewing the next steps, beyond this thesis.
8.2: General Strengths and Limitations of the Study 
8.2.1: Strengths
According to the Roll Back Malaria partnership, the ideal HMM strategy should have three 
components, an effective communication strategy; training of community based providers 
on the skills and knowledge necessary to deliver adequate healthcare; and a guaranteed 
supply of high quality pre-packaged anti-malarial medication (RBM, 2005). The HMM 
intervention in this evaluation was designed to contain all these components and therefore 
allows for one to determine outcomes that can be achieved through the implementation of 
such an optimum intervention.
This study also addresses some of the knowledge gaps identified from reviews 
carried out on available HMM intervention studies as discussed in Chapter 2. It has been 
argued that most studies limit their indicators to intermediate outcome measures such as 
provider knowledge and behaviour rather than those more closely linked to health 
outcomes. Although this study did not assess the effect of the intervention on mortality and 
morbidity, the impact on community drug use was evaluated, which is in line with the 
RBM target of improving coverage of effective treatment. Few studies evaluate the 
outcome of their intervention in different socio-economic groups. This is something that 
has been evaluated in this study and allows for one to interpret if the coverage of the
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intervention was equitable and reached the poorest of society, who are in most need of 
improved access to treatment. More generally, many reviews comment on the few studies 
available that evaluate HMM interventions in the private retail sector, and literature on 
ACT subsidies in the private sector is especially limited. This study increases the pool of 
available evidence on this topic, and is the first study to assess the impact of ACT 
subsidies on ACT coverage at the community level.
Several reviews have documented the challenges of drawing firm conclusions about 
strategies to improve retail sector treatment provision due to studies often having weak 
designs such as lacking adequate controls (Goodman et ah, 2007; Smith (b) et ah, 2009; 
Wafula & Goodman, 2010; Hopkins et ah, 2007; Smith (a) 2009). In order to address 
weaknesses observed in previous study designs, this study was evaluated using a cluster 
randomised controlled design, comparing pre and post data to significantly reduce the 
influence of chance, bias, or confounding due for example to variations in public sector 
drug stocks, weather patterns and malaria awareness campaigns (Habicht et ah, 1999; 
Vandenbroucke, 2008; Victora et ah, 2004; Atkins, 2007). This improves the accuracy in 
interpreting the effects of the intervention. Also, the designs of previous HMM 
interventions do not allow for comparability across studies mainly due to different outcome 
indicators being monitored from one study to the next. In order to ensure indicators 
selected could be compared to other similar studies in Kenya, and to ensure relevant policy 
issues were addressed, a stakeholder meeting was held during the initial stages of this 
study design. Stakeholders included the Ministry of Health, DOMC, the pharmacy and 
poisons regulatory body (PPB), PSI (members of the implementation team), KWRT (the 
evaluators of the intervention), and other organizations that have either carried out or are 
interested in carrying out similar studies such as the Kenya Red Cross and SHEF. The 
purpose of the meeting was to formulate a list of indicators to be used across all HMM 
studies in Kenya. The indictors were collated from DOMC targets, GF and RBM 
Monitoring and Evaluation Reference Group (RBM MERG M&E) frameworks, and the
draft monitoring and evaluation (M&E) guidelines for the global ACT subsidy. The 
indicators used in this study were derived from this list. Involving important stakeholders 
such as the DOMC and the PPB from the beginning of the study was important in ensuring 
the success of implementing and evaluating the study intervention. Apart from approving 
the study indicators, the DOMC played an important role in determining the direction and 
design of the study. The DOMC also designed the training materials for retailers and 
attended training sessions. The PPB played a significant role in ensuring PPB regulations 
were adhered to. This was important since having AL available in retail outlets was 
potentially a very sensitive issue requiring expert pharmaceutical guidance. In the field, 
MOH staff and leaders of the community were informed and gave consent for the study to 
take place. At the end of the study, the main study outcomes were then disseminated to the 
relevant ministry of health staff both at headquarters in Nairobi and also to the Provincial 
and District staff from the study sites. As described in Chapter 3, this involvement helped 
in stakeholders having ownership of the study and impacted on its acceptance and ability to 
inform national malaria policy.
Having three different data collection activities in one study is another strength. The 
weaknesses of one data collection activity can be supported by the strength of another. For 
example in the provider survey, interviewees knew that they were being interviewed and 
therefore may have given responses that they felt were appropriate but were not necessarily 
true. The validity of the responses could be confirmed through the mystery shopper survey 
where interviewees were unaware that they were being surveyed. Data from one activity 
can therefore be used to support findings from another, enhancing the reliability of the 
findings.
8.2.2: Limitations
Specific limitations for each data collection method are highlighted in the relevant results 
chapters. In this section the limitations of the overall study design are considered.
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While randomised controlled trials are argued to have high internal validity, there is 
concern that they may lack external validity because the study design demands 
implementation practices that would be unrealistic in operational settings, as described in 
Chapter 3. In this study, the HMM intervention was designed as much as possible to mimic 
what would happen in a typical, real life scenario. However, to avoid contamination of 
control sub-locations, consumer education had to be controlled, meaning that mass media 
techniques such as radio and TV spots could not be used. In addition, the delivery of the 
drug had to be made directly to trained outlets. Both these methods of implementation 
would not be feasible on a larger scale where it would be more practical and efficient to 
use mass media campaigns, and take advantage of the usual drug supply chains. On the 
other hand, stock outs of the intervention’s treatment were observed, indicating that the 
implementation team were not able to ensure 100% delivery of the intervention and 
adherence to its recommendations by providers. In fact, it is possible that stockouts would 
have been rarer without direct delivery, as shopkeepers would have had wider choice of 
suppliers of subsidised ACT. This places the study in the category of ‘public health 
programme efficacy’, described by Victora et al., (2004) (see Chapter 3), where the 
delivery mechanism and the compliance to its recommendations are at the level of ‘best 
practice’ as opposed to the extremes of being ‘ideal’ or ‘routine’. The outcomes of such a 
study look more at the efficacy of the intervention (i.e. which aims to show whether the 
intervention can produce the desired outcomes under ideal conditions) as opposed to 
programme effectiveness where the intervention is implemented with no additional efforts 
made to ensure delivery or dose uptake (under ‘routine’ conditions), resulting in outcomes 
that are more likely under ‘real life’ conditions. This means that the results may to some 
degree overestimate the impact that would be seen under routine conditions.
Two other factors that may limit the strength of the study design are the process of 
randomisation and blinding. A modified randomisation process was used to select sub­
locations in order to reduce the potential for contamination. The creation of a buffer zone
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around selected sub-locations meant that sub-locations meeting the selection criteria did 
not all have an equal chance of being selected for the study. Baseline data from the studies 
however indicate that control and intervention arms had similar characteristics. 
Additionally due to the design of the community awareness activities, it was not possible 
to blind the participants or data collectors. The presence of Tibamal® promotional items 
such as wall paintings and barazas made it obvious which sub-locations were in the 
intervention arm and which were in the control arm. Knowing which arm one was in may 
to some degree have influenced the responses given by interviewees or recorded by field 
staff or their actions. For example, in the provider survey, a provider in the control arm 
who is aware of the counselling advice of AL may not feel as pressurised to give full 
details of his knowledge as a trained provider in the intervention arm selling Tibamal® who 
may be scared of the possibility of being blacklisted by PSI. Similarly a caregiver in the 
intervention arm may be more aware that AL is the appropriate treatment and therefore 
subject to stronger social desirability bias to state that they used AL even if they did not. 
This may have artificially enhanced the positive impacts of the intervention recorded.
There are also limitations observed in reviews looking at HMM studies that also
apply to this study. A cost-effectiveness analysis could not be carried out mainly because
any data on costs may have been overestimated due to the need to deliver drugs directly to
retail outlets, and the small scale of the pilot which meant that economies of scale could
not be exploited. Also, it was hoped that the period between implementation of the
intervention and follow-up data collection would be close to 12 months, to allow for one to
judge the sustainability of the observed outcomes. However, the delay in gaining approval
from the PPB on deregulation of AL meant implementation was delayed, reducing the
period between implementation and evaluation to 8 months after Tibamal® distribution
began and 4 months after the start of community awareness activities. It is not known if
with time caregivers forget the community awareness activity messages and therefore
demand less AL, or if caregivers may become more used to and positive about the product,
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increasing its demand. Similarly providers may with time forget the knowledge gained in 
training, reducing the impact of the intervention on the quality of services received by the 
provider. Lastly, it was not possible to assess the impact of the intervention on the potential 
development of ACT resistance, which could be a cause of concern as the intervention did 
substantially increase ACT use, with adherence to full treatment doses being far from 
optimal.
8.3: DISCUSSION OF KEY FINDINGS
The primary objective of this study was to evaluate to what extent the provision of pre­
packaged, subsidized, AL delivered through private sector retailers would improve the 
coverage of prompt effective anti-malarial treatment. The household survey showed that 
the intervention was able to significantly increase the percentage of children receiving AL 
treatment on the same day or following day of fever onset by 25% points. This was more 
than double the coverage observed in the control arm at follow-up. There are many 
possible factors that could have contributed to this increase in AL coverage.
The one day training of providers was able to improve their knowledge on malaria 
treatment and diagnosis and opinions of ACTs. The provider survey showed a significant 
increase in the percentage of providers having heard of Tibamal®, the intervention’s 
branded AL, by 78% points, when the intervention arm was compared to the control arm at 
follow-up. The same survey showed a 24% point increase in those knowing that AL was 
the recommended first line treatment for uncomplicated malaria, and by follow-up 80% of 
outlets in the intervention arm thought that AL was more effective than other antimalarial 
treatments. The training also seemed to have an effect on provider behaviour. The mystery 
shopper survey showed that a significantly larger percentage of providers prescribed AL 
for the treatment of fever in a four year old child when the intervention arm was compared 
to the control arm, at follow-up. Providers were also able to pass on the treatment subsidy 
to caregivers, selling Tibamal® at the recommended retail price of 20KSH. This was
213
observed in both the household and mystery shopper survey where over 90% of purchased 
Tibamal® was bought at the recommended retail price. The subsided price was calculated 
to make AL as affordable as other more commonly used, but less effective antimalarial 
monotherapies. Passing on the subsidy to caregivers made the treatment as price 
competitive as other more popular antimalarial monotherapies. The increased 
competitiveness of the subsidised Tibamal® compared to other monotherapies was 
observed in the household survey which showed a tendency for those already using some 
kind of antimalarial monotherapy at baseline to be more likely to substitute it for Tibamal® 
at follow-up. Apart from cost, the intervention was able to improve the availability of 
Tibamal® in retail outlets, bringing the treatment physically closer to the community. The 
provider survey showed that at follow-up, the supply of Tibamal® significantly increased 
the percentage of outlets stocking any kind of AL brand by 32% points when the control 
arm was compared to the intervention arm. This resulted in a significant decline in 
household travel time to the nearest retail source of AL, by walking, from around half an 
hour in the control group to ten minutes in the intervention arm.
Caregivers’ knowledge of malaria and treatment behaviour appeared to also have
been positively affected by the intervention. The household survey showed a 75% point
increase in the percentage of caregivers having heard of Tibamal® in the intervention arm
compared to the control arm, at follow-up. Most of the information regarding Tibamal®
was reported to have been sourced by word of mouth from healthcare staff and ‘other
people’, who would have most likely seen a poster, wall paintings and packaging of the
product or attended one of the community activities which included barazas. Part of the
significant increased uptake of AL could be attributed to the success of the community
awareness activities in increasing caregivers’ awareness of the treatment, and as a result
generating consumer demand for the product. This seems to be important since the
provider survey showed that consumer demand was by far the greatest factor that
influenced what treatments providers stocked and sold to consumers. The household
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survey also showed that the intervention did not deter caregivers away from healthcare 
facilities, but instead influenced those who usually bought treatment for fever from a retail 
outlet to purchase AL.
Although data from the household survey showed that coverage of AL had 
significantly improved, it still fell below the 80% target set by the RBM. Two factors 
directly linked to the intervention could possibly explain the limits to the impact observed. 
Firstly, at follow-up, only 43% of all possible outlets that conformed to the selection 
criteria and could have supplied Tibamal® had been included into the intervention, limiting 
the availability of the treatment. Reasons given by PSI for this relatively low uptake of the 
intervention have been discussed in Chapter 5 and include that some outlets identified for 
inclusion were unable to attend the training due to other commitments or were closed when 
invitations to attend the training were being given. Even after receiving training some 
outlets may have changed the type of business they were running and stopped selling 
medication, closed up their business, or relocated to outside the study area. Other trained 
outlets were given the opportunity to buy and stock Tibamal®, but were unable to because 
they did not have the funds to purchase the treatment from the sales staff. Secondly, stock 
outs of AL within two weeks prior to the survey were reported in 33% of outlets in the 
intervention arm at follow-up. This stock out could have also reduced the availability of 
AL within the communities, and may have impacted negatively on the percentage being 
treated with AL. Careseeking patterns may also limit the increase in treatment coverage. 
Some fevers are not treated with any antimalarial with or without the interventions, 
because caregivers perceive them as very mild or as having another cause, or because they 
cannot afford even the cheapest antimalarial on the market. In these cases, it may be much 
harder to shift caregiver behaviour to the use of ACT.
One of the specific objectives of the study was to determine the distribution of the 
benefits of retail sector delivery of AL by socio-economic status. The household survey
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was able to demonstrate that there was no correlation observed between increasing wealth 
and the probability of receiving AL. This indicates that the benefits of the intervention 
were equally spread throughout all socio-economic classes. The intervention was therefore 
able to reach the poorest in the community who are the least able to access effective 
malaria treatment and would therefore be the most likely to benefit from such an 
intervention. This finding should however be interpreted with some caution. One of the 
potential weaknesses of using asset-based measures to measure socio-economic status in 
this rural part of Kenya is that many households tend to have similar durable items, access 
to utilities and infrastructure. This exposes the data to the problem of clumping (as 
described in appendix 4) making it difficult to differentiate between poor and very poor 
households (Vyas & Kumaranayake (2006)). Other studies looking at the impact of 
subsidising ACTs on access across different socio-economic groups had varied findings. 
One study also carried out in Western Kenya showed that an ACT subsidy more than 
tripled the treatment’s use by illiterate-headed households, which were classified as the 
poorest households, while the impact on literate households was much less (Cohen et al, 
2011). A study in Tanzania showed ACTs tended to be stocked more often in shops 
frequented by individuals of higher socioeconomic status (Cohen et al, 2010), and in 
Uganda, ACT market share was lower among those in the lower socioeconomic status 
groups (Schaferhoff & Yamey, 2011).
Other specific objectives of the study were to determine the impact of the
intervention on the proportion of children being treated appropriately and adhering to the
correct dose; and to determine if private sector retailers can deliver AL to appropriate
standards of quality. Adherence was measured as reporting consumption of exactly the
correct number of tablets for the child’s age within three days of receiving the medication.
To be able to adhere to the correct dose, caregivers needed to have received the correct
dose from the provider. The household survey showed that an average of 75% of
caregivers across both arms at follow-up that received AL received the correct dose for
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their child’s fever from a retail outlet. The intervention seemed to have no effect on this as 
there was an insignificant difference observed between the arms. This is not in line with 
what was observed in the mystery shopper survey, where more than 90% of caregivers 
received the correct dose for their child at follow-up. The difference in percentages 
observed between the surveys could have been due to the different data collection methods. 
In the household survey, caregivers were able to access treatment from their choice of 
provider. If one of the providers dispensing the wrong dose was being accessed by many 
caregivers, this would have had a negative effect on the percentage of caregivers receiving 
the correct dose. However, in the mystery shopper survey all outlets were only interviewed 
once, reducing the impact of such a provider on the outcome. Also, the scenario presented 
to the provider in the mystery shopper survey ensured that the age of the child was 
mentioned. In the household survey, it was up to the provider to ask the age of the child. It 
could be that some providers were complacent, forgetting to ask the child’s age and 
dispensing the AL pack that was either available in the outlet (if the other had gone out of 
stock) or randomly selecting one of the two packs to dispense, regardless of the child’s 
age. Another reason could be due to the price of non-intervention AL. It could be that some 
caregivers were unable to afford the full dose of the unsubsidised AL in outlets where 
Tibamal® was not available, therefore only purchasing the number of tablets that they 
could afford, even though it was insufficient for their child. By contrast mystery shoppers 
had sufficient funds to purchase a complete does of whatever was suggested by the 
provider. Other reasons given for providers in the household survey not giving the correct 
dosage to the caregiver are discussed further in Chapter 7.
It seems from the household survey that the percentage of children adhering to AL
treatment remained unchanged post-intervention. One possible explanation for this is
linked to relatively low levels of appropriate dosing advice given to caregivers. The
household survey showed 35% of specialised drug outlets were reported to have correctly
counselled caregivers on how to administer the treatment, and just under half of all outlets
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provided the correct dosing information in the mystery shopper survey. The provider 
survey revealed that after training of providers, only 13% of respondents in the 
intervention arm knew the correct dosing advice for a four year old child suffering from 
fever. All this is despite the provision of job aids providing guidance on dosing in some 
trained outlets. However, it should be noted that the percentage of outlets with job aids was 
extremely low, found in only 22% of all outlets in the intervention arm. Information from 
the FGDs may also help in revealing why trained providers do not counsel all patients they 
dispense AL to. Majority of retailers, especially those from general stores, stated that in 
many instances, they would “have many customers to attend to” and hence not have “time 
to discuss with a patient to satisfaction” (Kedenge, 2011).
Passing on the correct dosing information to the caregiver may not necessarily result 
in 100% adherence of recipients to the treatment as sometimes caregivers ignore the advice 
given to them. A review carried out on interventions designed to improve adherence to 
antimalarial treatments showed that pre-packaging of treatment, the use of blister 
packaging, giving patients both verbal and pictorial instructions on how to administer the 
medication, training providers on the correct counselling advice while providing job aids to 
help in dispensing the correct dose, and community education to encourage adherence have 
all shown positive results (Yeung & White, 2005). Many of these activities were 
implemented in the intervention however no significant improvements were observed at 
follow-up. This may be due to many factors. The AL available in government facilities at 
baseline (the most sourced AL at baseline) was already in a blister pack and had some 
pictorial diagrams on the packaging on dosing advice. It is worth questioning if the 
additional pictorial diagrams added onto the intervention’s packaging had any additional 
effects to adherence. Also, patients from healthcare facilities should be routinely 
counselled on how AL is to be administered. It could be that the percentage of recipients 
being counselled on AL in retail outlets remained similar to those in government health 
facilities, post-intervention. The FGDs could also provide further insight into obstacles
caregivers experience, causing them not to adhere to the dosing guidelines, despite the 
intervention’s community awareness campaigns.
Another objective was to determine if private sector retailers can deliver AL to 
appropriate standards of quality for the treatment of fever in children under five years. In 
addition to providing the correct dose as described above, ‘appropriate standards of 
quality’ consists of adequate counselling advice being given by the provider on issues 
concerning AL, and appropriate storage of AL to maintain its efficacy. The quality of 
counselling advice has been briefly discussed in the above, when looking at dosing advice, 
which showed that there is still room for improvement on the percentage of providers 
counselling on how to administer AL. Apart from the dose that should be administered to 
the child, other counselling advice that should be given by retailers are what to do if the 
child vomits after taking the treatment, what to do if the child does not get better and what 
foods to give the child. The provider survey showed that although the intervention did 
improve knowledge on counselling advice, there was considerable room for improvement. 
Overall the greatest change in knowledge was observed with 66% of respondents in the 
intervention arm at follow-up knowing the correct advice on what to do if the child does 
not improve. This was a 17% point difference from baseline. The mystery shopper survey 
revealed similar results, with most providers giving appropriate advice at follow-up in the 
intervention arm, on what to do if the child does not get better, however this remained 
below 35%. As already discussed in Chapter 7, healthcare workers also perform poorly on 
provision of AL counselling advice. A study carried out by Zurovac et al., (2011) showed 
that regularly sending reminder text messages to healthcare workers’ phones on good 
counselling practices can significantly improve the percentage of malaria patients being 
correctly managed.
The provider survey was able to assess the storage of AL. AL was to be stored off
the floor, out of direct sunlight, in a dry area and with the packaging intact. At follow-up
over 80% of outlets were storing AL according to these requirements, however it seems
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that this had little to do with the intervention since there was an insignificant difference 
when compared to those storing AL appropriately in the control arm. The provider survey 
also revealed that less than 1% of outlets had expired stocks of AL in both arms at follow- 
up.
The context analysis data were able to highlight potential external factors that may 
have influenced the study outcomes. A table of all contextual factors identified is presented 
in appendix 10. Although it is not possible to assess the quantitative impact of these 
influences on the study outcomes, of all the factor identified, two main factors likely to 
have had a significant impact on the study outcomes: the issuing of a government directive 
to halt the production and supply of less effective monotherapies; and the erratic AL 
supplies experienced in government health facilities. During the study period, the MOH 
PPB circulated letters to all importers, manufacturers, wholesale dealers, distributors and 
retailers, restricting the manufacturing, supply and sale of artemisinin monotherapies, SP 
and amodiaquine by the end of 2008. This was enforced by inspection teams visiting 
outlets and shutting down those selling medications illegally. The provider survey shows 
that at baseline 50% of outlets stocked amodiaquine and this decreased to below 20% at 
follow-up, and communication with a predominant amodiaquine manufacturer confirmed it 
had terminated its production of the drug. Although this activity was not part of the 
intervention, and would have affected control and intervention areas in the same way, it 
created an enabling environment for the intervention to be implemented. This directive is 
likely to have reduced the availability of some antimalarial monotherapies such as SP and 
amodiaquine, decreasing competition between AL and these treatments and hence 
facilitating the increase in AL’s market share when the subsidy was introduced, and the 
increase in coverage observed in the household survey.
Since the introduction of free AL into government facilities, supplies of AL in this
sector have experienced fluctuations, with periods of very low stocks alternating with
periods of average or good stock levels (Kangwana et al., 2009; DOMC 2010; Amin et al.,
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2007). During the baseline survey, AL stocks within government health facilities in the 
study areas were extremely low (>appendix 9). This period of low stocks was experienced 
nation-wide, and had been caused in large part by delayed government procurement of the 
treatment (Kangwana et al., 2009). The poor availability of AL is likely to explain the low 
percentage of caregivers accessing this treatment at baseline. AL levels had picked up by 
follow-up, and this may have contributed to increased usage of the treatment reported by 
caregivers, however this would have affected both the intervention and control arms.
In summary, this study shows that the intervention was able to improve coverage of 
effective antimalarial treatment, including to the poorest in society. It also improved 
knowledge of providers and caregivers, and accessibility and affordability of ACT. 
However, the intervention was unable to impact on the level of appropriate counselling 
delivered by retailers or adherence practices of recipients of the treatment.
Only 21 studies were identified as having evaluated the impact of HMM
interventions in improving access to effective antimalarial treatment through the private
retail sector, using similar indicators (refer to chapter 2). As discussed in Chapter 2, there
are limitations in comparing other study findings to the ones reported here, including the
diversity in HMM strategies being evaluated, with no two strategies being the same;
variations in the time period between implementation of the intervention and evaluation of
the study outcomes; few studies carrying out hypothesis testing making the significance of
any changes hard to interpret; and many studies having poor study designs such as a very
low sample size or having no comparison group, exposing the results to potential bias.
However, some general comparisons can be made. Studies in Tanzania and Uganda
showed that subsidising ACTs led to their rapid uptake and a decrease in the use of
antimalarial monotherapies, with good adherence to recommended retail prices (Talisuna
et al., 2009; Sabot et al., 2009; Sabot et al., 2008. In Tanzania there was a 53% point
increase in consumers purchasing antimalarials for a child under five in the intervention
arms compared to a 6% point increase in the control arm (Sabot et al., 2008). In Uganda
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there was a 55% point increase in subsidised ACTs purchased from a licensed drug shop 
for children under five years old (Talisuna et al, 2009). In both countries the price of 
subsidised ACTs remained comparable or below the price of sub-optimal antimalarials. By 
contrast studies in Cambodia and Senegal showed that ACT subsidies had no significant 
effect on ACT availability, which remained low in both countries and irregular in 
Cambodia. In Cambodia after one year of supplying subsidised ACTs, only 6% of private 
retail outlets stocked children’s doses and in Senegal only 43% stocked children’s doses 
(Sabot et al, 2008). The poor market penetration in Cambodia was associated with retail 
prices above the recommended retail prices. No other published data are yet available on 
the impact of private sector ACT subsidies on coverage of prompt effective treatment, and 
robust data on other strategies to improve ACT coverage are limited. There is however 
evidence that provision of ACTs through CHWs could also lead to high levels of ACT 
coverage, with a multicountry study in Ghana, Nigeria, and Uganda finding that 59% of 
children reporting fever in the past two weeks had received an ACT from a CHW (Ajayi et 
al., 2009). Two studies contained IEC components as part of their HMM intervention. One 
IEC strategy in Zambia involving the use of trained village health motivators and vendors 
educating mothers (Kaona & Tuba, 2003), and another in Cambodia, using mass media 
campaigns (Sabot et al., 2008) were able to improve caregivers’ knowledge on malaria 
(Kaona & Tuba, 2003; Sabot et al, 2008). Studies evaluating the effect of training of retail 
outlet providers to improve their knowledge and behaviour on malaria and its treatment 
have mostly shown positive findings (Kaona & Tuba, 2003; Sabot et al, 2008; Oshiname & 
Brieger, 1992; Tavrow et al, 2003; Gilpin et al, 2006; Greer et al, 2004; Muturi, 2001; 
Abuya et al, 2009; Nsimba, 2006; Marsh et al, 1999; Marsh et al, 2004; Twafik et al, 
2006). Most of these studies showed training having a higher impact on provider 
knowledge and behaviour when compared to the study discussed in this thesis. This could 
be due to a variety of factors including some interventions having a relatively short time 
period between training and evaluation; some interventions incorporating regular
monitoring and supervision of providers post training; and some interventions having 
longer training sessions or the training sessions being more involving, either by being on a 
one on one basis or tailored to be less didactic (refer to the ‘negotiation sessions’ discussed 
in Chapter 2).
Lessons learnt from studies carried out on the impact of subsidising ACTs in the 
private sector have shown that on a national scale such an intervention will likely only 
have modest changes on ACT price, availability and market share; that it is questionable 
whether such subsides will increase ACT usage on a national scale, and that ACTs may 
still remain out of reach to the poorest in society (Schaferhoff & Yamey, 2011).
8.4: POLICY IMPLICATIONS
A key policy implication of this study is that the type of intervention implemented, 
involving subsidised pre-packaged ACT, together with training and IEC activities, is 
potentially an important tool in increasing ACT coverage. The findings also allay to some 
degree some concerns that had been expressed about subsidising ACT in the private sector. 
For example, some stakeholders had been worried that providing effective treatment 
outside of formal health facilities would deter patients away from this sector to the private 
sector. Our study showed no evidence of this type of migration during the period between 
the roll out of the intervention and follow-up data collection activities. Secondly, some 
have argued that releasing ACTs into the private sector may increase it misuse, with 
private sector customers being much less likely to adhere to treatment doses. However, in 
this study adherence to treatment received from the retail sector was similar to that from 
health facilities. Thirdly, there have been fears of private suppliers engaging in “price 
gouging” where they fail to pass on the subsidy to the consumer, but in this case adherence 
to the recommended prices was good. A final concern is that even with the subsidy, the 
intervention may not reach the poorest groups. This study has shown that such subsidies 
can benefit all socio-economic groups in poor rural communities.
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However, the study also points to several areas where further work on intervention 
design is required, particularly around poor counselling advice. This may have been a 
reflection of lack of improvement in knowledge on how to dispense the medication despite 
providers having undergone training and a lack of incentives for retailers to spend time 
providing advice when they will not benefit from it financially and may have many 
customers. Additional interventions are also clearly needed to improve adherence for both 
facility and retail careseekers. At the provider level this could be improved through 
provider refresher training, continuous supervision and ensuring that a high percentage of 
outlets receive dispensing job aids. At the caregiver level, adherence might be improved by 
enhancing the instructions on packaging and by more intensive IEC activities.
However, in using these results to develop policy recommendations a number of 
issues should be considered. First, care must be taken in extrapolating these findings to 
other areas or even to a national scale. The study was undertaken in three districts only, all 
within one province in Kenya, and was restricted to rural areas. In some respects these 
districts can be considered relatively representative of the region and to some extent Kenya 
as a whole. Recent national data in the lake endemic region showed fever prevalence was 
41%. Of those fevers 40% received an antimalarial, 24% received an ACT and 16% 
received this ACT on the same or next day of fever developing. Of those who had 
treatment sought for their fever, 36% received it from the private sector (private health 
facilities, pharmacies and shops). Only 10% of fevers had blood samples taken for malaria 
testing. Across Kenya as a whole national data showed an average of 35% of fevers being 
treated with an antimalarial 18% receiving an ACT, 11% receiving it on the same or next 
day, 33%% receiving treatment from the private sector and 12% having a blood sample 
taken for a malaria test (DOMC, 2011). Data from this study showed fever prevalence to 
average 29%, antimalarial use at 50%, AL use at 27% and AL use the same day or 
following day this was 20%. Care sourced from the private sector was slightly over 44% 
and only 9% of children were reported to have had a malaria test done. ITN use and
education levels reported in this study are also similar to those reported in national surveys 
(MIS 2010; DOMC, 2009); 58% of households in the control arm and 60% in the 
intervention arm were classified as poor, compared to a national average of 54% (CBS 
1999). However unlike many regions in Kenya, the study areas have very high levels of 
malaria endemicity compared with the rest of the country, and a relatively active retail 
drug market, with many specialized drug stores. Reasons for limiting the study to such a 
setting have been explained in Chapter 4 ‘Study Design and Methodology’. The 
characteristics of the study sites may have influenced treatment seeking behaviour and 
provider practices in these areas. The effects of these characteristics have been described in 
Chapter 2. For example, in malaria endemic areas, where people are more familiar with the 
symptoms of malaria, self-treatment may be more common than other forms of care. 
Having an active retail market may also be indicative of a high level of self-treatment. If 
this is true then one would expect the intervention to have a greater impact in such areas 
since it targets a large source of treatment in the retail sector. On the other hand, one would 
expect the intervention to have less impact in areas where public sector AL supplies are 
good, although reliable drug supply chains are not common in sub Saharan Africa. The 
area of residence has been shown to influence treatment seeking practices. Whether rural 
or urban, the location of residence may be an indicator of more fundamental factors such as 
beliefs in different types of treatment, ease in accessing different healthcare sectors or be a 
reflection of socio-economic status. Assuming rural areas are linked with poorer SES, one 
would expect reducing the cost of treatment through a subsidy to have a more positive 
impact on its coverage than in better off areas. However, in poorer areas there may be more 
people who cannot even afford the subsidised price of AL, meaning that the intervention 
could have a greater impact in better-off settings. On the other hand, in other areas the 
intervention could have additional benefits in the form of crowding out artemisinin 
monotherapies, reducing the potential for artemisinin resistance to develop. This advantage 
was not apparent in this setting as use of artemisinin monotherapies was so low at baseline,
but would be important in areas where artemisinin monotherapies have a significant high 
market share such as Nigeria, the Democratic Republic of Congo, and Cambodia 
(O’Connell et al., 2011; O’Connell, 2009). In sum, the impact of the study intervention in 
these areas may therefore be different to other areas with different environments and 
therefore practices and the generalisability of the results to other areas should be carefully 
considered. However, the results are likely to be applicable to many rural settings where 
use of drug retailers is high.
The study results could be considered as a positive indication of the potential impact
of AMF-m. However, there are a number of differences between this pilot and the AMF-m
roll out, meaning that the results should be used with caution for predicting AMF-m
impact. Under AMF-m subsidised drugs will be distributed through existing private and
public sector distribution chains. By contrast, as described above, Tibamal® was distributed
directly to retail outlets in order to avoid contamination of control areas; it is possible that
use of existing private sector distribution chains may either improve or worsen retail sector
availability, and the likely impact on final retail prices is unclear. This intervention was
targeted at children under 3-59 months only, but under AMF-m subsidised drugs will be
available to all age groups. No mass media promotion was used in the pilot, again to avoid
contamination, though this is supposed to be a major feature of AMF-m roll out,
potentially enhancing provider knowledge of malaria symptoms, treatment and consumer
demand. This pilot included all medicine retailers including general stores however, most
countries planning to implement AMF-m intend to restrict the availability of subsidised AL
to registered pharmacies and in some cases drug stores. In Africa, Ghana and Nigeria
deregulated the classification of their ACTs to an OTC medication. Other countries such as
Madagascar, Uganda, Niger and Kenya have maintained the classification of their ACTs as
POM. It is unclear how such a narrower range of retail outlets will have similar outcomes
on AL access, provider knowledge and behaviour. Further analysis of these data by retail
type do show that there are differences in key outcomes such as AL availability, price and
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counselling advice between general stores and specialised drug stores in the intervention 
area, with specialised drug stores being generally better stocked and more knowledgeable 
on counselling advice, but having less competitive prices than general stores {appendix 5). 
However, this study shows that although at baseline general stores tended to perform worse 
than specialised drug stores, the improvement in practices such as asking for danger signs, 
dispensing of antimalarials and dispensing of AL seemed to be greater in general stores 
than specialised drug stores, indicating that general stores benefited more from the 
intervention than specialised drug stores.
In Kenya AMF-m drugs are supposed to be restricted to registered pharmacies. 
Registered pharmacies are extremely rare outside of towns in Kenya, implying that either 
the impact on rural ACT availability will be very limited, or that subsidised ACT will leak 
to other drug retailers who will not, however, have received any AMF-m related training, 
which could compromise quality of dispensing.
The first co-payments for Phase I of AMF-m were made in August 2010, to Ghana 
and Kenya. Phase 1 is planned to run until December 2012, when it will be reviewed to 
assess whether it should be continued. An independent evaluation will assess the impact of 
AMF-m on affordability, price, use and market share of effective malaria treatment using a 
before and after study focused on outlets and documentation of context. Baseline outlet 
(provider) surveys were carried out in all AMF-m pilot countries in late 2010, with follow- 
up surveys planned in late 2011. While this evaluation has the advantage that it will be 
studying nationwide roll-out under operational conditions, it also faces a number of 
limitations. The inability to find appropriate comparator countries and limited financial 
resources meant that the intervention will be evaluated using a probability instead of a 
plausibility design (refer to Chapter 3). The effect of AMF-m on ACT use will be derived 
from secondary data from national household surveys such as the DHS, however these may 
not be timed appropriately for the AMF-m evaluation. The time between initial roll out and
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endpoint evaluations may also be considered too short to evaluate the long term effects of 
AMF-m as full nationwide rollout could take much longer than that for small scale pilots 
(Macro & LSHTM, 2010). For these reasons, the findings of the Tibamal® study are still 
likely to be useful to policy makers even once the AMF-m independent evaluation results 
are available.
The thesis results also need to be considered in the light of other current policy 
debates. At the start of this study, WHO recommended that all febrile children under five 
years living in malaria endemic regions should be treated presumptively with effective 
antimalarial treatment. The RBM monitored this recommendation by setting country 
targets of an 80% coverage of appropriate antimalarial treatment within 24 hours of fever 
onset (World Malaria Report, 2008). The HMM intervention described in this study was 
able to significantly increase the percentage of children being treated presumptively with 
effective anti-malarial treatment, although coverage did not reach the 80% target suggested 
by the RBM partnership. This RBM target has since been amended to achieving universal 
coverage (RBM, 2008).
International policy is now leaning towards diagnostic confirmation of all suspected 
malaria cases prior to treating. As a result some stakeholders feel that interventions such 
as the Tibamal® one to improve ACT coverage should only be implemented where they 
can be accompanied by expanded access to diagnosis. The introduction of diagnostics into 
the private retail sector alongside subsidising ACT has its advantages. Targeting anti­
malarial treatment to those who would benefit from it will in turn reduce the numbers 
unnecessarily exposed to the potential side effects of the treatment; potentially improve the 
cost-effectiveness of malaria treatment programmes by reducing over-prescribing of 
malaria treatments; and reduce the potential for the emergence of drug resistance as less 
individuals will have sub-therapeutic doses of treatment in their blood, therefore reducing 
selection pressure for resistant parasite strains (Whitty et al., 2004). However, there are
several obstacles to increasing diagnostic coverage in retail outlets. Testing may introduce
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an additional cost to treatment which patients may have been avoiding by accessing 
treatment from retail outlets, rather than health facilities. Tests require blood to be drawn 
which in outlets with poor health and safety practices may expose patients and staff to 
blood transmitted diseases such as Hepatitis B and HIV. Microscopes are expensive to 
purchase and maintain, and require training of staff for them to be used effectively. RDTs 
are easier to use to detect parasitaemia, however they are heat sensitive, which may be a 
concern in tropical countries.
Currently few data are available on the effects of introducing diagnostics to retail 
outlets. The limited evidence available suggests that this may not be straightforward, For 
example, a study in Western Kenya revealed that having subsidised RDTs in retail outlets 
did not change prescribing practices much with 60% of patients testing negative still being 
treated for malaria (Cohen, 2010). Similarly, the study in Cambodia described in Chapter 
2, showed that even though subsidised RDTs were provided alongside subsidised ACTs, 
through the private sector, the availability and use of RDTs was still low (Sabot et al.,
2008). Although a number of other studies are underway in Uganda (FIND,, 2011; Uganda 
NMCP, 2011), this area remains a topic of great debate and a research priority.
Finally'it is important that the benefits and challenges of retail sector ACT provision
are considered in comparison with other potential strategies to improved malaria treatment
coverage, such as enhancing public sector provision or use of CHWs. In the public sector,
widespread stockouts of essential drugs are a common occurrence, and represent one of the
main causes of low public facility utilisation, reducing the quality of care received and
increasing the economic burden on households who are forced to buy stocked out drugs
from alternative private providers. Despite numerous attempts to strengthen public
medicine supply, such as reforms to central medical stores and replacement of “push”
systems with demand-based “pull” systems, these problems persist. A number of
innovative initiatives are now being used to address this, including SMS based monitoring
of drug supplies (SMS for Life, Tanzania) (Barrington et ah, 2010); hiring district level
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commodity planners (Zambia Access to ACT Initiative (The World Bank, 2010); allowing 
public facilities to purchase from private supplies (e.g. Tanzania, Niger); and the Stop 
Stock-outs Campaign (http://stopstockouts.org).
CHWs have been shown to provide high levels of ACT coverage, with a 
multicountry study in Ghana, Nigeria, and Uganda finding that 59% of children reporting 
fever in the past two weeks had received ACT from a CHW (Ajayi et al, 2009). There is 
renewed interest in the potential for CHWs to deliver a range of Primary Health Care 
(PHC) interventions including malaria treatment (Nsabangani et al, 2007, Tiono et al, 
2008, Ajayi et al, 2008). In Kenya for example, there is talk of rolling out a “Community 
Strategy” based on CHW care, with the aim of using CHWs to supply malaria treatment 
within the AMF-m framework to communities in need (Ministry of Health Kenya, 2009). 
Additional advantages of using CHWs over retail providers include possible greater ease in 
introducing RDTs alongside ACTs, and the potential to provide care for other causes of 
fever at the same time Mukanga et al, (2011). The WHO has been moving away from 
home management of malaria towards a strategy of integrated community case 
management (iCCM). ICCM provides a more holistic approach encompassing not only the 
treatment of malaria, but also pneumonia and diarrhoea which are the other major causes 
of morbidity and mortality in children under five. In this strategy, front line workers such 
as CHWs are equipped with the knowledge and supplies required to diagnose and treat 
these conditions. Studies carried out on iCCM have shown that it has the potential to 
improve treatment coverage and quality of care (World Malaria Report, 2011). However, 
there have been previous concerns raised regarding CHW’s poor retention, the need to 
provide them with incentives, motivation and supervision (HENNET, 2007). More 
evidence is required to compare the costs and benefits of different HMM strategies at 
scale.
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8.5: CO NCLUSIO N
This study has demonstrated that an HMM intervention involving the provision of pre­
packaged, subsidized AL delivered through the private retail sector accompanied by a one 
day training of providers and community awareness activities can significantly improve 
coverage of prompt effective anti-malarial treatment. The intervention was also successful 
in distributing the treatment equitably, reaching those poorest in the community who are in 
most need of the intervention. However, the intervention was less successful in improving 
adhering and dispensing practices.
Outstanding questions that require further research include an assessment of how 
such an intervention will perform at a larger scale and in other parts of the country, given 
the regional variation in epidemiology, health facilities, retail sector activity and socio­
economic status. Further investigation is also needed on strategies to improve provider 
knowledge and application of this knowledge. There is also potential to introduce rapid 
diagnostic tests in retail outlets, as has been done nationwide in Cambodia (Sabot et al.,
2009), and piloted in Western Kenya (Cohen, 2010). Further investigation is clearly 
needed on whether and how this can be operationalized in Kenya. Further work is also 
needed on designing an effective system to monitor pharmacovigilance when ACTs are 
distributed more widely outside formal facilities. Finally, I did not conduct a cost- 
effectiveness analysis as part of this evaluation because the small scale clustered design 
meant that costs were unlikely to be representative of standard implementation. However, 
as such interventions are scaled up, it is important that such cost and cost-effectiveness 
studies are conducted to compare the value for money and affordability of ACT subsidy 
interventions with other approaches for improving malaria treatment using the public 
sector and community based strategies.
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APPENDICIES
APPENDIX I
SAM PLING  PR O C EDU RES
Steps in selection of study sub-locations
• Sub-locations were allocated random numbers which were then sorted in ascending 
order.
• The sub-location at the top of the list was entered into the study as an intervention 
site, and removed from the sampling frame.
• Sub-locations on the list that were within two sub-locations of the selected sub­
location were removed from the sampling frame. These sub-locations created the 
buffer to minimize possible contamination between study sites.
• Sub-locations within the new sampling frame were re-assigned random numbers 
and sorted in ascending order. This time the sub-location at the top of the list was 
entered into the control arm and removed from the list.
• All sub-locations on the list that were within two sub-locations of the selected 
control sub-location were then removed from the lis t.
• This process continued, alternating between intervention and control arm allocation 
until 3 intervention and 3 control sub-locations had been selected within each 
district. Teso and Busia districts neighbour each other, it was therefore important 
that any sub-locations selected near the border of these two districts were at least 
two sub-locations away from each other, regardless of the district borders. Sub­
locations selected that were near to each other across borders had to be replaced by 
another selected through the same randomisation process.
Steps in selection of Enumeration areas
• A list of all EAs in the selected sub-districts was made with their total populations.
• Running cumulative population totals were calculated, together with a total
population.
• The total population was divided by 3, the number of EAs I wish to select within a 
sub-location, the output of which was called the sampling interval (SI).
• A random number was chosen between 1 and the SI, this was called the Random 
Start (RS).
• The first EA selected was the one in which the RS fell within its cumulative
population i.e. between the cumulative number that proceeded the previous EA on
the list and the cumulative total assigned to that EA.
• The RS was then added to the SI to calculate the 2nd RS, which was used to identify 
the 2nd EA, as described above.
• The 3rd RS was calculated as RS + 2SI, which was used to identify the 3rd EA.
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APPENDIX 2 
COMMUNITY AWARENESS MATERIALS 
Dispensing Aids and Promotional Items for the Intervention
Dosing Schedule Tibamal
Tibamal® work aids used by retailers
Tibamal® promotional T-shirtAn example of the Tibamal8 wall painting
Tiba maalum
Tibamal * Calendar
Tibamal m
Pen
Tibamal® promotional pen Tibamal® poster
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APPENDIX 3
KEY INDICATORS FOR ACT ACCESS STUDIES IN KENYA
Background
Kenya has been delivering artemisinin combination therapy (ACT) through the public 
sector since mid-2006. Early evaluations show this led to an increase in the percentage of 
children under 5 receiving antimalarials from 14% to 26% within 48 hours, of whom 30% 
received artemether-lumefantrine (AL). However, access remains well below the Roll 
Back Malaria target of 60%, with the majority of patients still failing to receive prompt 
effective treatment. The Ministry of Health (MOH) is committed to exploring alternative 
delivery channels that can complement existing facility-level delivery, and thus improve 
community access to ACT. These could include delivery through drug retailers, 
Sustainable Health Enterprise Foundation (SHEF) clinics, Community Owned Resource 
Persons (CORPs) or other volunteers. Pilots of such interventions have been proposed by a 
number of groups, and the Pharmacy and Poisons Board (PPB) is expected to approve a 
special dispensation to allow over the counter (OTC) status for AL for these pilots.
The Division of Malaria Control (DOMC) is keen to ensure that evidence arising from 
these pilots is of high quality and based on common indicators, to facilitate comparison of 
results and identification of policy implications. This paper therefore outlines core 
indicators which should be included in all studies, and identifies optional complementary 
indicators which may also be included. In addition, each pilot may wish to add their own 
indicators that address outcomes specific to their interventions or interests. The indicators 
have been identified through consideration of DOMC targets, Global Fund (GF) and Roll 
Back Malaria Monitoring and Evaluation Reference Group (RBM MERG M&E) 
frameworks, and the draft monitoring and evaluation (M&E) guidelines for the global ACT 
subsidy.
Guidelines on Study Design
All studies must include either:
• Pre and post-intervention data
• Intervention and control groups
It is strongly recommended that both are included (i.e. pre and post for intervention and 
control groups). However, this may be infeasible for some studies, for example where the 
intervention has already begun, or where no appropriate control groups exist.
Cluster randomisation of outlets to intervention and control groups reduces the potential 
for bias. However, it may be infeasible for some interventions which need to function at a 
certain minimum scale, or where “contamination” would be likely between clusters (e.g. 
residents from control clusters could visit outlets in intervention clusters or receive 
communication messages targeted at the intervention group). In most cases it is therefore 
likely that there may be only 1 or 2 control and intervention areas.
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Study Indicators
Indicators have been divided into 3 groups:
A. Indicators to be included in all studies (please refer to back page for summary)
B. Optional complementary indicators
C. Indicators likely to be beyond the scope of pilot studies
A. Indicators to be Included in all Studies 
Al: Household Survey Indicators
Indicator 1: The proportion of children under 5 years with fever in the past 2 weeks who 
started treatment with a first line ACT within 24 and 48 hours offever onset, overall, by 
socio-economic group (SEG) and treatment source
• This will be the primary indicator for all studies. It is a standard RBM indicator 
collected as part of the Multiple Indicator Custer Surveys (MICS) and the 
Demographic and Health Surveys (DHS) and a core GF indicator.
• It requires collection through a household survey, which will represent an 
additional expense for some pilots. However, it is essential in order to measure the 
overall impact on ACT coverage from both facility and non-facility sources. This is 
important as an intervention with high levels of ACT provision through non-facility 
sources would not be considered a success if it reduced facility provision, and 
possibly even reduced ACT coverage overall.
• All compulsory household survey indicators focus on children under 5 years as the 
most biologically vulnerable group. Older groups are also important, but their 
inclusion would increase the complexity of the household survey. The same 
indicators for these groups are therefore considered optional.
• 2 weeks is the standard recall period for this indicator.
• I focus on fever (rather than malaria) as the majority of febrile illnesses do not 
receive parasitological confirmation, and fever is the main symptom used in clinical 
diagnosis. In addition, for most communities in Africa, fever is the prompt for 
seeking treatment.
• I have included both 24 and 48 hours (although RBM targets have been specified in 
terms of 24 hours), as treatment within 48 hours could still be considered prompt. 
The denominator for 24 (48) hours should be all individuals reporting fever, visited 
2 (3) or more days after symptoms began. Surveys must therefore also ask when 
symptoms began.
• The indicator should be collected by SEG in view of the emphasis placed on equity 
by both the Kenyan MOH, and RBM. All surveys should therefore include the 
standard asset indicators from the Kenya (K)DHS (collection of asset indicators is 
much quicker and more reliable than collection of income or expenditure data). 
Households should then be allocated to national SEGs on the basis of national 
KDHS weights. This is preferable to calculating a study specific asset index and 
SEGs, as, for example, households in socio-economic quintile 3 in one study area 
could be in quintile 5 in another.
• The indicator should be collected by treatment source (e.g. public, faith-based 
organisations (FBOs) and commercial facilities, pharmacies, other retail outlets and 
CORPs) in order to know through which channels the intervention is achieving its 
goals.
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• Study teams should choose a sample size capable of detecting at least a 20 
percentage point increase in ACT coverage in the target group (5% significance, 
80% power, allowing for clustering if such sampling is used). As a rough guide, 
assuming an initial proportion of 11% (KEMRI/Wellcome Trust, 2007), with a 
simple random sample of households this would require a minimum of 65 
childhood fevers per group (before and after, or control and intervention). In areas 
with moderate to high malaria transmission you are likely to need to visit between 2 
and 4 households to find one childhood fever, meaning that you should sample at 
least 260 households in each group. If a cluster design is used it would be 
conservative to double this requirement to 520 households per group.
• It is recommended that tools such as picture boards are used to facilitate recall of 
drugs used.
Indicator 2: The proportion of children under 5 years with fever taking a first line ACT 
who adhered to the treatment dose, by source
• Adherence is important in both treatment efficacy and reducing the risk of the 
development of resistance.
• As ACT is a 3 day course, the denominator should be individuals interviewed 3 or 
more days after ACT treatment began.
• The indicator should be measured by source to indicate any variations in adherence 
across treatment types.
• Adherence will be defined as taking the quantity of drug specified in MOH 
guidelines by age group over 3 days (i.e. excludes both under and over dosing).
• Timing of doses within the 3 days will not be considered due to problems of precise 
time recall.
Indicator 3: The proportion of children under 5 years with fever who took an anti- 
malarial monotherapy in the past 2 weeks
• This assesses whether the intervention has succeeded in crowding monotherapies 
from the market, which are undesirable because they create competition that may 
decrease the demand for more effective combination therapies such as ACTs. The 
availability of artemisinin monotherapies increases the likelihood of the 
development of resistance to artemisinin, thus reducing the useful therapeutic life 
(UTL) of the ACTs.
Indicator 4: The proportion of children under 5 years with fever in the past 2 weeks who 
sought treatment by source (e.g. from public, mission & commercial health facilities, 
pharmacies, other retail outlets, CORPs, traditional healers and other sources)
• This indicator will allow assessment of any changes in treatment seeking patterns 
as a result of the intervention, for example whether there is a shift away from 
facilities, or from shops to CORPs, or an overall increase in the proportion seeking 
any care.
• The indicator covers any use of each outlet type, irrespective of the order in which 
they were used. One child may therefore use more than one source.
A2: Provider Survey Indicators
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Indicator 5: The median price charged by non-facility outlets for a first line ACT by age 
band
• The price charged is important in order to assess affordability and whether 
subsidies are being passed onto final users i.e. are providers adhering to 
recommended retail prices or to free provision depending on the intervention 
design.
• I propose collecting drug price data from the provider survey rather than the 
household survey because of the difficulties of recall of costs in household surveys, 
the problems of separating the cost of a single drug from other payments, and 
problems of standardisation due to variation in patient age and dose obtained. It is 
possible that providers may not admit diverging from recommended prices under 
direct questioning, so an optional alternative is to validate price data through the 
patient- provider encounter indicators -  see below.
• The median rather than the mean is generally used for cost and price data as the 
data tend to be skewed.
Indicator 6: The proportion of non-facility outlets with no expired first line ACT 
available in stock
Indicator 7: The proportion of non-facility outlets reporting stock outs of the first line 
ACT within the past 2 weeks
• A stock out is regarded as any period of time the facility does not contain stock. 
Restricting stock outs to a minimum period of time may complicate data collection 
in addition, an efficient supply chain should ensure that drugs are always available 
for customers to purchase.
Indicator 8: The proportion of non-facility outlets storing first line ACT appropriately
• Storage conditions include: (1) Off floor, (2) Out of direct sunlight, (3) Dry area, 
(4) Away from foodstuff, (5) All conditions met. “Appropriate storage” is defined 
as item (5) i.e. all storage conditions (1-4) have been met.
Indicator 9: The proportion of non-facility outlets that have copies of the materials/ job 
aids required by the intervention (e.g. leaflets, posters, guidelines)
A3: Intervention Cost Indicators
Ideally one would want cost data from all pilots in order to compare:
Indicator 10: Implementation cost per intervention area
• The cost of the intervention will provide information on the size of budget required 
to roll out a similar intervention either at a regional or national level.
• Costs should take into account all items that were paid for during the planning and 
rollout of the intervention. These include for example, costs of purchasing the anti- 
malarial drugs, costs of transport of staff and goods to and from intervention sites, 
salaries paid to all staff who played a part in planning and implementation of the 
intervention, and costs incurred from the development of information, education 
and communication materials.
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Indicator 11: The cost-effectiveness in terms of the incremental cost per additional child 
receiving prompt ACT treatment
However, there are a number of challenges:
• Pilots tend to operate on a small scale and therefore costs may not be representative 
of larger scale operations, when costs per capita may fall significantly.
• Considerable effort is required to ensure that cost data collected are comparable.
• Cost data collection and analysis requires specific skills that may not be available 
to all partners.
A costing consultant will therefore be hired by the MOH to work with each team to 
estimate costs for scaled up operation of each pilot. This will facilitate the use of 
standardised methods and unit costs where appropriate, and avoid basing policy decisions 
on unrepresentative costs from differing small scale operations. It is therefore compulsory 
for all pilots to keep records of resource use, and to collaborate with the MOH in any 
costing analysis required.
A4: Pharmacovigilance Indicators
Pilots will be required to collaborate with regulatory authorities (PPB, MOH) to ensure that 
any pharmacovigilance requirements are met within their intervention design.
B. Optional complementary indicators
Bl: Household Survey Indicators
• Indicators 1-4 could he adapted to consider Individuals o f 5 years and over
• Indicator 1 could be adapted to consider all antimalarials, or all “effective ” 
antimalarials
• The proportion o f non-target household members receiving intervention ACT (e.g. 
adults receiving paediatric ACT i f  ACT is targeted at children only; pregnant 
women receiving A CT)
• Household cost o f fever episode (for all completed episodes)
• The proportion o f households within 30 minutes to 1 hour travel time from a first 
line ACT source
• The proportion o f caregivers with knowledge o f malaria symptoms, danger signs, 
ACT and correct ACT dose for 2 year old
B2: Provider Survey Indicators
• Total volume o f ACT distributed per capita in public and private sectors
• The proportion o f sub-locations with at least one ACT source
• Availability o f public sector ACT in inappropriate outlets
• Availability o f private sector intervention ACT in inappropriate outlets
• The proportion o f non-facility outlets with first line ACT stock records that
correspond with physical counts
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The above indicators require a detailed understanding of a variety of factors for all service 
providers in the locality including the numbers, nature and antimalarial stocks. This is 
unlikely to be feasible for all studies.
B3: Patient- Provider Encounters Indicators
In addition to the household and provider surveys, it is necessary to include some 
evaluation of patient-provider interaction to give better information on actual (rather than 
self-reported) provider behaviour. Patient-provider interaction can be assessed by a number 
of methods including the following:
• Direct observation requires data collectors to directly observe the behaviour of the 
provider for the purpose of describing over the counter prescribing and dispensing 
practices.
• Mystery shopper study, where data collectors pose as ordinary customers. It 
provides similar information to direct observation, except the observer does not 
have to stay at the site for a substantial period of time; the potential bias from 
observation is eliminated and the scenarios assessed can be standardised between 
outlets. This technique does however raise some ethical concerns because informed 
consent is not obtained from the medicine seller before the study is conducted.
• Exit interviews provide information to determine how well each patient/caregiver 
understood the instructions given by the provider and also can be used as a record 
of reported patient provider interactions.
• Vignette surveys. These are short hypothetical scenarios described to the 
interviewee with the intention of eliciting a response from them. For example ‘what 
would you do if a care giver presented with a 2 year old child with fever?’. The 
response is used to portray perceptions, opinions, beliefs and attitudes of the 
interviewee. The responses however do not provide any information on the actions 
of the care giver if presented with a similar real life situation as beliefs do not 
always translate into action.
• Management information systems involve using retrospective data collected by the 
non-facility outlet to determine the prescribing and dispensing practices of the 
provider
Data will not be strictly comparable between the above methods. However, no single 
method is possible in all studies for practical reasons. For example, it would not be 
efficient to do an exit interview where there are only a few customers per day; neither is it 
possible to use mystery shoppers at a clinic. Each study should therefore include the 
method most suitable to them.
Indicators for the patient provider encounters include:
• The proportion o f non-facility outlet staff that dispense an appropriate first line 
ACT to patients presenting with fever
• The proportion o f non-facility outlet staff that dispense the correct dose o f first line 
ACT to patients presenting with fever
• The proportion o f non-facility outlets that provide appropriate information to 
patients/ caregivers on how to give/ take the first line ACT
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• The proportion o f encounters where non-facility outlet staff asked one or more 
clinical questions to determine severity o f malaria
• The proportion o f non facility outlet staff who told patients/ caregivers about any 
signs o f progressive illness and recommended a referral visit to a doctor or clinic i f  
the signs appear
• The median price charged for an ACT dose by age group
B4: Qualitative Data Indicators
It is also recommended that studies include qualitative data collection activities such as 
focus group discussions and in-depth interviews with household members, providers and 
others involved in the distribution chain. These will complement, validate and help 
interpret the quantitative indicators, providing a richer understanding of the reasons behind 
achievements and constraints in implementation. Qualitative data may also be used to 
inform the design of quantitative instruments.
B5: Diagnostic Indicators
Diagnosis can be either clinical (presumptive) or parasitologically confirmed (microscopy 
or rapid diagnostic tests). It is likely that a mix of diagnostic approaches will be used 
across the studies. Where parasitologically confirmed diagnosis is used in an intervention, 
the following indicators should be evaluated:
• The proportion o f non-facility outlets staff able to confirm a malaria diagnosis 
according to national guidelines using the approved diagnostic
• The proportion o f non-facility outlet patients who undergo a malaria diagnostic 
test
• The sensitivity and specificity o f a diagnostic test. Diagnostics should be of high 
sensitivity since false negatives may result in failure to treat, and of high specificity 
to avoid over diagnosis and subsequent over treatment.
• The proportion o f non facility outlets reporting stock outs o f the approved 
diagnostic or components required for its proper functioning, within the past 2 
weeks
C. Indicators Likely to be Beyond the Scope of Pilot Studies 
Cl: Morbidity and Mortality Indicators
Final health outcome measures such as number of severe malaria cases and number of 
malaria fatalities would clearly be desirable. However, they are difficult to obtain for 2 
reasons:
• They are relatively rare events and therefore require very large sample sizes;
• Many severe cases and deaths are not seen at health facilities and therefore are 
difficult to identify; over 60% of deaths in Kenya and in the sub-region occur at 
home.
It is therefore not expected that most studies will include these indicators. Exceptions may 
be large scale studies which could consider facility reports of severe cases, or studies 
taking place within demographic surveillance areas where community-based malaria 
mortality rates can be assessed based on verbal autopsy.
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C2: Drug Resistance Indicators
Pilots are unlikely to be able to measure the impact of their intervention on drug resistance 
directly through treatment failure rates or genetic resistance markers. Measuring such 
outcomes would require large sample sizes, long time frames, and considerably increase 
evaluation costs in terms of collection of blood samples and laboratory analysis.
C3: Drug Quality Indicators
All pilots will use ACT supplies from quality certified sources and will therefore not be at 
risk of poor quality from sub-standard or fraudulent manufacturing. However, it is possible 
that the storage and handling of ACT in the supply chain could negatively affect quality, 
and these intermediate outcomes are therefore included under the provider survey. Again, 
additional laboratory tests would be required to assess the impact of storage and handling 
on actual quality.
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A PPEN D IX  4
PCA ANALYSIS
There are several ways to determine household wealth/ socio-economic status which 
include standard economic measurers of monetary information such as household income, 
consumption or expenditure measures, however a limitation in using these measures is the 
extensive data collection required which may be both time consuming and costly. As a 
result asset-based measures are increasingly being used to determine socio-economic status 
of households (Vyas & Kumaranayake (2006)). In this technique, data are collected on 
households asset ownership, and housing characteristics. Principal component analysis 
(PCA) is used to determine appropriate weights for the assets, and produce a range of 
critical points which allows households to be differentiated by varying socio-economic 
levels. Further details on the use of this technique can be found in Filmer & Pritchett 
(2001)).
The presence of certain household assets (selected on the basis of those included in 
the 2003 Kenyan Demographic and Health survey (CBS,2004)) was recorded to assess the 
wealth of the household. A wealth index was constructed by assigning weights to each 
asset using PCA with weights based on the first principal component only. Missing asset 
data was replaced with the mean value for that variable, the mean derived from other 
households within the same enumeration area (Vyas & Kumaranayake (2006)). Each 
household was then assigned to a specific wealth quintile, those falling into the first 
quintile being most poor and those in the fifth quintile being least poor. All interviewed 
households were included in the PCA, regardless of whether they contained children under 
five. The PCA was conducted separately for baseline and follow-up surveys.
Baseline
The survey included data on 65 asset indicators. At baseline two asset indicator variables, 
‘using bottled water’ and ‘having an unlisted ‘other’ type of floor’ were dropped from the 
analysis because of zero variance. The first principal component explained 6% of the 
variability in the SES variables. Table A4.1 reports the baseline weights from the principal 
components analysis of the remaining 63 variables, with the greatest weight given to 
having a cement floor: 0.379, a television: 0.294, corrugated iron sheets for the roof: 0.277, 
owning a ventilated pit latrine: 0.245, and owning a phone: 0.233. It should be noted that 
cooking with electricity was attributed a negative weight from the PCA, implying that a 
household cooking with electricity will be ranked lower in terms of SES than a household 
that does not cook with electricity. An explanation for this may be that the PCA strongly 
correlated cooking with electricity with variables associated with a lower SES, such as 
dumping waste on the street or empty plot (Vyas & Kumaranayake (2006)). The difference 
that ownership of each asset made to the household’s PCA score is also displayed on Table 
A4.1 and was calculated by dividing the weight of each variable by its standard deviation. 
The greatest impact on the PCA score was having a tiled roof at 2.69, followed by a fridge 
at 2.118 and a car at 1.911.
The difference observed in mean socio-economic scores between the 1st and 2nd quintile 
was 0.671, the 2nd and 3rd quintile, 0.643 and the 3rd and 4th quintile, 0.759. The difference 
in mean socio-economic scores remained relatively equal between these quintiles, 
suggesting a uniformly distributed SES. The relatively small differences seen between the 
mean SES scores in these quintiles indicates that wealth does not change much moving 
from households in a lower quintile to those in a higher quintile. A histogram (Figure 
A4.1) plotting the socio economic scores shows scores were heavily skewed to the left, 
which may indicate evidence of truncation. This tends to occur if there are not sufficient
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indicators to allow one to tell between the poor and the very poor and may also be a 
possible explanation for the relatively small difference seen in wealth between the lower 
quintiles.
A larger gap exists between the mean socio-economic scores of the 4th and 5th 
quintile of 2.880, suggesting those in the highest quintile are disproportionately wealthier 
than those in the lower quintiles.
Table A4.1; Baseline PCA outputs
Variable Mean StandardDeviation Weight
Impact 
on PCA 
score
Tiled roof 0 . 0 0 1 0.03 0.081 2.69
Fridge 0 . 0 0 2 0.046 0.098 2.118
Car 0.009 0.095 0.182 1.911
Vinyl or asphalt strips floor 0 0.017 0.031 1.759
Rain water 0 . 0 0 2 0.039 0.063 1.608
Own a ventilated improved pit latrine 0.029 0.167 0.245 1.469
Cooking with gas 0 . 0 0 1 0.035 0.051 1.467
Solar power 0.024 0.152 0.218 1.43
Ceramic tiled floor 0 . 0 0 1 0.035 0.049 1.413
Carpet floor 0 . 0 0 2 0.043 0.059 1.386
Cooking with Kerosene/ Paraffin 0 . 0 0 1 0.025 0.031 1.24
Cement floor 0.106 0.308 0.379 1.231
Motorcycle 0.015 0 . 1 2 1 0.144 1.191
Electricity 0.004 0.06 0.07 1.155
Television 0.105 0.306 0.294 0.959
Cooking with charcoal from wood/ coal/ lignite 0.026 0.158 0.145 0.918
Infrequent collection of waste by government 0 0.017 0.015 0.837
Pays for private collection of waste 0 . 0 0 1 0.025 0 . 0 2 0.819
Water from closed borehole or well in compound/ plot 0.055 0.227 0.168 0.739
Pays no rent on house (squatting) 0 . 0 0 1 0.03 0 . 0 2 0 . 6 6 8
Share a ventilated improved pit latrine 0.027 0.162 0.105 0.643
Corrugated Iron sheets roof 0.479 0.5 0.277 0.553
Water piped into compound/ plot 0.007 0.083 0.046 0.545
Phone 0.366 0.482 0.233 0.483
Regular collection of waste by government 0 . 0 0 1 0.03 0.015 0.483
Pays no rent on house with consent of owner 0.009 0.092 0.038 0.41
Radio 0.691 0.462 0.164 0.354
Waste disposed in other method 0 . 0 0 1 0.025 0.008 0.34
Water from open borehole or well in compound/ plot 0.05 0.217 0.072 0.333
Asbestos sheets roof 0 . 0 0 1 0.035 0 . 0 1 1 0.315
Bicycle 0.595 0.491 0.146 0.298
Parquet or Polished wood floor 0 0.017 0.005 0.292
Waste composted 0.53 0.499 0 . 1 2 2 0.245
Water from public tap 0.016 0.127 0.03 0.236
Wooden planks floor 0.007 0.085 0 . 0 2 0.229
Water piped into dwelling 0.005 0.07 0.015 0.214
Own land 0.863 0.344 0.055 0.161
Share flush toilet 0.008 0.087 0.007 0.083
Own a pit latrine 0.375 0.484 0.035 0.072
Other roof 0 . 0 0 1 0.035 0 . 0 0 1 0 . 0 2
Water from closed borehole or well in open public 0.234 0.423 -0 . 0 2 1 -0.049
Water from open borehole or well in open public 0.125 0.331 -0.018 -0.054
Number of residents per sleeping room 2 . 8 8 1.511 -0.097 -0.064
Owns a flush toilet 0.006 0.076 -0.005 -0.065
Tin can roof 0.004 0.063 -0.009 -0.142
Table continued on next page
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Table A4.1; Baseline PCA outputs continued
Variable Mean StandardDeviation Weight
Impact 
on PCA 
score
Other toilet facility 0.004 0.063 -0 .0 1 -0.156
Staying on land with owners consent 0.136 0.342 -0.053 -0.156
Waste dumped in street/ empty plot 0.108 0.311 -0.057 -0.184
Waste dumped, buried, burned in compound 0.359 0.48 -0.093 -0.193
Water from stream or river/ pond/ lake/ dam/ spring 0.5 0.5 -0.098 -0.195
Shares a pit latrine 0.481 0.5 -0 . 1 0 1 -0 . 2 0 2
Water from other source 0.007 0.085 -0.018 -0.214
Cooking with electricity 0 . 0 0 1 0.035 -0.009 -0.267
Renting house 0 . 0 0 1 0.025 -0.007 -0.276
Cooking with other fuel 0 . 0 0 1 0.03 -0.009 -0.291
Does not have a toilet [bush/ field] 0.071 0.257 -0.094 -0.364
Renting land 0 . 0 0 1 0.035 -0.013 -0.381
Own house 0.99 0 .1 -0.039 -0.393
Concrete roof 0 0.017 -0.007 -0.395
Squatting on land 0 . 0 0 1 0.025 -0 . 0 1 1 -0.434
Grass or thatch/ Makuti roof 0.514 0.5 -0.281 -0.562
Cooking with Firewood/ Straw/ Dung 0.97 0.169 -0.147 -0 . 8 6 6
Earth/ sand/ mud/ dung floor 0.883 0.321 -0.384 -1.193
Figure A4.1: Histogram of baseline PCA scores
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Follow-up
At follow-up 12 asset indicator variables were dropped from the analysis because of zero 
variance. These were owning floors made from: parquet or polished wood, vinyl or asphalt 
strips or any other type of floor not listed; owning a roof made from: tin cans, asbestos 
sheets or tiles; cooking with electricity, using bottled water, and having waste: collected on 
a regular or irregular basis by the government, by a private company or waste collected in 
any other way not listed. The first principal component explained 7% of the variability in 
the SES variables. Table A4.2 reports the follow-up weights from the principal 
components analysis of the remaining 53 variables, with the greatest weight given to
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having a cement floor: 0.375, having a corrugated iron sheet roof: 0.3, owning a television: 
0.287, owning a ventilated pit latrine: 0.23, and owning a phone: 0.214. The difference that 
ownership of each asset made to the household PCA score is also displayed on Table A4.2 
and is calculated by dividing the weight of each variable by its standard deviation. The 
greatest impact on the PCA score was having a concrete roof at 3.374, followed by a 
ceramic tiled floor at 2.75 and a fridge at 2.186.
Similar to baseline, the difference observed in mean socio-economic scores between the 1st 
and 2nd quintile was 0.761, the 2nd and 3rd quintile, 0.690 and the 3rd and 4th quintile, 0.784. 
The difference in mean socio-economic scores remained relatively equal between these 
quintiles, suggesting a uniformly distributed SES. The relatively small differences seen 
between the mean SES scores in these quintiles indicates that there the wealth does not 
change much moving from household in a lower to a higher quintile. As at baseline a 
histogram (Figure A4.2) plotting PCA scores showed evidence of truncation. A larger gap 
in the average index exists between the 4th and 5th quintile of 2.817, suggesting those in the 
highest quintile is disproportionately wealthier than those in the lower quintiles.
Table A4.2: Follow-up PCA outputs
Variable Mean StandardDeviation Weight
Impact on 
PCA score
Concrete roof 0 0.018 0.06 3.374
Ceramic tiled floor 0.001 0.025 0.069 2.75
Fridge 0.003 0.053 0.116 2.186
Cooking with Kerosene/ Paraffin 0 0.018 0.037 2.088
Electricity 0.003 0.056 0.113 2.019
Car 0.009 0.095 0.185 1.949
Owns a flush toilet 0.001 0.025 0.047 1.864
Carpet floor 0.001 0.025 0.046 1.84
Solar power 0.022 0.147 0.211 1.441
Own a ventilated improved pit latrine 0.026 0.16 0.23 1.432
Cooking with gas 0 0.018 0.025 1.422
Cement floor 0.114 0.318 0.375 1.18
Water from other source 0.001 0.031 0.035 1.15
Motorcycle 0.021 0.142 0.161 1.131
Water from stream or river/ pond/ lake/ dam/ 
spring 0.002 0.04 ,0.042 1.063
Piped into dwelling 0.002 0.043 0.046 1.051
Television 0.113 0.316 0.287 0.906
Cooking with charcoal from wood/ coal/ 
lignite 0.018 0.134 0.115 0.863
Share a ventilated improved pit latrine 0.019 0.136 0.116 0.856
Piped into compound/ plot 0.003 0.056 0.042 0.758
Corrugated Iron sheets roof 0.514 0.5 0.3 0.599
Closed borehole or well in compound/ plot 0.061 0.24 0.142 0.592
Phone 0.46 0.498 0.214 0.429
Radio 0.682 0.466 0.17 0.364
Bicycle 0.587 0.492 0.146 0.296
Own house 0.985 0.122 0.036 0.294
Wooden planks floor 0 0.018 0.005 0.293
Own land 0.902 0.297 0.087 0.292
Waste composted 0.424 0.494 0.135 0.273
Open borehole or well in compound/ plot 0.047 0.212 0.056 0.263
Cooking with other fuel 0.001 0.035 0.007 0.203
Owns a pit latrine 0.416 0.493 0.041 0.083
Table continued on next page
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Table A4.2: Follow-up PCA outputs continued
Variable Mean StandardDeviation Weight
Impact on 
PCA score
Renting land 0.001 0.025 0.001 0.024
Closed borehole or well in open public 0.265 0.441 -0.012 -0.027
Number of residents per sleeping room 2.752 1.425 -0.101 -0.071
Public tap 0.04 0.196 -0.022 -0.114
Open borehole or well in open public 0.156 0.363 -0.042 -0.115
Water from stream or river/ pond/ lake/ dam/ 
spring 0.423 0.494 -0.057 -0.115
Waste dumped, buried, burned in compound 0.473 0.499 -0.097 -0.194
Waste dumped in street/ empty plot 0.103 0.304 -0.06 -0.196
Other roof 0.001 0.035 -0.008 -0.215
Shares a pit latrine 0.471 0.499 -0.108 -0.216
Share flush toilet 0.001 0.035 -0.008 -0.22
Pays no rent on house with consent of owner 0.014 0.115 -0.029 -0.249
Staying on land with owners consent 0.097 0.296 -0.086 -0.29
Does not have a toilet [bush/ field] 0.064 0.245 -0.079 -0.321
Other toilet facility 0.001 0.035 -0.016 -0.457
Renting house 0.001 0.035 -0.018 -0.508
Grass or thatch/ Makuti roof 0.484 0.5 -0.301 -0.602
Cooking with Firewood/ Straw/ Dung 0.98 0.14 -0.12 -0.852
Earth/ sand/ mud/ dung floor 0.884 0.32 -0.382 -1.195
Other toilet facility 0 0.018 -0.024 -1.326
Squatting on land 0 0.018 -0.024 -1.326
Figure A4.2: Histogram of follow up PCA scores
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APPEN D IX  5
PROVIDER SURVEY ANALYSIS BY OUTLET TYPE
INTRODUCTION
This appendix presents sub analyses carried out separately on specialized drug stores and 
retail outlets general stores, using what are considered to be the most important or 
informative indicators from Chapter 5 (Provider Survey Chapter) to assess whether the 
effects of the effects of the intervention were similar across outlet type. Due to the low 
numbers of outlets within each group, especially with specialized drug stores, and also 
minimising the negative effects of running multiple hypothesis tests this sub analyses can 
only be descriptive in nature
RESULTS
Table A5.1: Sample of outlets successfully interviewed, by type
Number of outlets by 
type:
Specialised drug store 
General store
Baseline 
Control Intervention
n (%) 
49/53 (92.5) 
214/242 (88.4)
n (%) 
53/59 (89.8) 
152/165 (92.1)
Control 
n (%) 
56/69 (81.2) 
262/299 (87.6)
Follow-up
Intervention 
n(%) 
74/79 (93.7) 
246/272 (90.4)
Table A5.2: Educational background and age of staff who usually or occasionally serve 
customers- Specialised drug store (mean of cluster summaries from the 9 intervention and 9 
control clusters)
Percentage of outlets with at least one Control Intervention % (SD)
employee occasionally/ usually serving % (SD)
customers :
Any clinical related training1
Baseline 67.4 (20.1) 59.3 (29.7)
Follow-up 78.8(18.6) 72.6(18.5)
Pharmacy/ pharmacy related training2
Baseline 33.2 (23.4) 30.4(18.4)
Follow-up 41.3(14.6) 2 2 . 6  (2 2 .8 )
Nurse/ Nurse related training3
Baseline 34.2 (20.7) 29.1 (19.7)
Follow-up 47.3 (28.5) 55.5 (19.6)
Medical doctor training4
Baseline 1.6 (4.8) 8 . 6  (9.8)
Follow-up 3.2 (9.5) 3.3 (5.1)
Primary school incomplete or no education
Baseline 12.5 (16.3) 12.1 (11.4)
Follow-up 0 (0 ) 6.1 (9.9)
Below 16 years of age
Baseline 2.8 (8.3) 0 (0)
Follow-up 0 (0) 0 (0)
1 Any clinical related training consists of: pharmacy, nurse and medical doctor related training; 2 Pharmacy related 
training includes pharmacy studied to a certificate or diploma level; 3Nurse related training includes studying nursing to a 
certificate level (nurse aid) and diploma level; 4 Medical doctor training includes clinical officer who studied medicine to 
a diploma level
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Table A5.3: Educational background and age of staff who usually or occasionally serve
customers- General store (mean of cluster summaries from the 9 intervention and 9 control
clusters)
Percentage of outlets with at least one 
employee occasionally/ usually serving 
customers :
Control % (SD) Intervention % (SD)
Any clinical related training1
Baseline 10.1 (4.9) 9.1 (11.9)
Follow-up 1 . 8  (1 .8 ) 2.7 (3.2)
Pharmacy/ pharmacy related training2
Baseline 4.0 (5.8) 3.2 (5.1)
Follow-up 0 (0 ) 0.3 (1.0)
Nurse/ Nurse related training3
Baseline 6 . 1  (5.9) 4.7 (7.5)
Follow-up 1 . 8  (1 .8 ) 2.7 (3.2)
Medical doctor training4
Baseline 1.2 (2.7) 1.2 (2.3)
Follow-up 0 (0 ) 0 (0 )
Primary school incomplete or no education
Baseline 30.0(12.1) 33.1 (18.7)
Follow-up 28.1 ( 1 2 .2 ) 34.7 (12.8)
Below 16 years of age
Baseline 3.5 (7.0) 4.0 (4.1)
Follow-up 4.0 (4.0) 2.8 (3.5)
1 Any clinical related training consists of: pharmacy, nurse and medical doctor related training; 2 Pharmacy related 
training includes pharmacy studied to a certificate or diploma level; 3Nurse related training includes studying nursing to a 
certificate level (nurse aid) and diploma level; 4 Medical doctor training includes clinical officer who studied medicine to 
a diploma level
Table A5.4: Percentage of outlets that had at least one Tibamal® trained (mean of cluster 
summaries from the 9 intervention and 9 control clusters)
Tibamal® training: Control % (SD) Intervention % (SD) Difference in means
______________________________________________________________________ (95%CI)
Specialised drug stores 0 (0) 56.3 (14.3)
General stores 1.1 (2.3) 38.4(13.8)
56.3 (46.2, 66.4) 
37.2(27.4, 47.1)
Table A5.5: Availability of AL in retail outlets- Specialised drug store (mean of cluster
summaries from the 9 intervention and 9 control clusters)
AL availability: Control 
% (SD) 
n
Intervention 
% (SD) 
n
Difference in means 
(95%CI)
Percentage of retail outlets with 
AL (including Tibamal®) in stock 
Baseline
Follow-up
3.8 (7.7)
2
32.4 (21.7) 
19
5.4 (15.2) 
2
60.1 (26.7) 
47
27.8 (3.4, 52.1)
Percentage of retail outlets with 
unexpired AL (including 
Tibamal®) in stock 
Baseline
Follow-up
3.8 (7.7)
2
26.8 (23.0) 
18
3.6(10.1)
2
57.4 (31.7) 
46 30.5 (2.9, 58.2)
Percentage of retail outlets with 
unexpired Tibamal® in stock 
Follow-up 0 (0 )
0
48.5 (25.7) 
40 48.5 (30.3, 6 6 .6 )
Percentage of outlets claiming to 
usually stock Tibamal® at follow-
up2
Follow-up 2.2 (6.7) 
1
63.1 (25.6) 
51 60.9 (42.2, 79.6)
Table A5.6: Availability of AL in retail outlets- General store (mean of cluster summaries from 
the 9 intervention and 9 control clusters)
AL availability: Control (N=9) Intervention (N=9) Difference in means
% (SD) % (SD) (95%CI)
n n
Percentage of retail outlets with 
AL (including Tibamal®) in stock 
Baseline
Follow-up
0 (0 )
0 (0 )
1.2 (2.5)
2
30.0 (11.4) 
72
30.0 (21.9,38.0)
Percentage of retail outlets with 
unexpired AL (including 
Tibamal®) in stock 
Baseline
Follow-up
0 (0 )
0 (0 )
0.7 (2.2)
1
29.5 (11.7) 
71 29.5 (21.2, 37.8)
Percentage of retail outlets with 
unexpired Tibamal® in stock 
Follow-up
0 (0 ) 29.5 (11.7) 71 29.5 (21.2, 37.8)
Percentage of outlets claiming to 
usually stock Tibamal® at follow-
up2
Follow-up
0 (0 ) 36.6 (12.2) 
8 8
36.6 (28.0, 45.2)
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Table A5.7: AL storage and stock outs at follow-up -Specialised drug store (mean of cluster
summaries)
AL storage and stock outs: Control (N=8 ) Intervention (N=9) Difference in means
____________________________________ % (SD) % (SD)_____________(95%CI)
Percentage of retail outlets storing 
all packs of AL appropriately 78.8 (24.7) 70.7 (33.7) -8.0 (-39.0, 22.9)
Percentage of retail outlets with AL 
available, reporting stock outs of 
any of the AL packs within the past 
2  weeks
6.3 (17.7) 39.9 (28.5) 33.7 (8.7, 58.6)
Table A5.8: AL storage and stock outs at follow-up -General stores (mean of cluster summary 
from the 9 intervention clusters)
AL storage and stock outs: Control (N=9) Intervention (N=9) Difference in means
___________________________________ % (SD) % (SD)_____________(95%CI)
Percentage of retail outlets storing 
all packs of AL appropriately 85.9 (17.5)
Percentage of retail outlets with AL 
available, reporting stock outs of 
any of the AL packs within the past 
2  weeks
25.5 (17.0)
Table A5.9: Median stock out days and tablet price of AL- Specialised drug stores (cluster 
summaries from the 9 intervention and 9 control clusters)
AL median stock out days and retail Control (N=9) Intervention (N=9)
price at follow-up: Median Median
________________________________________ (25%, 75% IQR) ________ (25%, 75% IQR)
Median stock out days in outlets where 
AL was available (per AL available) 3 (3, 3) 5.4 (3.4, 9)
Retail price per AL tablet -KSH 
(including Tibamal®)
Baseline 14.6(4.2, 25) 19.4(19.4, 19.4)
Follow-up 11.25 (6.32, 12.50) 3.33 (2.50, 3.33)
Table A5.10: Median stock out days and tablet price of AL- General stores (cluster summaries 
from the 9 intervention and 9 control clusters)
AL median stock out days and retail Control (N=9) Intervention (N=9)
price at follow-up: Median Median
_________________________________________ (25%, 75% IQR)_________ (25%, 75% IQR)
Median stock out days in outlets where 
AL was available (per AL available) 3.6 (2.8, 6 .8 )
Retail price per AL tablet -KSH 
(including Tibamal®)
Baseline
Follow-up - 1.67(1.67, 3.33)
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Table A 5 .ll:  The percentage of outlets found with one or more anitmalarials in stock (mean
of cluster summaries from the 9 intervention and 9 control clusters)
Control % (SD) Intervention % (SD) Difference in means 
____________________________________________ (95% Cl)
Percentage of specialised drug 
store with AM in stock: 
Baseline 
Follow-up
97.8 (6 . 7) 
88.6(18.9)
97.2 (5.5) 
89.8(11.2) 1.2 (-14.3, 16.7)
Percentage of general store with 
AM in stock:
Baseline
Follow-up
41.8 (12.5) 
29.2(11.2)
52.1 (12.7) 
45.6 (7.9) 16.4 (6.7,26.0)
Table A5.12: Antimalarials available, per retail outlet- Specialised drus stores (mean of 
cluster summaries from the 9 intervention and 9 control clusters)
Percentage of specialised drug 
store with certain AM in stock:
Control % (SD) Intervention % (SD) Difference in means 
(95% Cl)
Amodiaquine:
Baseline
Follow-up
96.4 (7.4) 
37.3 (31.2)
94.0 (8.2) 
28.9(16.4) -8.4 (-33.4, 16.5)
Sulphadoxine-pyrimethamine:
Baseline
Follow-up
83.0 (25.4) 
51.9 (25.1)
78.5 (19.8) 
67.4 (12.4) 15.5 (-4.2, 35.3)
Quinine:
Baseline
Follow-up
47.3 (27.3) 
59.6(16.5)
46.1 (13.6) 
48.9(19.3) -10.7 (28.6,7.3)
Chloroquine:
Baseline
Follow-up
5.0(10.0)
0 (0 )
5.4 (15.2) 
0 (0 ) 0 (0 ,0 )
Artemisinin monotherapy: 
Baseline 
Follow-up
27.2 (27.5) 
17.4(17.3)
14.5 (15.7) 
4.4 (5.4) -13.0 (-25.8, -0.2)
AL (including Tibamal®): 
Baseline 
Follow-up
3.8 (7.7) 
32.4 (32.4)
5.4 (15.2) 
60.1 (26.7) 27.8 (3.4, 52.1)
Tibamal®:
Baseline
Follow-up 0 (0 ) 48.5(25.7) 48.5 (30.3, 6 6 .6 )
ACT:
Baseline
Follow-up
3.5 (7.2) 
9.8 (12.5)
0 (0 )
0 (0 ) -9.8 (-18.6,-1.0)
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Table A5.13: Antimalarials available, per retail outlet- General store (mean of cluster
summaries from the 9 intervention and 9 control clusters)
Percentage of general stores Control % (SD) Intervention % (SD) Difference in means
with certain AM in stock:_______________________________________________________ (95% Cl)
Amodiaquine:
Baseline
Follow-up
38.5 (9.2) 
16.3 (7.4)
43.6(15.2) 
10.5 (5.2) -5.8 (-12.2, 0.6)
Sulphadoxine-pyrimethamine:
Baseline
Follow-up
14.7 (10.0) 
15.5 (12.4)
20.9 (10.7) 
17.5 (9.4) 2.0 (-9.0,13.0)
Quinine:
Baseline
Follow-up
2 . 1  (2 .6 ) 
0.5 (1.4)
0.5 (1.5) 
0 (0 ) -0.5 (-1.5, 0.5)
Chloroquine:
Baseline
Follow-up
0 (0 )
0 (0 )
0 (0 )
0 (0 ) 0 (0 ,0 )
Artemisinin monotherapy: 
Baseline 
Follow-up
0 (0 )
0 (0 )
0 (0 ) 
0.4 (1.3) 0.4 (-0.5, 1.3)
AL (including Tibamal®): 
Baseline 
Follow-up
0 (0 )
0 (0 )
1.2 (2.5) 
30.0(11.4) 30.0 (21.9,38.0)
Tibamal®:
Baseline
Follow-up 0 (0 ) 30.0(11.4) 30.0 (21.9,38.0)
ACT:
Baseline
Follow-up
0 (0 )
0 (0 )
0 (0 ) 
0.4 (1.3) 0.4 (-0.5, 1.4)
Table A5.14: Providers’ knowledge on symptoms of uncomplicated and uncomplicated 
malaria in a four year old child and symptoms of adverse drug reactions to AL (mean of 
cluster summaries from the 9 intervention and 9 control clusters)
Providers’ knowledge on symptoms of 
uncomplicated malaria in a four year 
old child:
Control (N=9) 
% (SD)
Intervention (N=9) % 
(SD)
Difference in means 
(95%CI)
Specialised drug store:
Baseline 
Follow-up 
General store:
Baseline
Follow-up
1 0 0
1 0 0
95.8 (3.0) 
96.2(1.8)
92.0(17.1)
1 0 0
94.9 (4.7) 
99.3 (1.5)
0  (1 0 0 ,1 0 0 )
3.0 (1.4, 4.7)
Providers’ knowledge on symptoms of 
complicated malaria in a four year old 
child:
Specialised drug store:
Baseline 
Follow-up 
General store:
Baseline
Follow-up
80.6(18.3) 
84.3 (17.0)
71.7 (7.0) 
81.4(10.1)
87.9 (14.8) 
89.5 (14.4)
77.0 (14.0) 
83.7(11.4)
5.2 (-10.5, 20.9)
2.3 (-8.4, 13.0)
Percentage of respondents knowing AL 
ADR symptoms 
Specialised drug store:
Baseline 
Follow-up 
General store:
Baseline
Follow-up
53.4 (33.1) 
51.2(15.5)
18.0(6.6)
15.8(13.3)
53.9 (53.9)
41.9 (25.0)
1 1 . 8  (8 .6 ) 
2 0 . 1  (2 0 .2 )
-9.4 (-30.1, 11.4)
4.3 (-12.7,21.4) 
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Table A5.15: Providers knowing the recommended treatment for uncomplicated malaria
(mean of cluster summaries from the 9 intervention and 9 control clusters)
Percentage knowing the first line Control (N=9) Intervention (N=9) Difference in means
AM for uncomplicated malaria: % (SD)____________ %_(SD)_____________ (95%CI)_____
Specialised drug store:
Baseline 66.5(28.2) 66.3 (18.6)
Follow-up 81.0(21.1) 83.9(11.0) 2.9 (-14.0, 19.7)
General store:
Baseline 31.2(10.4) 22.9(12.5)
Follow-up 38.3 (14.4) 66.8(12.0) 28.6 (-15.3,41.8)
Table A5.16: Advice on where to first seek treatment for uncomplicated malaria in a four 
year old child- Specialised drug store (mean of cluster summaries from the 9 intervention and 9 
control clusters)
Advice on where to seek treatment: Control (N=9) Intervention (N=9) % Difference in means
% (SD) (SD) (95%CI)
Health facility:
Baseline 19.8 (13.6) 21.1 (33.2)
Follow-up 2 0 . 8  (18.8) 6.4 (10.2) -14.4 (-29.5, 0.8)
Buy medication from a retail outlet:
Baseline 74.7 (17.2) 76.3 (33.0)
Follow-up 72.1 (23.6) 91.4(10.8) 19.3 (1.0,37.6)
Traditional healer:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0  (0 ,0 )
Would not know what to do:
Baseline 0 (0 ) 0 (0 )
Follow-up 1.6 (4.8) 0 (0 ) -1.6 (-5.0, 1.8)
Other2:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0 (0 ,0 )
P value refers to the level of significance of the unadjusted difference between control and intervention arms at follow-
up. P value remains the same when adjusted for outlet type. 2 Other includes treatment at home with western medications,
keeping the child warm when it is cold and maintaining good hygiene.
Table A5.17: Advice on where to first seek treatment for uncomplicated malaria in four year
old child- General store (mean of cluster summaries from the 9 intervention and 9 control
clusters)
Advice on where to seek treatment: Control (N=9) Intervention (N=9) % Difference in means
% (SD) (SD) (95%CI)
Health facility:
Baseline 43.1 (19.5) 45.6(14.8)
Follow-up 51.0(13.6) 30.81 (11.9) -20.2 (-7.4, -32.9)
Buy medication from a retail outlet:
Baseline 47.7(18.5) 47.5 (15.5)
Follow-up 45.3(14.6) 64.3 (9.7) 19.0 (31.4, 6 .6 )
Traditional healer:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0 (0 ,0 )
Would not know what to do:
Baseline 6.3 (2.3) 3.3 (3.2)
Follow-up 2.5 (3.1) 1.5 (2.3) -1.0 (-3.7, 1.8)
Other2:
Baseline 0.8 (1.7) 0.4 (1.2)
Follow-up 0(0) 0.5 (1.4) 0.5 (-0.5,1.4)
*P value refers to the level o f significance o f the unadjusted difference between control and intervention arms at follow- 
up. P value remains the same when adjusted for outlet type. 2 Other includes treatment at home with western medications, 
keeping the child warm when it is cold and maintaining good hygiene.
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Table A5.18: Advice on where to first seek treatment for complicated malaria in a four year
old-Specialised drug store (mean of cluster summaries from the 9 intervention and 9 control
clusters)
Advice on where to seek treatment: Control Intervention Difference in means
(N=9) % (SD) (N=9) % (SD)_________ (95%CI)
Health facility:
Baseline
Follow-up
60.3 (17.0) 
79.5 (13.4)
64.9 (20.0.)
72.9 (14.0) -6 . 6  (-20.2, 7.1)
Buy medication from a retail outlet: 
Baseline 
Follow-up
30.6 (17.4) 
20.8. (17.7)
33.1 (17.8) 
23.0 (.13.1) 2.2 (-13.4, 17.8)
Traditional healer: 
Baseline 
Follow-up
0 (0 )
0 (0 )
0 (0 )
0 (0 ) 0  (0 ,0 )
Would not know what to do: 
Baseline 
Follow-up
0 (0 ) 
1.6 (4.8)
0 (0 )
0 (0 ) -1.6 (-5.0, 1.8)
Other2:
Baseline 1.4 (4.2) 
Follow-up 1.6 (4.8) 
2Other includes praying and sponging the child.
1.8 (5.1) 
3.3 (7.1) 1.7 (-4.3, 7.8)
Table A5.19: Advice on where to first seek treatment for complicated malaria in a four ye 
old-General store (mean of cluster summaries from the 9 intervention and 9 control clusters)
Advice on where to seek treatment: Control 
(N=9) % (SD)
Intervention 
(N=9) % (SD)
Difference in means 
(95%CI)
Health facility:
Baseline
Follow-up
75.4(16.9)
84.8(7.1)
80.3(10.9) 
90.4 (4.3) 5.6 (-0.2,11.5)
Buy medication from a retail outlet: 
Baseline 
Follow-up
14.0 (14.4) 
9.0 (4.9)
14.4 (9.7) 
4.9 (4.8) -1.6 (-6.5, 3.2)
Traditional healer: 
Baseline 
Follow-up
0 (0 )
0 (0 )
0 (0 )
0 (0 ) 0  (0 ,0 )
Would not know what to do: 
Baseline 
Follow-up
5.6(3.0) 
4.6 (3.7)
3.1 (4.8) 
2.3 (2.8) -2.3 (-5.6, 0.1)
Other2:
Baseline
Follow-up
0.3 (0.9) 
1.4 (1.7)
1.1 (3.3) 
0 . 6  (1 .8 ) -0.8 (-2.5, 0.9)
2Other includes praying and sponging the child.
Table A5.20: Respondents giving the correct dispensing advice for AL use in a four year old- 
Specialised drug store (mean of cluster summaries from the 9 intervention and 9 control clusters)
Percentage of respondents that 
knew the correct AL advice:
Control (N=9) 
% (SD)
Intervention (N=9) 
% (SD)
Difference in means 
(95%CI)
AL administration: 
Baseline 
Follow-up
3.6 (7.4) 
2.2 (6.7)
0 (0 )
25.6(21.7) 23.4 (7.4, 39.5)
What to do if the child vomits 
AL:
Baseline
Follow-up
0 (0 )
8.7(13.8)
0 (0 )
18.6(14.1) 9.9 (4.0, 23.8)
What to do if the child does not 
improve:
Baseline
Follow-up
70.9 (12.6) 
60.3 (23.2)
70.4 (21.2)
80.5 (18.6) 20.2 (-0.8,41.2)
Foods to give the child with AL: 
Baseline 
Follow-up
16.9(19.3) 
5.7 (10.0)
11.6(11.4) 
40.9 (16.3) 35.1 (21.6, 48.6)
261
Table A5.21: Respondents giving the correct dispensing advice for AL use in a four year old-
General store (mean of cluster summaries from the 9 intervention and 9 control clusters)
Percentage of respondents that Control (N=9) Intervention (N=9) Difference in means
knew the correct AL advice:__________ % (SD)___________% (SD)___________ (95%CI)
AL administration: 
Baseline 
Follow-up
0 (0 ) 
1 . 1  (1 .8 )
0 (0 ) 
9.5 (8.5) 8.4 (2.3,14.6)
What to do if the child vomits 
AL:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 6.4 (6.4) 6.4 (1.9,11.0)
What to do if the child does not 
improve:
Baseline 40.0(11.5) 40.3 (15.9)
Follow-up 35.4 (.17.8) 60.6 (15.3) 25.1 (8 .6 , 41.7)
Foods to give the child with AL:
Baseline 6.5 (6.5) 5.9 (5.9)
Follow-up 6.0 (6.0) 22.8(11.3) 16.8(7.8,25.8)
Table A5.22: Respondents’ referral practices for suspected AL ADRs- Specialised drug store
(mean of cluster summaries from the 9 intervention and 9 control clusters)
Referral practices for suspected AL Control (N=9) Intervention (N=9) Difference in 
ADRs: % (SD) % (SD) means (95%CI)
Percentage of outlets that would 
immediately refer patients to a health 
facility for a suspected ADR:
Baseline 24.3 (18.3) 50.7 (20.9)
Follow-up 30.6(15.2) 39.2(23.1) 8.5 (-11.0,28.0)
Percentage of outlets that had observed 
a suspected AL ADR:
Baseline 32.8(34.3) 24.7(33.1)
Follow-up 30.9(25.8) 25.2(13.4) -5.7 (-26.2, 14.9)
Table A5.23: Respondents’ referral practices for suspected AL ADRs- General store (mean of 
cluster summaries from the 9 intervention and 9 control clusters)
Referral practices for suspected AL Control (N=9) Intervention (N=9) Difference in
ADRs: % (SD) % (SD) means (95%CI)
Percentage of outlets that would 
immediately refer patients to a health 
facility for a suspected ADR:
Baseline 27.0(12.9) 21.9(15.4)
Follow-up 39.5(10.9) 46.2(13.6) 6 . 6  (-5.7, 19.0)
Percentage of outlets that had observed 
a suspected AL ADR:
Baseline 8 . 8  (9.0) 11.4(11.5)
Follow-up 7.2 (8.3) 6 . 6  (6.9) -0.6 (-8.3,7.0)
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Table A5.24: Respondents’ use of CHW referral forms at follow-up (mean of cluster
summaries from the 9 intervention and 9 control clusters)
CHW referral forms: Control (N=9) Intervention (N=9)
% (SD) % (SD)
Percentage of outlets with CHW forms
Specialised drug outlets: 1.9 (5.6) 56.1 (23.5)
General store: 2.0 (1.9) 32.7(16.9)
A PPEN D IX  6
HOUSEHOLD SURVEY SUB-GROUP ANALYSIS
Table 7.4: Percentage of febrile children for whom care was obtained from general stores at 
baseline by characteristic of the child (mean of cluster summaries of the 9 intervention and 9 
control clusters)
Children’s characteristics:
Control (N=9) 
% (SD) 
n=41
Intervention (N=9) 
% (SD) 
n=55
Difference in means 
(95% Cl)
Age:
3 months to < 36 months 
36-59 months
7.2 (4.7) 
10.9 (7.7)
10.5 (5.1) 
16.7 (9.2)
3.2 (8.2,-1.7) 
5.8 (14.3, -2.7)
Sex:
Male
Female
7.8 (6.7) 
8 . 6  (7.2)
12.5 (4.7) 
12.9 (7.5)
4.7 (10.5,-1.1) 
4.3 (11.6,-3.1)
Household head’s education 
Primary incomplete 
Primary complete and above
7.3 (4.9) 
8.2 (7.1)
13.6 (8.9) 
11.6(6.7)
6.3 (13.5, -0.8) 
3.4(10.3, -3.5)
ITN use:
ITN use last night 
No ITN use last night
1.7 (1.1) 
3.1 (3.4)
3.0 (2.3)
4.0 (1.8)
1.2 (3.0, -0.6) 
0.9 (3.6,-1.8)
Socio-economic status (wealth quintiles):
Quintile 1 (most poor) 13.8 (12.3) 
Quintile 2 (very poor) 4.5 (7.7) 
Quintile 3 (poor) 2.2 (6.7) 
Quintile 4 (less poor) 7.0 (15.0) 
Quintile 5 (least poor) 15.5 (10.8) 
n= number of febrile children obtaining care from the general store
12.6(15.3) 
15.6(14.3) 
9.6(13.5) 
1 2 .0 (1 1 .2 ) 
4.8 (7.1)
1.3 (12.6, -15.2) 
11.1 (22.6, -0.4)
7.4 (18.1,-3.2) 
5.0(18.2, -8.2)
-10.7 (-1.6, -20.0)
Table 7.4: Percentage of febrile children for whom care was obtained from general stores at 
follow up by characteristic of the child (mean of cluster summaries of the 9 intervention and 9 
control clusters)
Children’s characteristics:
Control (N=9) 
% (SD) 
n=67
Intervention (N=9) 
% (SD) 
n=113
Difference in means 
(95% Cl)
Age:
3 months to < 36 months 
36-59 months
13.7 (6.4) 
31.9(27.9)
25.5 (25.5)
24.5 (16.9)
11.8(2.7, 20.9) 
-7.4 (15.7, -30.4)
Sex:
Male
Female
17.6 (9.4) 
22.5 (13.3)
24.9 (12.9) 
25.8 (15.0)
7.3 (18.5, -4.0) 
3.2 (17.4,-11.0)
Household head’s education 
Primary incomplete 
Primary complete and above
23.3 (17.2) 
14.8 (7.2)
25.3(11.3) 
25.1 (14.8)
2.0 (16.5,-12.5) 
10.3 (22.0, -1.3)
ITN use:
ITN use last night 
No ITN use last night
18.7(11.4)
20.6(11.4)
23.5 (15.2) 
25.9(13.4)
4.8 (18.3,-8.7) 
5.3 (17.8, -7.2)
Socio-economic status (wealth quintiles): 
Quintile 1 (most poor)
Quintile 2 (very poor)
Quintile 3 (poor)
Quintile 4 (less poor)
Quintile 5 (least poor) 
n= number of febrile children obtaining care
20.5 (20.1) 
17.0(18.6) 
27.8(15.3) 
25.4 (31.5)
25.6 (30.9)
; from the general store
25.4(13.4)
22.5 (17.3) 
32.8 (19.6)
21.5 (23.2) 
12.9(15.5)
4.9(21.9,-12.2) 
5.5 (23.4, -12.5) 
5.0 (22.6, -12.6) 
-3.8 (23.8, -31.5) 
-12.7 (11.7, -37.1)
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Table 7.5: Percentage of febrile children for whom care was obtained from specialised drug
stores at baseline by characteristic of the child (mean of cluster summaries o f the 9 intervention
and 9 control clusters)
Children’s characteristics: Control (N=9) 
% (SD) 
n=113
Intervention (N=9) 
% (SD) 
n=168
Difference in means 
(95% Cl)
Age:
3 months to < 36 months 
36-59 months
29.0 (9.1) 
32.5 (12.1)
35.6(10.4)
40.4(16.1)
6 . 6  (16.4, -3.2) 
7.8 (22.1, -6.4)
Sex:
Male
Female
35.6(12.4) 
24.2 (8.4)
36.6(13.0)
36.6(18.2)
1.5 (13.8, -11.7) 
12.4 (26.6,-1.7)
Household head’s education:
Primary incomplete 
Primary complete and above
29.0 (14.2) 
31.9(9.4)
31.2(12.3)
43.7(11.6)
2.1 (15.4, -11.1) 
11.8(22.4, 1.2)
ITN use:
ITN use last night 
No ITN use last night
7.8 (4.6)
6 . 8  (2.7)
13.1 (6 .6 ) 
9.3 (5.3)
5.3 (10.9, -0.4)
2.3 (6.7, -1.6)
Socio-economic status (wealth quintile): 
Quintile 1 (most poor)
Quintile 2 (very poor)
Quintile 3 (poor)
Quintile 4 (less poor)
Quintile 5 (least poor)
34.1 (28.1) 
34.3 (18.8)
26.2 (30.0) 
31.9(17.8) 
36.5 (25.8)
33.4(17.1)
30.7(12.8)
37.9(18.5)
42.0 (27.4)
46.1 (33.5)
0.7 (22.6, -23.9) 
3.7 (12.3,-19.8) 
11.8(32.6, -9.1) 
10.1 (33.2, -13.0) 
9.6 (39.4, -20.3)
n= number o f febrile children obtaining care from the specialised drug store
Table 7.5: Percentage of febrile children for whom care was obtained from specialised drug 
stores at follow up by characteristic of the child (mean o f cluster summaries o f  the 9 intervention 
and 9 control clusters)
Children’s characteristics: Control (N=9) 
% (SD) 
n=78
Intervention (N=9) 
% (SD) 
n= 1 2 1
Difference in means 
(95% Cl)
Age:
3 months to < 36 months 
36-59 months
25.7 (10.2) 
13.8(13.3)
25.4 (16.0) 
35.3 (18.0)
-0.3 (13.1,-13.7) 
21.5 (5.6, 37.3)
Sex:
Male
Female
24.8 (3.4) 
19.5(13.4)
30.2(19.2) 
27.3 (13.3)
5.4 (19.1,-8.4) 
7.9(21.2, -5.5)
Household head’s education:
Primary incomplete 
Primary complete and above
18.3 (5.2)
27.4 (13.0)
31.2 (19.1) 
26.4 (14.6)
13.0 (27.0,-1.1) 
-1.1(12.8,-14.9)
ITN use:
ITN use last night 
No ITN use last night
22.4 (9.4) 
20.1 (12.3)
28.9(16.0) 
27.1 (15.9)
6.5 (19.6, -6.7) 
7.0 (21.2,-7.2)
Socio-economic status (wealth quintile): 
Quintile 1 (most poor)
Quintile 2 (very poor)
Quintile 3 (poor)
Quintile 4 (less poor)
Quintile 5 (least poor)
20.5 (16.7)
28.5 (17.4) 
15.8(16.5) 
31.3 (23.9)
19.5 (21.1)
28.1 (18.7) 
28.2(17.1) 
22.6 (25.7) 
31.0(24.2) 
32.7(11.9)
7.6 (25.4,-10.1) 
-0.3 (17.0, -17.5) 
6 . 8  (28.3, -14.8) 
-0.3 (23.7, -24.4) 
13.2 (30.3, -3.9)
n= number of febrile children obtaining care from the specialised drug store
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A PPEN D IX  7
HOUSEHOLD SURVEY: FURTHER ANALYSIS ON TREATMENT SEEKING
BEHAVIOUR
Table A7.1 shows a breakdown of actions taken by caregivers to treat their child suffering 
from a fever with two weeks prior to the interview. As a first action most care givers 
reported visiting either a government facility or a specialised drug store to obtain 
treatment. No significant differences were observed between actions in the control 
compared to the intervention arm. Similar patterns were observed in subsequent actions 
taken and very few caregivers reported taking more than three actions.
Table A7.1: Actions taken to treat children with fever in the last two weeks, by order of 
action (mean of cluster summaries from the 9 intervention and 9 control clusters)
Action number: Control % (SD) Intervention % (SD) Difference in means
______________________________________________________________________________(95% Cl)
1 st
Government facility:
Baseline 30.1 (11.3) 23.8(11.7)
Follow-up 33.6(15.8) 26.4 (9.4) -7.2 (5.8, -20.2)
Specialised drug store:
Baseline 28.9 (14.9) 37.0(16.2)
Follow-up 22.7(10.0) 28.9 (16.7) 6.2 (19.9, -7.5)
General store:
Baseline 10.1 (4.5) 12.4 (4.7)
Follow-up 19.7 (9.6) 25.6(13.7) 5.9 (17.7, -5.9)
Missionary/Private facility:
Baseline 5.8 (5.1) 6.3 (6.2)
Follow-up 8.9 (5.3) 6 . 1  (8 .1 ) -2.8 (4.0, -9.6)
Traditional healer:
Baseline 0.5 (1.4) 0 (0 )
Follow-up 0.4 (1.2) 0.6 (1.9) 0.2 (1.8,-1.3)
Others:
Baseline 13.0 (6.0) 6 . 6  (6 .2 )
Follow-up 8 . 6  (5.6) 5.7 (2.8) -2.9 (1.5, -7.3)
2 nd
Government facility:
Baseline 2.5 (2.8) 3.1(4.0)
Follow-up 2.8 (3.0) 1.6 (1.4) -1.1 (1.2, -3.5)
Specialised drug store:
Baseline 5.1 (4.2) 4.6 (3.6)
Follow-up 0.9 (1.7) 1.3 (1.6) 0.4 (2.1,-1.2)
General store:
Baseline 0.8 (1.3) 1.0 (1.4)
Follow-up 0.4 (1.2) 1.5 (2.1) 1.1 (2.9, -0.6)
Missionary/Private facility:
Baseline 1.6 (1.9) 2 . 0  (1 .8 )
Follow-up 0.4 (1.3) 0 (0 ) -0.4 (0.5,-1.4)
Traditional healer:
Baseline 0 (0 ) 0 (0 )
Follow-up 0.3 (0.8) 0 (0 ) -0.3 (0.3, -0.8)
Others:
Baseline 1 . 1  (1 .8 ) 1.5 (1.9)
Follow-up 0.6 (1.3) 1.4 (2.0) 0.7 (2.4,-1.0)
Table continues onto next page
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Table A7.1 continued
3rd
Government facility:
Baseline 0 (0 ) 0.5 (0.8)
Follow-up 0 (0 ) 0 . 2  (0 .6 ) 0.2 (0.7, -0.2)
Specialised drug store:
Baseline 0.2 (0.5) 0.4 (1.1)
Follow-up 0.3 (0.8) 0 . 2  (0 .6 ) -0.1 (0.6, -0.7)
General store:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0 (0 , 0 )
Missionary/Private facility:
Baseline 0 (0 ) 0.4 (1.2)
Follow-up 0 (0 ) 0 (0 ) 0 (0 , 0 )
Traditional healer:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0 (0 , 0 )
Others:
Baseline 0.3 (0.8) 0 . 2  (0 .6 )
Follow-up 0.2 (0.7) 0 (0 ) 0.2 (-0.3, 0.8)
4th
Government facility:
Baseline 0 (0 ) 0 . 2  (0 .6 )
Follow-up 0 (0 ) 0 . 2  (0 .6 ) 0 . 2  (0 .6 , -0 .2 )
Specialised drug store:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0 (0 , 0 )
General store:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0  (0 , 0 )
Missionary/Private facility:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0 (0 , 0 )
Traditional healer:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) o (0 , 0 )
Others:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0 (0 , 0 )
Other includes treatment at home with home-made remedies or western medication, traditional healers or 
prayers.
Types of AM prescribed by source
Table A7.2 shows the percentage of antimalarial monotherapies dispensed over the total 
number of visits made to each source of care. Amodiaquine was the most common 
monotherapy to be received, mostly from specialised drug stores followed by general 
stores. Overall there was a decline in amodiaquine dispensing from baseline to follow-up. 
There was a significant difference in amodiaquine dispensed from general stores between 
the arms with a decline to 3.1% (SD: 5.7%) of caregivers reporting to receive it in the 
intervention arm and 23.5% (15.5%) in the control arm. By the time of the study, 
amodiaquine was no longer being supplied to government hospitals, so it is surprising to 
see caregivers reporting to have received amodiaquine from this source. There are several
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potential explanations for this, including the possibility that some facilities had stock 
remaining after supply was discontinued, and may have used this when the first line 
therapy was out of stock
Quinine was the second most common monotherapy dispensed. At the time of study, 
quinine was Kenya’s second line therapy for uncomplicated malaria and also used as first 
line treatment in complicated malaria (DOMC, 2007). Quinine was most commonly 
dispensed from mission and private hospitals, as well as government facilities. No 
significant difference was observed in the dispensing of quinine from baseline to follow- 
up. Few caregivers reported receiving SP, with the majority having received it from 
mission or private facilities. Both chloroquine and artemisinin monotherapies were 
reported to have been received by very few caregivers. One caregiver visit to a government 
facility in the control arm (0.4% (SD:1.3%) and one in the intervention arm 0.8% 
(SD:2.4%), were reported to have resulted in chloroquine being dispensed, however the 
supply of chloroquine to government facilities was discontinued many years ago and it is 
very likely that the caregivers may have misidentified the monotherapy they received.
Table A7.2: Types of antimalarial monotherapy prescribed by number of visits to source
(mean of cluster summaries from the 9 intervention and 9 control clusters)
Antimalarial monotherapy Control % (SD) Intervention % (SD) Difference in means
source:_______________________________________________________________________ (95% Cl)_____
Amodiaquine:
Specialised drug store:
Baseline 44.5 (16.2) 43.9(14.1)
Follow-up 20.3 (19.9) 6.4 (6.4) 13.9 (-1.1,28.9)
Mission_Private:
Baseline 16.0(26.9) 18.9 (.14.5)
Follow-up 6.3 (13.8) 7.4 (22.2) -1.1 ( -19.6,17.4)
Government facility:
Baseline 20.8 (14.5) 18.1 (15.6)
Follow-up 4.7 (5.6 ) 6.2 (6.9) -1.5 (-7.8,4.8)
General stores:
Baseline 23.5 (20.7) 18.7(17.8)
Follow-up 23.5 (15.5) 3.1 (5.7) 20.4 (8.7, 32.1)
Other sources:
Baseline 14.6(11.8) 9.2(11.3)
Follow-up 4.4 (13.3) 3.7(11.1) 0.7 (-11.5,13.0)
Sulphadoxine-
pyrimethamine
Specialised drug store:
Baseline 1.8 (4.0) 9.0 (3.9)
Follow-up 6.0 (7.7) 3.8 (7.3) 2.2 (-5.3, 9.7)
Mission_Private:
Baseline 12.5 (35.4) 4.4(9.1)
Follow-up 13.3 (33.2) 0 (0 ) 13.3 (-10.1,36.8)
Government facility:
Baseline 0.9 (1.8) 1.9 (2.6)
Follow-up 3.7 (11.1) 0 (0 ) 3.7 (-4.1, 11.6)
General stores:
Baseline 8.5 (13.4) 6.5 (9.8)
Follow-up 2.5 (5.2) 3.1 (6 .6 ) -0.6 (-6 .6 , 5.3)
Other sources:
Baseline 1.2 (3.7) 5.8 (9.0)
Follow-up 4.4 (13.3) 3.7(11.1) 0.7 (-11.5, 13.0)
Table continues onto next page
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Table A7.2 continued
Quinine:
Specialised drug store:
Baseline 1.0 (3.0) 0.9 (2.7)
Follow-up 3.4 (5.4) 4.2 (8 .8 ) -0.8 (-8.1, 6.5)
Mission_Private:
Baseline 28.1 (36.8) 23.1 (34.3)
Follow-up 11.5 (18.8) 22.2(44.1) -10.7 (-44.6, 23.1)
Government facility:
Baseline 14.9(19.4) 14.4(15.5)
Follow-up 7.9 (10.1) 10.1 (5.2) -2.2 (-10.2, 5.8)
General stores:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0 (0 ,0 )
Other sources:
Baseline 0 (0 ) 0 (0 )
Follow-up 3.2 (9.5) 1.9 (5.6) 1.3 (-6.5, 9.1)
Chloroquine:
Specialised drug store:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0.5 (1.6) -0.5 (-1.7, 0.6)
Mission_Private:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0 (0 ,0 )
Government facility:
Baseline 0.4 (1.3) 0.8 (2.4)
Follow-up 0 (0 ) 0 (0 ) 0  (0 ,0 )
General stores:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0  (0 ,0 )
Other sources:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0 (0 ,0 )
Artemisinin monotherapy:
Specialised drug store:
Baseline 0.4 (1.3) 0.4 (1.2)
Follow-up 0 (0 ) 2.8 (8.3) -2.8 (-8.7, 3.1)
Mission_Private:
Baseline 0 (0 ) 3.7(11.1)
Follow-up 0 (0 ) 0 (0 ) 0 (0 ,0 )
Government facility:
Baseline 1.2 (3.7) 5.6(16.7)
Follow-up 0 (0 ) 0.4 (1.3) -0.4 (-1.4, 0.5)
General stores:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0 (0 ,0 )
Other sources:
Baseline 0 (0 ) 0 (0 )
Follow-up 0 (0 ) 0 (0 ) 0 (0 ,0 )
Others includes receiving treatment at home with western medications and other health facilities not classified in the 
above such as army sanatoriums.
REFERENCES
Division of Malaria Control (DOMC) (2007) Transitional plan for implantation of 
Artemisinin-based combination therapy (ACT) malaria treatment policy in Kenya. 
Royal Pharmaceutical Management Plus.
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APPENDIX 9
AL SUPPLIES IN GOVENRMENT HEALTH FACILITIES
Supplies o f  AL at governm ent health facilities were m onitored during the study period, 
from Septem ber 2008 to August 2009. Calls were made to the pharm acy departm ent o f 
each facility every one to two m onths and inform ation was collected on the availability o f 
AL packs for the four patient weight groups o f AL on the interview day, including details 
o f any stock outs. The duration o f  any stock outs was detailed from respondents reviewing 
stock cards in the pharmacy.
Generally, supplies o f AL in governm ent health facilities during the study period tended to 
fluctuate. In Septem ber 2008, one m onth after baseline data collection was complete, 
supplies o f the 6 tablet pack o f AL were only available in ha lf o f health facilities. Details 
o f  AL supplies for April to August 2008, during baseline data collection activities, were 
not collected. However, interviews with m em bers o f the DHM Ts and m inutes o f  meetings 
during that time revealed com plaints o f severely low to non-existent supplies o f AL. 
Towards the end o f  the year, there were generally sufficient supplies o f  all packs o f  AL, 
available in more than 90% o f all facilities. AL availability in January and April 2009 was 
generally low, w ith the m edication being available in less than h a lf  o f  facilities, but by the 
time o f the start o f  follow-up data collection AL supplies had picked up again, with the 6, 
12 and 24 packs found in m ore than 90% o f facilities in M ay-June 2009, though by the end 
o f  data collection in August 2009, they had again fallen to around the 50% m ark (Figure 
A9.1). The longest duration facilities were out o f  stock o f  A L was observed in April 2009 
where facilities without AL rem ained out o f stock for 32 to 89 days. M ore details on AL 
availability trends in Kenyan governm ent health facilities and reasons for stock outs can be 
found in Kangw ana et al., (2009) and the M CH report (DOM C, 2010).
Figure A9.1: Availability of AL on Survey Day
97% 97%100%
■ 6 t a b l e t  pack
■ 12 t a b l e t  pack
■ 18 t a b l e t  pack
■ 24  t a b l e t  pack70% 66%66°J
S ep t -0 8  Nov-08 Jan -0 9  Apr-09  M a y - J u n e  09 Aug-09
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REFERENCES
Kangwana BB, Njogu J, Wasunna B, Kedenge SV, Memusi DN et al., (2009) Malaria drug 
shortages in Kenya: a major failure to provide access to effective treatment. Am J 
Trop Med Hyg. May;80(5):737-8.
Division of Malaria Control (DOMC), Kenya (2010) Monitoring Outpatient Malaria Case 
Management under the 2010 Diagnostic and Treatment Policy in Kenya.
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APPENDIX 11
Analyses was carried out to assess whether caregivers’ health seeking behaviour and providers’ 
referral behaviours varied with their physical distance to the nearest public health facility. For 
caregivers’ treatment seeking behaviour, the median distance of households to the nearest public health 
facility was assessed for each source of care that was sourced for children suffering from fever (refer 
to table 7.2). For providers’ referral behaviour, the median distance of outlets to the nearest public 
health facility was assessed for each type of referral suggested for complicated malaria cases in 
children under five (refer to table 5.19).
CAREGIVERS’ HEALTH SEEKING BEHAVIOUR
Figure A ll.l:  Median distance (km) of household to nearest public health facility for caregivers 
seeking care at each outlet type. Baseline.
in
co -
CNI -
O
GF_distance
GSdistance
otherdistance
specialised_drug_outletsdistance
missprivdistance
Median distances from the caregivers’ household to the nearest public health facility, for caregivers who sourced care from 
different outlets: government health facilities (GF_distance)=2.0km; specialised drug outlet
(spcialised_drug_outletdistance)=2.6km; general store (GSdistance)=2.5km; mission/ private health facility 
(missprivdistance)=3. lkm; other=2.2km.
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Figure A11.2: Median distance (km) of household to nearest public health facility for caregivers 
seeking care at each outlet type. Follow-up.
C N  -
U G F distance J  sp ec ia lised  drug outletsd istan ce
1 G S d istan ce m issprivdistance
3  oth erd istan ce
Median distances from the caregivers household to the nearest public health facility, for caregivers who sourced care from 
different outlets: government health facilities (GF_distance)=2.0km; specialised drug outlet
(spcialised_drug_outletdistance)=2.6km; general store (GSdistance)=2.5km; mission/ private health facility 
(missprivdistance)=2.7km; other=3.4km.
PROVIDERS’ REFERRAL BEHAVIOURS 
Figure A 11.3: Median distance (km) of provider to nearest public health facility for providers 
stating that they would refer complicated cases to each outlet type. Baseline.
] hf_distance 
] dk_distance
] shop_distance  
other_distance
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Median distances from th e providers outlet to  th e  nearest public health facility, for providers w ho would refer 
com plicated cases to  different sources o f care: governm ent health facilities (GF_distance)=1.9km;
shop(shop_distance)=2.4km ; would not know w here to  refer patient (dk_distance)=1.8km; other=2.3km .
Figure A11.4: Median distance (km) of provider to nearest public health facility for providers 
stating that they would refer complicated cases to each outlet type. Follow-up.
10 -
CO
o -
hf_distance 
dk distance
shop_distance 
other distance
Median distances from the providers outlet to the nearest public health facility, for providers who would refer complicated 
cases to different sources of care: government health facilities (GF_distance)=2.3km; shop(shop_distance)=2.2km; would 
not know where to refer patient (dk_distance)=2.8 km; other=2.3km.
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APPENDIX 12
A separate ‘difference in difference’ analysis was carried out below on certain indicators from the 
mystery shopper survey (Chapter 6) and household survey (Chapter 7). A difference in difference 
analysis was carried out on indicators where baseline and follow data raised the possibility of a 
differential effect between the arms, but which did not necessarily appear to be of statistical 
significance. The analysis was carried out out by first calculating the difference between basleine and 
follow up for each cluster. Then a mean difference for the control and intervention arm was calculated. 
Finally, the difference in difference was obtained by calculating the difference between the mean 
difference in the control arm and the mean difference in the intervention arm, and an unpaired t-test 
was run assess the significance of the differences observed. In the difference in difference approach, 
adjustments are not made for covariates, so this analysis was carried out unadjusted. The analysis has 
been limited to tables 6.3, 6.6, 6.9 and 7.4. One limitation of the difference in difference analysis is 
that it is exposed to a phenomenon known as ‘regression to the mean’. This is caused by random 
variation in the measured endpoints, where clusters with low observed values at baseline are expected 
to show an increase in the outcome value at follow-up and vice versa. Therefore it is generally 
preferred to control for baseline values by including it as a covariate in the analysis, as described in 
Chapter 4 in the methodology section (Hayes & Moutlon, 2009). The results below should therefore be 
interpreted with caution.
Table A6.3: Percentage of outlets where retailers asked whether the child had at least one sign of severe 
disease, using difference in difference analysis (mean of cluster summaries from the 9 intervention and 9 
control clusters)
Mean 
difference in 
control (N=9) 
% (SD)
Mean difference in 
intervention 
(N=9)
% (SD)
Mean difference in 
difference 
(95% Cl)
P-value
Unadjusted
All outlets 0.9 (15.5) 10.6 (17.4) 9.7 (6.7, 26.2) 0.2283
Information based on outlets interviewed both for mystery shopper and provider survey.
Table A 6.6: Reasons given for not dispensing, of those retailers not dispensing any drugs, using 
difference in difference analysis (mean of cluster summaries from the 9 intervention and 9 control clusters) 
(multiple responses allowed)
Reasons for not 
dispensing any 
drug:
Mean difference 
in control (N=9) 
% (SD)
Mean difference 
in intervention 
(N=9)
% (SD)
Mean difference in 
difference 
(95% Cl)
P-value
Unadjusted
No drugs in stock 1 0 . 8  (2 0 .6 ) -16.5 (26.0) -27.3 (-50.8, -3.8) 0.0253
No antimalarials in 
stock
10.0 (8.4) 23.8(15.6) 13.7(1.1,26.3) 0.0343
No suitable drugs in 
stock1
14.0 (19.0) 13.7 (24.4) -0.3 (-22.1,21.5) 0.9768
Referred to a 
specialized drug 
store
2.9 (27.1) 4.4 (24.0) 1.6 (-24.0, 27.1) 0.8991
Referred to a health 
facility
4.8 (27.1) -7.6 (21.5) -12.4 (-36.9,12.0) 0.2979
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Shopkeeper said they had no suitable drugs in stock which generally meant that either they did not feel they had appropriate drugs to 
treat the stated symptoms, or that they did not have appropriate drugs to treat children of the stated age (4 years)
Table A6.9: Specific antimalarials dispensed by retailers, using difference in difference analysis (mean of 
cluster summaries from the 9 intervention and 9 control clusters)
Anitmalarials
dispensed:
Mean difference 
in control (N=9) 
% (SD)
Mean difference in 
intervention 
(N=9)
% (SD)
Mean difference in 
difference 
(95% Cl)
P-value
Unadjusted
AL 1.2 (1.9) 25.4 (6.9) 24.1 (19.1,29.2) 0.0001
Tibamal® 0 (0) 24.4 (7.0) 24.4 (19.5, 29.3) 0.0001
Amodiaquine -11.7(7.9) -23.5 (12.4) -11.9 (-22.2,-1.5) 0.0274
SP 3.1 (9.6) -5.0(10.3) -8.1 (-18.1, 1.8) 0.1036
Quinine 1.9 (2.5) 1.9 (3.3) 0.0 (-2.9,2.9) 0.9999
Other drugs1 0.4 (3.2) 0.3 (3.9) -0.1 (-3.7, 3.4) 0.9299
Other drugs are non-antimalarials and non-antipyretics and include: Antibiotics (Amoxicillin, Cotrimoxazole and Trimethoprim), 
Antihistamines (Chlorpheniramine), Antihelminthics (Levamisole), and Bronchodilators (Salbutamol).
Rank sum test: unadjusted analysis, p=0.0003; adjusted analysis, p=0.0003. This test was carried out on the main outcome 
indicator because of its robustness and its sensitivity to any shifts in distribution between control and intervention clusters. (Hayes 
& Moulton, 2009)
Table A7.4: Anti-malarial treatment obtained for children aged 3-59 months with fever in the previous 
two weeks, using difference in difference analysis (a comparison of the 9 intervention and 9 control clusters)
Treatment seeking behaviour indicators
Mean 
difference in 
control (N=9) 
% (SD)
Mean 
difference in 
intervention 
(N=9)
% (SD)
Mean difference in 
difference 
(95% Cl)
P-value
Unadjusted
Children who received an antimalarial 11.4 (8.6) 18.5(12.4) 7.1 (17.8, -3.5) 0.1740
Children who received an antimalarial 
monotherapy -7.0(11.8) -26.6 (9.5) -19.6 (-8.9,-30.3) 0.0013
Children who received any brand of AL 17.1 (13.9) 45.8 (13.6) 28.7 (42.4, 15.0) 0.0004
Children who received any brand of AL on 
the same day or following day of fever onset 14.5 (8.4) 40.2 (12.4) 25.7 (36.2, 15.1) 0.0001
Total number of children with fever in the previous two weeks present in the control arm: Baseline=353; Follow-up=344 
Total number of children with fever in the previous two weeks present in the intervention arm: Baseline=413; Follow-up=417 
SD= standard deviation, CI=confidence interval, N= number of clusters
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